<SEC-DOCUMENT>0001125345-21-000115.txt : 20211102
<SEC-HEADER>0001125345-21-000115.hdr.sgml : 20211102
<ACCEPTANCE-DATETIME>20211102160506
ACCESSION NUMBER:		0001125345-21-000115
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		50
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211102
DATE AS OF CHANGE:		20211102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		211371183

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mgnx-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:a503bed0-470c-42a0-8ff2-08d40b83c4e7,g:0544a414-ac6d-4106-af60-27149bd97a9a,d:dd97f2f67fc84defb53bffbcae4606c1--><html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:mgnx="http://macrogenics.com/20210930" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80L2ZyYWc6NzdlNWM4NmZhOGJhNDU1Y2ExM2YzODk2ZmE1YWRiYzIvdGFibGU6MjVkMjBhNmEyODRjNDczZGFmNzZiYWU1NjdkY2ExNTAvdGFibGVyYW5nZToyNWQyMGE2YTI4NGM0NzNkYWY3NmJhZTU2N2RjYTE1MF8yLTEtMS0xLTA_70cca93f-6a7d-4b0d-aaf2-dec1356ea106">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80L2ZyYWc6NzdlNWM4NmZhOGJhNDU1Y2ExM2YzODk2ZmE1YWRiYzIvdGFibGU6MjVkMjBhNmEyODRjNDczZGFmNzZiYWU1NjdkY2ExNTAvdGFibGVyYW5nZToyNWQyMGE2YTI4NGM0NzNkYWY3NmJhZTU2N2RjYTE1MF80LTEtMS0xLTA_18de2dbe-4a76-47f7-beea-ca52a80ad575">2021</ix:nonNumeric><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80L2ZyYWc6NzdlNWM4NmZhOGJhNDU1Y2ExM2YzODk2ZmE1YWRiYzIvdGFibGU6MjVkMjBhNmEyODRjNDczZGFmNzZiYWU1NjdkY2ExNTAvdGFibGVyYW5nZToyNWQyMGE2YTI4NGM0NzNkYWY3NmJhZTU2N2RjYTE1MF81LTEtMS0xLTA_7c70e672-275a-4f8b-a1ed-845df807bbdf">Q3</ix:nonNumeric><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80L2ZyYWc6NzdlNWM4NmZhOGJhNDU1Y2ExM2YzODk2ZmE1YWRiYzIvdGV4dHJlZ2lvbjo3N2U1Yzg2ZmE4YmE0NTVjYTEzZjM4OTZmYTVhZGJjMl8xMzA_69b61279-fb06-425a-adbd-ddfed19f67b8">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80L2ZyYWc6NzdlNWM4NmZhOGJhNDU1Y2ExM2YzODk2ZmE1YWRiYzIvdGV4dHJlZ2lvbjo3N2U1Yzg2ZmE4YmE0NTVjYTEzZjM4OTZmYTVhZGJjMl8xMzE_65d8c756-9219-4a1a-a8f1-05794aaba3e2">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id224a007af7345f691c25b480130a570_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i972ac0a554d046a68379be874acd54db_I20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i68797193d4fe4a28bd0077b1e12763e2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaabf44798f0b4137a1cd062271187dd4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ie95edcd295ff48deb8618fc650417b92_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i546c554a2ee0420ea96d3bc20bc2c290_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0bcdbf862314e17ae8630e4eb589a85_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6657edfefea4b1a9ed79a2168bc7a7b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie043cccbc0a44110a07e3bb61c428168_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie137008876174548934b7aa0f11bbbdb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80e0db72700b4ea497dbe948db25aa20_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcc05602c5ac4fa59eb68dfc1e898e5c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide26e919725d41559b15da9dcb0a928b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i959a5d44e3314580a0ac18e02aa9bafd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a9ca21023dc4df0baec03f9c4eba112_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4c884e39a884f8696523d9a33f5ef35_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib92c6189b72c447b8f1068b900a46c1f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0089074df40749cda994bd08f7cebc31_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34562cb47376442eaa203ab6023eb363_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic813efc42fbc4dd58d2a1dd2d3f5c0cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1395e2e157c84e9e97a685f193961623_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie54467d33fdf45529db11e8c19a075f6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92e491e03d244d95acc39155f4bff6be_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b5ad3e626c04694aaf53610a83fce1f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3c55b26f9e94031991eb2780805e604_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b75e289c90849cd817e71ea9a94d6c9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic74e7b8118db41abafcc6bb0b8372824_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fcc348fc5e847e88eeadde0e0adcb08_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i190ac348f6dc46a6ac38f0d568759b66_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd365da76df34d2db894b5c3007130a3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7c5ea5419494505aabe9e7465d4670b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51fffa70c15f473db18a09340f835b36_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic43acc02e0294959a3b21f958b70bc69_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i205d61628986439484c21a2ed5ad4721_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i844325c47f4d4863abe97d247a5fd1ac_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie86acd1be8634256903051e3b678e662_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3179fb8dbc27438ca7ed7fc6348f29f6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i586b4fc28f444eae89cd1925d85aa640_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id78260ca3b734c09b0e4cfd6e30b6911_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i763636992b5f478e80241f5eeae0f30d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38708c79101b4e3fbc43d1d6b323a03a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35415a234ac242ad8ea5c77e9808c2e9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i529e813dc38c4c33ae7cd08cb044ea48_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0ccd33dc63c47e189ad4827959e843a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdf5cd80b6b14743a7ea631042c021c3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf40af9b54464df4b7d3b1125f9d9179_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c8f4c62b536483799b051a34289338d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d126b1a843b404783a3465235814e27_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38a56f6d9c814dac9d125191db3566f1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66955da827134291bef28c2ecf6e4055_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic06875b187ec41dcb7b1a15821218d7e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65cfd5b11203487cb6091fe2f919527c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f4ad9aa86ed438781238f7412b23e01_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69bcf518b6f64b4eb86f5f40a6061a93_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43d0b4f45e374b469456ad8fc84bf839_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b7835f8392d46518da425a3f19dd697_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6f9507cd9244da6a3c17dd33edf8e68_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7099a1f0709642f8b56969b8d261b209_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefa62144550e44079146bf982176865e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9712c2e2c25f4f469e19daccd541cabc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fb90850307344bdb2b62e4c657ff389_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf4d14e52ac44346ae2be66f1872b003_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02b854e6798d4d0bbd747c741fec06ad_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4383e6ffc54437af3047cc7d551c59_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8465dd5b84f4677b7ef351c4e4a0629_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72077576d2d24e2fb5a5f8426cae9925_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88bdee85e14740838ddaa61690920077_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43929274060145538939cfbe9ebb7d7f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66fa665eac24481292baf200368ca1ba_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33d616f3a92c43cbae84e15bf03190f8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf50d256b04c4e70a85bd5224d72ca21_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i906aa4f6d4c44c3ba0e305e35a7203c3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1164dbdf167740b2a496f6c88f38aac9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2935a1f381274d3ebe662dedbebbad3e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2dbb00d209747a99fb78cfa9687763f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad092482cde8453e9195f68fb28e18f2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dac9970dbca4aaba71fb397a9144b68_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a8e94f9c23740d392d77be412cf1da4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab4b7193bca147449377324fe98c3afe_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7da6fadb64042b4b028fc24eeb8c6ed_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffca67721b4c43308a8bf5b3985400f5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb94e98144414013a4b367b085227a01_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i304344aae2b14aa6b471cf77a9f4df60_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d5fe7dc9ce749d7b4b4343243fc3448_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1471592823d141ed9982b46286c25e2a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6c9cdd4f1d3447cb695fe45e3422587_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia65ece20c394482b8251eff40d234644_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d00c49127754d849e79ffd0f091a235_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aef0259fe304602914853bd229b6a2f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac5626cc0d4d4f3eada7c592f37e6549_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3d2893df5534deda5831f679ba7dd0d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id48171a2cf134b9b877b17e3ab1d96bf_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a74388d699f4bd2ac58facdd9a4fd7b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia640a3c02d1f4c75a6f0cc21b9c2cb6d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17cb614f00584923a41b3f540fa1cdbc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabf613c73d3e4483a06ea6e38d8e670b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e6b518462554e3cbdf3a5cadf5c10ea_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b8bfb356e214cc9bfe9904bbc293017_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73eb53766d6c4804a4e1e66a6df09c91_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49de27c2929345d3a226185a435ab868_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f048a39b44649b29657ceea4301f358_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a7ed9e27b984af2aae1adfbb2125ce5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f0c1670d044e009dba1531620dc1c1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb0787f0e3644860ba06eb1034fbb65b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1ffbd08270d44d085deecec92b01243_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0d6f6806ba94e9ea50c537546db47a7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee759986b4274d298c370fdb8432435b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i148258350c6645d79c0d898ac35f6d87_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i747a2e68687f4fe8b192d169ccefd610_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea0bbc8e396f4f45a85696892ed3b146_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib121748b3b90427eb1b071912d8f8abb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ea12fcac00647eda4be75a5c687a73b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i288f5153e6b2498db8daba718939f0f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7451a81074d647e295bf3e8ebedffdb7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76162ba1a18c4fc4a980bcbba9264153_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0e6f330c4624be993d0a2175e6edb7c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3585fd01cc1840feb99f41bf29e5c7e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4da6d04d2658412081cbb06f08d92d03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6438be1c7813480081d80920f7c7256d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80cbb34246294317b7336589ccf4350d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebfbafa88c384397839bf6d6ddd589b5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i845134cd6052477bb77c2afc3b82e0ee_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia973c2256c1241e39d7549dbe6a90f11_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie69edf146b6449f7a4fb9cf05187e1ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46a6e5fff27f4b6aa874171e8585d54f_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06955b87c4604f8fb996dcb42b4dc99e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fa4f2d5e48b4142942ab255dbbf4e2b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i022010ba69a04e73be7fc39c277aa5bc_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a6d5f9b9cb64ef1ab9cf00828b18921_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22af05f406eb42a18864db9d550fb33b_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i427f349d621a4e20beb2de97f08f189f_I20210615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a20cea58d2e41dda0b283e8e60b23c0_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c7dc4c308654b92a9b7eb8aa5fae842_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44f9acd305254e98bb6059421e41afc8_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6b3220211b34177a70814841776348e_D20180101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i8f96961f110f4bd4a365d1cacb888a9d_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i793df4da4f6949ae8dc1104d14ce9e42_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="performanceobligation"><xbrli:measure>mgnx:performanceObligation</xbrli:measure></xbrli:unit><xbrli:context id="i326f19028f6848eb90307ed07e34fb13_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaf80bf80aa94dcdbe58a0b47d56866c_D20170101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if11ae315139b4747abb6df067daf9f16_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34ebcecab85244bd9dbc6977705c7569_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98c0801d3b474ff6844f020bcdb35bd9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cfb8e8a76924dac915a6ac2232abba3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bdcdeefecaa42989b7b67f34d47899a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9531fc2fc03846f0b3768319934b4340_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if320066be1564b01af8dde722a25c31e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98e991fb934846ab820b5a844c8830c5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4badc0f60dd14b6c8755357f7ac540fc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc0dbc0dc52e4ad7bf077e11b26f5987_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a0c5813a0c46d786211fb05433da01_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b58dca81bae4ab9b749cdc5b02a267b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie336f44ff7bd44ad8432ae58b5fff68f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1fee744e4cf4ed1ad933a71b09d6beb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i383ab32255d644eaafc819796aa2870d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9d0c680036d4325b5e7f41d64399b60_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad7dbfa657cb4e6f87748b9ddf1e390c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3465bc8d05de421897c972d4b8fedeb8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd7958be040c4fb89b305414df69d203_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c250244fd7d4e4c9b409d38eb292272_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f28dba3b3c54be6951e63e82446015d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03d23314d63d45c8b35e795aaedab122_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if34089b9b5874ac5840731a4dd93f241_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83adad7f523245b7b6e58f66a3dab006_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a238ce78ac74f1b93c817ced866efa2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4022bd5da2824c7c8f8ee74203011a7d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida2095e4cb994efe825c83b7c2569119_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f5dc2b032524391af7887b322598d1d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8143c485591543ca8f9fa0ad6b05a533_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iede70fcdb85b4d5fadb7c778a198437a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee958037590e47f9a647d7b398e799cb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i821467e83ad44bf4936cba83c4bf74cc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i251e9fe0e95a4f3f862b554c5b106612_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35541777167844639ae2fde64553a505_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0b95e5cfec444d08b7a167a497b2f2b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b4c7ba6a9524139b98444a380751a27_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic57fab8151e64ac0a42999af4054508d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0d488d61f554e5a8b0ce225092751fc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99ab726c228e4d1680ccc1ddfb59679a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3ab9f0060de41d18476fe3926db09c0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="molecule"><xbrli:measure>mgnx:Molecule</xbrli:measure></xbrli:unit><xbrli:context id="i99a92e56710a44499fbc841789c43ddd_D20150915-20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-15</xbrli:startDate><xbrli:endDate>2015-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71658aa1f269459cad8b975de86ba7af_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i487dec63017c4855b07e934da1351f90_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb2565b6e20a47c380508ecb56852d3e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01719b83dd334b3c8168fc3fa1f48b83_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91df6dfeabf04146832cafe879f6de8d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4219cd04f594173989928403a1925f5_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i079475de71ee41f681213c129639bcad_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87bf914abe0d42daa70a6e228105c4dc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0829ae725ca14ae7a41646663f3d6410_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e8e35470de0483c81155d2739ab9223_I20131031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5cf9831d6f24c2083b89a5456858d7b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc4bd8d3b0504ef79236bd4a23c915f8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1afe44d7fcb449e8b8c3d8ac3bf6d9d6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bae4045ab9643abbbe939388775bc12_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0961f8433264f3a91406325b6f8539c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1204e1a45b146edb8cf23bbe529b211_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1a6178e54834b4f981abb57a3f32174_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40192326e650444490369c6d8aed8c29_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i596efc1d3c914e7c99e852a6397e9d68_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c37fd8583354f3e9a46dbbaef70aed7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie49c054c4de84c13bf9cf4e74329ad89_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1017f0e3d160493698b4b137f53cf6b9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9edd978d79794c06ae717443ae5079d0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2db8a1a06494bb9acad2b6f55b81bac_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i671b1a548fa8453f8d15112d62dc2c2c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc9b2b5b948945ceb440f809f174f953_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic04f6c80a7bb4625a1ae6e61e5c93184_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f5fcdf3d7064037aaefd67693a0f61c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="idd97f2f67fc84defb53bffbcae4606c1_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV84Mg_75047b5c-a00c-4624-ae84-5dd6223719ad">10-Q</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6NjUzYmFiMTI3YTk0NGE3MzgzMDdhMzJlN2YzNDNjNmUvdGFibGVyYW5nZTo2NTNiYWIxMjdhOTQ0YTczODMwN2EzMmU3ZjM0M2M2ZV8wLTAtMS0xLTA_a33063f5-85f8-4d9f-80d7-d41570ae2a21">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8xMTc_8aad6e6e-1b6e-4955-85d5-15d3d7876277">September 30, 2021</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6YzIyOGZlNzc5ZGUzNGMzZGFkMmRkNzI5NjQ5N2RhZjAvdGFibGVyYW5nZTpjMjI4ZmU3NzlkZTM0YzNkYWQyZGQ3Mjk2NDk3ZGFmMF8wLTAtMS0xLTA_ab1aae69-8b0f-4207-98e4-fad2dc72c161">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8yMDg_3e48943f-0d0b-4c86-9a5e-4445ea3ddc5d">001-36112</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8yMTE_d2185158-390b-4416-af10-64958c61b273">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6NTk3NDMyOGQwYzg2NDBhM2E1MzBiNTRkNGMzY2FhMzAvdGFibGVyYW5nZTo1OTc0MzI4ZDBjODY0MGEzYTUzMGI1NGQ0YzNjYWEzMF8wLTAtMS0xLTA_364f2baf-a2b7-4d36-af74-5cc2010faebe">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6NTk3NDMyOGQwYzg2NDBhM2E1MzBiNTRkNGMzY2FhMzAvdGFibGVyYW5nZTo1OTc0MzI4ZDBjODY0MGEzYTUzMGI1NGQ0YzNjYWEzMF8wLTEtMS0xLTA_39e3cc63-dddd-48ee-8819-f3fbfdc8728c">06-1591613</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6NTk3NDMyOGQwYzg2NDBhM2E1MzBiNTRkNGMzY2FhMzAvdGFibGVyYW5nZTo1OTc0MzI4ZDBjODY0MGEzYTUzMGI1NGQ0YzNjYWEzMF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmMGRhZDFjYzRhYzg0OWY4ODNiMTMwMzViNGQ0OGI0OF81_d977fccf-8748-4ff2-9c60-fa84ff2e9dcb">9704 Medical Center Drive</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6NTk3NDMyOGQwYzg2NDBhM2E1MzBiNTRkNGMzY2FhMzAvdGFibGVyYW5nZTo1OTc0MzI4ZDBjODY0MGEzYTUzMGI1NGQ0YzNjYWEzMF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmMGRhZDFjYzRhYzg0OWY4ODNiMTMwMzViNGQ0OGI0OF84_57d2476b-070a-4249-b0ad-01ad8cbc9bff">Rockville</ix:nonNumeric>, <ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6NTk3NDMyOGQwYzg2NDBhM2E1MzBiNTRkNGMzY2FhMzAvdGFibGVyYW5nZTo1OTc0MzI4ZDBjODY0MGEzYTUzMGI1NGQ0YzNjYWEzMF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmMGRhZDFjYzRhYzg0OWY4ODNiMTMwMzViNGQ0OGI0OF8xMg_5334c548-0d77-490a-8abc-373551d3ac3b">Maryland</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6NTk3NDMyOGQwYzg2NDBhM2E1MzBiNTRkNGMzY2FhMzAvdGFibGVyYW5nZTo1OTc0MzI4ZDBjODY0MGEzYTUzMGI1NGQ0YzNjYWEzMF8zLTEtMS0xLTA_dc906af2-bfd1-491c-8048-70eca85c2408">20850</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip code)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8yNzA_f439bb3c-70a4-48f0-9d19-af62dd770559">301</ix:nonNumeric>-<ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8yNzM_56f860df-a261-44da-99d5-f94c388fb65c">251-5172</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6MDEwMGNjMDhiMDU5NGI3Y2ExMTFiZjU4NWQ0ZmQ1ZjgvdGFibGVyYW5nZTowMTAwY2MwOGIwNTk0YjdjYTExMWJmNTg1ZDRmZDVmOF8xLTAtMS0xLTA_10748155-9129-47ea-872c-50edc6113b8d">Common Stock, par value $0.01 per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6MDEwMGNjMDhiMDU5NGI3Y2ExMTFiZjU4NWQ0ZmQ1ZjgvdGFibGVyYW5nZTowMTAwY2MwOGIwNTk0YjdjYTExMWJmNTg1ZDRmZDVmOF8xLTEtMS0xLTA_d64ba663-5bf7-4bb5-aeaf-ccca5470ab1d">MGNX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6MDEwMGNjMDhiMDU5NGI3Y2ExMTFiZjU4NWQ0ZmQ1ZjgvdGFibGVyYW5nZTowMTAwY2MwOGIwNTk0YjdjYTExMWJmNTg1ZDRmZDVmOF8xLTItMS0xLTA_c558a435-b19c-4892-8143-b7146d58df12">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8xOTE3_aab32676-f36c-4bdc-85c7-50db59ba73b5">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8xOTE1_60b0c9a8-00b2-4f71-aaea-7bed8b9a5b7a">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "accelerated filer," "large accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:23.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6OGI0ZGNkMzgxNTljNGM4Zjg3ZDIzMjNmMmQ2NjRjZDQvdGFibGVyYW5nZTo4YjRkY2QzODE1OWM0YzhmODdkMjMyM2YyZDY2NGNkNF8wLTAtMS0xLTA_c672719c-ad65-43d8-ac52-410cd7126e64">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6OGI0ZGNkMzgxNTljNGM4Zjg3ZDIzMjNmMmQ2NjRjZDQvdGFibGVyYW5nZTo4YjRkY2QzODE1OWM0YzhmODdkMjMyM2YyZDY2NGNkNF8yLTMtMS0xLTA_eff5c8fa-6e47-4a7c-bdc0-ef4d9677d23f">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6OGI0ZGNkMzgxNTljNGM4Zjg3ZDIzMjNmMmQ2NjRjZDQvdGFibGVyYW5nZTo4YjRkY2QzODE1OWM0YzhmODdkMjMyM2YyZDY2NGNkNF80LTEtMS0xLTA_f6702109-8958-4f4c-bc2a-5dff6f6c7cdd">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160; &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8xOTE2_aa6d9942-d26a-4a6e-9092-08b7bd1e82cb">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;29, 2021, <ix:nonFraction unitRef="shares" contextRef="i972ac0a554d046a68379be874acd54db_I20211029" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8xODI4_639e7a8d-89d7-49c1-8303-5b8f3e3eeeb9">61,258,001</ix:nonFraction> shares of the registrant's common stock, par value $0.01 per share, were outstanding.</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="idd97f2f67fc84defb53bffbcae4606c1_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:23.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_13">FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_16">Financial Statements</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_19">Consolidated Balance Sheets at</a> September&#160;30, 2021 (unaudited) and December&#160;31, 2020</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_22">Consolidated Statements of Operations and Comprehensive Loss for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_22">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_22"> months ended</a> September&#160;30, 2021<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_22"> and </a>September&#160;30, 2020<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_22"> (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_25">Consolidated Statements of Stockholders' Equity for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_25">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_25"> months ended </a>September&#160;30, 2021<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_25"> and </a>September&#160;30, 2020<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_25"> (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_28">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_28">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_28"> months ended </a>September&#160;30, 2021<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_28"> and </a>September&#160;30, 2020<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_28"> (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_31">Notes to Consolidated Financial Statements (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_61">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_82">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_85">Controls and Procedures</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;II.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_88">OTHER INFORMATION</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_91">Legal Proceedings</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_94">Risk Factors</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_97">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_100">Exhibits</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idd97f2f67fc84defb53bffbcae4606c1_103">Signatures</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idd97f2f67fc84defb53bffbcae4606c1_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Quarterly Report on Form 10-Q. Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Item 1A. Risk Factors" of our Annual Report on Form 10-K for the year ended December&#160;31, 2020), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity and duration of the impact of the COVID-19 global pandemic on our business, operations, clinical programs, manufacturing, financial results and other aspects of our business;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to commercialize MARGENZA and our plans to develop and commercialize our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and successfully maintain sales and commercial distribution capabilities or establish or maintain relationships with third-party collaborators to successfully commercialize any of our product candidates; </span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes of our ongoing and planned clinical trials and the timing of those outcomes, including when clinical trials will be initiated or completed, and when data will be reported or regulatory filings will be made;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and our ability to obtain and maintain regulatory approvals for MARGENZA and our product candidates and the labeling for any approved products;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital through the capital markets or through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding product candidates currently being developed by our collaborators;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits and future operation of our existing collaborations; </span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recover the investment in our manufacturing capabilities;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our products;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant competition in our industry;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of litigation and the failure to successfully defend lawsuits and other claims against us and our expectations regarding the outcome of any regulatory or legal proceedings;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic, political and other risks associated with our international operations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to receive research funding and achieve anticipated milestones under our collaborations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss or retirement of key members of management;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully execute our growth strategy, including any delays in our planned future growth; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to maintain effective internal controls.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idd97f2f67fc84defb53bffbcae4606c1_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_16"></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_19"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfNC0xLTEtMS0w_cac17c7f-e9a9-4c4d-9983-d7d558a3a141">190,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfNC0zLTEtMS0w_6a1464de-31b5-4d03-b18f-8c04362718ee">181,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfNS0xLTEtMS0w_51f0d823-4fc5-450e-9e65-16fbe1a46b4b">108,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfNS0zLTEtMS0w_02643257-46d4-48f4-a7b3-c7ed554efbd3">91,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfNi0xLTEtMS0w_549802fa-16aa-4ece-90f3-ce040c6f5ccb">13,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfNi0zLTEtMS0w_b375600a-057c-4dcf-ac4b-6e02a75a6a10">23,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfNy0xLTEtMS0w_8b86fbb5-ecfe-4f4c-b1b6-72f4df45018e">3,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfNy0zLTEtMS0w_69dd2439-d3e9-4314-98d0-d34976629026">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfOC0xLTEtMS0w_1a23ef45-3101-403c-95fa-9ec97274356c">18,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfOC0zLTEtMS0w_a95a9410-ca24-405f-864a-a4331c3c9d0e">16,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTAtMS0xLTEtMA_c98a101f-b27d-4369-8b6d-2a10af3a7ae4">334,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTAtMy0xLTEtMA_d25bbcb0-440d-4bc5-ae83-0860d77deec2">312,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTEtMS0xLTEtMA_1fb9bc4f-955a-4be3-a94b-196697f99151">38,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTEtMy0xLTEtMA_e7cdcb8d-146d-4b49-9e34-a833b933a770">42,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTMtMS0xLTEtMA_b3775c8f-4dba-48da-adca-4666e4469f59">18,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTMtMy0xLTEtMA_d7d07705-0c3f-4a4d-babd-67174539dafc">23,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTQtMS0xLTEtMA_7e57fe6c-2ffb-4354-bb67-86e9e517155c">392,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTQtMy0xLTEtMA_2e5890fc-a9db-41be-890a-e222fd6ea9de">378,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTgtMS0xLTEtMA_50cae4ab-3958-43f6-8839-f35f16b2158f">6,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTgtMy0xLTEtMA_04049a75-f222-46f8-8bdd-d474908b9b43">8,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTktMS0xLTEtMA_4dba9d53-9e34-4afe-9769-afbebca78b9c">41,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTktMy0xLTEtMA_dd78a0f8-d4fe-416a-a6de-e0890009a210">34,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjAtMS0xLTEtMA_4ab98e2a-aeec-4ecc-9054-812294d82601">16,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjAtMy0xLTEtMA_35521871-9a7e-4b42-882a-4389797ef679">4,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjEtMS0xLTEtMA_f5f49756-bc00-4bee-bc5a-834dbc78526b">4,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjEtMy0xLTEtMA_f3d71d1f-f0dd-48aa-b918-7006374002f1">3,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjMtMS0xLTEtMA_8de81a20-a1be-422b-862c-a04fc0fa4268">68,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjMtMy0xLTEtMA_eccd51ca-3a84-42f8-883a-bbafe33f0855">50,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjQtMS0xLTEtMA_8d507369-d18a-41fa-b235-351f5409203d">9,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjQtMy0xLTEtMA_41609079-4c34-410f-b252-061862b2fd03">6,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjUtMS0xLTEtMA_23dc53bd-e754-494a-8c45-ec7ed62a5a8a">22,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjUtMy0xLTEtMA_5ea74473-9528-484c-a499-7a5516d8f639">25,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjYtMS0xLTEtMA_f20bd31d-2c3a-4d25-a4b3-8347c741a200">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjYtMy0xLTEtMA_86c91384-cd94-4de2-baf7-fa508074aa07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjctMS0xLTEtMA_74ff7ad6-d02b-42b4-a1ae-9a79051f08cc">100,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjctMy0xLTEtMA_a23a6c9d-919e-4ad5-89c5-055a5d04d5bb">82,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjFkYjA0ZWQ1MGNjYTQ1NzBiZmQ2MzNmY2Q3Zjc5MjljXzE4_0bd3c71b-ce6e-41ad-9974-5a86a950847e"><ix:nonFraction unitRef="usdPerShare" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjFkYjA0ZWQ1MGNjYTQ1NzBiZmQ2MzNmY2Q3Zjc5MjljXzE4_441fb2f0-cac5-4a78-a181-a794e1a6f457">0.01</ix:nonFraction></ix:nonFraction> par value -- <ix:nonFraction unitRef="shares" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjFkYjA0ZWQ1MGNjYTQ1NzBiZmQ2MzNmY2Q3Zjc5MjljXzM0_2eca3546-d748-479d-812a-828b1cd76243"><ix:nonFraction unitRef="shares" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjFkYjA0ZWQ1MGNjYTQ1NzBiZmQ2MzNmY2Q3Zjc5MjljXzM0_3f5d4b8f-f9b5-4a9e-a5d4-568329354168">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjFkYjA0ZWQ1MGNjYTQ1NzBiZmQ2MzNmY2Q3Zjc5MjljXzU2_367c5e38-6a66-479e-bcdb-285fa875d7f2">61,254,693</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjFkYjA0ZWQ1MGNjYTQ1NzBiZmQ2MzNmY2Q3Zjc5MjljXzYz_81e5fc6d-7965-4279-94da-b75fb2a7c3ec">56,244,771</ix:nonFraction> shares outstanding at September&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjktMS0xLTEtMA_8adb0b05-3421-4746-807e-eed4ce9774a8">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjktMy0xLTEtMA_546ef5c7-cf1e-4e0c-a8a1-effc0d6d1ad1">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzAtMS0xLTEtMA_ee26899f-9215-4146-ab32-4f1a0bdbf55b">1,206,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzAtMy0xLTEtMA_a279348d-d81b-4db8-b0a6-fa82e880b41d">1,067,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzEtMS0xLTEtMA_b1796355-9498-4381-909d-0d28cb772911">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzEtMy0xLTEtMA_3627e04f-178f-4ed7-a81c-77619eab6614">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzItMS0xLTEtMA_781e5240-6e17-4c54-a6d8-dcde583dc8e6">915,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzItMy0xLTEtMA_4a1dd4a6-d04f-40cd-813a-0ebdb89a4bce">771,821</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzMtMS0xLTEtMA_0e7ce53d-2098-4501-8c13-83a15a99e3ef">291,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzMtMy0xLTEtMA_8926dc00-828d-45f1-af49-14f272f064fe">295,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzQtMS0xLTEtMA_562ee555-ead4-42ab-9f51-e27821b30931">392,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzQtMy0xLTEtMA_f997970b-65ba-48f2-a4a9-34634b68a54b">378,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="idd97f2f67fc84defb53bffbcae4606c1_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.770%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from collaborative and other agreements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie95edcd295ff48deb8618fc650417b92_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMy0xLTEtMS0w_7ed09cca-dcbe-4bf1-889b-0b0f3f2eebeb">11,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546c554a2ee0420ea96d3bc20bc2c290_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMy0zLTEtMS0w_78238e22-59e6-4471-8749-9cb273f3553e">17,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bcdbf862314e17ae8630e4eb589a85_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMy01LTEtMS0w_a8358d0d-9085-4347-a3de-1bf00061a798">54,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6657edfefea4b1a9ed79a2168bc7a7b_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMy03LTEtMS0w_f555960c-6209-435c-a7dc-cf4ef18e688f">46,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie043cccbc0a44110a07e3bb61c428168_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNC0xLTEtMS0w_af3333dc-45b1-4152-93d4-680b8a7bccd1">3,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie137008876174548934b7aa0f11bbbdb_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNC0zLTEtMS0w_b9b6f2d4-cb09-4e3c-9f25-e8db6cac2456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e0db72700b4ea497dbe948db25aa20_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNC01LTEtMS0w_001ea1db-fac2-434a-8aec-970c5945d1fd">7,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcc05602c5ac4fa59eb68dfc1e898e5c_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNC03LTEtMS0w_58d54b4b-0a23-4641-8c2a-9de8cdc75356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from government agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide26e919725d41559b15da9dcb0a928b_D20210701-20210930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNS0xLTEtMS0w_71795be2-45eb-49a7-bbb9-45c6c02837e6">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959a5d44e3314580a0ac18e02aa9bafd_D20200701-20200930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNS0zLTEtMS0w_d7910416-3778-4a51-ad3d-6bc4c5becd32">838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a9ca21023dc4df0baec03f9c4eba112_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNS01LTEtMS0w_136e25f9-06cb-431b-8f3f-91ca997c200a">1,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c884e39a884f8696523d9a33f5ef35_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNS03LTEtMS0w_c5cd438d-b913-42fe-9edd-eafc0f04425a">6,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNi0xLTEtMS0w_9077bc8b-04ba-4d2b-9808-4ea6b63abe72">15,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNi0zLTEtMS0w_8af8165b-63ff-4d38-b017-0d50c4a82efd">18,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNi01LTEtMS0w_6f8ae691-d8c7-4cc2-9cd3-c811e8f9f6d3">63,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNi03LTEtMS0w_577d34aa-8b19-4ac3-8caf-5e637f4e774e">52,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfOC0xLTEtMS0w_5952b991-822d-43da-accd-5e6be1849a0d">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfOC0zLTEtMS0w_db105f46-48ad-4569-9d0b-7ad9fe33697c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfOC01LTEtMS0w_6bca272f-1a1e-481b-b738-d33564dab82f">1,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfOC03LTEtMS0w_d22970f9-fc39-4640-a5bd-911a7c1d31a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfOS0xLTEtMS0w_86bffb1d-5bcc-4ebf-8c8c-94733e31acde">49,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfOS0zLTEtMS0w_2fd76b62-b83e-448c-9e00-82ff2366c624">44,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfOS01LTEtMS0w_ef85bee4-abfb-4758-920a-8be477417f44">158,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfOS03LTEtMS0w_f206e267-5b85-447e-b390-dcb73eb7e39e">150,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTAtMS0xLTEtMA_4a3bae6f-32c0-4b3f-95f6-1d7c71767a9d">17,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTAtMy0xLTEtMA_b2cc5d3f-dc06-4e61-8cb7-7ca47aeee434">9,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTAtNS0xLTEtMA_30b38445-d177-4cff-a36b-bc9bf00df03b">47,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTAtNy0xLTEtMA_36807b7e-e817-43ae-81fa-9fb52c801f62">30,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTEtMS0xLTEtMA_5fff8af8-6a8b-44ed-a504-d971e933a138">68,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTEtMy0xLTEtMA_8811e265-52fe-4360-8dd6-1169e7fb6710">54,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTEtNS0xLTEtMA_414f689f-dead-4838-b473-ed03cd1b18e0">207,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTEtNy0xLTEtMA_9ac6a863-902c-4f74-b13c-e11e4f5e1696">181,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTItMS0xLTEtMA_cee6a29b-1bb9-4e5b-b2e7-fc25b71a0b69">52,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTItMy0xLTEtMA_b0f71713-53d0-4777-b7ee-7c91b41856e8">36,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTItNS0xLTEtMA_c7546796-cafd-4140-b006-0830104445d3">144,559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTItNy0xLTEtMA_d75a7612-b8db-4896-8339-fbba27082a40">128,890</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTMtMS0xLTEtMA_7b8e9ab9-dee3-4d82-a900-7ac282a0260e">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTMtMy0xLTEtMA_2432baf9-7a55-438e-886d-b9c3331ca907">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTMtNS0xLTEtMA_ea954632-d934-4dc2-8dc1-fe4130d6ace2">466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTMtNy0xLTEtMA_509b1b01-84ad-4938-88b2-dec9de52cff9">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTQtMS0xLTEtMA_45f38355-aa77-4206-acfe-b65ddbb38b65">52,886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTQtMy0xLTEtMA_4c68f508-11e1-4354-827b-7ef1067edf6f">36,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTQtNS0xLTEtMA_4350258d-d635-4373-93cd-4a397dc1847d">144,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTQtNy0xLTEtMA_594a9693-ab59-46ea-b493-048fce045d42">127,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTYtMS0xLTEtMA_5330f3e7-3b78-4b42-bab6-d3bc6794754d">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTYtMy0xLTEtMA_601c38a6-788d-4b6a-bb0a-0170ea150303">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTYtNS0xLTEtMA_51e4a4cc-0f4f-4ce7-bbbe-34711fb72f6f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTYtNy0xLTEtMA_cd980516-1807-445d-946d-ce56486fd18e">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTctMS0xLTEtMA_b798c11a-c59d-4c0a-b4b8-ccba17673d11">52,890</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTctMy0xLTEtMA_659a9e5b-aee3-4933-9e9a-b20ccdbf9e54">36,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTctNS0xLTEtMA_97558506-fb85-4879-b1f5-f77ac76acaec">144,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTctNy0xLTEtMA_61b0f249-f371-420e-80a9-bd8f6b5363f5">127,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTktMS0xLTEtMA_b70dd40a-90a9-4750-a89b-fa4665bdd11b"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTktMS0xLTEtMA_cce7a1fe-1295-49b1-9156-40fe76b8ea89">0.86</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTktMy0xLTEtMA_6b253566-cc86-4759-bead-96d2235e4c83"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTktMy0xLTEtMA_6dfe97eb-3272-4162-a69e-6b0847cd47c5">0.66</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTktNS0xLTEtMA_21270a9c-067e-43d5-8f59-ba7a3fdee5b2"><ix:nonFraction unitRef="usdPerShare" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTktNS0xLTEtMA_73b09653-c011-43dc-ab84-6ae1c37c9c34">2.42</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTktNy0xLTEtMA_6a8efc67-0977-4518-aa06-394eed2f53ed"><ix:nonFraction unitRef="usdPerShare" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTktNy0xLTEtMA_8f86d321-2a8b-4595-a943-60e0986eb82a">2.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMjAtMS0xLTEtMA_8a3b85d1-99d4-4f62-8987-2df9957271e3"><ix:nonFraction unitRef="shares" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMjAtMS0xLTEtMA_8fabe284-973d-4492-ae52-c10d45519112">61,169,754</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMjAtMy0xLTEtMA_1b07b37e-525c-4036-853e-e0768aaa7315"><ix:nonFraction unitRef="shares" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMjAtMy0xLTEtMA_f3ce892f-5baf-49c6-823b-286e9b0b7c78">54,463,412</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMjAtNS0xLTEtMA_10f23b12-b4f1-4fbe-9c3e-7e12ffdf1931"><ix:nonFraction unitRef="shares" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMjAtNS0xLTEtMA_25b20744-7194-4e31-b12d-b983379184ac">59,494,836</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMjAtNy0xLTEtMA_1ce313a8-2b70-4338-9921-8bd377da893c"><ix:nonFraction unitRef="shares" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMjAtNy0xLTEtMA_2382d24c-5c23-4445-bceb-8b82df2b1f99">51,176,884</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="idd97f2f67fc84defb53bffbcae4606c1_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.083%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.398%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib92c6189b72c447b8f1068b900a46c1f_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMi0xLTEtMS0w_e6786b4f-19aa-481f-8671-25d18bd92f00">56,244,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92c6189b72c447b8f1068b900a46c1f_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMi0zLTEtMS0w_91bb0fa9-afb7-4bc4-82b7-f7d0bd2978b8">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0089074df40749cda994bd08f7cebc31_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMi01LTEtMS0w_67cb466c-70f7-4e59-9571-19a21e6c5227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0089074df40749cda994bd08f7cebc31_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMi03LTEtMS0w_68a953b2-4b76-438e-b5f0-c1ee74c48fd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34562cb47376442eaa203ab6023eb363_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMi05LTEtMS0w_0946843f-5152-40bc-b306-51f7c9364064">1,067,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic813efc42fbc4dd58d2a1dd2d3f5c0cb_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMi0xMS0xLTEtMA_2e7f2cf3-2880-4ce7-a7d1-4080c2ee4944">771,821</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1395e2e157c84e9e97a685f193961623_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMi0xMy0xLTEtMA_7cacad62-6a69-4d1a-a147-548eb9405991">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMi0xNS0xLTEtMA_9972be50-4259-4863-8c9b-280c6544d57c">295,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54467d33fdf45529db11e8c19a075f6_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMy05LTEtMS0w_0d3338ba-a035-4cb0-8105-60353988aef1">5,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92e491e03d244d95acc39155f4bff6be_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMy0xNS0xLTEtMA_9fa073eb-d370-446e-aaac-1841d06b7680">5,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b5ad3e626c04694aaf53610a83fce1f_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNC0xLTEtMS0w_c97e39cb-f515-442a-ade7-c194ab41d2b2">3,622,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5ad3e626c04694aaf53610a83fce1f_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNC0zLTEtMS0w_9984216c-d8aa-422d-a440-6461520244bb">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54467d33fdf45529db11e8c19a075f6_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNC05LTEtMS0w_33867b88-68e2-4896-a87d-99470c1fafb0">98,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92e491e03d244d95acc39155f4bff6be_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNC0xNS0xLTEtMA_b1a6938e-7e0e-4040-96ab-b1a05c2fa96b">98,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b5ad3e626c04694aaf53610a83fce1f_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNS0xLTEtMS0w_f7b3a22c-c3aa-4ce2-b552-1f1d570b91d3">144,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5ad3e626c04694aaf53610a83fce1f_D20210101-20210331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNS0zLTEtMS0w_c5c5edcd-4b6f-41ff-b442-d4f1045dbae1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54467d33fdf45529db11e8c19a075f6_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNS05LTEtMS0w_b17cfc94-362b-4348-8452-f58219e37cf1">2,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92e491e03d244d95acc39155f4bff6be_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNS0xNS0xLTEtMA_ea239c11-5263-4d24-803e-7fe38be9ed1c">2,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c55b26f9e94031991eb2780805e604_D20210101-20210331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNi0xMy0xLTEtMA_d83b1646-c934-4672-9472-31fb351c6a3e">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92e491e03d244d95acc39155f4bff6be_D20210101-20210331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNi0xNS0xLTEtMA_1d69d65d-3b04-4bfc-a2bd-5fbd7b0ce0cd">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b75e289c90849cd817e71ea9a94d6c9_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNy0xMS0xLTEtMA_cb62e9f2-ee5e-4e1a-a021-333e6a9ed8f7">51,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92e491e03d244d95acc39155f4bff6be_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNy0xNS0xLTEtMA_5b4ca2ff-1022-4c04-8e0d-f26f047354ea">51,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic74e7b8118db41abafcc6bb0b8372824_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOC0xLTEtMS0w_890dd3be-4881-4c12-8e79-d6a2e82c2f36">60,011,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic74e7b8118db41abafcc6bb0b8372824_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOC0zLTEtMS0w_a774d3fb-74f5-4ceb-a957-3897adc0bf61">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0fcc348fc5e847e88eeadde0e0adcb08_I20210331" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOC01LTEtMS0w_2b40e2c0-f5ad-4c31-81d4-ca17a62bf00a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fcc348fc5e847e88eeadde0e0adcb08_I20210331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOC03LTEtMS0w_0d49ec52-f540-4b88-9433-58ab2ad02649">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i190ac348f6dc46a6ac38f0d568759b66_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOC05LTEtMS0w_f137d1f5-e138-42b7-865c-a890b622255e">1,173,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd365da76df34d2db894b5c3007130a3_I20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOC0xMS0xLTEtMA_dd73f6c0-5025-4755-abd7-8a3207d6dd00">823,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7c5ea5419494505aabe9e7465d4670b_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOC0xMy0xLTEtMA_ba7c5e67-e660-46dc-9c7a-5be14c71f873">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51fffa70c15f473db18a09340f835b36_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOC0xNS0xLTEtMA_7876dce3-fe22-4f83-96c8-4d0d9ee5dff3">350,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43acc02e0294959a3b21f958b70bc69_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOS05LTEtMS0w_b0b47563-ca4e-4299-8bf8-b0ab55b343dc">6,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i205d61628986439484c21a2ed5ad4721_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOS0xNS0xLTEtMA_56492991-0042-4ccd-b64f-0bd676aa4c0c">6,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i844325c47f4d4863abe97d247a5fd1ac_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTAtMS0xLTEtMA_6e0060ae-ef49-4ec5-8d3f-97e9e2cc6e2c">122,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844325c47f4d4863abe97d247a5fd1ac_D20210401-20210630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTAtMy0xLTEtMA_0340530b-f0a5-4a73-b3e9-5a0cab48b1eb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43acc02e0294959a3b21f958b70bc69_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTAtOS0xLTEtMA_df89558a-4b05-460e-9231-f89b48f7592c">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i205d61628986439484c21a2ed5ad4721_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTAtMTUtMS0xLTA_4b73c7f5-196b-44d0-8a4e-17e302a3129b">2,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie86acd1be8634256903051e3b678e662_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTEtMTMtMS0xLTA_0b403a50-6cfc-4608-b441-ef2220da98ba">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i205d61628986439484c21a2ed5ad4721_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTEtMTUtMS0xLTA_5a222556-2e24-4213-956d-cd37fc655f07">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3179fb8dbc27438ca7ed7fc6348f29f6_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTItMTEtMS0xLTA_acbcf1f4-bd66-4a2a-a975-a31c6636069b">39,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i205d61628986439484c21a2ed5ad4721_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTItMTUtMS0xLTA_165c8a63-5336-4cf6-a849-4676434f36ba">39,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i586b4fc28f444eae89cd1925d85aa640_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTMtMS0xLTEtMA_090fb3cf-fa4b-436e-a830-90466658ba96">60,133,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586b4fc28f444eae89cd1925d85aa640_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTMtMy0xLTEtMA_ba82662c-c6d6-4a5e-8550-23a58b4fa2b3">601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id78260ca3b734c09b0e4cfd6e30b6911_I20210630" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTMtNS0xLTEtMA_21ad2d53-a9fc-438d-8edf-bc1a94eba13a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78260ca3b734c09b0e4cfd6e30b6911_I20210630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTMtNy0xLTEtMA_252b18ed-a3f3-4786-aada-d76ee3716dea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i763636992b5f478e80241f5eeae0f30d_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTMtOS0xLTEtMA_af51ec25-e620-43a6-a35b-1bb3ea2a2a7a">1,181,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38708c79101b4e3fbc43d1d6b323a03a_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTMtMTEtMS0xLTA_76c9a0be-bc68-46b6-bd53-cf3c08329bfc">863,028</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35415a234ac242ad8ea5c77e9808c2e9_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTMtMTMtMS0xLTA_24920050-171e-4aaa-b1ac-fa67bda7933c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529e813dc38c4c33ae7cd08cb044ea48_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTMtMTUtMS0xLTA_03b04bc9-938e-4f45-a2e5-d7d1dfe7b5a3">319,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ccd33dc63c47e189ad4827959e843a_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTQtOS0xLTEtMA_9017519e-82de-49bc-8da4-508a1aa16b99">6,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTQtMTUtMS0xLTA_a5cc743a-fc84-43a8-a171-a3c649cb3113">6,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibdf5cd80b6b14743a7ea631042c021c3_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtMS0xLTEtMTU5NzU_9f21f3b0-daae-488d-b4e8-aad83fd6e51f">958,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf5cd80b6b14743a7ea631042c021c3_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtMy0xLTEtMTU5NzU_29be4a89-6b4a-49cb-a72a-aa28fde132f8">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ccd33dc63c47e189ad4827959e843a_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtOS0xLTEtMTU5NzU_15af3d7a-e1c4-415a-9260-4c1ea42df556">19,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtMTUtMS0xLTE2NzA2_a8896a55-25e4-469c-b3b0-9a7da0b8afaf">19,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibdf5cd80b6b14743a7ea631042c021c3_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtMS0xLTEtMA_065854c2-548b-47ac-8d3e-8c8966ec6c5f">162,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf5cd80b6b14743a7ea631042c021c3_D20210701-20210930" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtMy0xLTEtMA_b23892d1-e840-40b2-a9de-4fbd8c94693a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf40af9b54464df4b7d3b1125f9d9179_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtNS0xLTEtMA_bebfb9e4-d5fb-415f-907e-7992301d7c84">66,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf40af9b54464df4b7d3b1125f9d9179_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtNy0xLTEtMA_d8dd2175-0a6b-4b43-a396-31c519e71be6">1,457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ccd33dc63c47e189ad4827959e843a_D20210701-20210930" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtOS0xLTEtMA_b3325eda-41d2-49e4-8018-d184e0813336">789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtMTUtMS0xLTA_6abdbabe-a14b-4972-969f-210166f56082">666</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idf40af9b54464df4b7d3b1125f9d9179_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTYtNS0xLTEtMTQ4Mzc_db7fe390-21c3-4641-98e3-f5140ba900f4">66,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf40af9b54464df4b7d3b1125f9d9179_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTYtNy0xLTEtMTQ4NDM_8f0bb8e0-1e9f-4036-a652-c2a33d996616">1,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0ccd33dc63c47e189ad4827959e843a_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTYtOS0xLTEtMTQ4NDk_be9aef8a-8909-4782-9d9d-7950ca2114d7">1,457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c8f4c62b536483799b051a34289338d_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTYtMTMtMS0xLTA_cd500df5-a275-4302-9827-0cd2fd64b0f4">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTYtMTUtMS0xLTA_134b1b11-913e-4662-a11f-b74833046ea6">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d126b1a843b404783a3465235814e27_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTctMTEtMS0xLTA_fc53bcdc-5c10-44ac-9fcd-bf1db0d0c1e1">52,886</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c8f4c62b536483799b051a34289338d_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTctMTMtMS0xLTA_7192fa18-18f0-4083-a492-bcf67fade141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTctMTUtMS0xLTA_0457a1ac-29e6-4638-a0fb-06845ea1a665">52,886</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38a56f6d9c814dac9d125191db3566f1_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTgtMS0xLTEtMA_aa2d4e70-6ce6-4833-b3ba-35dd7280c10f">61,254,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a56f6d9c814dac9d125191db3566f1_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTgtMy0xLTEtMA_82df51ea-286c-4475-bcfb-c56e77a349df">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66955da827134291bef28c2ecf6e4055_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTgtNS0xLTEtMA_03ba5adf-2680-44ed-b8c0-009a363954c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66955da827134291bef28c2ecf6e4055_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTgtNy0xLTEtMA_f5d71598-4102-4d92-bf6d-205d0b96a9e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06875b187ec41dcb7b1a15821218d7e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTgtOS0xLTEtMA_51c0c450-4f47-4788-ba51-2267b706e7a2">1,206,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65cfd5b11203487cb6091fe2f919527c_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTgtMTEtMS0xLTA_e7afb03b-3f67-40ba-b0cf-7531e24e33ca">915,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f4ad9aa86ed438781238f7412b23e01_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTgtMTMtMS0xLTA_5ca22035-593d-4340-bbbd-d24be5787239">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTgtMTUtMS0xLTA_5d2f96fe-8236-4ea6-912d-afd1b6eb9057">291,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.253%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69bcf518b6f64b4eb86f5f40a6061a93_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMi0xLTEtMS0w_a15ffbf6-3cf8-4fc4-812f-887350a1f076">48,958,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69bcf518b6f64b4eb86f5f40a6061a93_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMi0zLTEtMS0w_192f8adb-c090-4cf7-872a-80a69e8ae2ec">490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43d0b4f45e374b469456ad8fc84bf839_I20191231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMi01LTEtMS0w_1b98f35b-dd2f-4a99-a529-221a224f7baa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d0b4f45e374b469456ad8fc84bf839_I20191231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMi03LTEtMS0w_a86aafd0-9464-44f8-9904-baabc02b85ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b7835f8392d46518da425a3f19dd697_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMi05LTEtMS0w_dc539bfd-3445-47b7-9cad-2be4587189e5">872,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6f9507cd9244da6a3c17dd33edf8e68_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMi0xMS0xLTEtMA_0186e585-56f2-4409-b445-6bbf2b954e41">642,082</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7099a1f0709642f8b56969b8d261b209_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMi0xMy0xLTEtMA_897871b8-dcfb-468c-a619-a691eeced08b">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefa62144550e44079146bf982176865e_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMi0xNS0xLTEtMA_052aa2ad-4777-4dd9-85b3-82c5d52316fd">230,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9712c2e2c25f4f469e19daccd541cabc_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMy05LTEtMS0w_0a621d71-2dda-4fad-a890-e3d5f31146dc">4,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb90850307344bdb2b62e4c657ff389_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMy0xNS0xLTEtMA_a76ad6cc-3df2-4fdb-909d-5b7063bd20fe">4,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf4d14e52ac44346ae2be66f1872b003_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNC0xLTEtMS0w_1a3eb77b-6b8a-44fb-b15b-e19cdf805f68">172,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf4d14e52ac44346ae2be66f1872b003_D20200101-20200331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNC0zLTEtMS0w_442d0e8e-1a5c-43e4-8cc6-10413751af82">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9712c2e2c25f4f469e19daccd541cabc_D20200101-20200331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNC05LTEtMS0w_5dce817a-817b-4ff2-805e-3cca0c162359">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb90850307344bdb2b62e4c657ff389_D20200101-20200331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNC0xNS0xLTEtMA_43869383-eef7-4525-98b0-3b41d3adf260">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b854e6798d4d0bbd747c741fec06ad_D20200101-20200331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNS0xMy0xLTEtMA_8ac23c2d-2fa0-4ad2-83db-8732a78899f7">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb90850307344bdb2b62e4c657ff389_D20200101-20200331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNS0xNS0xLTEtMA_364aa964-ee8e-4fcb-aa11-a1c4b2d2698c">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd4383e6ffc54437af3047cc7d551c59_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNi0xMS0xLTEtMA_73ad7f30-9995-49a3-bd09-254dae0d0f30">44,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fb90850307344bdb2b62e4c657ff389_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNi0xNS0xLTEtMA_389d6e25-e9e2-44cb-89ae-c2460a3ccce6">44,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8465dd5b84f4677b7ef351c4e4a0629_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNy0xLTEtMS0w_1ab27c52-fa84-4209-ba59-83bb2a1f535e">49,131,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8465dd5b84f4677b7ef351c4e4a0629_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNy0zLTEtMS0w_ac09f133-ce4f-4cc4-9004-45408da88c40">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72077576d2d24e2fb5a5f8426cae9925_I20200331" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNy01LTEtMS0xNjczMQ_88abb7a7-a06c-4ec0-8a37-84e3e08504df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72077576d2d24e2fb5a5f8426cae9925_I20200331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNy03LTEtMS0xNjczMQ_015ed250-6e9f-4e33-9974-330376408189">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bdee85e14740838ddaa61690920077_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNy05LTEtMS0w_e400de54-ff7d-4bf9-a19d-12628f7886d7">876,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43929274060145538939cfbe9ebb7d7f_I20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNy0xMS0xLTEtMA_cb3077c0-502a-4cf5-8c2c-165a86e07635">686,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66fa665eac24481292baf200368ca1ba_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNy0xMy0xLTEtMA_6c2689d0-4509-442e-9f73-5a9ba8dbf773">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33d616f3a92c43cbae84e15bf03190f8_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNy0xNS0xLTEtMA_63c294e8-116d-460e-ad1c-b0219deb5092">190,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf50d256b04c4e70a85bd5224d72ca21_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfOC05LTEtMS0w_06a485e4-3473-4e16-ac66-4fd818e6510d">5,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906aa4f6d4c44c3ba0e305e35a7203c3_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfOC0xNS0xLTEtMA_ba12c892-2b79-45a1-9227-3d37a4db8b32">5,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1164dbdf167740b2a496f6c88f38aac9_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfOS0xLTEtMS0w_6369764f-05bb-4a82-adce-ada7a9bd2c00">4,060,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164dbdf167740b2a496f6c88f38aac9_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfOS0zLTEtMS0w_d9a84ed2-7ad5-45bc-8a75-03b089c29b6f">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf50d256b04c4e70a85bd5224d72ca21_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfOS05LTEtMS0w_9f9f0b9d-2eae-4730-a320-111588d7ea72">96,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906aa4f6d4c44c3ba0e305e35a7203c3_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfOS0xNS0xLTEtMA_7e8b5103-a2ce-426b-ab0f-6015f186ec88">96,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1164dbdf167740b2a496f6c88f38aac9_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTAtMS0xLTEtMA_b8f36021-ae98-40dc-8a67-99d0b4391aab">173,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164dbdf167740b2a496f6c88f38aac9_D20200401-20200630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTAtMy0xLTEtMA_fb41874c-ed4d-473f-8b89-81e1467ed640">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf50d256b04c4e70a85bd5224d72ca21_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTAtOS0xLTEtMA_ff044165-dcb7-40f2-90b0-b79b731c789a">2,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906aa4f6d4c44c3ba0e305e35a7203c3_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTAtMTUtMS0xLTA_2d1179c9-eba7-4503-9396-618f5bb53c01">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2935a1f381274d3ebe662dedbebbad3e_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTEtMTMtMS0xLTA_50742170-5af8-4941-b404-ed624b2df204">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i906aa4f6d4c44c3ba0e305e35a7203c3_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTEtMTUtMS0xLTA_95f1d228-376e-45f8-8752-a3ea0464cfc6">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2dbb00d209747a99fb78cfa9687763f_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTItMTEtMS0xLTA_21d9fcd5-2e67-406f-9705-534abf96c9a2">46,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i906aa4f6d4c44c3ba0e305e35a7203c3_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTItMTUtMS0xLTA_097e4516-fe05-4d29-8868-9fccdcaae5d1">46,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad092482cde8453e9195f68fb28e18f2_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTMtMS0xLTEtMA_2a6e5d56-05db-4544-9c25-0b7da01a1c96">53,365,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad092482cde8453e9195f68fb28e18f2_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTMtMy0xLTEtMA_0f75e959-ce9f-4c19-afd0-866a04b79895">534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7dac9970dbca4aaba71fb397a9144b68_I20200630" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTMtNS0xLTEtMA_0be01de7-e7f6-4e09-b56b-6f7499d2b906">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dac9970dbca4aaba71fb397a9144b68_I20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTMtNy0xLTEtMA_b524d0a6-8bf9-4501-94b7-a2a692569002">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a8e94f9c23740d392d77be412cf1da4_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTMtOS0xLTEtMA_d502bdc4-a09f-4481-a5ed-13cc709e8be6">980,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab4b7193bca147449377324fe98c3afe_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTMtMTEtMS0xLTA_62fb5f54-5c3e-4a6b-b98f-d5b8339d6419">733,691</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7da6fadb64042b4b028fc24eeb8c6ed_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTMtMTMtMS0xLTA_5c2b9ec9-453c-442a-a5cb-3c5c71f7888a">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffca67721b4c43308a8bf5b3985400f5_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTMtMTUtMS0xLTA_b4281aa5-122e-46a0-945f-2bbd00d480be">247,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb94e98144414013a4b367b085227a01_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTQtOS0xLTEtMTU5ODQ_c517def8-381a-48ea-995c-0bad174aba82">5,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTQtMTUtMS0xLTE1OTg0_c4cb17d7-e42d-402c-8e70-9c3b6f4af91b">5,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i304344aae2b14aa6b471cf77a9f4df60_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTQtMS0xLTEtMTQwODk_0406d1d9-347a-4435-bfed-3cc9ed699a79">2,552,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i304344aae2b14aa6b471cf77a9f4df60_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTQtMy0xLTEtMTQwOTY_a79cd1e7-0416-488a-bb2c-c21a611f855d">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb94e98144414013a4b367b085227a01_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTQtOS0xLTEtMTQxMDI_43b7ddaa-abb8-4d26-998f-cafd14df4401">73,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTQtMTUtMS0xLTE0MTA4_37bb8b57-6006-4f13-862e-33c77cd64581">73,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i304344aae2b14aa6b471cf77a9f4df60_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTUtMS0xLTEtMA_d76a1d05-ca30-4c2b-b202-ba13507f6a32">257,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i304344aae2b14aa6b471cf77a9f4df60_D20200701-20200930" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTUtMy0xLTEtMA_bc975e20-3d66-4698-b180-a22e74ac2b82">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d5fe7dc9ce749d7b4b4343243fc3448_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTUtNS0xLTEtMA_d98b8edc-d622-4796-849e-f20c3af6b0a1">74,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d5fe7dc9ce749d7b4b4343243fc3448_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTUtNy0xLTEtMA_3201f834-7494-47d3-a762-27a373bc22ef">2,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb94e98144414013a4b367b085227a01_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTUtOS0xLTEtMA_8c678040-3368-46f1-8442-44c114620d33">2,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTUtMTUtMS0xLTA_32ce4b0c-19fe-40f4-9f76-6da78793f3b8">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3d5fe7dc9ce749d7b4b4343243fc3448_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTctNS0xLTEtMTQ2Mjc_7c3bb7c4-29de-409e-83a3-221141b80c09">74,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d5fe7dc9ce749d7b4b4343243fc3448_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTctNy0xLTEtMTQ2Mzg_ad895e1d-71c9-47f8-a988-bb239a290a15">2,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb94e98144414013a4b367b085227a01_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTctOS0xLTEtMTY3MDg_19e0562a-5a91-48f1-bbfe-5de1ad0cd368">2,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1471592823d141ed9982b46286c25e2a_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTYtMTMtMS0xLTA_f1ffc63e-aa6f-4ac2-b67a-882fe39bbd4c">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTYtMTUtMS0xLTA_235b7fec-115d-4f90-815a-7af972dd4171">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6c9cdd4f1d3447cb695fe45e3422587_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTctMTEtMS0xLTA_d1b07507-1df9-4f8d-a1fc-7c44d7752ff9">36,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTctMTUtMS0xLTA_e7d0bffc-5db5-47b5-9065-8305056e7374">36,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia65ece20c394482b8251eff40d234644_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTgtMS0xLTEtMA_91864c4a-9038-4323-888c-b77e4968e04f">56,174,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia65ece20c394482b8251eff40d234644_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTgtMy0xLTEtMA_e80636d7-1cc7-405b-b56b-a8f721fc770a">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d00c49127754d849e79ffd0f091a235_I20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTgtNS0xLTEtMA_32446886-4a7f-423b-a572-fe90e2c76551">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d00c49127754d849e79ffd0f091a235_I20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTgtNy0xLTEtMA_4be95d3c-82f0-437f-9eb0-53c9c9795f24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aef0259fe304602914853bd229b6a2f_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTgtOS0xLTEtMA_6779dc3b-fe6d-45c9-8cf4-6cddc6ed7518">1,060,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac5626cc0d4d4f3eada7c592f37e6549_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTgtMTEtMS0xLTA_67010ab5-188b-468f-9622-7518e730409d">769,734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3d2893df5534deda5831f679ba7dd0d_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTgtMTMtMS0xLTA_2bc98471-2cdc-4916-bcb1-32a8cb2405b0">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id48171a2cf134b9b877b17e3ab1d96bf_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTgtMTUtMS0xLTA_64ed0ac1-93e4-4c2b-9132-2378bc04f29b">291,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="idd97f2f67fc84defb53bffbcae4606c1_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:68.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMy0xLTEtMS0w_ec332339-9cb6-4bef-9f4d-bbce81313585">144,093</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMy0zLTEtMS0w_91cd1aa2-ec2b-405c-81d1-46e9cb961041">127,652</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfNS0xLTEtMS0w_b9073d0b-8aca-4c15-ad42-acd018d63d5b">8,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfNS0zLTEtMS0w_cf9ee1f2-7b4c-4d52-b318-82a85ba0dae1">9,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums and discounts on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfNi0xLTEtMS0w_0dcdeded-b4e9-4698-923b-f978c6bb677e">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfNi0zLTEtMS0w_8ca601e5-5365-4f04-9f28-edd60c41e734">387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfNy0xLTEtMS0w_b537632a-3511-4b7e-b151-2e26f807fd2c">17,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfNy0zLTEtMS0w_290a4f40-f177-43e1-ad3a-79a24ea54fb1">15,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfOC0xLTEtMS0xNzQ5Nw_c173cfc2-1dcf-405b-b73e-7f352c67cecb">1,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfOC0zLTEtMS0xNzUwNg_f18649b2-2e71-4b39-a287-09534f60c328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfOS0xLTEtMS0w_bfec0561-4e65-4927-ad58-a54d0cdbfa02">9,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfOS0zLTEtMS0w_f91889b1-ff9a-46ed-956c-611451c977a5">6,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTAtMS0xLTEtMA_8734e34b-9e28-4344-a050-45458715344c">5,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTAtMy0xLTEtMA_22bdff76-cbd8-41cb-9a56-759b035161f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTEtMS0xLTEtMA_4c824d78-f625-47de-a7e0-65855c61dfee">1,080</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTEtMy0xLTEtMA_2172a386-731c-4825-bdac-469ff2db4ca7">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTItMS0xLTEtMA_6d3f1502-b559-4c37-9278-8fe571dcaf7e">5,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTItMy0xLTEtMA_fde6325f-0d94-4215-a902-78a879b8b4c3">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTMtMS0xLTEtMA_e19633a2-83bd-40ff-9312-405327c69db7">1,931</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTMtMy0xLTEtMA_a6211f7e-c5bf-4c7a-bdb9-66494e9d5cad">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTQtMS0xLTEtMA_4697804f-2b8c-468b-8e9f-f64ba74bbaf5">7,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTQtMy0xLTEtMA_4797d741-b624-4cec-bc8e-ceb3af137057">5,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTUtMS0xLTEtMA_5841e2c0-9773-42bc-a181-3a210ce74812">2,701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTUtMy0xLTEtMA_3681bafa-6a11-4508-9e5d-581b496c5fca">2,113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTYtMS0xLTEtMA_95469175-46f0-4f93-a973-c5102e6601bb">14,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTYtMy0xLTEtMA_27b7bddb-75e2-4bf2-9711-0edeb2ef3a12">4,816</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTctMS0xLTEtMA_02df6559-cf3e-4fb1-b19f-171a01f15524">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTctMy0xLTEtMA_bceb39eb-4aae-417b-8063-a91f53e00ea7">2,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTgtMS0xLTEtMA_227add9c-b29c-4607-aab0-522d8991dfad">89,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTgtMy0xLTEtMA_cba78efa-3719-4946-a883-6d7b7732f9c9">106,365</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjAtMS0xLTEtMA_d4c4e350-2ba3-4438-a355-0eca93d02701">164,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjAtMy0xLTEtMA_4319ed53-5f9a-4488-a263-b1f9aa81b0ea">151,230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale and maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjEtMS0xLTEtMA_5e1507e5-859c-42fe-bdf8-8a810a548b28">146,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjEtMy0xLTEtMA_5af8ff38-2391-46a4-a58c-d454afd412a3">161,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjItMS0xLTEtMA_1fab2a92-1379-48b5-81d6-d2f2d7bc5f7a">4,826</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjItMy0xLTEtMA_8f6cf3e8-2fe1-4083-9162-504aac35e095">2,346</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjMtMS0xLTEtMA_b11fa958-a7c5-4d4a-ad03-c1a059308a4b">23,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjMtMy0xLTEtMA_7e3816eb-df64-4168-873f-e78fc5b99990">8,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjUtMS0xLTEtMA_27694f57-19ae-49c3-8110-741f620affcf">117,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjUtMy0xLTEtMA_35f2e477-726a-4c9e-bee1-2730ec8fdd42">170,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises and ESPP purchases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjYtMS0xLTEtMA_6afc4dc5-d32e-4030-84c0-ae2a58dc7d2a">5,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjYtMy0xLTEtMA_d01fb93b-f6e5-4d69-b3cd-2afe33b5d7f6">4,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjctMS0xLTEtMA_b8a26b3e-74f9-4e50-be86-16047ba42034">1,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjctMy0xLTEtMA_41403c0c-12be-4d79-9873-dff787cd41c1">2,011</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjgtMS0xLTEtMA_ecca0519-8c8b-413f-a44a-24bcd975ccc6">121,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjgtMy0xLTEtMA_f5d0553f-77d2-433c-8519-9d6434c66aac">173,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjktMS0xLTEtMA_5e261881-e33b-4ad7-beae-eb5fed78892a">9,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjktMy0xLTEtMA_32115326-4c2f-4cbc-8be9-63805d09343c">75,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMzAtMS0xLTEtMA_7b2aede9-36b5-4dc6-b8ae-00f14dd352b8">181,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefa62144550e44079146bf982176865e_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMzAtMy0xLTEtMA_8ecad74d-a1c5-44af-bf3c-70ed56cf0342">126,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMzEtMS0xLTEtMA_53a552f1-fedb-4225-a2b5-754e0192e14c">190,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id48171a2cf134b9b877b17e3ab1d96bf_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMzEtMy0xLTEtMA_1fce7179-d9db-449e-9851-ba07df48504e">201,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software included in accounts payable or accruals</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMzQtMS0xLTEtMA_e10c26fe-3514-432d-8cc3-da1718d5aa33">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMzQtMy0xLTEtMA_6bea7e9a-d012-47b7-994e-27914a8d849a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="idd97f2f67fc84defb53bffbcae4606c1_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_34"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8zNC9mcmFnOjY2ZDU5ZDlkYmQ1YjRmMzg4ZjZkNWQzMTBmZWE0YzBkL3RleHRyZWdpb246NjZkNTlkOWRiZDViNGYzODhmNmQ1ZDMxMGZlYTRjMGRfNTEzMQ_6c7ff079-255e-4c4c-beb8-0dcd35190914" continuedAt="i74beb1ef63e341c280af099cdcd4b76e" escape="true">Nature of Operations</ix:nonNumeric></span></div><ix:continuation id="i74beb1ef63e341c280af099cdcd4b76e"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the business</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. In December 2020, the U.S. Food and Drug Administration (FDA) approved MARGENZA (margetuximab-cmkb) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.  The Company launched MARGENZA in collaboration with its commercialization partner, Eversana Life Science Services, LLC (Eversana), in March 2021. In addition, the Company has a pipeline of product candidates in human clinical testing that have been created primarily using its proprietary, antibody-based technology platforms. The Company believes its product candidates have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital, and anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities. Based on the Company&#8217;s most recent cash flow forecast, the Company believes its current cash, cash equivalents and marketable securities is sufficient to fund its operating plans for a minimum of twelve months from the date that this Quarterly Report was filed. The Company plans to meet its near-term operating requirements primarily through cash and marketable securities on hand, and a combination of product sales and current and future strategic collaborations and alliances and marketing, distribution or licensing arrangements.  In the longer term, the Company plans to meet its operating requirements by generating revenue from product sales to the extent its other product candidates receive marketing approval and can be commercialized, or by potential future equity or debt issuances. There can be no assurances that new sources of capital will be available to the Company on commercially acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require the Company to give up some or all rights to a product or technology at less than its full potential value. If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, and/or downsize its organization.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to the COVID-19 pandemic, the Company will continue to evaluate the nature and extent of the impact of the pandemic on its business and financial position.</span></div><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8zNC9mcmFnOjY2ZDU5ZDlkYmQ1YjRmMzg4ZjZkNWQzMTBmZWE0YzBkL3RleHRyZWdpb246NjZkNTlkOWRiZDViNGYzODhmNmQ1ZDMxMGZlYTRjMGRfNTEyNw_e3756ac0-9d50-4e46-9216-9b2242917842" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2020 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2021.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_37"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 2. <ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8zNy9mcmFnOmRhOWNjZDk4ZWFlZDRiNWI5MjA1MTM2OWI4MjJjY2UyL3RleHRyZWdpb246ZGE5Y2NkOThlYWVkNGI1YjkyMDUxMzY5YjgyMmNjZTJfODc2MQ_b4766ac5-c913-46bf-93ba-b67788683167" continuedAt="i688d5088de7140a58abb398347e8609e" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i688d5088de7140a58abb398347e8609e" continuedAt="i176eb42c59a645c68405bb4bfb88008f"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, the Company adopted the following significant accounting policies in addition to those previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020. </span></div><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8zNy9mcmFnOmRhOWNjZDk4ZWFlZDRiNWI5MjA1MTM2OWI4MjJjY2UyL3RleHRyZWdpb246ZGE5Y2NkOThlYWVkNGI1YjkyMDUxMzY5YjgyMmNjZTJfODc2Mg_bd82088c-7448-4afc-9bf7-ef5364f3435c" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the FDA in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of sales in the statement of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8zNy9mcmFnOmRhOWNjZDk4ZWFlZDRiNWI5MjA1MTM2OWI4MjJjY2UyL3RleHRyZWdpb246ZGE5Y2NkOThlYWVkNGI1YjkyMDUxMzY5YjgyMmNjZTJfODc2Mw_b310b033-e304-4a4b-b7e8-58a30e034cfd" continuedAt="i719eea799a7645329ca39608f548857a" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue, Net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606). The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the three and nine months ended September 30, 2021, the shipping costs incurred were immaterial. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the nine months ended September 30, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i176eb42c59a645c68405bb4bfb88008f"><ix:continuation id="i719eea799a7645329ca39608f548857a"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div></ix:continuation><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8zNy9mcmFnOmRhOWNjZDk4ZWFlZDRiNWI5MjA1MTM2OWI4MjJjY2UyL3RleHRyZWdpb246ZGE5Y2NkOThlYWVkNGI1YjkyMDUxMzY5YjgyMmNjZTJfODc2NA_b7b17f8d-7a9f-4a51-8306-8d32ea48f11f" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of product sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8zNy9mcmFnOmRhOWNjZDk4ZWFlZDRiNWI5MjA1MTM2OWI4MjJjY2UyL3RleHRyZWdpb246ZGE5Y2NkOThlYWVkNGI1YjkyMDUxMzY5YjgyMmNjZTJfODc2NQ_caaa3799-4cad-46e9-9459-3978a8016c74" continuedAt="i53305511b8084dddada444e04cf9a4dc" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 is part of the FASB&#8217;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The adoption of this standard as of January 1, 2021 had no impact on the Company's consolidated financial statements and related disclosures.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i53305511b8084dddada444e04cf9a4dc">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these ASUs will not have a material impact on the Company's consolidated financial statements</ix:continuation>.</span></div></ix:continuation><div id="idd97f2f67fc84defb53bffbcae4606c1_40"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RleHRyZWdpb246N2Y0OGQyMzJmZTBjNDJkN2IyMWYxMTA3ZjZmNjg3NDdfMzE2Mw_630eb02c-b06d-4aec-876a-78722cc9c329" continuedAt="i36d7be8e80574718bc72168a022adae7" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-indent:36pt"><ix:continuation id="i36d7be8e80574718bc72168a022adae7" continuedAt="i218b736467624f3b9cabd986f10df2ec"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RleHRyZWdpb246N2Y0OGQyMzJmZTBjNDJkN2IyMWYxMTA3ZjZmNjg3NDdfMzE2NQ_f6295774-a8da-40da-9a4a-fda91b5dbdaf" continuedAt="i0adf98402f70401ba3b6fd8e7abcf0ac" escape="true"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value </span></ix:nonNumeric></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i218b736467624f3b9cabd986f10df2ec"><ix:continuation id="i0adf98402f70401ba3b6fd8e7abcf0ac" continuedAt="i81a735ef4391496280ecf1ed4b6a9e2d"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div></ix:continuation><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i81a735ef4391496280ecf1ed4b6a9e2d">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</ix:continuation> </span></div><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RleHRyZWdpb246N2Y0OGQyMzJmZTBjNDJkN2IyMWYxMTA3ZjZmNjg3NDdfMzE2Ng_68f3070b-9fd3-4b9c-ab42-a57ba536eae0" escape="true"><div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:15pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a74388d699f4bd2ac58facdd9a4fd7b_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNC0xLTEtMS0w_ae5ec16e-a05d-4c04-aace-12cb740052cd">15,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia640a3c02d1f4c75a6f0cc21b9c2cb6d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNC0zLTEtMS0w_8d314587-28a9-444c-9622-4d3dbca674ec">15,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17cb614f00584923a41b3f540fa1cdbc_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNC01LTEtMS0w_b4776ab6-7e89-4fb4-ac82-bfe24313ee31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf613c73d3e4483a06ea6e38d8e670b_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNS0xLTEtMS0w_61b05f52-a3ab-48d7-85ae-9ce42e05665e">68,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e6b518462554e3cbdf3a5cadf5c10ea_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNS0zLTEtMS0w_24866f4b-286f-485f-9b15-7cdae0a5f123">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b8bfb356e214cc9bfe9904bbc293017_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNS01LTEtMS0w_6c1323b8-e0a3-458f-926c-b3562c53ebf9">68,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73eb53766d6c4804a4e1e66a6df09c91_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNi0xLTEtMS0w_9015ef4b-c5a7-4638-a31d-7094c3a49b55">12,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49de27c2929345d3a226185a435ab868_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNi0zLTEtMS0w_9cbcf752-a0a7-4327-98ce-34983fbc25ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f048a39b44649b29657ceea4301f358_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNi01LTEtMS0w_7db74217-ce69-48de-946d-ea801dfd81e0">12,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a7ed9e27b984af2aae1adfbb2125ce5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNy0xLTEtMS0w_78c0f04d-7073-4015-9ce8-f9ad2519edf9">47,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f0c1670d044e009dba1531620dc1c1_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNy0zLTEtMS0w_f339d576-5b07-42db-84ea-210a4336f2f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb0787f0e3644860ba06eb1034fbb65b_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNy01LTEtMS0w_e49d75fe-0148-453c-9b8a-cb29f3eef271">47,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1ffbd08270d44d085deecec92b01243_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfOS0xLTEtMS0w_552e457d-10da-4ee1-bf2a-2cacee04e695">143,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d6f6806ba94e9ea50c537546db47a7_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfOS0zLTEtMS0w_84a46618-2cbf-4710-b369-81399500aa20">15,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee759986b4274d298c370fdb8432435b_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfOS01LTEtMS0w_d8dcb80a-eb6f-409b-be09-e2237032739c">127,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148258350c6645d79c0d898ac35f6d87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNC0xLTEtMS0w_c45a017a-f0a6-41de-8c95-4e2796d6dfb1">49,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i747a2e68687f4fe8b192d169ccefd610_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNC0zLTEtMS0w_d7786d43-b4e9-485e-99bc-8b09f081776a">49,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0bbc8e396f4f45a85696892ed3b146_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNC01LTEtMS0w_9c346550-0984-43e0-abcd-103b1b3b7050">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib121748b3b90427eb1b071912d8f8abb_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNS0xLTEtMS0w_3e1f990f-b92c-42ff-8282-5e3a00db43dd">60,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ea12fcac00647eda4be75a5c687a73b_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNS0zLTEtMS0w_6d799146-32b3-4c99-ace3-9d5ca36b8ef9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i288f5153e6b2498db8daba718939f0f2_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNS01LTEtMS0w_ad0f1f73-277e-4e64-8801-5f78369851ba">60,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7451a81074d647e295bf3e8ebedffdb7_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNy0xLTEtMS0w_a167402b-c89c-486d-a3d1-c156e4eaf0d6">33,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76162ba1a18c4fc4a980bcbba9264153_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNy0zLTEtMS0w_cbc1de87-4873-4d23-80b8-a433b930f4eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e6f330c4624be993d0a2175e6edb7c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNy01LTEtMS0w_a5d009e7-8f70-4338-997f-3b9c28a07838">33,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3585fd01cc1840feb99f41bf29e5c7e2_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfOS0xLTEtMS0w_9cb2a1ff-3999-4a8c-9774-23a6c7f289ed">143,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4da6d04d2658412081cbb06f08d92d03_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfOS0zLTEtMS0w_be6ac094-59dd-4996-b4ac-8b3438c4189c">49,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6438be1c7813480081d80920f7c7256d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfOS01LTEtMS0w_cbf12785-9ca2-4e79-b1ad-fe013f921775">94,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at September&#160;30, 2021 includes approximately $<ix:nonFraction unitRef="usd" contextRef="ie1ffbd08270d44d085deecec92b01243_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RleHRyZWdpb246N2Y0OGQyMzJmZTBjNDJkN2IyMWYxMTA3ZjZmNjg3NDdfMjUwNA_35799333-f877-4f38-8fa4-406260c21669">34.8</ix:nonFraction> million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2020 includes approximately $<ix:nonFraction unitRef="usd" contextRef="i3585fd01cc1840feb99f41bf29e5c7e2_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RleHRyZWdpb246N2Y0OGQyMzJmZTBjNDJkN2IyMWYxMTA3ZjZmNjg3NDdfMjY0OQ_b8eabb1a-97fd-4820-8e88-536c1caf53ae">52.0</ix:nonFraction> million reported in cash and cash equivalents on the consolidated balance sheet.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods presented, and the Company has no Level 3 securities in its portfolio.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="idd97f2f67fc84defb53bffbcae4606c1_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RleHRyZWdpb246MDY5MGRmYzJmNjE0NDJlZmIyM2Q4NmVlYWU3NjlkM2ZfMTAyNw_2b075568-30bd-441c-9ba9-98652d7371f2" continuedAt="ibc183475c7e041a091383c5bb9a2e1e0" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="ibc183475c7e041a091383c5bb9a2e1e0" continuedAt="ib1b43f77282241c3b5fbcea908829cbe"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RleHRyZWdpb246MDY5MGRmYzJmNjE0NDJlZmIyM2Q4NmVlYWU3NjlkM2ZfMTAyOQ_0ee85b01-bfd5-4355-9aac-7d44c920751a" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.724%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80cbb34246294317b7336589ccf4350d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfMi0xLTEtMS0w_8b119cf4-ab10-4291-b2ab-8f96f19a5284">68,019</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80cbb34246294317b7336589ccf4350d_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfMi0zLTEtMS0w_f01c654a-5abd-4594-9a74-92e60036c4d2">2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80cbb34246294317b7336589ccf4350d_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfMi01LTEtMS0w_bf86baea-717b-4cd1-8420-f42830cc1e2c">4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80cbb34246294317b7336589ccf4350d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfMi03LTEtMS0w_9526c24b-184c-4b5f-933d-abd2c0f17970">68,017</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebfbafa88c384397839bf6d6ddd589b5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfMy0xLTEtMS0w_be41c70c-a9ca-4e8a-a4a8-d57bbc8e30bf">12,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebfbafa88c384397839bf6d6ddd589b5_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfMy0zLTEtMS0w_46286b83-e482-416c-8bae-e9af1013ec12">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebfbafa88c384397839bf6d6ddd589b5_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfMy01LTEtMS0w_e12e3e2c-4cee-4c7c-b104-32ceb8d95431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebfbafa88c384397839bf6d6ddd589b5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfMy03LTEtMS0w_9eacf5f8-ba58-45e6-a8ea-e3aaa9c784a3">12,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i845134cd6052477bb77c2afc3b82e0ee_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfNC0xLTEtMS0w_24d5859b-777b-4b13-8735-c88bd54d72a3">28,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i845134cd6052477bb77c2afc3b82e0ee_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfNC0zLTEtMS0w_131afb5e-abb5-49d9-a936-e7755bd94216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i845134cd6052477bb77c2afc3b82e0ee_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfNC01LTEtMS0w_eed1c999-3841-4960-a168-0e60624e1e73">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i845134cd6052477bb77c2afc3b82e0ee_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfNC03LTEtMS0w_e061b37b-e436-4cbb-9809-8eb6d596e8f5">28,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfNS0xLTEtMS0w_03a9ba54-fc2f-41da-8757-b96f0b9263f0">108,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfNS0zLTEtMS0w_9e517b50-23a4-4ae2-a84d-d3e45b63f9ec">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfNS01LTEtMS0w_26728454-5775-4a63-8bf9-614ce873882b">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfNS03LTEtMS0w_22f05aa4-bf52-4bd5-acfa-f90c1fa0745e">108,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia973c2256c1241e39d7549dbe6a90f11_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfMi0xLTEtMS0w_c3b1d221-2116-463b-a31e-6cbbf8723e56">60,630</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia973c2256c1241e39d7549dbe6a90f11_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfMi0zLTEtMS0w_ed21ea33-2b2e-4f63-82a3-e830a7b593ad">1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia973c2256c1241e39d7549dbe6a90f11_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfMi01LTEtMS0w_36e63f9b-daa1-46e8-8bbd-8abac83906e0">7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia973c2256c1241e39d7549dbe6a90f11_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfMi03LTEtMS0w_773243c7-fe19-48e1-b7fb-b34adfcd9599">60,624</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie69edf146b6449f7a4fb9cf05187e1ff_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfNC0xLTEtMS0w_c480cb8e-5e24-4ba0-8b76-77020cdb6ec7">30,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie69edf146b6449f7a4fb9cf05187e1ff_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfNC0zLTEtMS0w_daeefbcb-47bd-45b4-8f3b-740ad7bcec93">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie69edf146b6449f7a4fb9cf05187e1ff_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfNC01LTEtMS0w_51047ea8-4aca-4e4f-806b-3db81dd40a51">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie69edf146b6449f7a4fb9cf05187e1ff_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfNC03LTEtMS0w_4bdadf5b-64fa-4e67-b424-d88bf5117cf9">30,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfNS0xLTEtMS0w_d283dfc1-fe56-4589-9ec7-232e9f79fd38">91,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfNS0zLTEtMS0w_c9483aa5-5826-433b-acc6-a30bbef30e48">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfNS01LTEtMS0w_63000d68-fc9d-4e6b-94b9-606c3f0b32fa">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfNS03LTEtMS0w_d94f4e7e-4cce-47fc-b2ef-7252db13ff5f">91,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ib1b43f77282241c3b5fbcea908829cbe">All available-for-sale marketable debt securities held as of September&#160;30, 2021 and December&#160;31, 2020 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of September&#160;30, 2021 and December&#160;31, 2020 were in a loss position for less than 12 months.&#160; Unrealized losses on available-for-sale debt securities as of September&#160;30, 2021 and December&#160;31, 2020 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, <ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RleHRyZWdpb246MDY5MGRmYzJmNjE0NDJlZmIyM2Q4NmVlYWU3NjlkM2ZfNjc2_31d1a0f1-3bcf-4ee0-a5f3-5ec8871ac8b9"><ix:nonFraction unitRef="usd" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RleHRyZWdpb246MDY5MGRmYzJmNjE0NDJlZmIyM2Q4NmVlYWU3NjlkM2ZfNjc2_c44c2bed-ed30-4cc9-ba63-bc4a878be7a6">no</ix:nonFraction></ix:nonFraction> allowance for credit losses related to the Company's available-for-sale debt securities was recorded for any periods presented. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80Ni9mcmFnOmFjOTlmZjlhZGI2NDQ4YTI4MTBiNWNhZGU1ZmZlOTVhL3RleHRyZWdpb246YWM5OWZmOWFkYjY0NDhhMjgxMGI1Y2FkZTVmZmU5NWFfNDQy_176aab48-2098-4168-9d95-edf8da45939d" continuedAt="idec4012f18b54e07801a390c78761aff" escape="true">Inventory, Net</ix:nonNumeric></span></div><ix:continuation id="idec4012f18b54e07801a390c78761aff" continuedAt="i689646b9ae70436eb786d2de5135b722"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80Ni9mcmFnOmFjOTlmZjlhZGI2NDQ4YTI4MTBiNWNhZGU1ZmZlOTVhL3RleHRyZWdpb246YWM5OWZmOWFkYjY0NDhhMjgxMGI1Y2FkZTVmZmU5NWFfNDQz_03270e59-0aeb-4d74-a685-b3c827ebfc33" escape="true"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80Ni9mcmFnOmFjOTlmZjlhZGI2NDQ4YTI4MTBiNWNhZGU1ZmZlOTVhL3RhYmxlOmY5Y2Y1ZTk2ZTI2OTQ4NmM5YTUxMTMxMWNhMWY0NzFiL3RhYmxlcmFuZ2U6ZjljZjVlOTZlMjY5NDg2YzlhNTExMzExY2ExZjQ3MWJfMi0xLTEtMS0w_9f1241be-a4dc-4905-8965-8e5ecfe11779">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80Ni9mcmFnOmFjOTlmZjlhZGI2NDQ4YTI4MTBiNWNhZGU1ZmZlOTVhL3RhYmxlOmY5Y2Y1ZTk2ZTI2OTQ4NmM5YTUxMTMxMWNhMWY0NzFiL3RhYmxlcmFuZ2U6ZjljZjVlOTZlMjY5NDg2YzlhNTExMzExY2ExZjQ3MWJfMy0xLTEtMS0w_5ad299aa-9266-41dd-83ad-5e252b4b354b">3,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80Ni9mcmFnOmFjOTlmZjlhZGI2NDQ4YTI4MTBiNWNhZGU1ZmZlOTVhL3RhYmxlOmY5Y2Y1ZTk2ZTI2OTQ4NmM5YTUxMTMxMWNhMWY0NzFiL3RhYmxlcmFuZ2U6ZjljZjVlOTZlMjY5NDg2YzlhNTExMzExY2ExZjQ3MWJfNC0xLTEtMS0w_1c5a1286-d3ee-4f9f-baf2-8f827f7b1cb2">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80Ni9mcmFnOmFjOTlmZjlhZGI2NDQ4YTI4MTBiNWNhZGU1ZmZlOTVhL3RhYmxlOmY5Y2Y1ZTk2ZTI2OTQ4NmM5YTUxMTMxMWNhMWY0NzFiL3RhYmxlcmFuZ2U6ZjljZjVlOTZlMjY5NDg2YzlhNTExMzExY2ExZjQ3MWJfNS0xLTEtMS0w_18226065-7fc4-47df-94cf-98e3385b35b1">3,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:31.5pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i689646b9ae70436eb786d2de5135b722">Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of September&#160;30, 2021, is net of a reserve of $<ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80Ni9mcmFnOmFjOTlmZjlhZGI2NDQ4YTI4MTBiNWNhZGU1ZmZlOTVhL3RleHRyZWdpb246YWM5OWZmOWFkYjY0NDhhMjgxMGI1Y2FkZTVmZmU5NWFfMTA5OTUxMTYyOTAwOA_bf81735f-4bf4-45af-8111-0ba1bb3000cb">1.6</ix:nonFraction> million for unsaleable inventory which is reflected in cost of product sales for the three and nine months ended September 30, 2021.</ix:continuation>  </span></div><div style="margin-top:3pt"><span><br/></span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_49"></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfMTE4NQ_b81e6dd4-7333-47da-b530-e6b9db3a7380" continuedAt="i84dd405e3aa242b98a4064fe611c9732" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i84dd405e3aa242b98a4064fe611c9732" continuedAt="i03b8d6531ddd4d12b5de33167a8421f1">In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="i46a6e5fff27f4b6aa874171e8585d54f_D20201101-20201130" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfMjE4_851cb4aa-43a8-4702-9c03-8e5e3e3bf8bf">100.0</ix:nonFraction> million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the three months ended March 31, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i06955b87c4604f8fb996dcb42b4dc99e_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfNTk0_cf3af9a4-39ef-40a7-9c1b-68540cc2dd42">3,622,186</ix:nonFraction> shares </ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i03b8d6531ddd4d12b5de33167a8421f1" continuedAt="i1396d67fa2c5402cab67ad004f6a945d"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of common stock at a weighted average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3fa4f2d5e48b4142942ab255dbbf4e2b_I20210331" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfNjYx_1a469f1a-9240-4433-92b7-35c2fe440577">27.60</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i06955b87c4604f8fb996dcb42b4dc99e_D20210101-20210331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfNzA4_351a2546-116e-4769-a72b-5736e38ef6fd">98.2</ix:nonFraction> million, net of underwriting discounts and commissions and other offering expenses. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#8217;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i46a6e5fff27f4b6aa874171e8585d54f_D20201101-20201130" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfMTA0MA_b1476fc9-da58-4029-b694-5896768a3f3a">100.0</ix:nonFraction>&#160;million to an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i022010ba69a04e73be7fc39c277aa5bc_D20210401-20210430" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfMTA4Mw_7704851e-6495-4c4b-b2ec-bc4e1a23a160">300.0</ix:nonFraction>&#160;million.  During the three and nine months ended September 30, 2021, the Company did not sell any shares of common stock related to the ATM Offering.  </span></div></ix:continuation><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1396d67fa2c5402cab67ad004f6a945d">As part of the consideration for the rights granted to Zai Lab US LLC under the collaboration and license agreement described more fully in Note 7, Collaboration and Other Agreements, the Company and Zai Lab US LLC entered into a separate stock purchase agreement (Stock Purchase Agreement).  Under this Stock Purchase Agreement, Zai Lab US LLC paid the Company approximately $<ix:nonFraction unitRef="usd" contextRef="i4a6d5f9b9cb64ef1ab9cf00828b18921_D20210601-20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfNTQ5NzU1ODE0MjI0OA_b895ab78-1658-4f92-8145-2f0df3b8fb68">30.0</ix:nonFraction> million to purchase <ix:nonFraction unitRef="shares" contextRef="i22af05f406eb42a18864db9d550fb33b_D20210601-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfNTQ5NzU1ODE0MjI2NA_acb8946b-ed33-47a7-ab9f-8327953a5e32">958,467</ix:nonFraction> newly issued shares of the Company's common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfMTA5OTUxMTYzMjkyNg_5dffed8d-59a3-4e73-bdcf-75f4fd54ef6c">0.01</ix:nonFraction>, at a fixed price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i427f349d621a4e20beb2de97f08f189f_I20210615" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfNTQ5NzU1ODE0MjM0Ng_9262208a-df7a-47b5-9e0a-eb3362dca488">31.30</ix:nonFraction> (Offering) which represented a $<ix:nonFraction unitRef="usd" contextRef="i4a20cea58d2e41dda0b283e8e60b23c0_D20210601-20210630" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:PremiumReceivedOnStockPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfNTQ5NzU1ODE0MjM4MQ_4848ba33-fc6f-45ea-ad07-0edfcddcc5cc">10.4</ix:nonFraction> million premium over the share price on the Stock Purchase Agreement date. The Offering closed in July 2021.</ix:continuation>  </span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_52"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMzA4Mzc_85131fa5-ee9d-40ec-aec1-4c2a3b47e0b0" continuedAt="iaba72f25878547a1abe5d92723d7bf5c" escape="true">Collaboration and Other Agreements </ix:nonNumeric></span></div><ix:continuation id="iaba72f25878547a1abe5d92723d7bf5c" continuedAt="idb755630b1ed496b9360a4048054327f"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte License Agreement</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab  (formerly known as MGA012 and INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i8c7dc4c308654b92a9b7eb8aa5fae842_D20170101-20171231" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNzE0_c02e8812-466f-4b5e-bf75-c8c99d8eb1fa">150.0</ix:nonFraction> million in 2017. In July 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal.  Incyte&#8217;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte is reviewing the CRL and will discuss next steps with the FDA.  More recently, Incyte withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal.   </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab.  Assuming successful development and commercialization of retifanlimab by Incyte, the Company could receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="i44f9acd305254e98bb6059421e41afc8_I20171231" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTY2MQ_540d2e07-ea4a-4e56-99bd-f14ed1668628">420.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i44f9acd305254e98bb6059421e41afc8_I20171231" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTcxNQ_32e751c6-36d6-457c-8bab-bab88b06ffb4">330.0</ix:nonFraction> million in commercial milestones. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="ia6b3220211b34177a70814841776348e_D20180101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTgzNA_f4f45af7-5e8c-4d30-994b-797d69864b62">70.0</ix:nonFraction> million in development milestones under the Incyte License Agreement.  If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of <ix:nonFraction unitRef="number" contextRef="i8f96961f110f4bd4a365d1cacb888a9d_D20170101-20171231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjAwOQ_ccbb5d47-36ff-4562-aacc-5a18e3096e15">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i793df4da4f6949ae8dc1104d14ce9e42_D20170101-20171231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjAxNQ_85b778a6-ebb4-446d-a13b-d128bfea3167">24</ix:nonFraction>% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company evaluated the Incyte License Agreement under ASC 606 and identified the following <ix:nonFraction unitRef="performanceobligation" contextRef="i44f9acd305254e98bb6059421e41afc8_I20171231" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjU1Nw_955d4c82-76b3-477d-a846-1a038ce5721f">two</ix:nonFraction> performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte License Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="i44f9acd305254e98bb6059421e41afc8_I20171231" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMzM0NA_d48a230d-1d4f-48dd-88a2-36290ea25a2d">154.0</ix:nonFraction> million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="idb755630b1ed496b9360a4048054327f" continuedAt="i236395ca665f411a88eb1ea7ef921f04"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From 2018 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, it became probable that a significant reversal of cumulative revenue would not occur for deve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">lopment milestones totaling $<ix:nonFraction unitRef="usd" contextRef="ia6b3220211b34177a70814841776348e_D20180101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNDkyMw_f4f45af7-5e8c-4d30-994b-797d69864b62">70.0</ix:nonFraction> million related to </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#8217;s initiation of a Phase 3 clinical trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.  Therefore the associated consideration was added to the estimated transaction price.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="i326f19028f6848eb90307ed07e34fb13_D20170101-20171231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNTE5OQ_452e30b7-af62-4bf9-8eae-47877590987e">150.0</ix:nonFraction> million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017.  The $<ix:nonFraction unitRef="usd" contextRef="idaf80bf80aa94dcdbe58a0b47d56866c_D20170101-20181231" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNTMyNA_8c227d1a-3239-46fd-8728-ca5ffae51b13">4.0</ix:nonFraction> million allocated to the clinical activities was recognized ratably as services were performed over a period spanning 2017 and 2018.  During the nine months ended September 30, 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">it became probable that a significant reversal of cumulative revenue would not occur for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="if11ae315139b4747abb6df067daf9f16_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNTU3NQ_86af62c1-f18a-485a-9b1c-1471d20a1b4a">15.0</ix:nonFraction> million in milestones related to development progress of retifanlimab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue. <ix:nonFraction unitRef="usd" contextRef="i34ebcecab85244bd9dbc6977705c7569_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNTc3MA_8d175a8a-0ae0-4785-b280-55449ed2a082"><ix:nonFraction unitRef="usd" contextRef="i98c0801d3b474ff6844f020bcdb35bd9_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNTc3MA_aa6a433b-9e9e-475e-92e9-c8079ca9ceaa">No</ix:nonFraction></ix:nonFraction> revenue was recognized under the Incyte License Agreement during the three and nine months ended September 30, 2021.  During the three and nine months ended September 30, 2020, $<ix:nonFraction unitRef="usd" contextRef="i7cfb8e8a76924dac915a6ac2232abba3_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNDM5ODA0NjU0MzUyOQ_153450bb-3ba6-4e65-a1cd-9bf4b213ef4d"><ix:nonFraction unitRef="usd" contextRef="i4bdcdeefecaa42989b7b67f34d47899a_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNDM5ODA0NjU0MzUyOQ_17f7e0d0-45d3-4f35-be7c-da3e0f90d1c8">15.0</ix:nonFraction></ix:nonFraction> million in milestone revenue was recognized under the Incyte License Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement).  The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services.  During the three months ended September 30, 2021 and 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i9531fc2fc03846f0b3768319934b4340_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNjkzOQ_023dc796-c54f-4af9-8592-8c0689d431e7">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if320066be1564b01af8dde722a25c31e_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNjk0Ng_a844d648-a959-43dd-ada3-d3e9db1eb4b2">0.7</ix:nonFraction> million, respectively, for services performed under the Incyte Clinical Supply Agreement. During the nine months ended September 30, 2021 and 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i98e991fb934846ab820b5a844c8830c5_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNzA4Nw_1bfe1439-99c2-4faf-8523-051f98c6066b">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4badc0f60dd14b6c8755357f7ac540fc_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNzA5NA_42aea264-36f6-4241-9a76-61f76c5af110">8.1</ix:nonFraction> million, respectively, for services performed under the Incyte Clinical Supply Agreement.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte Commercial Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services.  During the three and  nine months ended September 30, 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="icc0dbc0dc52e4ad7bf077e11b26f5987_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfODQxMA_5465d1c5-3731-4eca-a955-298fef5a7c1b">1.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i59a0c5813a0c46d786211fb05433da01_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfODQxNw_7e385209-32b4-427d-bf68-94bb1503b4f7">7.4</ix:nonFraction>&#160;million, respectively, for services performed under the Incyte Commercial Supply Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab Limited</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2018 Zai Lab Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab)  under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab (formerly known as MGD013), a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i1b58dca81bae4ab9b749cdc5b02a267b_D20180101-20181231" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTM2Ng_c89e2986-430f-43da-8879-86752e70c865">25.0</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="i1b58dca81bae4ab9b749cdc5b02a267b_D20180101-20181231" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTM3MA_8ded64f1-0ef4-489b-b98a-1c37ac0de7dd">22.5</ix:nonFraction> million after netting value-added tax withholdings of $<ix:nonFraction unitRef="usd" contextRef="i1b58dca81bae4ab9b749cdc5b02a267b_D20180101-20181231" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:NonrefundablePaymentTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTQxOQ_829f9dff-e308-42cd-ae92-f71e5b7bf15a">2.5</ix:nonFraction> million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="ie336f44ff7bd44ad8432ae58b5fff68f_I20200331" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTU2NQ_3e06fced-13d2-451a-bd39-ecd9a7dd4cd1">140.0</ix:nonFraction> million in development and regulatory milestones, $<ix:nonFraction unitRef="usd" contextRef="ia1fee744e4cf4ed1ad933a71b09d6beb_D20200101-20200331" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTYxMA_7ed25cd8-5532-429f-a1ef-67fb0197eb1f">4.0</ix:nonFraction> million of which ($<ix:nonFraction unitRef="usd" contextRef="ia1fee744e4cf4ed1ad933a71b09d6beb_D20200101-20200331" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:RevenuesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTYyMw_77595063-deda-4a07-9418-742d583411c0">3.6</ix:nonFraction> million after netting value-added tax withholdings of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i236395ca665f411a88eb1ea7ef921f04" continuedAt="ic869460ef8534203bcd92ffc35b13f6a"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia1fee744e4cf4ed1ad933a71b09d6beb_D20200101-20200331" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:RevenuesTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTY3Mg_3bb43ba1-5c3b-4904-9d73-ba27752537e3">0.4</ix:nonFraction> million) was earned during the three months ended March 31, 2020. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to <ix:nonFraction unitRef="number" contextRef="i383ab32255d644eaafc819796aa2870d_D20180101-20181231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTgyOQ_21989fe4-a5ae-4dd0-8189-c8b4eba17b10">20</ix:nonFraction>% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and <ix:nonFraction unitRef="number" contextRef="ia9d0c680036d4325b5e7f41d64399b60_D20180101-20181231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTk1Mg_71fd251f-349f-4961-9ba7-ecef8b555965">10</ix:nonFraction>% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $<ix:nonFraction unitRef="usd" contextRef="i1b58dca81bae4ab9b749cdc5b02a267b_D20180101-20181231" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTEyNTc_8ded64f1-0ef4-489b-b98a-1c37ac0de7dd">22.5</ix:nonFraction> million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the tebotelimab performance obligation was recognized on a straight-line basis as the Company performed research and development activities under the agreement. The fixed consideration related to the margetuximab performance obligation was also recognized on a straight-line basis as the Company performed research and development activities under the agreement due to the short-term nature of the recognition period. Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate. The variable consideration related to the margetuximab performance obligation was recognized upon certain regulatory achievements during 2020.  The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="iad7dbfa657cb4e6f87748b9ddf1e390c_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:RevenuesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTMzMTk_ccc409ff-42af-472a-8b03-08767acefce2">3.6</ix:nonFraction>&#160;million during the nine months ended September 30, 2020 under the 2018 Zai Lab Agreement.  There was <ix:nonFraction unitRef="usd" contextRef="i3465bc8d05de421897c972d4b8fedeb8_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTMzODE_21f1f9d1-6002-4107-b62e-e7e1b513b56e"><ix:nonFraction unitRef="usd" contextRef="idd7958be040c4fb89b305414df69d203_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTMzODE_955621af-5c88-44d3-9c26-d3b1839779dc">no</ix:nonFraction></ix:nonFraction> revenue deferred under this agreement as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021 or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Zai Lab Clinical Supply Agreements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements).  The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  During the three months ended September 30, 2021 and 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i0c250244fd7d4e4c9b409d38eb292272_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTQzNzI_66cb9f60-e3cd-4fed-ac9c-f05964cab670">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8f28dba3b3c54be6951e63e82446015d_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTQzNzk_40dce5b8-63a1-41f1-b133-3ee5bde1ddf8">0.5</ix:nonFraction> million, respectively, related to the Zai Lab Clinical Supply Agreements. During the nine months ended September 30, 2021 and 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i03d23314d63d45c8b35e795aaedab122_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTQ1MDQ_ddb579bf-31aa-4556-a063-7b61afaa06f7">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if34089b9b5874ac5840731a4dd93f241_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTQ1MTE_0b1c8aed-f631-4204-b946-4c0740d8d54b">1.9</ix:nonFraction> million, respectively, related to the Zai Lab Clinical Supply Agreements.  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Zai Lab Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#8217;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ic869460ef8534203bcd92ffc35b13f6a" continuedAt="ic5f8f42f25cd430a989c280a9db6078d"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay the Company $<ix:nonFraction unitRef="usd" contextRef="i427f349d621a4e20beb2de97f08f189f_I20210615" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:OptInFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTU1ODU_a01149d4-4bb8-46a3-8960-9678a252e8e7">85.0</ix:nonFraction>&#160;million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i4a6d5f9b9cb64ef1ab9cf00828b18921_D20210601-20210630" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTYzNDk_e6be771e-0a30-403f-b2be-63ee9b998f84">25.0</ix:nonFraction>&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into the Stock Purchase Agreement whereby Zai Lab paid the Company approximately $<ix:nonFraction unitRef="usd" contextRef="i4a6d5f9b9cb64ef1ab9cf00828b18921_D20210601-20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTY2NTM_b895ab78-1658-4f92-8145-2f0df3b8fb68">30.0</ix:nonFraction> million to purchase shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTY3MTY_1da96673-0677-4ed7-820d-c1c7244f59df">0.01</ix:nonFraction>, at a fixed price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i427f349d621a4e20beb2de97f08f189f_I20210615" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTY3NDA_9262208a-df7a-47b5-9e0a-eb3362dca488">31.30</ix:nonFraction> which represented a $<ix:nonFraction unitRef="usd" contextRef="i4a20cea58d2e41dda0b283e8e60b23c0_D20210601-20210630" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:PremiumReceivedOnStockPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTY3NzQ_4848ba33-fc6f-45ea-ad07-0edfcddcc5cc">10.4</ix:nonFraction> million premium over the share price on the Stock Purchase Agreement date. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the Programs, the Company could receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="i427f349d621a4e20beb2de97f08f189f_I20210615" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTY5OTY_3f50f268-2c81-4874-bb53-20cab7daac13">800.0</ix:nonFraction>&#160;million in development and regulatory milestones and $<ix:nonFraction unitRef="usd" contextRef="i427f349d621a4e20beb2de97f08f189f_I20210615" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTcwNDQ_5786e6c4-7422-4755-bc3e-b0c9b78c279d">600.0</ix:nonFraction>&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai Lab&#8217;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#8217;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#8217;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the estimated transaction price is $<ix:nonFraction unitRef="usd" contextRef="i427f349d621a4e20beb2de97f08f189f_I20210615" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTg3OTc_c87fbfed-d68e-42c3-8345-2b3f9bc1dc16">40.4</ix:nonFraction> million, consisting of the $<ix:nonFraction unitRef="usd" contextRef="i4a6d5f9b9cb64ef1ab9cf00828b18921_D20210601-20210630" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTg4MTk_0c3f3191-4f92-4af3-9533-da329c50a3e7">25.0</ix:nonFraction> million upfront payment, the $<ix:nonFraction unitRef="usd" contextRef="i4a20cea58d2e41dda0b283e8e60b23c0_D20210601-20210630" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:PremiumReceivedOnStockPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTg4NDM_7798bfed-3337-4809-a3f4-509ac0e17851">10.4</ix:nonFraction> million premium related to the purchase of the Company&#8217;s common stock, and the estimated $<ix:nonFraction unitRef="usd" contextRef="i4a6d5f9b9cb64ef1ab9cf00828b18921_D20210601-20210630" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTg5Mjc_305165d6-e5ac-4e58-87cd-bf32376f7b02">5.0</ix:nonFraction> million expected to be reimbursed by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $<ix:nonFraction unitRef="usd" contextRef="i427f349d621a4e20beb2de97f08f189f_I20210615" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTk4MDE_c8b04961-0bcc-4fc3-9494-0946a647dd51">40.4</ix:nonFraction> million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes the market is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#8217;s estimate of the probability of success for each Program. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to the Lead Program license and related research and development services performance obligation is being recognized over time as the research and development activities are performed. The Company will utilize a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. During the three and nine months ended September 30, 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i83adad7f523245b7b6e58f66a3dab006_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTA5OTUxMTY1OTIwNQ_d39520f1-c694-4b22-900f-53205a4f5f0a">3.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4a238ce78ac74f1b93c817ced866efa2_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTA5OTUxMTY1OTIyMA_46b0d990-faac-4b15-b2f8-968b256963fc">18.1</ix:nonFraction> million, respectively, under the 2021 Zai Lab Agreement.  As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i4022bd5da2824c7c8f8ee74203011a7d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjE0NDc_6dbdd3f3-038f-4599-b776-e60596096403">17.8</ix:nonFraction> million in deferred revenue under the agreements, $<ix:nonFraction unitRef="usd" contextRef="i4022bd5da2824c7c8f8ee74203011a7d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjE0OTI_90e40781-6e04-402d-bf8b-825bdde59114">13.6</ix:nonFraction> million of which is current and $<ix:nonFraction unitRef="usd" contextRef="i4022bd5da2824c7c8f8ee74203011a7d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjE1MTk_58019752-a45a-4189-8ea2-4d3b8b13b76b">4.2</ix:nonFraction> million of which is non-current.  </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><ix:continuation id="ic5f8f42f25cd430a989c280a9db6078d" continuedAt="ia8a31046833a4dc0a6175462671d14a4"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Biotech, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a research collaboration and license agreement with Janssen Biotech, Inc. (Janssen) to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#8217;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ida2095e4cb994efe825c83b7c2569119_D20201201-20201231" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjIwMjc_54741d60-bcc1-4115-86c4-f22dbacd7ddb">20.0</ix:nonFraction>&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i8f5dc2b032524391af7887b322598d1d_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjIxNTY_eeef2750-2994-46e1-993c-a467c89bcea4">312.0</ix:nonFraction>&#160;million in potential milestone payments and tiered royalties of up to <ix:nonFraction unitRef="number" contextRef="ida2095e4cb994efe825c83b7c2569119_D20201201-20201231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjIyMjE_4f897625-4f4e-49ec-bfac-3eb6d447fd5a">10</ix:nonFraction>% on worldwide product sales. </span><span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#8217;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="i8f5dc2b032524391af7887b322598d1d_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjMzMDA_2417da2d-442d-4f94-bdcd-fb156069510f">22.2</ix:nonFraction>&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="i8143c485591543ca8f9fa0ad6b05a533_D20201201-20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjQ5MTU_678cd655-ddd4-413d-b0a9-e22500ee7da0">20.0</ix:nonFraction>&#160;million allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $<ix:nonFraction unitRef="usd" contextRef="ida2095e4cb994efe825c83b7c2569119_D20201201-20201231" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjUwNDk_a7878e33-7ff7-4c9b-94b9-b8f81067295d">2.2</ix:nonFraction>&#160;million allocated to the research and development activities is being recognized over the Company&#8217;s involvement in the research term, which is estimated to be less than two years. During the three and nine months ended September 30, 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="iede70fcdb85b4d5fadb7c778a198437a_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjUyODM_1abeeb05-d06e-44c8-9160-0dd7d768a71e">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iee958037590e47f9a647d7b398e799cb_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjUyOTA_e4e4c6b9-1678-407d-9870-5a02a35fe484">1.1</ix:nonFraction>&#160;million, respectively, for research and development activities performed under the Janssen Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab Agreement, I-Mab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i821467e83ad44bf4936cba83c4bf74cc_D20190101-20191231" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjYwNTI_89f18b43-a6b7-4d8b-9d82-a7669e19f08d">15.0</ix:nonFraction> million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="i251e9fe0e95a4f3f862b554c5b106612_I20191231" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjYxNjE_d9b38178-da20-4479-a2e5-19832bfacf07">135.0</ix:nonFraction> million in development and regulatory milestones, of which $<ix:nonFraction unitRef="usd" contextRef="i35541777167844639ae2fde64553a505_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTA5OTUxMTY2Njk2MA_064cecdc-fd7e-449d-a9ce-1dd84aecf013">5.0</ix:nonFraction> million  has been earned from the inception of the I-Mab Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to <ix:nonFraction unitRef="number" contextRef="ia0b95e5cfec444d08b7a167a497b2f2b_D20190101-20191231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjYyOTA_ce74684f-eb98-4d04-b257-bf9aa6a2c9e2">20</ix:nonFraction>% on annual net sales in I-Mab's territory.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ia8a31046833a4dc0a6175462671d14a4" continuedAt="i6d30add956734525969a6a34211f142e"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined that the $<ix:nonFraction unitRef="usd" contextRef="i821467e83ad44bf4936cba83c4bf74cc_D20190101-20191231" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjcwOTE_89f18b43-a6b7-4d8b-9d82-a7669e19f08d">15.0</ix:nonFraction> million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $<ix:nonFraction unitRef="usd" contextRef="i821467e83ad44bf4936cba83c4bf74cc_D20190101-20191231" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjc1MDY_78fd89b2-2dc3-4c5d-8a0f-2e674b577665">1.0</ix:nonFraction> million. I-Mab paid the Company for the cost of this study as the costs were incurred and I-Mab received a one-time credit of eighty percent of the total amount of such costs against the milestone achieved during the three months ended September 30, 2021, at which point the Company reassessed the transaction price for that milestone. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Revenue under the I-Mab Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, i n management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations.  The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i1b4c7ba6a9524139b98444a380751a27_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjg5MzY_471fc448-81b3-4477-b8be-7eb98e6c1d3f"><ix:nonFraction unitRef="usd" contextRef="ic57fab8151e64ac0a42999af4054508d_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjg5MzY_4d8b3c8c-28c6-437c-859b-f321c5e38bb6">1.0</ix:nonFraction></ix:nonFraction> million  during each of the three month periods ended September&#160;30, 2021 and 2020  under the I-Mab Agreement.  During the nine months ended September 30, 2021 and 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i35541777167844639ae2fde64553a505_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjkwNDU_8cf25977-969e-464d-a97c-39b4f74b48e8">3.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib0d488d61f554e5a8b0ce225092751fc_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjkwNTI_90a150c2-b738-4cf2-a4bb-c43ed6abe084">3.5</ix:nonFraction> million, respectively, under the I-Mab Agreement.  At September&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="i99ab726c228e4d1680ccc1ddfb59679a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjkxMDU_44a0e027-a023-41f3-81b3-60002a45d9e5">8.1</ix:nonFraction> million of revenue was deferred under this agreement, $<ix:nonFraction unitRef="usd" contextRef="i99ab726c228e4d1680ccc1ddfb59679a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjkxNTQ_49365f1b-046a-4818-9557-a1260bc8b991">2.7</ix:nonFraction> million of which was current and $<ix:nonFraction unitRef="usd" contextRef="i99ab726c228e4d1680ccc1ddfb59679a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjkxODI_2f5d2dc7-9000-4d85-8e5d-c462ea44e7c0">5.3</ix:nonFraction> million of which was non-current.   At December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="ia3ab9f0060de41d18476fe3926db09c0_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjkyMjA_8f521893-9331-40e0-8381-7be9f32f370b">11.4</ix:nonFraction> million of revenue was deferred under this agreement, $<ix:nonFraction unitRef="usd" contextRef="ia3ab9f0060de41d18476fe3926db09c0_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjkyNjk_029dde45-ee0c-415b-a2cb-53dd02b47aea">4.5</ix:nonFraction> million of which was current and $<ix:nonFraction unitRef="usd" contextRef="ia3ab9f0060de41d18476fe3926db09c0_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjkyOTc_acdd5f16-291a-430b-a66a-901e6ccf5bf7">6.9</ix:nonFraction> million of which was non-current.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur fo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r a $<ix:nonFraction unitRef="usd" contextRef="i1b4c7ba6a9524139b98444a380751a27_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTA5OTUxMTY2NjgwNg_8f9929a7-565f-400f-ab75-e7165b1f7d78">5.0</ix:nonFraction>&#160;million milestone ($<ix:nonFraction unitRef="usd" contextRef="i1b4c7ba6a9524139b98444a380751a27_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:RevenuesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTA5OTUxMTY2NjgyMA_e3bbed22-9da5-4092-998b-089862d07889">4.5</ix:nonFraction>&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to <ix:nonFraction unitRef="molecule" contextRef="i99a92e56710a44499fbc841789c43ddd_D20150915-20150915" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjk1MzM_1f08d9ee-7bb9-4b3e-8ef2-0cc7b357e2cf">two</ix:nonFraction> DART molecules, including MGD014 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div></ix:continuation><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6d30add956734525969a6a34211f142e">Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of September 30, 2021 is $<ix:nonFraction unitRef="usd" contextRef="i71658aa1f269459cad8b975de86ba7af_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="mgnx:TotalPotentialValueUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTA5OTUxMTY2Njk2OQ_eb95597b-2c05-4ec0-9c61-f5513c1bf93c">25.1</ix:nonFraction> million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023.    During the three months ended September 30, 2021 and 2020, the Company recognized revenue under the NIAID Contract of $<ix:nonFraction unitRef="usd" contextRef="i487dec63017c4855b07e934da1351f90_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMzA3MDI_306b0c7b-83f4-49ef-b49b-51d9d3a42bd0">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibb2565b6e20a47c380508ecb56852d3e_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMzA3MDk_63990157-8d14-440d-a7b9-b33016f018e3">0.8</ix:nonFraction> million, respectively.  During the nine months ended September 30, 2021 and 2020, the Company recognized revenue under the NIAID Contract of $<ix:nonFraction unitRef="usd" contextRef="i01719b83dd334b3c8168fc3fa1f48b83_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMzA4MDk_54d30da6-6ffb-4e55-9050-fa4344c53016">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i91df6dfeabf04146832cafe879f6de8d_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMzA4MTY_7cdafb8c-346c-43c3-a315-b84b5fb9a010">6.2</ix:nonFraction> million, respectively.</ix:continuation>  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_55"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNTM0Ng_8d010dc7-f66b-4cad-a889-148bf8b66db9" continuedAt="id16c7255d5654036b1f0fa681cac0df2" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="id16c7255d5654036b1f0fa681cac0df2" continuedAt="ia4f2969a1fbd47daabf1ec46b102deec"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved <ix:nonFraction unitRef="shares" contextRef="ie4219cd04f594173989928403a1925f5_I20170531" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDI3_ac849a40-bf85-45ee-8c89-2646bdf52542">800,000</ix:nonFraction> shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i079475de71ee41f681213c129639bcad_D20170501-20170531" decimals="INF" name="mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNjI2_d25773b5-92ef-4c36-818c-8a2d8cd04f4a">10</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="i079475de71ee41f681213c129639bcad_D20170501-20170531" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfODcz_5ad56616-a42b-45ea-9d59-94368606473f">85</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the last day of the offering period.  During the nine months ended September&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i87bf914abe0d42daa70a6e228105c4dc_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMTAwMw_8d9cd328-0cf5-4774-85f8-7d0400599991">12,305</ix:nonFraction> shares of common stock were purchased under the 2016 ESPP.   </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ia4f2969a1fbd47daabf1ec46b102deec" continuedAt="i6930a5a60d414718986077e811a41b63"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Option Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of September&#160;30, 2021, under the 2003 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i0829ae725ca14ae7a41646663f3d6410_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMTkyNQ_2727aeb8-7253-4244-8b6a-b715e79d2072">188,944</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0829ae725ca14ae7a41646663f3d6410_I20210930" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMjAwMw_fb94a2e3-4d92-480f-b9b8-74c37e93c887">2.94</ix:nonFraction> per share.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) <ix:nonFraction unitRef="shares" contextRef="i5e8e35470de0483c81155d2739ab9223_I20131031" decimals="INF" format="ixt:num-dot-decimal" name="mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMjQxNQ_432a1e58-040e-4d4f-af45-064252dcad42">1,960,168</ix:nonFraction> shares, (b) <ix:nonFraction unitRef="number" contextRef="if5cf9831d6f24c2083b89a5456858d7b_D20210101-20210930" decimals="3" format="ixt:num-dot-decimal" name="mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMjQzMA_e790101e-1c9e-463f-b93e-823dd9d640c7">4.0</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the nine months ended September&#160;30, 2021, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to <ix:nonFraction unitRef="shares" contextRef="ibc4bd8d3b0504ef79236bd4a23c915f8_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMjc4Mg_359c9a67-7ace-49d2-b205-050a04e2a4d0">13,856,781</ix:nonFraction>.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of September&#160;30, 2021, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ibc4bd8d3b0504ef79236bd4a23c915f8_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMzM1OA_7265d757-e428-4718-bb84-2200bd1c8650">8,341,645</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibc4bd8d3b0504ef79236bd4a23c915f8_I20210930" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMzQzNg_217e6466-bccb-446a-b325-fd4311f030e6">21.94</ix:nonFraction> per share under the 2013 Plan.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNTM0MA_595bf2d4-af63-4f9c-baf1-78419d5ef64d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1afe44d7fcb449e8b8c3d8ac3bf6d9d6_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfMi0xLTEtMS0w_0f67ea31-eb61-4a0f-9752-539b2b3b3471">3,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bae4045ab9643abbbe939388775bc12_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfMi0zLTEtMS0w_6a448b70-dedf-4c77-881c-4dd61280498a">3,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0961f8433264f3a91406325b6f8539c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfMi01LTEtMS0w_408b41ee-038a-4521-8caf-3ff648b22403">8,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1204e1a45b146edb8cf23bbe529b211_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfMi03LTEtMS0w_52464c3a-25e8-4521-b6a8-956097472467">8,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a6178e54834b4f981abb57a3f32174_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfMy0xLTEtMS0w_3ee941f1-ab63-42eb-8a3f-6d3bce5f07aa">3,249</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40192326e650444490369c6d8aed8c29_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfMy0zLTEtMS0w_ae508969-c1e2-4a4b-a824-0eb3dffda032">2,773</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596efc1d3c914e7c99e852a6397e9d68_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfMy01LTEtMS0w_b7135a7e-c263-47bc-937f-7207e558546d">8,820</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c37fd8583354f3e9a46dbbaef70aed7_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfMy03LTEtMS0w_e05931e7-693d-4be1-af43-bd1e5791c004">7,337</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfNC0xLTEtMS0w_7d247994-ceb3-463b-8763-ab27a4267b7d">6,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfNC0zLTEtMS0w_51045dbd-55d6-45e6-9195-b9daa1415a57">5,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfNC01LTEtMS0w_43f820b9-9ed5-48c4-8b7e-ca3b285ad43d">17,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfNC03LTEtMS0w_0ce8b05b-273f-410c-b768-563de98b26c8">15,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNTM0OA_4f3197bf-6d5b-4d1b-8480-fa4bcbb87bbc" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfMi0xLTEtMS0w_18b6c500-33f7-41b0-85fb-dec1cfb7202d">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfMi0zLTEtMS0w_71c2ea85-4b26-4a36-9e8a-82bc1b57320a">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie49c054c4de84c13bf9cf4e74329ad89_D20210101-20210930" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfMy0xLTEtMS0wL3RleHRyZWdpb246Yjk2MTJkN2M0OWQxNGMyZWI0Y2FlMWRhZDI1NzQzMGZfNA_f409e958-ad36-4453-a386-0e476ba4f625">86.2</ix:nonFraction>% -<ix:nonFraction unitRef="number" contextRef="i1017f0e3d160493698b4b137f53cf6b9_D20210101-20210930" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfMy0xLTEtMS0wL3RleHRyZWdpb246Yjk2MTJkN2M0OWQxNGMyZWI0Y2FlMWRhZDI1NzQzMGZfOA_64cc19cc-5432-4e42-8486-0dbc318d0061">87.4</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9edd978d79794c06ae717443ae5079d0_D20200101-20200930" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfMy0zLTEtMS0wL3RleHRyZWdpb246ODI0ZTMyZTYzOGJlNGM0NGE4ODEzYjM5ZTM0NjY1ZTlfNA_725fa324-0288-4de5-8be1-5133bc93cebc">67.3</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="if2db8a1a06494bb9acad2b6f55b81bac_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfMy0zLTEtMS0wL3RleHRyZWdpb246ODI0ZTMyZTYzOGJlNGM0NGE4ODEzYjM5ZTM0NjY1ZTlfOQ_3fd06fe5-ad82-4486-a54e-515f28fff11d">109</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie49c054c4de84c13bf9cf4e74329ad89_D20210101-20210930" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfNC0xLTEtMS0wL3RleHRyZWdpb246Y2Y1MDFmOGQxZmI2NGQ2NThmMWExZmZkMWEzZDYzZWVfNA_8a2d84be-b77b-464a-ae2b-3e0846cad87f">0.6</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i1017f0e3d160493698b4b137f53cf6b9_D20210101-20210930" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfNC0xLTEtMS0wL3RleHRyZWdpb246Y2Y1MDFmOGQxZmI2NGQ2NThmMWExZmZkMWEzZDYzZWVfOQ_c09fd288-2668-402f-b086-b03c48d73ede">1.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9edd978d79794c06ae717443ae5079d0_D20200101-20200930" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfNC0zLTEtMS0wL3RleHRyZWdpb246YWYxNTUyMDc4MjRiNDc1NzllNGQ2ZDM3YmQwOWE4OWRfNA_750dc1ea-ac79-4b45-9f70-2b72ee1c1ca0">0.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="if2db8a1a06494bb9acad2b6f55b81bac_D20200101-20200930" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfNC0zLTEtMS0wL3RleHRyZWdpb246YWYxNTUyMDc4MjRiNDc1NzllNGQ2ZDM3YmQwOWE4OWRfOQ_e8391b99-2969-4a31-b63f-51986c0d823c">1.8</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfNS0xLTEtMS0w_40563dfd-0902-4e3b-98a3-6a7b4ea05819">6.25</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfNS0zLTEtMS0w_0edb7dc4-00cf-42b9-bc65-618ddd8d746f">6.25</ix:nonNumeric> years</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i6930a5a60d414718986077e811a41b63"><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNTM0Mw_01fe7786-8aa7-48e9-b0fc-c776057d7906" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the nine months ended September&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfMS0xLTEtMS0w_df64cd27-09d0-40c1-8607-a4b2aa81c947">7,258,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfMS0zLTEtMS0w_7a08f5b4-9075-4236-b54f-9086454a6726">21.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i671b1a548fa8453f8d15112d62dc2c2c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfMS01LTEtMS0w_87e1e5bd-efb6-4e55-b5ed-0ceafa6cb67c">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfMi0xLTEtMS0w_9fc364e6-1645-4589-aea9-80a9e4d31cff">1,914,846</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfMi0zLTEtMS0w_884d124e-5531-4022-9cf3-dd308820fc47">20.86</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfMy0xLTEtMS0w_652f226d-71c6-4f6f-a865-1ff39f7857bf">302,649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfMy0zLTEtMS0w_f7d1abb9-735d-4614-a508-5eeac3305cb5">17.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNC0xLTEtMS0w_39b45ebc-df69-421a-b761-701cd35bdbce">339,961</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNC0zLTEtMS0w_9f7c3193-4d69-4554-90ca-168198d7a628">19.12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNS0xLTEtMS0w_ea666986-a555-4457-a120-3507c369c377">8,530,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNS0zLTEtMS0w_22419b4b-dc27-4fa4-82d2-f1e374fe84cd">21.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNS01LTEtMS0w_f023004a-2887-495f-bd82-112a6b0bbb18">6.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNS03LTEtMS0w_8cd73cc0-6c7a-441b-9240-fc1ea99f9dec">19,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of September 30, 2021:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNy0xLTEtMS0w_158bd106-e078-4a3b-b5d2-4386fd3205c6">5,314,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNy0zLTEtMS0w_7aabc5a9-3ba6-46e8-8e16-88d7f1d569d2">22.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNy01LTEtMS0w_cf9743c2-a48b-488c-8774-3fde688d2cf5">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNy03LTEtMS0w_1f9a0e83-9b91-4684-97e0-8ffbf3880b86">10,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfOC0xLTEtMS0w_a4eda3bf-9cd0-484c-b5c6-2ff206a58963">8,135,407</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfOC0zLTEtMS0w_53441b84-095c-4ee6-8834-dd0e4868a627">21.62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfOC01LTEtMS0w_8e646b0c-d404-4941-9c36-da3aad53fd64">6.7</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfOC03LTEtMS0w_e92cfbf1-2c9d-4165-b154-c171622a8e61">18,793</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during the nine months ended September&#160;30, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMzk3Mg_1e7c4ab3-90a6-4a12-8aee-d0690d2c5e53">15.21</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMzk3OQ_1f142ab7-d798-4d30-bb27-ce570360f0ba">10.50</ix:nonFraction>, respectively. The total intrinsic value of options exercised during the nine months ended September&#160;30, 2021 and 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDA5OQ_7b87d298-b0b4-4353-829a-e9d407310aa4">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDEwNg_6f57c686-9ad8-43c6-b90b-f0e533ade237">3.9</ix:nonFraction> million, respectively.  The total cash received for options exercised during the nine months ended September&#160;30, 2021 and 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDIyNg_6544fa26-5fb7-4869-b0e6-fefa0401829d">5.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDIzMw_5f7c3350-aa39-45e1-a9f0-de999193a466">4.5</ix:nonFraction> million, respectively.  The total fair value of shares vested in the nine months ended September&#160;30, 2021 and 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDM0MQ_f69b0142-9ce1-4272-8443-62601b861fcd">14.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDM0OA_38cf8474-eba8-413f-9718-e9f4562465ce">12.4</ix:nonFraction> million, respectively. As of September&#160;30, 2021, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $<ix:nonFraction unitRef="usd" contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDUxMA_27893f4d-c04c-4229-a72b-160c2a749dec">36.3</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDYwMQ_c4d3c6cd-6857-49c8-a55e-3c2d2cb8d7af">2.6</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company awarded restricted stock units (RSUs) under the 2013 Plan to all employees with at least six months of service as of the date of grant except executive officers. Each RSU entitled the holder to receive one share of the Company's common stock when the RSU vested. The RSUs vested in two equal installments on the first and second anniversary of the grant date and have all vested as of September&#160;30, 2021. Compensation expense was recognized on a straight-line basis. The Company also grants RSUs to employees from time to time as a component of their compensation.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNTM0NA_b3d10068-2c64-4b61-8e0f-2d4a39bebc3d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the nine months ended September&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc9b2b5b948945ceb440f809f174f953_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfMS0xLTEtMS0w_6b2f3023-e3f4-4869-839d-0f579650d603">209,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icc9b2b5b948945ceb440f809f174f953_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfMS0zLTEtMS0w_283e6c9b-e383-4b47-92b6-841e869a1120">15.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic04f6c80a7bb4625a1ae6e61e5c93184_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfMi0xLTEtMS0w_2406e19e-788e-460a-825f-ff350a1b8634">16,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic04f6c80a7bb4625a1ae6e61e5c93184_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfMi0zLTEtMS0w_58e4070f-378d-4845-9cf7-d43c0e253649">26.27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic04f6c80a7bb4625a1ae6e61e5c93184_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfMy0xLTEtMS0w_e3c6877b-27a5-4cf5-93d8-842747b0bafb">184,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic04f6c80a7bb4625a1ae6e61e5c93184_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfMy0zLTEtMS0w_ad65e8f5-37cc-4117-8f34-880f20019b2f">15.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic04f6c80a7bb4625a1ae6e61e5c93184_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfNC0xLTEtMS0w_c061a681-f2bc-4471-a74f-b3c440a81285">17,650</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic04f6c80a7bb4625a1ae6e61e5c93184_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfNC0zLTEtMS0w_d24a912f-ce78-4308-8a62-e240611c1ba9">15.32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f5fcdf3d7064037aaefd67693a0f61c_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfNS0xLTEtMS0w_e8784745-5c9c-4c12-96cc-6f77f2ea8a4b">24,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f5fcdf3d7064037aaefd67693a0f61c_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfNS0zLTEtMS0w_22fa1d04-3b3c-4072-9c17-362172fc35fa">25.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i2f5fcdf3d7064037aaefd67693a0f61c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNTE3Mg_0e3c27ce-3600-4bca-9d06-e7f2341aa5b1">0.5</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of approximately <ix:nonNumeric contextRef="ic04f6c80a7bb4625a1ae6e61e5c93184_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNTMzOA_05b14583-0848-4c3a-a2a0-735f016eec87">2.3</ix:nonNumeric> years.</span></div></ix:continuation><div id="idd97f2f67fc84defb53bffbcae4606c1_58"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 9. <ix:nonNumeric contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81OC9mcmFnOjdiNDdhY2QyYWM0NzQyODRhMzQ4YjU2NjMyMjMxZjI1L3RleHRyZWdpb246N2I0N2FjZDJhYzQ3NDI4NGEzNDhiNTY2MzIyMzFmMjVfMTE2OQ_9a27d4b5-13ae-4cc4-a639-85d9524fd74e" continuedAt="ie306102d6f8e49e3ac699d642c79cd96" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="ie306102d6f8e49e3ac699d642c79cd96">On September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial.   On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint.  The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020.  Plaintiff filed an Opposition brief on January 29, 2021, to which the Company filed a timely reply. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal.</ix:continuation> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="idd97f2f67fc84defb53bffbcae4606c1_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations is based upon our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q, which have been prepared by us in accordance with U.S. generally accepted accounting principles (GAAP), for interim periods and with Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended. This discussion and analysis should be read in conjunction with these unaudited consolidated financial statements and the notes thereto as well as in conjunction with our audited consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-indent:45pt"><span><br/></span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_64"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. In December 2020, the U.S. Food and Drug Administration (FDA) approved MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. We launched MARGENZA in March 2021.  In addition, we have a pipeline of product candidates in human clinical testing, including eight immuno-oncology programs, that have been created primarily using our proprietary, antibody-based technology platforms. We believe our product candidates have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our company, developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, business planning and raising capital. We have financed our operations primarily through the public and private offerings of our securities, collaborations with other biopharmaceutical companies, and government grants and contracts.&#160;Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of September&#160;30, 2021, anticipated and potential collaboration payments and product revenues, should enable us to fund our operations through 2023, assuming our programs and collaborations advance as currently contemplated. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through September&#160;30, 2021, we had an accumulated deficit of $915.9 million. We expect that over the next several years this deficit will increase as we increase our expenditures in research and development in connection with our ongoing activities with several clinical trials, and incur costs related to commercial product sales.&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has negatively impacted the global economy, created significant financial market volatility, disrupted global supply chains, and resulted in a significant number of infections and deaths worldwide.  In addition, several national, state and local governments have placed restrictions on people from gathering in groups or interacting within a certain physical distance. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, although there has been some negative impact on our business and operations, including, for example, slowed clinical trial enrollment, we have been able to mitigate against more severe impacts of the COVID-19 pandemic on our business and operations.  However, the COVID-19 pandemic could have a more significant negative impact on our business in the future depending on the depth of the effects and the duration of the crisis. In response to the COVID-19 pandemic, we have been focused on keeping our employees safe, continuing patients on trials, and maintaining our manufacturing capabilities and research efforts.  The COVID-19 pandemic and its variants are evolving and we continue to monitor our business very closely to try and mitigate any potential impacts. We expect the pandemic to continue to have some near-term impact on the initiation of new studies and on clinical trial enrollment.  Significant delays in the timing of our clinical trials and in regulatory reviews could adversely affect our ability to commercialize the product candidates in our pipeline. We are classified as a government contractor and are required to comply with Executive Order 14042. We are in the process of executing this Executive Order, which requires that all our employees be fully vaccinated against COVID-19, unless legally entitled to an accommodation due to a disability or religious belief, practice or observance. It is uncertain to what extent compliance with the vaccine mandate may result in workforce attrition or difficulty securing future labor needs. If attrition is significant, our business could be adversely affected.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, we cannot precisely predict the impact that the COVID-19 pandemic will have in the future due to numerous uncertainties, including the severity, duration and resurgences of the disease and new variants, actions </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that may be taken by governmental authorities, the impact to the business of potential variations or disruptions in our supply chain, and other factors identified in Part II, Item 1A. &#8220;Risk Factors&#8221; in this Form 10-Q and "Item 1A. Risk Factors" of our Annual Report on Form 10-K for the year ended December&#160;31, 2020. Given these uncertainties, the COVID-19 pandemic could disrupt the business of certain of our collaborators and impact our business operations and our ability to execute on our associated business strategies and initiatives, and adversely impact our consolidated results of operations and/or our financial condition in the future. We will continue to closely monitor and evaluate the nature and extent of the impact of the COVID-19 pandemic to our business, consolidated results of operations, and financial condition. </span></div><div><span><br/></span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_67"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Our current collaborations include the following:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Incyte. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab (also known as INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while we retain the right to develop our pipeline assets in combination with retifanlimab. Incyte paid us an upfront payment of $150.0 million under the terms of the agreement. On July 23, 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal.  Incyte&#8217;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte is reviewing the CRL and will discuss next steps with the FDA. More recently, Incyte withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal.   </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte leads global development of retifanlimab. Assuming successful development and commercialization of retifanlimab by Incyte, we could receive total development and regulatory milestones of up to approximately $420.0 million and up to $330.0 million in commercial milestones. We received $70.0 million of the total development milestones through September&#160;30, 2021. If retifanlimab is approved and commercialized, we would be eligible to receive tiered royalties of 15% to 24% on any global net sales and we have the option to co-promote retifanlimab with Incyte. We retain the right to develop our pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and us commercializing our asset(s), if any such potential combinations are approved. We also have an agreement with Incyte under which we are to perform development and manufacturing services for Incyte's clinical needs of retifanlimab (Incyte Clinical Supply Agreement) and another agreement under which we are entitled to manufacture a portion of Incyte&#8217;s global commercial supply of retifanlimab (Incyte Commercial Supply Agreement). </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Zai Lab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2018, we entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab (formerly known as MGD013), a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development in its territory. </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Zai Lab paid us an upfront payment of $25.0 million less foreign withholding tax of $2.5 million. Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, we could receive up to $140.0 million in development and regulatory milestones, of which we have already received $4.0 million ($3.6 million net of foreign withholding tax). In addition, Zai Lab would pay us tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances.</span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into two agreements under which we are to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements).  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates our DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by us. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while we receive commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay us $85.0 million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from us to develop, manufacture and commercialize two additional molecules (license-only programs). Zai Lab granted us a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to us.</span></div><div style="padding-left:54pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both us and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with us to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid us an upfront payment of $25.0 million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, we and Zai Lab entered into a separate stock purchase agreement (Stock Purchase Agreement) whereby Zai Lab paid us approximately $30.0 million to purchase 958,467 newly issued shares of our common stock, par value $0.01, at a fixed price of $31.30 (Offering) which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. The Offering closed in July 2021.</span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the Programs under the 2021 Zai Lab Agreement, we could receive up to $1.4 billion in development, regulatory and commercial milestones. In addition, Zai Lab would pay us tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai's territory, subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, we may also receive reimbursements from Zai Lab for certain research and development costs incurred by us. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">I-Mab Biopharma.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2019, we entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates our proprietary Fc Optimization technology platform (I-Mab Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by us. <br/> <br/>Under the terms of the agreement, I-Mab paid us an upfront payment of $15.0 million. Assuming successful development and commercialization of enoblituzumab, we could receive up to $135.0 million in development and regulatory milestones of which $5.0 million  has been earned from the inception of the I-Mab Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, I-Mab would pay us tiered royalties ranging from mid-teens to 20% on annual net sales in its territories.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Janssen. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech, Inc. (Janssen). The research collaboration will incorporate our proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the agreement, Janssen paid us an upfront payment of $20.0 million and will be responsible for funding all expenses. We will also be eligible to receive up to $312.0 million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_70"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="text-indent:39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our consolidated financial statements. Except as described below with respect to revenue recognition for product revenue and inventory, during the nine months ended September 30, 2021, there have been no material changes with respect to our critical accounting policies disclosed in Part II, Item&#160;7, of our Annual Report on Form 10-K for the year ended December&#160;31, 2020. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we believe regulatory approval is probable and expect future economic benefit from the sales of a product candidate to be realized,we capitalize manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving our first approval from the FDA in December 2020, we expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for us of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, we began capitalizing our third-party contract manufacturing MARGENZA inventory costs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue, Net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606). We have written contracts with each of our customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell our product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the three and nine months ended September 30, 2021, the shipping costs incurred to ship the product were immaterial. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during nine months ended September 30, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may provide customers with discounts which are explicitly stated in our contracts.  These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby we pay fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which we believe to be consistent with fair market value. We have determined such services received to date are not distinct from the sale of products to our customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, we offer the specialty distributors product return rights pursuant to written contracts and/or our returned goods policies. We estimate the amount of product sales that may be returned by our customers and record an estimated liability and a reduction of revenue in the period the related product revenue is recognized. We currently estimate product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since we do not have our own returns experience. Our estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to our customers who directly purchase the product from us. In such cases, customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and we generally issue credits for such amounts within a few weeks of the customer&#8217;s notification to us of the resale. Chargebacks consist of credits we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expect to issue for units that remain in the distribution channel at each reporting period end that we expect will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which we have not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. Our liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Customer discounts are recorded as reductions of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of product sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  We expect cost of product sales to continue to be positively impacted as we sell through inventory that was expensed prior to FDA approval of MARGENZA. We are currently unable to estimate how long it will be until we begin selling product manufactured post FDA approval.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:39pt"><span><br/></span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_73"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our revenue for the three and nine months ended September&#160;30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other agreements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from government agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">63.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in revenue of $2.5 million for the three months ended September 30, 2021 compared to the three months ended September 30, 2020 was primarily due to:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition during the three months ended September 30, 2020 of a $15.0 million development milestone from Incyte related to the initiation of a Phase 3 clinical trial of retifanlimab.  There was no such milestone recognized during the three months </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended September 30, 2021; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $0.7 million in revenue recognized under the National Institute of Allergy and Infectious Diseases (NIAID) contract due to decreased development costs related to the second DART molecule.  </span></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by:  </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of $4.5 million in net milestone revenue under the I-Mab Agreement; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of $3.7 million in revenue from the 2021 Zai Lab Agreement executed in June 2021;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$3.6 million in net product revenue from sales of MARGENZA which was approved by the FDA in December 2020; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">$1.4 million recognized under the Incyte Commercial Supply Agreement which was executed in late 2020.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in revenue of $11.1 million for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020 was primarily due to:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of $18.0 million in revenue from the 2021 Zai Lab Agreement executed in June 2021;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$7.7 million in net product revenue from sales of MARGENZA which was approved by the FDA in December 2020;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$7.4 million recognized under the Incyte Commercial Supply Agreement which was executed in October 2020; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of $4.5 million in net milestone revenue under the I-Mab Agreement.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases were partially offset by:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition during the nine months ended September 30, 2020 of a $12.0 million payment from Boehringer Ingelheim International GmbH for retention of rights to two DART molecules;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of approximately $7.1 million in revenue recognized under the Incyte Clinical Supply Agreement due to decreased development activity; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $4.9 million in revenue recognized under the  NIAID contract due to decreased development costs related to the second DART molecule; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $3.6 million in revenue recognized under the 2018 Zai Lab Agreement due to a milestone being recognized in the first quarter of 2020.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-bottom:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales for the three and nine months ended September 30, 2021 consisted primarily of reserves for unsaleable inventory, as well as product royalties. Product sold during the three and nine months ended September 30, 2021 consisted of drug product that was previously charged to research and development expense prior to FDA approval of MARGENZA, which favorably impacted our gross margin for the three and nine months ended September 30, 2021. No similar cost of product sales was recognized during the three and nine months ended September 30, 2020, as there were no sales of MARGENZA during those periods.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our research and development expense for the three and nine months ended September&#160;30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:34.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margetuximab</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC018</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flotetuzumab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retifanlimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tebotelimab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enoblituzumab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMGC936</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DART molecules under HIV government contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other programs (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">158.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">150.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  Includes research and discovery projects, as well as early preclinical and terminated molecules.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expense for the three months ended September 30, 2021 increased by $5.1 million compared to the three months ended September 30, 2020 primarily due to:</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development, manufacturing and clinical trial costs related to MGC018;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development of discovery projects and preclinical molecules; </span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased clinical trial enrollment costs related to enoblituzumab; and</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased clinical trial costs related to IMGC936.</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These increases were partially offset by:</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">decreased clinical trial and BLA support costs for margetuximab; and</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">decreased development and manufacturing costs related to flotetuzumab.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our research and development expense for the nine months ended September 30, 2021 increased by $7.8 million compared to the nine months ended September 30, 2020 primarily due to:</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased MGC018 development, manufacturing and clinical trial costs related to our Phase 1 dose expansion study;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development of discovery projects and preclinical molecules;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased flotetuzumab development and clinical trial costs related to our Phase 1/2 dose expansion study; </span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">IND preparation activities for MGD024; and</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased clinical trial costs related to our MGD019 Phase 1 dose expansion study.</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These increases were partially offset by:</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased clinical trial and BLA support costs for margetuximab;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development and manufacturing costs related to retifanlimab due to timing of manufacturing activities for Incyte under the Incyte supply agreements;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development and manufacturing costs related to tebotelimab; and</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development and manufacturing costs related to our NIAID contract.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect our research and development expense will continue to increase as we progress our pipeline of product candidates. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $7.4 million for the three months ended September 30, 2021 compared to the three months ended September 30, 2020, and by $17.3 million for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020, due to costs related to the launch of MARGENZA, as well as increased labor-related costs and legal expenses.  We expect our selling, general and administrative expense to continue to increase as we continue the launch of  MARGENZA.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in other income for the three months ended September 30, 2021 compared to the three months ended September 30, 2020 is primarily due to increased investment income. The decrease in other income for the nine months ended September 30, 2021 compared to the three and nine months ended September 30, 2020 is primarily due to decreased investment income.</span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_76"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, we have primarily funded our operations with proceeds from the sale of our common stock in equity offerings, revenue from our multiple collaboration agreements, and contracts and grants from NIAID.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews our available liquidity relative to our operating budget and forecast to monitor the sufficiency of our working capital, and anticipates continuing to draw upon available sources of capital, including equity and debt instruments,  to support our product development activities. There can be no assurances that new sources of capital will be available to us on commercially acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require us to give up some or all rights to a product or technology at less than its full potential value. If we are unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, we will assess our capital resources and may be required to delay, reduce the scope of, or eliminate one or more of our product research and development programs or clinical studies, and/or downsize our organization</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of September&#160;30, 2021, plus consideration received from Zai Lab in July 2021, as well as anticipated and potential collaboration payments, and product revenues should enable us to fund our operations through 2023, assuming our programs and collaborations advance as currently contemplated.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to our business, the COVID-19 pandemic might unfavorably impact our ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to the COVID-19 pandemic and its variants, we will continue to evaluate the nature and extent of the impact of the pandemic on our business and financial position. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a summary of our cash flows for the nine months ended September&#160;30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:64.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.494%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in operating activities reflects, among other things, the amounts used to advance our clinical trials and preclinical activities. The principal use of cash in operating activities for all periods presented was primarily the result of our net loss, adjusted for non-cash items. The nine months ended September&#160;30, 2021 benefited from the $25.0 million upfront payment under the 2021 Zai Lab Agreement and the $10.4 million premium over the share price under the Stock Purchase Agreement with Zai Lab.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities during the nine months ended September 30, 2021 is primarily due to purchases of marketable securities, partially offset by maturities of marketable securities.  Net cash provided by investing activities during the nine months ended September 30, 2020 is primarily due to maturities of marketable securities, partially offset by purchases of marketable securities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the nine months ended September&#160;30, 2021 reflects net cash proceeds from our securities offerings of approximately $98.2 million and approximately $19.6 million from Zai Lab under the Stock Purchase Agreement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_79"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission (SEC).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="idd97f2f67fc84defb53bffbcae4606c1_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary objective when considering our investment activities is to preserve capital in order to fund our operations.&#160;We also seek to maximize income from our investments without assuming significant risk.&#160;&#160;Our current investment policy is to invest principally in deposits and securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations, corporate debt obligations and money market instruments.&#160;&#160;As of September&#160;30, 2021, we had cash, cash equivalents and marketable securities of $298.9 million.&#160;&#160;Our primary exposure to market risk is related to changes in interest rates.&#160;&#160;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term maturities of our cash equivalents and marketable securities and the low risk profile of our marketable securities, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities. We have the ability to hold our marketable securities until maturity, and we therefore do not expect a change in market interest rates to affect our operating results or cash flows to any significant degree.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_85"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONTROLS AND PROCEDURES</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of September&#160;30, 2021. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in our periodic reports filed with the SEC (such as this Quarterly Report on Form 10-Q) has been appropriately recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Based on their evaluation of our disclosure controls and procedures as of September&#160;30, 2021, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the three months ended September 30, 2021 that materially affected, or are reasonably likely to materially effect, our internal control over financial reporting.</span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_88"></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_91"></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Legal Proceedings</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are or may be involved in various legal or regulatory proceedings, claims or  class actions related to alleged patent infringements and other  intellectual property rights, or alleged violation of commercial, corporate, securities, labor and employment, and other matters incidental to our business. We do not currently, however, expect such legal proceedings to have a material adverse effect on our business, financial condition or results of operations. However, depending on the nature and timing of a given dispute, an eventual unfavorable resolution could materially affect our current or future results of operations or cash flows.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See note 9, Commitments and Contingencies, to the consolidated financial statements of this Quarterly Report on Form 10-Q for more information.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_94"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:7.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk Factors</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been no material changes in the risk factors described in &#8220;Item 1A. Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="idd97f2f67fc84defb53bffbcae4606c1_97"></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2021, we entered into a stock purchase agreement in which we agreed to issue and sell to Zai Lab an aggregate of 958,467 newly issued shares of our common stock (Shares), with a per share purchase price of $31.30 for aggregate gross proceeds of approximately $30.0 million. We completed the private placement on July 1, 2021. Our offering and sale of the Shares were made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended. For more information, please refer to Part I, Item 2, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation - Collaborations - Zai Lab" in this Quarterly Report on Form 10-Q.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="idd97f2f67fc84defb53bffbcae4606c1_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:6.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:14.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31-1q32021.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31-2q32021.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32-1q32021.htm">Section 1350 Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32-2q32021.htm">Section 1350 Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Schema Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Calculation Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Definition Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Labels Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Presentation Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data (formatted as Inline XBRL and contained in Exhibit 101 filed herewith)</span></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idd97f2f67fc84defb53bffbcae4606c1_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MACROGENICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Koenig</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Karrels</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Karrels</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November 2, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit31-1q32021.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i12ec0392206645919ffe317909275a77_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended September&#160;30, 2021 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; November&#160;2, 2021 </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit31-2q32021.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i557ca54719fa4dceba603f48f7c044e1_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended September&#160;30, 2021 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President and Chief Financial Officer</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; November&#160;2, 2021 </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit32-1q32021.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i5face76466f74946983511f48cfd7631_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to 18 U.S.C. 1350</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Section 906 of the Sarbanes-Oxley Act of 2002</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the Registrant), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended&#160;September&#160;30, 2021&#160;of the Registrant (the Report), that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="padding-left:22pt;text-indent:-22pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;2, 2021 </font></div><div style="padding-left:252pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit32-2q32021.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ibe7b4a5566574897b1eefe139589f51c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.2</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to 18 U.S.C. 1350</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the Registrant), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended&#160;September&#160;30, 2021&#160;of the Registrant (the Report), that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;2, 2021 </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>mgnx-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a503bed0-470c-42a0-8ff2-08d40b83c4e7,g:0544a414-ac6d-4106-af60-27149bd97a9a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://macrogenics.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperations" roleURI="http://macrogenics.com/role/NatureofOperations">
        <link:definition>2101101 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments">
        <link:definition>2104103 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>2305301 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsDetails" roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails">
        <link:definition>2406401 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://macrogenics.com/role/MarketableSecurities">
        <link:definition>2107104 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://macrogenics.com/role/MarketableSecuritiesTables">
        <link:definition>2308302 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails">
        <link:definition>2409402 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNet" roleURI="http://macrogenics.com/role/InventoryNet">
        <link:definition>2110105 - Disclosure - Inventory, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetTables" roleURI="http://macrogenics.com/role/InventoryNetTables">
        <link:definition>2311303 - Disclosure - Inventory, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetDetails" roleURI="http://macrogenics.com/role/InventoryNetDetails">
        <link:definition>2412403 - Disclosure - Inventory, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://macrogenics.com/role/StockholdersEquity">
        <link:definition>2113106 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://macrogenics.com/role/StockholdersEquityDetails">
        <link:definition>2414404 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreements" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements">
        <link:definition>2115107 - Disclosure - Collaboration and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIncyteCorporationDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails">
        <link:definition>2416405 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsZaiLabDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails">
        <link:definition>2417406 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsJanssenDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails">
        <link:definition>2418407 - Disclosure - Collaboration and Other Agreements - Janssen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIMabBiopharmaDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails">
        <link:definition>2419408 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsNIAIDContractDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails">
        <link:definition>2420409 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://macrogenics.com/role/StockBasedCompensation">
        <link:definition>2121108 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://macrogenics.com/role/StockBasedCompensationTables">
        <link:definition>2322304 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2423410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionPricingAssumptionsDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails">
        <link:definition>2424411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2425412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationRestrictedStockUnitActivityDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails">
        <link:definition>2426413 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://macrogenics.com/role/CommitmentsandContingencies">
        <link:definition>2127109 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mgnx_JanssenCollaborationAndLicenseAgreementMember" abstract="true" name="JanssenCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementMember" abstract="true" name="IncyteMGA012AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" abstract="false" name="PotentialCommercialMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" abstract="false" name="NonrefundableUpfrontFeesNetOfTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" abstract="false" name="CollaborationAndOtherAgreementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mgnx_RevenuesFromLicenseAgreementsMember" abstract="true" name="RevenuesFromLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IncyteCorporationMember" abstract="true" name="IncyteCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" abstract="false" name="PotentialMilestonePaymentsAndRoyaltiesOnProductSales" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenueFromGovernmentAgreementsMember" abstract="true" name="RevenueFromGovernmentAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_OptInFee" abstract="false" name="OptInFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_JanssenBiotechIncMember" abstract="true" name="JanssenBiotechIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_StockIncentivePlan2013Member" abstract="true" name="StockIncentivePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ProceedsfromRoyaltiesPercent" abstract="false" name="ProceedsfromRoyaltiesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_RevenuesNetOfTaxWithholding" abstract="false" name="RevenuesNetOfTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" abstract="true" name="A2018ZaiLabCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IMabBiopharmaMember" abstract="true" name="IMabBiopharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" abstract="false" name="PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_IncyteMGA012SupplyAgreementMember" abstract="true" name="IncyteMGA012SupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_NonrefundablePaymentTaxWithholding" abstract="false" name="NonrefundablePaymentTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NonRefundableUpfrontFees" abstract="false" name="NonRefundableUpfrontFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabClinicalSupplyAgreementsMember" abstract="true" name="ZaiLabClinicalSupplyAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" abstract="false" name="ProceedsfromStockOptionsExercisedAndESPPPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandSixteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012ClinicalServicesMember" abstract="true" name="IncyteMGA012ClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" abstract="false" name="PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesTaxWithholding" abstract="false" name="RevenuesTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenueFromCollaborativeAgreementsMember" abstract="true" name="RevenueFromCollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PremiumReceivedOnStockPurchase" abstract="false" name="PremiumReceivedOnStockPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementClinicalActivitiesMember" abstract="true" name="IncyteMGA012AgreementClinicalActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" abstract="false" name="RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_TotalPotentialValueUnderAgreement" abstract="false" name="TotalPotentialValueUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabMember" abstract="true" name="ZaiLabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuance" abstract="false" name="CommonStockMaximumAmountAvailableForIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" abstract="false" name="DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_A2003StockIncentivePlanMember" abstract="true" name="A2003StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" abstract="false" name="RevenueInformationUsedToAssessVariableConsiderationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesFromGrantsMember" abstract="true" name="RevenuesFromGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" abstract="false" name="CommonStockMaximumAmountAvailableForIssuanceIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" abstract="true" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" abstract="true" name="IMabBiopharmaCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementTransactionPrice" abstract="false" name="CollaborativeAgreementTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" abstract="false" name="NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_A2021ZaiLabAgreementsMember" abstract="true" name="A2021ZaiLabAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" abstract="true" name="RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>mgnx-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a503bed0-470c-42a0-8ff2-08d40b83c4e7,g:0544a414-ac6d-4106-af60-27149bd97a9a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d74af645-2d36-4521-a9d0-a3b284e178d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9be71134-1c93-48ec-a599-e435200c7a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d74af645-2d36-4521-a9d0-a3b284e178d9" xlink:to="loc_us-gaap_AssetsCurrent_9be71134-1c93-48ec-a599-e435200c7a5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2362ae8b-311e-4611-b857-8fb42003bf49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d74af645-2d36-4521-a9d0-a3b284e178d9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2362ae8b-311e-4611-b857-8fb42003bf49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_71fa7840-2805-45d2-9723-08caa8ef6c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d74af645-2d36-4521-a9d0-a3b284e178d9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_71fa7840-2805-45d2-9723-08caa8ef6c01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2ddd50d6-86fd-4647-bcdf-1b89124add2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_f62c4130-4edc-4298-b693-56ce5dd35956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2ddd50d6-86fd-4647-bcdf-1b89124add2a" xlink:to="loc_us-gaap_Investments_f62c4130-4edc-4298-b693-56ce5dd35956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7105356f-17c0-40ab-a966-d048d022ef64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2ddd50d6-86fd-4647-bcdf-1b89124add2a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7105356f-17c0-40ab-a966-d048d022ef64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b83a5fc0-6f7a-4076-9128-3b311439fff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2ddd50d6-86fd-4647-bcdf-1b89124add2a" xlink:to="loc_us-gaap_InventoryNet_b83a5fc0-6f7a-4076-9128-3b311439fff8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_39c8fd00-0be9-4f28-a089-4ee10229e82c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2ddd50d6-86fd-4647-bcdf-1b89124add2a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_39c8fd00-0be9-4f28-a089-4ee10229e82c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dfe247d9-7941-42ef-8bfd-3ac0855cc60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2ddd50d6-86fd-4647-bcdf-1b89124add2a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dfe247d9-7941-42ef-8bfd-3ac0855cc60f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4aa42b71-5abf-4691-8cb5-0056992f9823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8fd17f7c-cfeb-4818-8079-434f983b5fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4aa42b71-5abf-4691-8cb5-0056992f9823" xlink:to="loc_us-gaap_Liabilities_8fd17f7c-cfeb-4818-8079-434f983b5fcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eb8d2432-1921-4260-bda8-235db331b2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4aa42b71-5abf-4691-8cb5-0056992f9823" xlink:to="loc_us-gaap_StockholdersEquity_eb8d2432-1921-4260-bda8-235db331b2df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4834652f-6e30-4a1b-80a2-b46b5def0ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_72148542-c42d-41bd-9828-cc4ee512cb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4834652f-6e30-4a1b-80a2-b46b5def0ca6" xlink:to="loc_us-gaap_AccountsPayableCurrent_72148542-c42d-41bd-9828-cc4ee512cb4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b4c93889-0a4e-458c-8dfb-9e25969e2ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4834652f-6e30-4a1b-80a2-b46b5def0ca6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b4c93889-0a4e-458c-8dfb-9e25969e2ca0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_56610a6b-7af1-4916-9c5b-4c93d6fa322b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4834652f-6e30-4a1b-80a2-b46b5def0ca6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_56610a6b-7af1-4916-9c5b-4c93d6fa322b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cd4d4d10-8c82-4ed8-b293-746a08c4c994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4834652f-6e30-4a1b-80a2-b46b5def0ca6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cd4d4d10-8c82-4ed8-b293-746a08c4c994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bc26bed6-a766-4446-a94b-9cc31e1305e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9ab246ff-ca80-45c9-9be7-1f2604194648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bc26bed6-a766-4446-a94b-9cc31e1305e8" xlink:to="loc_us-gaap_LiabilitiesCurrent_9ab246ff-ca80-45c9-9be7-1f2604194648" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_04da4940-5469-43c4-9cf0-d75fa3660291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bc26bed6-a766-4446-a94b-9cc31e1305e8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_04da4940-5469-43c4-9cf0-d75fa3660291" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8ab5ab5a-cb08-403b-bbbe-1a125e9cea3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bc26bed6-a766-4446-a94b-9cc31e1305e8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8ab5ab5a-cb08-403b-bbbe-1a125e9cea3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_44625ae5-ca86-4350-ac77-53d52f05b6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bc26bed6-a766-4446-a94b-9cc31e1305e8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_44625ae5-ca86-4350-ac77-53d52f05b6a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ed4b816e-8c95-4757-88c5-476ebf9b99fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cd90c43b-0eff-4110-b82a-4ea50217e26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ed4b816e-8c95-4757-88c5-476ebf9b99fb" xlink:to="loc_us-gaap_CommonStockValue_cd90c43b-0eff-4110-b82a-4ea50217e26c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_89363d8b-7719-4aca-84c1-f6b07cbfcc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ed4b816e-8c95-4757-88c5-476ebf9b99fb" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_89363d8b-7719-4aca-84c1-f6b07cbfcc3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33d67c4a-f261-40c4-a325-70f90037e2de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ed4b816e-8c95-4757-88c5-476ebf9b99fb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33d67c4a-f261-40c4-a325-70f90037e2de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1193bcba-e277-43a9-afdc-02c09cd50d00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ed4b816e-8c95-4757-88c5-476ebf9b99fb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1193bcba-e277-43a9-afdc-02c09cd50d00" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_741d2792-b1d2-448a-97c7-f006e5df8957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ffc0c720-f194-4f89-891d-2703cbc6d2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_741d2792-b1d2-448a-97c7-f006e5df8957" xlink:to="loc_us-gaap_Revenues_ffc0c720-f194-4f89-891d-2703cbc6d2f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_10c3bc93-d9f0-42d3-b12b-8b4c76466cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_741d2792-b1d2-448a-97c7-f006e5df8957" xlink:to="loc_us-gaap_CostsAndExpenses_10c3bc93-d9f0-42d3-b12b-8b4c76466cbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c1703c07-524c-4667-9e1a-147efa7032ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b7a39dfc-aa0c-4698-881b-19a3c9bccf76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c1703c07-524c-4667-9e1a-147efa7032ea" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b7a39dfc-aa0c-4698-881b-19a3c9bccf76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_88f48bca-2b6b-45e4-8ac7-6c0158e373c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c1703c07-524c-4667-9e1a-147efa7032ea" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_88f48bca-2b6b-45e4-8ac7-6c0158e373c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e196635e-1051-4204-85ec-811081a1dfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c1703c07-524c-4667-9e1a-147efa7032ea" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e196635e-1051-4204-85ec-811081a1dfe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_28fb5637-7f00-4c41-8a86-9ad6a0aef1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b4f05293-c1ce-4183-9208-ce5dd0c52cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_28fb5637-7f00-4c41-8a86-9ad6a0aef1c4" xlink:to="loc_us-gaap_OperatingIncomeLoss_b4f05293-c1ce-4183-9208-ce5dd0c52cd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0ad96c0b-44ad-4594-ba14-867f428be023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_28fb5637-7f00-4c41-8a86-9ad6a0aef1c4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0ad96c0b-44ad-4594-ba14-867f428be023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_628ffcd9-619f-4c7a-b335-440d4cac7a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ed32774f-8d4a-4f7a-ad45-2fab1dc032db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_628ffcd9-619f-4c7a-b335-440d4cac7a4a" xlink:to="loc_us-gaap_NetIncomeLoss_ed32774f-8d4a-4f7a-ad45-2fab1dc032db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_23908d46-ce34-418a-8b87-fcb81ba97ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_628ffcd9-619f-4c7a-b335-440d4cac7a4a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_23908d46-ce34-418a-8b87-fcb81ba97ee6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_56a2a21a-603f-4d72-955b-dea100e2d132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2ff2e852-b7a7-4b5b-adaf-492f9b71499d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_56a2a21a-603f-4d72-955b-dea100e2d132" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2ff2e852-b7a7-4b5b-adaf-492f9b71499d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2e2d0b87-a6a7-429d-a212-ed0a8831fd91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_56a2a21a-603f-4d72-955b-dea100e2d132" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2e2d0b87-a6a7-429d-a212-ed0a8831fd91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d0eadadd-fdde-4a4c-81f5-c1ec27cf8ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_56a2a21a-603f-4d72-955b-dea100e2d132" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d0eadadd-fdde-4a4c-81f5-c1ec27cf8ef0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13c200a5-eea8-4ff8-877f-817e3dcf5a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0e9d7a4b-3051-412c-8bd5-1f24ecca1d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13c200a5-eea8-4ff8-877f-817e3dcf5a8f" xlink:to="loc_us-gaap_NetIncomeLoss_0e9d7a4b-3051-412c-8bd5-1f24ecca1d7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e2ff2d5a-baaf-4428-b1f1-a4e229511f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13c200a5-eea8-4ff8-877f-817e3dcf5a8f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e2ff2d5a-baaf-4428-b1f1-a4e229511f21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_60848940-f5bd-40c5-a5b4-a1b345d2c198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13c200a5-eea8-4ff8-877f-817e3dcf5a8f" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_60848940-f5bd-40c5-a5b4-a1b345d2c198" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4e447f28-5d10-4058-a30a-abdd75ddbbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13c200a5-eea8-4ff8-877f-817e3dcf5a8f" xlink:to="loc_us-gaap_ShareBasedCompensation_4e447f28-5d10-4058-a30a-abdd75ddbbd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c2429bcc-d203-4271-849a-f65cc93b8315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13c200a5-eea8-4ff8-877f-817e3dcf5a8f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c2429bcc-d203-4271-849a-f65cc93b8315" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c03e2918-6741-4b6f-b677-87745ee824f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13c200a5-eea8-4ff8-877f-817e3dcf5a8f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c03e2918-6741-4b6f-b677-87745ee824f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2634f2eb-7647-4e17-8bbc-ea29e386d563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13c200a5-eea8-4ff8-877f-817e3dcf5a8f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2634f2eb-7647-4e17-8bbc-ea29e386d563" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_816e48d0-575d-496e-8fd8-746ec3229b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13c200a5-eea8-4ff8-877f-817e3dcf5a8f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_816e48d0-575d-496e-8fd8-746ec3229b3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_675d70e0-c47e-4c17-8305-4b12dabeb0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13c200a5-eea8-4ff8-877f-817e3dcf5a8f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_675d70e0-c47e-4c17-8305-4b12dabeb0b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_17fedaca-825f-4787-a194-75a545854e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13c200a5-eea8-4ff8-877f-817e3dcf5a8f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_17fedaca-825f-4787-a194-75a545854e3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_444337a4-5e5f-4b0d-b675-9df2756b2f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13c200a5-eea8-4ff8-877f-817e3dcf5a8f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_444337a4-5e5f-4b0d-b675-9df2756b2f45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_42b40687-e323-4656-8193-8a2aee9bf8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13c200a5-eea8-4ff8-877f-817e3dcf5a8f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_42b40687-e323-4656-8193-8a2aee9bf8b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e0bb9ce4-741c-4611-9d8d-ce3817b8cdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13c200a5-eea8-4ff8-877f-817e3dcf5a8f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e0bb9ce4-741c-4611-9d8d-ce3817b8cdcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2dd10da5-02da-4d71-8df9-377136872fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13c200a5-eea8-4ff8-877f-817e3dcf5a8f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2dd10da5-02da-4d71-8df9-377136872fcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_467e8fe3-9b7e-46c3-afe5-6390bdc78bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_965ea4f9-aad7-4502-89e8-470a83f9a018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_467e8fe3-9b7e-46c3-afe5-6390bdc78bad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_965ea4f9-aad7-4502-89e8-470a83f9a018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13d90650-7a52-48a7-9a09-ec9a79d051ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_467e8fe3-9b7e-46c3-afe5-6390bdc78bad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13d90650-7a52-48a7-9a09-ec9a79d051ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4708c6d4-93f0-48b5-839f-8c3ac418a1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_467e8fe3-9b7e-46c3-afe5-6390bdc78bad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4708c6d4-93f0-48b5-839f-8c3ac418a1c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c630a44f-c85e-4bf7-9fad-af9277569ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d63c0409-b850-48ce-a584-390a178d2b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c630a44f-c85e-4bf7-9fad-af9277569ae5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d63c0409-b850-48ce-a584-390a178d2b88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_fad86596-7b67-4bd0-a8ac-392a389a2f67" xlink:href="mgnx-20210930.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c630a44f-c85e-4bf7-9fad-af9277569ae5" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_fad86596-7b67-4bd0-a8ac-392a389a2f67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f58d9720-a9bc-4eb0-a1eb-e6665de40610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c630a44f-c85e-4bf7-9fad-af9277569ae5" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f58d9720-a9bc-4eb0-a1eb-e6665de40610" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3f326a4a-8372-4330-a502-d0d58bcb085e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c0bb6303-5642-463d-96e8-ba2e97da1fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3f326a4a-8372-4330-a502-d0d58bcb085e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c0bb6303-5642-463d-96e8-ba2e97da1fa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_58b6b3e1-9cef-4841-8f8a-3b484c87ee67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3f326a4a-8372-4330-a502-d0d58bcb085e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_58b6b3e1-9cef-4841-8f8a-3b484c87ee67" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_806bf1f4-2e6a-44d6-afb3-d443a0224238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8eee7a3a-d9da-42e9-b26f-20b97e44fbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_806bf1f4-2e6a-44d6-afb3-d443a0224238" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8eee7a3a-d9da-42e9-b26f-20b97e44fbbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_77606b8c-3352-41c4-a4ea-26b765eabba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_806bf1f4-2e6a-44d6-afb3-d443a0224238" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_77606b8c-3352-41c4-a4ea-26b765eabba5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_efc1f29b-70ed-4d25-81e9-f03e84874906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_806bf1f4-2e6a-44d6-afb3-d443a0224238" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_efc1f29b-70ed-4d25-81e9-f03e84874906" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#InventoryNetDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/InventoryNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fa10e61e-9a39-431a-a794-326fdfe62fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_59b7610d-7a67-4315-a148-d4d26a6fbe6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_fa10e61e-9a39-431a-a794-326fdfe62fcc" xlink:to="loc_us-gaap_InventoryWorkInProcess_59b7610d-7a67-4315-a148-d4d26a6fbe6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_817751ad-af6f-4aa7-9c3c-643fb01c8cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_fa10e61e-9a39-431a-a794-326fdfe62fcc" xlink:to="loc_us-gaap_InventoryRawMaterials_817751ad-af6f-4aa7-9c3c-643fb01c8cf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_1efbcad2-96db-4cb8-b6e9-9a85d07d0ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_fa10e61e-9a39-431a-a794-326fdfe62fcc" xlink:to="loc_us-gaap_InventoryFinishedGoods_1efbcad2-96db-4cb8-b6e9-9a85d07d0ef5" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>mgnx-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a503bed0-470c-42a0-8ff2-08d40b83c4e7,g:0544a414-ac6d-4106-af60-27149bd97a9a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="ife157b8304f84797985ac52667de6e24_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_23517bd1-ec85-4232-83eb-d43a53fcc230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:to="loc_us-gaap_RevenuesAbstract_23517bd1-ec85-4232-83eb-d43a53fcc230" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9dee226d-abd6-4e16-a0e9-b349e3677dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_23517bd1-ec85-4232-83eb-d43a53fcc230" xlink:to="loc_us-gaap_Revenues_9dee226d-abd6-4e16-a0e9-b349e3677dd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_82a823e0-2e16-4615-befa-2bb7d4ae59a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_82a823e0-2e16-4615-befa-2bb7d4ae59a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0b133dca-927b-4e1f-aa58-659c452e6d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0b133dca-927b-4e1f-aa58-659c452e6d3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5a74a869-812f-4d4b-89ac-edfb7c54b2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5a74a869-812f-4d4b-89ac-edfb7c54b2f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_385e02cc-bc07-4958-b17d-893382e547dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:to="loc_us-gaap_CostsAndExpenses_385e02cc-bc07-4958-b17d-893382e547dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f74e4aba-b657-4ebc-885e-0f588b02ef45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:to="loc_us-gaap_OperatingIncomeLoss_f74e4aba-b657-4ebc-885e-0f588b02ef45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ef7a4c75-b1ad-41ca-9e6a-edb809010160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ef7a4c75-b1ad-41ca-9e6a-edb809010160" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6af021b2-b915-4aba-ba44-8bee70d3f7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:to="loc_us-gaap_NetIncomeLoss_6af021b2-b915-4aba-ba44-8bee70d3f7b0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2d7f7280-80eb-4fda-a7e6-d28c73df0efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2d7f7280-80eb-4fda-a7e6-d28c73df0efa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_18db5ade-612b-4451-bf74-f46f2b68d1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2d7f7280-80eb-4fda-a7e6-d28c73df0efa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_18db5ade-612b-4451-bf74-f46f2b68d1b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_57c55199-cfcd-4e57-b949-6160abd151a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_57c55199-cfcd-4e57-b949-6160abd151a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7a6afb41-0187-4d98-bff1-e76228cbc6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:to="loc_us-gaap_EarningsPerShareBasic_7a6afb41-0187-4d98-bff1-e76228cbc6c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4ca0ef78-bf1c-4c0c-8d52-61e68ce10efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4ca0ef78-bf1c-4c0c-8d52-61e68ce10efe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c2349a81-d7dd-4f5a-87a6-fd8bd85a2dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c2349a81-d7dd-4f5a-87a6-fd8bd85a2dff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_43d478dc-48e9-45be-8c0f-ca5cab624bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_43d478dc-48e9-45be-8c0f-ca5cab624bd9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9a994a15-d971-4f2f-9ab4-83076f1336b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:to="loc_us-gaap_StatementTable_9a994a15-d971-4f2f-9ab4-83076f1336b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e4bc93e2-b9ff-4c60-928b-72151daabcdf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9a994a15-d971-4f2f-9ab4-83076f1336b4" xlink:to="loc_srt_ProductOrServiceAxis_e4bc93e2-b9ff-4c60-928b-72151daabcdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e4bc93e2-b9ff-4c60-928b-72151daabcdf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e4bc93e2-b9ff-4c60-928b-72151daabcdf" xlink:to="loc_srt_ProductsAndServicesDomain_e4bc93e2-b9ff-4c60-928b-72151daabcdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_89329d38-8dbc-4e95-b6d9-9e4f7ef990df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e4bc93e2-b9ff-4c60-928b-72151daabcdf" xlink:to="loc_srt_ProductsAndServicesDomain_89329d38-8dbc-4e95-b6d9-9e4f7ef990df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_bc32a8b4-5cea-4d68-9f99-5f45bc7f2153" xlink:href="mgnx-20210930.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89329d38-8dbc-4e95-b6d9-9e4f7ef990df" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_bc32a8b4-5cea-4d68-9f99-5f45bc7f2153" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_aa9b1dd3-457d-4f72-8878-138fef6538f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89329d38-8dbc-4e95-b6d9-9e4f7ef990df" xlink:to="loc_us-gaap_ProductMember_aa9b1dd3-457d-4f72-8878-138fef6538f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_17fc18e5-fff9-4ab5-b7a1-633f0875ca5a" xlink:href="mgnx-20210930.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89329d38-8dbc-4e95-b6d9-9e4f7ef990df" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_17fc18e5-fff9-4ab5-b7a1-633f0875ca5a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i77021fa6a5104b37900bc1a5837b17da_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_508b2cd9-6a88-4a87-ab30-e73c27f7036e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_508b2cd9-6a88-4a87-ab30-e73c27f7036e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_09f48395-a08e-43e7-ae03-b5d05b32e6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_SharesIssued_09f48395-a08e-43e7-ae03-b5d05b32e6fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11f48b29-c2c1-47bc-9671-be86a39abc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11f48b29-c2c1-47bc-9671-be86a39abc2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_82177561-d290-407e-afe3-b1f7294e8950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_82177561-d290-407e-afe3-b1f7294e8950" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_46fa2487-ba1f-4561-a7c5-28a5088477c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_46fa2487-ba1f-4561-a7c5-28a5088477c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9d67a393-e032-4c8f-bb29-b57452420e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9d67a393-e032-4c8f-bb29-b57452420e7b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_99ebc62e-2d67-4022-a63e-cec4e6552bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_99ebc62e-2d67-4022-a63e-cec4e6552bad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_2938953a-9e10-43e7-a317-3bc549ec483d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_2938953a-9e10-43e7-a317-3bc549ec483d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_46a8d194-45c1-4f62-9259-2474be0f5153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_46a8d194-45c1-4f62-9259-2474be0f5153" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_b7437093-ee3a-48d5-abb1-84096852b32e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_b7437093-ee3a-48d5-abb1-84096852b32e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_32600531-04cf-422f-8e72-4861bf017094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_32600531-04cf-422f-8e72-4861bf017094" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_61fa9adb-139e-4f76-8fdd-a8f20c50d0af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_NetIncomeLoss_61fa9adb-139e-4f76-8fdd-a8f20c50d0af" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_eea788eb-c82e-4e8a-886c-0ef04476791c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6591fef6-b602-4c74-8089-82015f7feeec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8ea7872b-0747-46b3-89f0-686051246949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_508b2cd9-6a88-4a87-ab30-e73c27f7036e" xlink:to="loc_us-gaap_StatementTable_8ea7872b-0747-46b3-89f0-686051246949" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5e902636-3657-49ea-a4db-51e7d821728b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8ea7872b-0747-46b3-89f0-686051246949" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5e902636-3657-49ea-a4db-51e7d821728b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5e902636-3657-49ea-a4db-51e7d821728b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5e902636-3657-49ea-a4db-51e7d821728b" xlink:to="loc_us-gaap_EquityComponentDomain_5e902636-3657-49ea-a4db-51e7d821728b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_167897aa-d22f-4dd6-aa97-7661430db927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5e902636-3657-49ea-a4db-51e7d821728b" xlink:to="loc_us-gaap_EquityComponentDomain_167897aa-d22f-4dd6-aa97-7661430db927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_dcc45f5e-2546-4c13-8ce1-0558a5b6a066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_167897aa-d22f-4dd6-aa97-7661430db927" xlink:to="loc_us-gaap_CommonStockMember_dcc45f5e-2546-4c13-8ce1-0558a5b6a066" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_46ca279e-58de-4b16-809d-35b58490826c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_167897aa-d22f-4dd6-aa97-7661430db927" xlink:to="loc_us-gaap_TreasuryStockMember_46ca279e-58de-4b16-809d-35b58490826c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d75f6601-b74d-4657-9da5-7d01ae5d84ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_167897aa-d22f-4dd6-aa97-7661430db927" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d75f6601-b74d-4657-9da5-7d01ae5d84ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4b237f35-97f4-4c1b-984f-e88e94b978eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_167897aa-d22f-4dd6-aa97-7661430db927" xlink:to="loc_us-gaap_RetainedEarningsMember_4b237f35-97f4-4c1b-984f-e88e94b978eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_87c4dcc5-59f2-4d79-a70f-f27736a635bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_167897aa-d22f-4dd6-aa97-7661430db927" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_87c4dcc5-59f2-4d79-a70f-f27736a635bf" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended" id="i928b507cb8f14c51a8a4f8d680b99a4c_FairValueofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_88a331b9-9ca3-4ba2-857b-f9abb1e434cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_35ef28d5-de79-4157-ab43-7c2f40540b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_88a331b9-9ca3-4ba2-857b-f9abb1e434cc" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_35ef28d5-de79-4157-ab43-7c2f40540b28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_33308d16-b922-44cf-bf49-f2796e79a237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_35ef28d5-de79-4157-ab43-7c2f40540b28" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_33308d16-b922-44cf-bf49-f2796e79a237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_30b2ffe0-4192-43f0-a38a-5b65564dd322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_35ef28d5-de79-4157-ab43-7c2f40540b28" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_30b2ffe0-4192-43f0-a38a-5b65564dd322" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e95c3b9e-32c2-4150-80ce-e3db13168ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_35ef28d5-de79-4157-ab43-7c2f40540b28" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e95c3b9e-32c2-4150-80ce-e3db13168ee2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91136124-7439-4cb7-b881-15a69b3a4ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_88a331b9-9ca3-4ba2-857b-f9abb1e434cc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91136124-7439-4cb7-b881-15a69b3a4ddd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4ebdd628-88e8-4745-869c-bb4af56cc136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91136124-7439-4cb7-b881-15a69b3a4ddd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4ebdd628-88e8-4745-869c-bb4af56cc136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4ebdd628-88e8-4745-869c-bb4af56cc136_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4ebdd628-88e8-4745-869c-bb4af56cc136" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4ebdd628-88e8-4745-869c-bb4af56cc136_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_23b45fb2-94a4-4a62-a24b-36c57b0162a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4ebdd628-88e8-4745-869c-bb4af56cc136" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_23b45fb2-94a4-4a62-a24b-36c57b0162a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_aaef1792-ceff-4233-9868-b7d1484fe61a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_23b45fb2-94a4-4a62-a24b-36c57b0162a2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_aaef1792-ceff-4233-9868-b7d1484fe61a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_abf0b63e-c220-4333-81ac-d91ba2a78778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91136124-7439-4cb7-b881-15a69b3a4ddd" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_abf0b63e-c220-4333-81ac-d91ba2a78778" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_abf0b63e-c220-4333-81ac-d91ba2a78778_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_abf0b63e-c220-4333-81ac-d91ba2a78778" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_abf0b63e-c220-4333-81ac-d91ba2a78778_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f1e3affa-c7ab-4bda-a3dd-dce646cb91bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_abf0b63e-c220-4333-81ac-d91ba2a78778" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f1e3affa-c7ab-4bda-a3dd-dce646cb91bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_56c172ea-0304-43e4-89b5-253986fceeda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f1e3affa-c7ab-4bda-a3dd-dce646cb91bd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_56c172ea-0304-43e4-89b5-253986fceeda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4f937011-5633-4230-a219-1fede1482557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f1e3affa-c7ab-4bda-a3dd-dce646cb91bd" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4f937011-5633-4230-a219-1fede1482557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c663851f-b8b2-44bd-a7ae-6c8292b139c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f1e3affa-c7ab-4bda-a3dd-dce646cb91bd" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c663851f-b8b2-44bd-a7ae-6c8292b139c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f0caf576-2252-460a-b3dc-d7ef24f68972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f1e3affa-c7ab-4bda-a3dd-dce646cb91bd" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f0caf576-2252-460a-b3dc-d7ef24f68972" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1dbc7107-1949-4aca-a064-4f988976871d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91136124-7439-4cb7-b881-15a69b3a4ddd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1dbc7107-1949-4aca-a064-4f988976871d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1dbc7107-1949-4aca-a064-4f988976871d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1dbc7107-1949-4aca-a064-4f988976871d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1dbc7107-1949-4aca-a064-4f988976871d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0b5e312-e915-41f8-b519-3561099789a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1dbc7107-1949-4aca-a064-4f988976871d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0b5e312-e915-41f8-b519-3561099789a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f6015465-8a68-4049-8dc1-73a4d89d5c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0b5e312-e915-41f8-b519-3561099789a0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f6015465-8a68-4049-8dc1-73a4d89d5c16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_316c09e6-aabe-48dd-98b1-b5bcd2c4e9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0b5e312-e915-41f8-b519-3561099789a0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_316c09e6-aabe-48dd-98b1-b5bcd2c4e9b3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="i1e63ac4f5ade46d39ba1a52bd4b9c44d_MarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9e1aedea-42c6-4ec2-a1d4-5c3b5e023dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_39b530f7-48d5-4f15-bedf-d095f21f630e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9e1aedea-42c6-4ec2-a1d4-5c3b5e023dc1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_39b530f7-48d5-4f15-bedf-d095f21f630e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_30c7644c-97dd-4d03-862b-afb53246f807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9e1aedea-42c6-4ec2-a1d4-5c3b5e023dc1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_30c7644c-97dd-4d03-862b-afb53246f807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_054bac90-0599-47f6-8b08-338ec4fb8695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9e1aedea-42c6-4ec2-a1d4-5c3b5e023dc1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_054bac90-0599-47f6-8b08-338ec4fb8695" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9e1b38f4-fbac-420f-8023-eea1c6f6ad9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9e1aedea-42c6-4ec2-a1d4-5c3b5e023dc1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9e1b38f4-fbac-420f-8023-eea1c6f6ad9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_0b9e739c-1143-42ba-83fd-45f15b5e7dde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9e1aedea-42c6-4ec2-a1d4-5c3b5e023dc1" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_0b9e739c-1143-42ba-83fd-45f15b5e7dde" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_09ee1739-66ae-4b86-ba20-08bc68619dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_0b9e739c-1143-42ba-83fd-45f15b5e7dde" xlink:to="loc_us-gaap_FinancialInstrumentAxis_09ee1739-66ae-4b86-ba20-08bc68619dfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09ee1739-66ae-4b86-ba20-08bc68619dfd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_09ee1739-66ae-4b86-ba20-08bc68619dfd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09ee1739-66ae-4b86-ba20-08bc68619dfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97044cc5-e8be-410c-aa59-414d69c6bcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_09ee1739-66ae-4b86-ba20-08bc68619dfd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97044cc5-e8be-410c-aa59-414d69c6bcf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f14cbc22-0af7-4bdf-ae79-8d7c62e905f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97044cc5-e8be-410c-aa59-414d69c6bcf3" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f14cbc22-0af7-4bdf-ae79-8d7c62e905f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_d639f079-43f4-4696-b1cf-9c20a66c9fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97044cc5-e8be-410c-aa59-414d69c6bcf3" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_d639f079-43f4-4696-b1cf-9c20a66c9fe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_bd595fd6-34f4-4157-b086-aac30c211041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97044cc5-e8be-410c-aa59-414d69c6bcf3" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_bd595fd6-34f4-4157-b086-aac30c211041" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended" id="icabd9735cd00475f821844eb96049984_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_94c76df2-1c72-4a2b-a53c-e60f564ce408" xlink:href="mgnx-20210930.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_94c76df2-1c72-4a2b-a53c-e60f564ce408" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6a6954e7-bacf-4402-b3d4-2cf9d5b13bda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6a6954e7-bacf-4402-b3d4-2cf9d5b13bda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7fedfb76-9f9c-430f-ba7b-4e5d95913b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7fedfb76-9f9c-430f-ba7b-4e5d95913b14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_80d9f201-dd4b-4116-abf4-e9250981714d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_80d9f201-dd4b-4116-abf4-e9250981714d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_8f565ca8-04ec-42a8-ac95-9991507a9361" xlink:href="mgnx-20210930.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_8f565ca8-04ec-42a8-ac95-9991507a9361" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b1e4baf4-3f86-465b-9f9e-e6c0423ea20e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b1e4baf4-3f86-465b-9f9e-e6c0423ea20e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3fb3bfb9-f6ec-4da5-9f36-da2009cf19c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3fb3bfb9-f6ec-4da5-9f36-da2009cf19c3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ddfe20cd-d464-4967-a691-2fdcd9e363a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ddfe20cd-d464-4967-a691-2fdcd9e363a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6593b116-98fb-4e69-8ab8-0cfe4362fb31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ddfe20cd-d464-4967-a691-2fdcd9e363a0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6593b116-98fb-4e69-8ab8-0cfe4362fb31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6593b116-98fb-4e69-8ab8-0cfe4362fb31_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6593b116-98fb-4e69-8ab8-0cfe4362fb31" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6593b116-98fb-4e69-8ab8-0cfe4362fb31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2c17f1b4-6fc3-405a-b8fe-52d35418fb44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6593b116-98fb-4e69-8ab8-0cfe4362fb31" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2c17f1b4-6fc3-405a-b8fe-52d35418fb44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_6ebd69b3-2737-4bbf-9fe4-47edcd29de72" xlink:href="mgnx-20210930.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2c17f1b4-6fc3-405a-b8fe-52d35418fb44" xlink:to="loc_mgnx_AtTheMarketOfferingMember_6ebd69b3-2737-4bbf-9fe4-47edcd29de72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e5df14b2-79c8-4e77-9faf-25fa55aacff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ddfe20cd-d464-4967-a691-2fdcd9e363a0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e5df14b2-79c8-4e77-9faf-25fa55aacff5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e5df14b2-79c8-4e77-9faf-25fa55aacff5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e5df14b2-79c8-4e77-9faf-25fa55aacff5" xlink:to="loc_us-gaap_EquityComponentDomain_e5df14b2-79c8-4e77-9faf-25fa55aacff5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6f6fa835-14a9-4648-bed8-83278e2b7391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e5df14b2-79c8-4e77-9faf-25fa55aacff5" xlink:to="loc_us-gaap_EquityComponentDomain_6f6fa835-14a9-4648-bed8-83278e2b7391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_79ca4cbe-a525-44b9-a13d-843589c8c225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6f6fa835-14a9-4648-bed8-83278e2b7391" xlink:to="loc_us-gaap_CommonStockMember_79ca4cbe-a525-44b9-a13d-843589c8c225" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended" id="idc9cb2e0093941a7a50979e648831964_CollaborationandOtherAgreementsIncyteCorporationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_f8c4adbe-2c42-4b0a-94b2-0d23d6cffe66" xlink:href="mgnx-20210930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_mgnx_NonRefundableUpfrontFees_f8c4adbe-2c42-4b0a-94b2-0d23d6cffe66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_cb4e8a8c-b18b-4d19-8be4-f01c5527a0fe" xlink:href="mgnx-20210930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_cb4e8a8c-b18b-4d19-8be4-f01c5527a0fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_4487eb9e-c6fd-415e-97b8-f973d0ab1718" xlink:href="mgnx-20210930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_4487eb9e-c6fd-415e-97b8-f973d0ab1718" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_5dd1565a-1111-4026-abe2-80248fa01411" xlink:href="mgnx-20210930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_5dd1565a-1111-4026-abe2-80248fa01411" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_e1f40a8c-7baf-4335-b05b-882d22600523" xlink:href="mgnx-20210930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_e1f40a8c-7baf-4335-b05b-882d22600523" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_f6b144c9-7960-4c38-804a-5be1a39aa0f8" xlink:href="mgnx-20210930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_mgnx_NumberOfPerformanceObligations_f6b144c9-7960-4c38-804a-5be1a39aa0f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_a1f61003-eab5-4af3-a031-8660c06dcfd2" xlink:href="mgnx-20210930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_a1f61003-eab5-4af3-a031-8660c06dcfd2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_467d2791-084c-4b33-b920-43f43f147071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_us-gaap_Revenues_467d2791-084c-4b33-b920-43f43f147071" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_4db9669b-6a43-40e3-9c98-a18c0e985d8a" xlink:href="mgnx-20210930.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_4db9669b-6a43-40e3-9c98-a18c0e985d8a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bb90457-0a53-4966-81fd-0f1e5bf6647c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bb90457-0a53-4966-81fd-0f1e5bf6647c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_396e0ce0-b6fe-46e2-9917-bac428f6ce18" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bb90457-0a53-4966-81fd-0f1e5bf6647c" xlink:to="loc_srt_ProductOrServiceAxis_396e0ce0-b6fe-46e2-9917-bac428f6ce18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_396e0ce0-b6fe-46e2-9917-bac428f6ce18_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_396e0ce0-b6fe-46e2-9917-bac428f6ce18" xlink:to="loc_srt_ProductsAndServicesDomain_396e0ce0-b6fe-46e2-9917-bac428f6ce18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ef9a1ab9-f035-4be6-92c4-6e300af2187d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_396e0ce0-b6fe-46e2-9917-bac428f6ce18" xlink:to="loc_srt_ProductsAndServicesDomain_ef9a1ab9-f035-4be6-92c4-6e300af2187d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_73dc28cb-ddce-4867-9c78-83635f5731e7" xlink:href="mgnx-20210930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ef9a1ab9-f035-4be6-92c4-6e300af2187d" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_73dc28cb-ddce-4867-9c78-83635f5731e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9908b448-190d-42bd-a582-313c93670900" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bb90457-0a53-4966-81fd-0f1e5bf6647c" xlink:to="loc_srt_RangeAxis_9908b448-190d-42bd-a582-313c93670900" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9908b448-190d-42bd-a582-313c93670900_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9908b448-190d-42bd-a582-313c93670900" xlink:to="loc_srt_RangeMember_9908b448-190d-42bd-a582-313c93670900_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f490fe51-8f00-4621-a3c2-5b33dde55ae7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9908b448-190d-42bd-a582-313c93670900" xlink:to="loc_srt_RangeMember_f490fe51-8f00-4621-a3c2-5b33dde55ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ae751741-28d1-41d1-a57f-ff24ebfd5f6d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f490fe51-8f00-4621-a3c2-5b33dde55ae7" xlink:to="loc_srt_MinimumMember_ae751741-28d1-41d1-a57f-ff24ebfd5f6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3886a91a-5ec8-42cb-8965-e27624e6c711" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f490fe51-8f00-4621-a3c2-5b33dde55ae7" xlink:to="loc_srt_MaximumMember_3886a91a-5ec8-42cb-8965-e27624e6c711" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4aee8cf6-4702-4f5a-ab61-9954c246c288" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bb90457-0a53-4966-81fd-0f1e5bf6647c" xlink:to="loc_srt_CounterpartyNameAxis_4aee8cf6-4702-4f5a-ab61-9954c246c288" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4aee8cf6-4702-4f5a-ab61-9954c246c288_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4aee8cf6-4702-4f5a-ab61-9954c246c288" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4aee8cf6-4702-4f5a-ab61-9954c246c288_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2884ed85-f7ad-4fa0-8bac-c1492fb080cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4aee8cf6-4702-4f5a-ab61-9954c246c288" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2884ed85-f7ad-4fa0-8bac-c1492fb080cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_3eb56b4d-2286-4185-be00-ac5479180dc9" xlink:href="mgnx-20210930.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2884ed85-f7ad-4fa0-8bac-c1492fb080cc" xlink:to="loc_mgnx_IncyteCorporationMember_3eb56b4d-2286-4185-be00-ac5479180dc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1824519c-c767-4d41-b5dc-1a0ad05509f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bb90457-0a53-4966-81fd-0f1e5bf6647c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1824519c-c767-4d41-b5dc-1a0ad05509f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1824519c-c767-4d41-b5dc-1a0ad05509f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1824519c-c767-4d41-b5dc-1a0ad05509f2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1824519c-c767-4d41-b5dc-1a0ad05509f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b3ff771f-3d74-4e11-a035-03bf4db91a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1824519c-c767-4d41-b5dc-1a0ad05509f2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b3ff771f-3d74-4e11-a035-03bf4db91a49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_78a991c4-aa34-4810-b8c9-897669fb69f0" xlink:href="mgnx-20210930.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b3ff771f-3d74-4e11-a035-03bf4db91a49" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_78a991c4-aa34-4810-b8c9-897669fb69f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_fb86fdde-b700-492c-a87d-5e4e122eeab3" xlink:href="mgnx-20210930.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_78a991c4-aa34-4810-b8c9-897669fb69f0" xlink:to="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_fb86fdde-b700-492c-a87d-5e4e122eeab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember_899560af-799c-4440-a8f3-287c6c46cb3c" xlink:href="mgnx-20210930.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b3ff771f-3d74-4e11-a035-03bf4db91a49" xlink:to="loc_mgnx_IncyteMGA012ClinicalServicesMember_899560af-799c-4440-a8f3-287c6c46cb3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012SupplyAgreementMember_ed9b5716-d1e5-4ea6-a427-f37ee9589693" xlink:href="mgnx-20210930.xsd#mgnx_IncyteMGA012SupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b3ff771f-3d74-4e11-a035-03bf4db91a49" xlink:to="loc_mgnx_IncyteMGA012SupplyAgreementMember_ed9b5716-d1e5-4ea6-a427-f37ee9589693" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended" id="i3be293e350f0451d99b274236c534c51_CollaborationandOtherAgreementsZaiLabDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_17cf9a62-063b-47e6-8b0a-1c89b711b336" xlink:href="mgnx-20210930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_NonRefundableUpfrontFees_17cf9a62-063b-47e6-8b0a-1c89b711b336" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_cdfe18c1-d5ad-4b34-880b-0dfcda5dd783" xlink:href="mgnx-20210930.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_cdfe18c1-d5ad-4b34-880b-0dfcda5dd783" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_a943094f-1fec-4c9a-a2b2-ab4e3a28e5fa" xlink:href="mgnx-20210930.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_a943094f-1fec-4c9a-a2b2-ab4e3a28e5fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f6703223-547b-4875-9e3a-7ef102951d8a" xlink:href="mgnx-20210930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f6703223-547b-4875-9e3a-7ef102951d8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_b9283fff-07c5-480d-a649-b48e5db960e3" xlink:href="mgnx-20210930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_b9283fff-07c5-480d-a649-b48e5db960e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding_e9fbd057-cd09-4a4b-8e13-7cae624b03f3" xlink:href="mgnx-20210930.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_RevenuesNetOfTaxWithholding_e9fbd057-cd09-4a4b-8e13-7cae624b03f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesTaxWithholding_30be0cb2-cbb9-4da7-813a-56607cf60e50" xlink:href="mgnx-20210930.xsd#mgnx_RevenuesTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_RevenuesTaxWithholding_30be0cb2-cbb9-4da7-813a-56607cf60e50" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_1146495a-0ea3-4dd5-acd4-810fcb563271" xlink:href="mgnx-20210930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_1146495a-0ea3-4dd5-acd4-810fcb563271" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_03ce5d94-c409-4ce8-87bd-c5f63e342fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_03ce5d94-c409-4ce8-87bd-c5f63e342fd1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ecd4865e-418d-4a4c-922b-4b137266a078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_us-gaap_Revenues_ecd4865e-418d-4a4c-922b-4b137266a078" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee_c06c05ec-0082-4f5c-bb64-9db6868b5cfe" xlink:href="mgnx-20210930.xsd#mgnx_OptInFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_OptInFee_c06c05ec-0082-4f5c-bb64-9db6868b5cfe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d3e45961-b20b-4ff8-87b3-46bf53aafef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d3e45961-b20b-4ff8-87b3-46bf53aafef2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_110fe69c-7998-4868-9184-3c94a567e480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_110fe69c-7998-4868-9184-3c94a567e480" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1da28f26-49ff-4fde-bd4a-c021bd89abc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1da28f26-49ff-4fde-bd4a-c021bd89abc3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_71fcae86-af5b-4163-9445-513e0b8846d2" xlink:href="mgnx-20210930.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_71fcae86-af5b-4163-9445-513e0b8846d2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_bb4850a7-caa2-45a3-af02-88ac46a408e6" xlink:href="mgnx-20210930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_bb4850a7-caa2-45a3-af02-88ac46a408e6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_292ef4f6-358f-4a0e-abb5-05f78d2bcb72" xlink:href="mgnx-20210930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_292ef4f6-358f-4a0e-abb5-05f78d2bcb72" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_b232e3ed-5299-4298-9dfa-143fdb33baaa" xlink:href="mgnx-20210930.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_b232e3ed-5299-4298-9dfa-143fdb33baaa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_02037420-6683-432f-ae19-c8b644206605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_02037420-6683-432f-ae19-c8b644206605" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_eef28d11-b612-498d-b3b8-58070d7a4f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_eef28d11-b612-498d-b3b8-58070d7a4f45" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0fd2bed7-7d1c-4066-8079-28baaadd7c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0fd2bed7-7d1c-4066-8079-28baaadd7c19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bed10ea8-39c9-4236-9472-23243299709f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0fd2bed7-7d1c-4066-8079-28baaadd7c19" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bed10ea8-39c9-4236-9472-23243299709f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bed10ea8-39c9-4236-9472-23243299709f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bed10ea8-39c9-4236-9472-23243299709f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bed10ea8-39c9-4236-9472-23243299709f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e5ed2e2f-66a6-4a0b-9e58-e31dff2e249d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bed10ea8-39c9-4236-9472-23243299709f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e5ed2e2f-66a6-4a0b-9e58-e31dff2e249d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_b0f14656-c784-4d8a-97ce-d8c39b2f4efc" xlink:href="mgnx-20210930.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e5ed2e2f-66a6-4a0b-9e58-e31dff2e249d" xlink:to="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_b0f14656-c784-4d8a-97ce-d8c39b2f4efc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_43fcbfd4-53fd-4f52-a2f0-55473ad43b84" xlink:href="mgnx-20210930.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e5ed2e2f-66a6-4a0b-9e58-e31dff2e249d" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_43fcbfd4-53fd-4f52-a2f0-55473ad43b84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_aa67e15f-7d52-44cf-80de-7143acb1aeb7" xlink:href="mgnx-20210930.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e5ed2e2f-66a6-4a0b-9e58-e31dff2e249d" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_aa67e15f-7d52-44cf-80de-7143acb1aeb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_d824cd4b-9d3f-4d87-bbf2-2d44c137fa53" xlink:href="mgnx-20210930.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e5ed2e2f-66a6-4a0b-9e58-e31dff2e249d" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_d824cd4b-9d3f-4d87-bbf2-2d44c137fa53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_abd86d70-4f2f-443d-9849-b659c85539b4" xlink:href="mgnx-20210930.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e5ed2e2f-66a6-4a0b-9e58-e31dff2e249d" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_abd86d70-4f2f-443d-9849-b659c85539b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bffdd4f3-c51a-4e23-9c8e-92d46c917757" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0fd2bed7-7d1c-4066-8079-28baaadd7c19" xlink:to="loc_srt_CounterpartyNameAxis_bffdd4f3-c51a-4e23-9c8e-92d46c917757" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bffdd4f3-c51a-4e23-9c8e-92d46c917757_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bffdd4f3-c51a-4e23-9c8e-92d46c917757" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bffdd4f3-c51a-4e23-9c8e-92d46c917757_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d91eafad-c0ae-4fde-9fa2-031bea0e4a48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bffdd4f3-c51a-4e23-9c8e-92d46c917757" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d91eafad-c0ae-4fde-9fa2-031bea0e4a48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_0f05f3a4-abe2-4d19-b593-e438a1a6ebf6" xlink:href="mgnx-20210930.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d91eafad-c0ae-4fde-9fa2-031bea0e4a48" xlink:to="loc_mgnx_ZaiLabMember_0f05f3a4-abe2-4d19-b593-e438a1a6ebf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a315bf16-ffd7-4e60-b766-0f0fb2ad5915" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0fd2bed7-7d1c-4066-8079-28baaadd7c19" xlink:to="loc_srt_RangeAxis_a315bf16-ffd7-4e60-b766-0f0fb2ad5915" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a315bf16-ffd7-4e60-b766-0f0fb2ad5915_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a315bf16-ffd7-4e60-b766-0f0fb2ad5915" xlink:to="loc_srt_RangeMember_a315bf16-ffd7-4e60-b766-0f0fb2ad5915_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2ea26a3c-ef28-4a25-a6d2-911679a4dae4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a315bf16-ffd7-4e60-b766-0f0fb2ad5915" xlink:to="loc_srt_RangeMember_2ea26a3c-ef28-4a25-a6d2-911679a4dae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fdf36963-aa1f-42d9-9045-3514deac686c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2ea26a3c-ef28-4a25-a6d2-911679a4dae4" xlink:to="loc_srt_MaximumMember_fdf36963-aa1f-42d9-9045-3514deac686c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_04c7852c-eae3-40b2-bbbf-4ec06bbe200a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0fd2bed7-7d1c-4066-8079-28baaadd7c19" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_04c7852c-eae3-40b2-bbbf-4ec06bbe200a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_04c7852c-eae3-40b2-bbbf-4ec06bbe200a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04c7852c-eae3-40b2-bbbf-4ec06bbe200a" xlink:to="loc_us-gaap_EquityComponentDomain_04c7852c-eae3-40b2-bbbf-4ec06bbe200a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cc117b44-c00a-44ce-8b46-cc34c2fb40cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04c7852c-eae3-40b2-bbbf-4ec06bbe200a" xlink:to="loc_us-gaap_EquityComponentDomain_cc117b44-c00a-44ce-8b46-cc34c2fb40cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7243130b-a2d0-4671-b7fb-8f71a337d8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cc117b44-c00a-44ce-8b46-cc34c2fb40cc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7243130b-a2d0-4671-b7fb-8f71a337d8e1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CollaborationandOtherAgreementsJanssenDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="extended" id="i41968c4e946e4a48859e370669b36833_CollaborationandOtherAgreementsJanssenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30b897fc-f857-4971-8c7f-7c5a04dab246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_74bb8f18-4d49-463f-ae5b-f68f4e030a05" xlink:href="mgnx-20210930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30b897fc-f857-4971-8c7f-7c5a04dab246" xlink:to="loc_mgnx_NonRefundableUpfrontFees_74bb8f18-4d49-463f-ae5b-f68f4e030a05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_ef4e4380-87f1-4082-9541-b4312ee6637f" xlink:href="mgnx-20210930.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30b897fc-f857-4971-8c7f-7c5a04dab246" xlink:to="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_ef4e4380-87f1-4082-9541-b4312ee6637f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_cd5df541-8492-4190-8479-f82512d6369a" xlink:href="mgnx-20210930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30b897fc-f857-4971-8c7f-7c5a04dab246" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_cd5df541-8492-4190-8479-f82512d6369a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_1bab74b9-f719-4bd8-af34-654b11bca94f" xlink:href="mgnx-20210930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30b897fc-f857-4971-8c7f-7c5a04dab246" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_1bab74b9-f719-4bd8-af34-654b11bca94f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1467e722-a37b-47b3-a4c2-a995db4e6cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30b897fc-f857-4971-8c7f-7c5a04dab246" xlink:to="loc_us-gaap_Revenues_1467e722-a37b-47b3-a4c2-a995db4e6cd0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_b4646e65-ab01-4c4f-87df-17ac46ce0923" xlink:href="mgnx-20210930.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30b897fc-f857-4971-8c7f-7c5a04dab246" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_b4646e65-ab01-4c4f-87df-17ac46ce0923" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fae8f7e7-1dbe-4088-91dd-628b51e70beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30b897fc-f857-4971-8c7f-7c5a04dab246" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fae8f7e7-1dbe-4088-91dd-628b51e70beb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_70902220-cb14-4dc0-aa04-5634cd81843b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fae8f7e7-1dbe-4088-91dd-628b51e70beb" xlink:to="loc_srt_CounterpartyNameAxis_70902220-cb14-4dc0-aa04-5634cd81843b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70902220-cb14-4dc0-aa04-5634cd81843b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_70902220-cb14-4dc0-aa04-5634cd81843b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70902220-cb14-4dc0-aa04-5634cd81843b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7015d9a5-a982-459c-9764-489df302a2d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_70902220-cb14-4dc0-aa04-5634cd81843b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7015d9a5-a982-459c-9764-489df302a2d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_5d3f2aa2-5080-4664-80b9-dd3bed740933" xlink:href="mgnx-20210930.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7015d9a5-a982-459c-9764-489df302a2d3" xlink:to="loc_mgnx_JanssenBiotechIncMember_5d3f2aa2-5080-4664-80b9-dd3bed740933" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_68cb64ec-7166-4bb6-bb4a-cf632d99cad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fae8f7e7-1dbe-4088-91dd-628b51e70beb" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_68cb64ec-7166-4bb6-bb4a-cf632d99cad9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_68cb64ec-7166-4bb6-bb4a-cf632d99cad9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_68cb64ec-7166-4bb6-bb4a-cf632d99cad9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_68cb64ec-7166-4bb6-bb4a-cf632d99cad9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_459a061d-590c-47cd-923d-3fb35b399910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_68cb64ec-7166-4bb6-bb4a-cf632d99cad9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_459a061d-590c-47cd-923d-3fb35b399910" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_865262db-ed85-4b0c-bd66-d4ef30b89299" xlink:href="mgnx-20210930.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_459a061d-590c-47cd-923d-3fb35b399910" xlink:to="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_865262db-ed85-4b0c-bd66-d4ef30b89299" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1aa2a74a-923f-483e-be49-f02df7cbd68c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fae8f7e7-1dbe-4088-91dd-628b51e70beb" xlink:to="loc_srt_ProductOrServiceAxis_1aa2a74a-923f-483e-be49-f02df7cbd68c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1aa2a74a-923f-483e-be49-f02df7cbd68c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1aa2a74a-923f-483e-be49-f02df7cbd68c" xlink:to="loc_srt_ProductsAndServicesDomain_1aa2a74a-923f-483e-be49-f02df7cbd68c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_edd74a78-fa89-42f8-9dfb-ae5d21884b0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1aa2a74a-923f-483e-be49-f02df7cbd68c" xlink:to="loc_srt_ProductsAndServicesDomain_edd74a78-fa89-42f8-9dfb-ae5d21884b0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_9243c159-bbc2-4cd4-9e0c-6ec1871f76e3" xlink:href="mgnx-20210930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_edd74a78-fa89-42f8-9dfb-ae5d21884b0c" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_9243c159-bbc2-4cd4-9e0c-6ec1871f76e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_a4714781-208e-4461-8a3f-8c688677097b" xlink:href="mgnx-20210930.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_edd74a78-fa89-42f8-9dfb-ae5d21884b0c" xlink:to="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_a4714781-208e-4461-8a3f-8c688677097b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended" id="i4cb8a324deca47319b5ec952f9d11b60_CollaborationandOtherAgreementsIMabBiopharmaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_fe4acbb9-97d1-42b1-bc37-4d6a370ea5db" xlink:href="mgnx-20210930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_mgnx_NonRefundableUpfrontFees_fe4acbb9-97d1-42b1-bc37-4d6a370ea5db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f3b7f883-c4ec-4115-bbc3-3f688367f02f" xlink:href="mgnx-20210930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f3b7f883-c4ec-4115-bbc3-3f688367f02f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_050a5af2-4711-4524-be2e-b51ff497fe28" xlink:href="mgnx-20210930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_050a5af2-4711-4524-be2e-b51ff497fe28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding_1d25d9dd-64c7-4928-9c09-be53a7065933" xlink:href="mgnx-20210930.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_mgnx_RevenuesNetOfTaxWithholding_1d25d9dd-64c7-4928-9c09-be53a7065933" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_02ea7a6b-565d-4590-a9b1-021840b43b7c" xlink:href="mgnx-20210930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_02ea7a6b-565d-4590-a9b1-021840b43b7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_1e9f1127-f1bf-4742-a42c-0f872080e590" xlink:href="mgnx-20210930.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_1e9f1127-f1bf-4742-a42c-0f872080e590" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0443523e-b7fc-40f5-a2d4-d8a090fcd7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_us-gaap_Revenues_0443523e-b7fc-40f5-a2d4-d8a090fcd7a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cd1f77cb-6e53-4f04-abc7-e6aa58f35030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cd1f77cb-6e53-4f04-abc7-e6aa58f35030" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_78584559-50b8-40d0-b7dc-4a44466320eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_78584559-50b8-40d0-b7dc-4a44466320eb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7927ce36-5827-45b3-926e-6df8764ebd72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7927ce36-5827-45b3-926e-6df8764ebd72" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2934805-ae77-4d6e-a19d-1efd41757162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2934805-ae77-4d6e-a19d-1efd41757162" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cdef4da8-66d5-4c93-8e7e-ddef09dc337a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2934805-ae77-4d6e-a19d-1efd41757162" xlink:to="loc_srt_CounterpartyNameAxis_cdef4da8-66d5-4c93-8e7e-ddef09dc337a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cdef4da8-66d5-4c93-8e7e-ddef09dc337a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_cdef4da8-66d5-4c93-8e7e-ddef09dc337a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cdef4da8-66d5-4c93-8e7e-ddef09dc337a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e47cadc-8099-47d0-88de-bdc4a2c072e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_cdef4da8-66d5-4c93-8e7e-ddef09dc337a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e47cadc-8099-47d0-88de-bdc4a2c072e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_4073243e-bd22-428d-ae72-3f482cd7bfb9" xlink:href="mgnx-20210930.xsd#mgnx_IMabBiopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e47cadc-8099-47d0-88de-bdc4a2c072e8" xlink:to="loc_mgnx_IMabBiopharmaMember_4073243e-bd22-428d-ae72-3f482cd7bfb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1e977fa-5f76-4723-8f5e-4226b727eb20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2934805-ae77-4d6e-a19d-1efd41757162" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1e977fa-5f76-4723-8f5e-4226b727eb20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f1e977fa-5f76-4723-8f5e-4226b727eb20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1e977fa-5f76-4723-8f5e-4226b727eb20" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f1e977fa-5f76-4723-8f5e-4226b727eb20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_265e4bac-bd8e-4fd4-bdde-add109eb4554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1e977fa-5f76-4723-8f5e-4226b727eb20" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_265e4bac-bd8e-4fd4-bdde-add109eb4554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_8624005e-9976-4f78-ab62-1dabbb75ac04" xlink:href="mgnx-20210930.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_265e4bac-bd8e-4fd4-bdde-add109eb4554" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_8624005e-9976-4f78-ab62-1dabbb75ac04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e6a62075-3f9c-4220-b9d0-7562d1be0c7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2934805-ae77-4d6e-a19d-1efd41757162" xlink:to="loc_srt_RangeAxis_e6a62075-3f9c-4220-b9d0-7562d1be0c7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e6a62075-3f9c-4220-b9d0-7562d1be0c7d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e6a62075-3f9c-4220-b9d0-7562d1be0c7d" xlink:to="loc_srt_RangeMember_e6a62075-3f9c-4220-b9d0-7562d1be0c7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_51c4f524-1191-423d-a702-97e04af22c7a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e6a62075-3f9c-4220-b9d0-7562d1be0c7d" xlink:to="loc_srt_RangeMember_51c4f524-1191-423d-a702-97e04af22c7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_30b8356e-88ac-454a-91fb-733122781e7a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_51c4f524-1191-423d-a702-97e04af22c7a" xlink:to="loc_srt_MaximumMember_30b8356e-88ac-454a-91fb-733122781e7a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended" id="ib96d818ee0f241368cd7b106239d59e5_CollaborationandOtherAgreementsNIAIDContractDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a163e54f-46be-412f-8e88-40ace20e3165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_dba7b3ab-71c0-4e9d-982d-b846f2627516" xlink:href="mgnx-20210930.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a163e54f-46be-412f-8e88-40ace20e3165" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_dba7b3ab-71c0-4e9d-982d-b846f2627516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_adbbc3c9-7a73-4eee-ae7e-2a9d1df782f7" xlink:href="mgnx-20210930.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a163e54f-46be-412f-8e88-40ace20e3165" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_adbbc3c9-7a73-4eee-ae7e-2a9d1df782f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a25aca5c-0b53-48f7-9180-13b2778f746d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a163e54f-46be-412f-8e88-40ace20e3165" xlink:to="loc_us-gaap_Revenues_a25aca5c-0b53-48f7-9180-13b2778f746d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ae216f9-be67-418e-88c6-dd4aeaa19616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a163e54f-46be-412f-8e88-40ace20e3165" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ae216f9-be67-418e-88c6-dd4aeaa19616" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_00317218-c494-45c9-ac51-e1a46aa2d274" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ae216f9-be67-418e-88c6-dd4aeaa19616" xlink:to="loc_srt_ProductOrServiceAxis_00317218-c494-45c9-ac51-e1a46aa2d274" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_00317218-c494-45c9-ac51-e1a46aa2d274_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_00317218-c494-45c9-ac51-e1a46aa2d274" xlink:to="loc_srt_ProductsAndServicesDomain_00317218-c494-45c9-ac51-e1a46aa2d274_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_18e1788f-5ca2-4a86-886c-fbe66379a3bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_00317218-c494-45c9-ac51-e1a46aa2d274" xlink:to="loc_srt_ProductsAndServicesDomain_18e1788f-5ca2-4a86-886c-fbe66379a3bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_46fa05ce-2b58-412a-8707-1aad61749df4" xlink:href="mgnx-20210930.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_18e1788f-5ca2-4a86-886c-fbe66379a3bc" xlink:to="loc_mgnx_RevenuesFromGrantsMember_46fa05ce-2b58-412a-8707-1aad61749df4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_31e16461-a211-4bd0-b823-f48eef3d7aea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ae216f9-be67-418e-88c6-dd4aeaa19616" xlink:to="loc_srt_CounterpartyNameAxis_31e16461-a211-4bd0-b823-f48eef3d7aea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31e16461-a211-4bd0-b823-f48eef3d7aea_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_31e16461-a211-4bd0-b823-f48eef3d7aea" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31e16461-a211-4bd0-b823-f48eef3d7aea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_784a67b5-3782-460c-91e4-df5acc8d3387" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_31e16461-a211-4bd0-b823-f48eef3d7aea" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_784a67b5-3782-460c-91e4-df5acc8d3387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_4973e343-6577-4491-bad9-68f91f3a61fe" xlink:href="mgnx-20210930.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_784a67b5-3782-460c-91e4-df5acc8d3387" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_4973e343-6577-4491-bad9-68f91f3a61fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_695ffedd-85e3-45e7-ae1b-550cda62e3bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ae216f9-be67-418e-88c6-dd4aeaa19616" xlink:to="loc_srt_RangeAxis_695ffedd-85e3-45e7-ae1b-550cda62e3bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_695ffedd-85e3-45e7-ae1b-550cda62e3bc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_695ffedd-85e3-45e7-ae1b-550cda62e3bc" xlink:to="loc_srt_RangeMember_695ffedd-85e3-45e7-ae1b-550cda62e3bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0e9be272-cab9-4674-971f-39340a9c01f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_695ffedd-85e3-45e7-ae1b-550cda62e3bc" xlink:to="loc_srt_RangeMember_0e9be272-cab9-4674-971f-39340a9c01f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_11a030c3-8c02-4383-95d7-37c5ccb78f56" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0e9be272-cab9-4674-971f-39340a9c01f2" xlink:to="loc_srt_MaximumMember_11a030c3-8c02-4383-95d7-37c5ccb78f56" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="i3cf6ef2a14d04338a79065b5e6afebcf_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3e1716c7-b7a6-460d-b3e0-4598aafe266a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3e1716c7-b7a6-460d-b3e0-4598aafe266a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_3a168f2b-8868-4e68-8a74-d4494e4946a3" xlink:href="mgnx-20210930.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_3a168f2b-8868-4e68-8a74-d4494e4946a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7cb31ae9-de0e-4b18-911a-82d45634a61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7cb31ae9-de0e-4b18-911a-82d45634a61b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c2de1eef-a363-4c1e-926f-563a94b7990f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c2de1eef-a363-4c1e-926f-563a94b7990f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_02b121ba-32ac-4ba5-8c4d-a0b3583bd9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_02b121ba-32ac-4ba5-8c4d-a0b3583bd9f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40c1f8c6-8f11-4bd4-9e84-1b7554e039dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40c1f8c6-8f11-4bd4-9e84-1b7554e039dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_32c01c2a-8a03-4b6e-a5f8-116886da8911" xlink:href="mgnx-20210930.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_32c01c2a-8a03-4b6e-a5f8-116886da8911" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_e730c3d1-d0bf-4394-9828-6866e80523b4" xlink:href="mgnx-20210930.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_e730c3d1-d0bf-4394-9828-6866e80523b4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff1d17ad-39ce-45ff-8a38-d0fc3a17c629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff1d17ad-39ce-45ff-8a38-d0fc3a17c629" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_26e81ed7-c5f0-46f0-917b-0c4e146e1c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff1d17ad-39ce-45ff-8a38-d0fc3a17c629" xlink:to="loc_us-gaap_PlanNameAxis_26e81ed7-c5f0-46f0-917b-0c4e146e1c61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_26e81ed7-c5f0-46f0-917b-0c4e146e1c61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_26e81ed7-c5f0-46f0-917b-0c4e146e1c61" xlink:to="loc_us-gaap_PlanNameDomain_26e81ed7-c5f0-46f0-917b-0c4e146e1c61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d26d6ec7-2ba0-435a-a1ae-e560eff3b366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_26e81ed7-c5f0-46f0-917b-0c4e146e1c61" xlink:to="loc_us-gaap_PlanNameDomain_d26d6ec7-2ba0-435a-a1ae-e560eff3b366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_6fe0c381-53be-402f-89e6-f8823041243c" xlink:href="mgnx-20210930.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d26d6ec7-2ba0-435a-a1ae-e560eff3b366" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_6fe0c381-53be-402f-89e6-f8823041243c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember_3c44654f-ceba-413c-9c4b-cbf3d778b44c" xlink:href="mgnx-20210930.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d26d6ec7-2ba0-435a-a1ae-e560eff3b366" xlink:to="loc_mgnx_A2003StockIncentivePlanMember_3c44654f-ceba-413c-9c4b-cbf3d778b44c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_963c9673-efd1-470b-bfa6-ca6d57358bc8" xlink:href="mgnx-20210930.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d26d6ec7-2ba0-435a-a1ae-e560eff3b366" xlink:to="loc_mgnx_StockIncentivePlan2013Member_963c9673-efd1-470b-bfa6-ca6d57358bc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_caaf919f-484b-465c-a018-b5cc765dc09a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5fe8fb74-9913-4eb5-81a9-5aec11b94a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_caaf919f-484b-465c-a018-b5cc765dc09a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5fe8fb74-9913-4eb5-81a9-5aec11b94a7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b295b3b8-41cb-4219-8f4a-dfc7cb4a1db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_caaf919f-484b-465c-a018-b5cc765dc09a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b295b3b8-41cb-4219-8f4a-dfc7cb4a1db9" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2aad4d25-e15b-4dee-9a46-0def71a824b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b295b3b8-41cb-4219-8f4a-dfc7cb4a1db9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2aad4d25-e15b-4dee-9a46-0def71a824b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2aad4d25-e15b-4dee-9a46-0def71a824b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2aad4d25-e15b-4dee-9a46-0def71a824b0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2aad4d25-e15b-4dee-9a46-0def71a824b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7160a7af-c246-4009-8226-c2d8ffcd5870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2aad4d25-e15b-4dee-9a46-0def71a824b0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7160a7af-c246-4009-8226-c2d8ffcd5870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4a00d58b-3ca1-4f5a-8368-31020b95c186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7160a7af-c246-4009-8226-c2d8ffcd5870" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4a00d58b-3ca1-4f5a-8368-31020b95c186" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_699bb0c1-842c-439d-b201-bc2119ff54b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7160a7af-c246-4009-8226-c2d8ffcd5870" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_699bb0c1-842c-439d-b201-bc2119ff54b9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended" id="i20cd4459f5fa4d6da4bdedae29eda323_StockBasedCompensationOptionPricingAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ee10299-a40f-46fe-a872-ddc8f550f75d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1f3306ae-5204-4be0-979f-9fe869d175cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ee10299-a40f-46fe-a872-ddc8f550f75d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1f3306ae-5204-4be0-979f-9fe869d175cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9c6718e8-8487-478d-b122-66e20af770a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ee10299-a40f-46fe-a872-ddc8f550f75d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9c6718e8-8487-478d-b122-66e20af770a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bf47d9f2-fe71-4509-adab-b83c75adff3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ee10299-a40f-46fe-a872-ddc8f550f75d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bf47d9f2-fe71-4509-adab-b83c75adff3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_249f5fbb-83a0-46c2-9310-4b7b61855e13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ee10299-a40f-46fe-a872-ddc8f550f75d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_249f5fbb-83a0-46c2-9310-4b7b61855e13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a88a264-4a96-4957-82b8-6c65277d520f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ee10299-a40f-46fe-a872-ddc8f550f75d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a88a264-4a96-4957-82b8-6c65277d520f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_590e9066-c361-451c-99e7-f5c2cce5fada" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a88a264-4a96-4957-82b8-6c65277d520f" xlink:to="loc_srt_RangeAxis_590e9066-c361-451c-99e7-f5c2cce5fada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_590e9066-c361-451c-99e7-f5c2cce5fada_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_590e9066-c361-451c-99e7-f5c2cce5fada" xlink:to="loc_srt_RangeMember_590e9066-c361-451c-99e7-f5c2cce5fada_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_70d68d98-6f43-44af-9c15-42f3f211faa0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_590e9066-c361-451c-99e7-f5c2cce5fada" xlink:to="loc_srt_RangeMember_70d68d98-6f43-44af-9c15-42f3f211faa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3b438574-fc00-4a48-bafe-dab6f75cda83" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_70d68d98-6f43-44af-9c15-42f3f211faa0" xlink:to="loc_srt_MinimumMember_3b438574-fc00-4a48-bafe-dab6f75cda83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0c33b846-de32-444a-97a4-bbb7c71b478a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_70d68d98-6f43-44af-9c15-42f3f211faa0" xlink:to="loc_srt_MaximumMember_0c33b846-de32-444a-97a4-bbb7c71b478a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#StockbasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended" id="i29d3a0c00bcd47f1a5c09ec61206b66e_StockbasedCompensationRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00740895-1ebe-426e-8ae5-aed64812afde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daf78d6b-53c6-458f-82f2-512edffef91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00740895-1ebe-426e-8ae5-aed64812afde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daf78d6b-53c6-458f-82f2-512edffef91f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_87f9f97f-9a26-4c25-acf1-95ae1143232e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daf78d6b-53c6-458f-82f2-512edffef91f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_87f9f97f-9a26-4c25-acf1-95ae1143232e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_02fa37ed-88ad-4251-adb4-60290b740ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daf78d6b-53c6-458f-82f2-512edffef91f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_02fa37ed-88ad-4251-adb4-60290b740ceb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_7bcf3b50-00b0-48fd-9170-32c008a72382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daf78d6b-53c6-458f-82f2-512edffef91f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_7bcf3b50-00b0-48fd-9170-32c008a72382" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_80e14dc6-9557-4711-af54-64b19590bec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daf78d6b-53c6-458f-82f2-512edffef91f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_80e14dc6-9557-4711-af54-64b19590bec6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c3628307-518b-4a4d-a90c-74a74195ed93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8569e129-271a-4f0a-a9f1-922035dd7b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00740895-1ebe-426e-8ae5-aed64812afde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8569e129-271a-4f0a-a9f1-922035dd7b41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1d0b2dbd-8d8d-4f7b-af15-4f23c55251eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8569e129-271a-4f0a-a9f1-922035dd7b41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1d0b2dbd-8d8d-4f7b-af15-4f23c55251eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ecb2357-387c-472a-ba98-d0d688f20535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8569e129-271a-4f0a-a9f1-922035dd7b41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ecb2357-387c-472a-ba98-d0d688f20535" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1dcb8688-058e-46bf-87ea-64743f8a97bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8569e129-271a-4f0a-a9f1-922035dd7b41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1dcb8688-058e-46bf-87ea-64743f8a97bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9977c942-9b17-4642-a002-b0285cfe44ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8569e129-271a-4f0a-a9f1-922035dd7b41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9977c942-9b17-4642-a002-b0285cfe44ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4b6aab3b-a397-4f4b-b3d3-f77b6f4cb754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6cf4c100-0417-4672-8ed5-3e2f286c556d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00740895-1ebe-426e-8ae5-aed64812afde" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6cf4c100-0417-4672-8ed5-3e2f286c556d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_347367f2-3247-46bc-b8f0-b78d72dc103a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00740895-1ebe-426e-8ae5-aed64812afde" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_347367f2-3247-46bc-b8f0-b78d72dc103a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d64c2da4-88e7-41c4-b8a7-179afbc69f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00740895-1ebe-426e-8ae5-aed64812afde" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d64c2da4-88e7-41c4-b8a7-179afbc69f1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_325f7364-cb55-4b2c-837d-299b28bca928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d64c2da4-88e7-41c4-b8a7-179afbc69f1e" xlink:to="loc_us-gaap_AwardTypeAxis_325f7364-cb55-4b2c-837d-299b28bca928" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_325f7364-cb55-4b2c-837d-299b28bca928_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_325f7364-cb55-4b2c-837d-299b28bca928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_325f7364-cb55-4b2c-837d-299b28bca928_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32f55d22-028c-4e95-917b-c49191959b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_325f7364-cb55-4b2c-837d-299b28bca928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32f55d22-028c-4e95-917b-c49191959b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1aa8b3ae-34f5-450e-9259-98999f650747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32f55d22-028c-4e95-917b-c49191959b53" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1aa8b3ae-34f5-450e-9259-98999f650747" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>mgnx-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a503bed0-470c-42a0-8ff2-08d40b83c4e7,g:0544a414-ac6d-4106-af60-27149bd97a9a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_4850b9dd-c2a5-4208-8333-2fb315c48b90_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_944b3824-c1b1-490a-b5d9-145051861a3d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_0c7108eb-5c4e-4840-8b01-c97e4e062f49_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_d839b8d3-3daf-4e3a-aac5-b4491f9d18b4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a920ce93-7dad-4183-a0f5-d31e2c806ef2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5082d3bf-768c-4411-8bab-d914f1aae65a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e44b2f46-910a-4685-a61b-09f4e0a55a9c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f20a34ab-0229-4788-9aa3-b8d9479370af_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_fc3ad89c-3259-4c78-956c-87a9c630eab8_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_bd61738b-7e03-4839-a3ed-e0e146f45f20_terseLabel_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercial milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialCommercialMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:href="mgnx-20210930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7a709f16-9fdd-416d-a193-2c780b35d2d4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_038117f1-8bf2-4aff-a25b-e7e516706241_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_36e522ea-e8b2-4854-a9ba-321a336e43a5_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d56bef62-274f-43e3-9f99-b53017537ced_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_31499dbb-c188-472c-9b06-c349c325cfc2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3b1c1436-7878-4e5c-9151-12667ec228e8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_346082fa-886d-4e1f-9878-8ea87441761f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_eb6bae82-940f-4de2-994b-24beba153744_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_8730f9d5-0b15-483a-858c-93e51a1d17e1_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential proceeds from royalties (percent)</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_label_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProceedsfromRoyaltiesPercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:href="mgnx-20210930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:to="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_a5b2d54b-430f-4732-bf2d-fa3da604cd84_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c7fb4c50-8b41-49d8-a592-5ba33aa6bd97_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_c052eb18-32ee-4e41-a70d-deaacb2ccc3f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_2b9fb695-0fa9-4b20-9c0e-dc8c45340e42_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_311853b8-0b3f-4795-9508-082523166b24_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_859607b4-412d-4692-939a-3566f7863fa7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_86cc6b25-b825-4b9b-b97e-4af7487eb8f8_terseLabel_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIAID</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_label_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NationalInstituteOfAllergyAndInfectiousDiseasesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="mgnx-20210930.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a75c633e-f11d-4093-8ea5-c3aad00ee3c5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ec5fec2-767e-427e-b195-900ed58c3227_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_eddf1178-a092-4ae4-9083-8a52b6324d8a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a1e8ab3e-3ac6-4fba-be2a-c11073b40c07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_1ee70683-0fe6-465c-b87b-b46f27a79bfa_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment, net of tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:href="mgnx-20210930.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:to="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_33f50ea4-9218-46d6-b981-4040515cce7d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b57c495a-d4f8-4295-9fe8-20aed7a29b3f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_527e1043-dc78-4c3a-9fb0-f82aa10cfabf_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6383a10f-762d-4218-8f8f-7409b8741201_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_fb5d1366-e8ab-409c-aaad-c1fd26b873a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_27790adc-35cf-4978-ab63-e94da7718ad6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e4b1ad5f-f7cc-4429-9271-801c7c957e19_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f3a88b23-dbb1-4289-b3b0-7a654fdba5e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_269b3a38-bebd-44ab-a834-999e589b38d5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ee10c22a-3b8a-49c7-a71b-ee391ebb2f8e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_bd502a44-a564-4e97-8801-9dd7612baadc_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_0c3f0c5f-4a53-4964-8cf6-030170b5f275_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_65ecca6f-3417-467b-9ba7-f3e1eba0ef5e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4b217154-69b2-483a-b90e-4cba9f44742e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_8028ae87-e2dd-4210-879f-5e940be5a8c5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_e9539c24-0de1-499a-a676-d22ba8ac1140_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesTaxWithholding_4f95487a-65a2-497b-a41d-cee6eb2f6b77_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, tax withholding</link:label>
    <link:label id="lab_mgnx_RevenuesTaxWithholding_label_en-US" xlink:label="lab_mgnx_RevenuesTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Tax Withholding</link:label>
    <link:label id="lab_mgnx_RevenuesTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_RevenuesTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesTaxWithholding" xlink:href="mgnx-20210930.xsd#mgnx_RevenuesTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesTaxWithholding" xlink:to="lab_mgnx_RevenuesTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_6fdc9389-5acd-4d9a-ba1e-ca2058027a66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9850d52b-e370-4155-b494-7ae55849cfe5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f44d7ed4-7d43-490e-9af6-34583816331a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012SupplyAgreementMember_7f428e34-83f1-454b-b8c3-ab894b12356b_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Supply Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012SupplyAgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Supply Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012SupplyAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012SupplyAgreementMember" xlink:href="mgnx-20210930.xsd#mgnx_IncyteMGA012SupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012SupplyAgreementMember" xlink:to="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_36b82484-1aa9-4c08-90a6-1c5212e3d6d8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_8061891e-3fd2-4824-84d2-9462bebe2a87_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember" xlink:href="mgnx-20210930.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementMember" xlink:to="lab_mgnx_IncyteMGA012AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_883ff4c9-0942-4868-8be4-7b1dd762162b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_57fc4394-67f3-42b9-bd19-2fb6a7a05952_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9f1c35b5-e2e0-4071-b931-a73e251ba08d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_09d9b665-2e7b-48d8-904a-f6095d1ad629_terseLabel_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity</link:label>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_3a5fa25f-4bde-41bb-8bb8-b8b15a8cfe3d_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_aee584fc-d0ef-409d-8779-1037f443d643_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ffe4973a-cbbc-40d8-bf87-31297a06b6dc_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ab6bf3f5-499c-4127-a75f-5bc03d49a427_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_59913980-50a1-4467-b14d-12599f27e579_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a64f1170-3f38-4c33-bd77-5ef32ce50001_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4e4dda4b-de63-4c6a-b338-246235dde0f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f4592716-ba7c-4659-916b-4fab6f5fda75_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9ed5155c-7dee-4b60-8ee7-ff4e2684d918_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f7b8b9c-ea91-42f7-9545-968eb49522f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_144118a6-9309-433b-aaa2-310bd228e79d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_25b32a1b-695d-4e04-a866-eaf6b9a6700a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3134e736-c75b-42d7-aa49-86d23dafbe59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_cd11efd3-a134-4345-8b4f-417430c36bdf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_cbf15b1d-5beb-439f-888c-030e1790ba1c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2c0fed45-db29-49e9-9def-1577be02faa2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_510eaca9-9393-4dd2-96d4-06c2237962a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b80c5afe-3787-45e6-a0a5-0d90232bdc50_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_d3bfe024-e485-412c-b513-8b05a5ae30f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_194462a5-c885-4a89-bc44-b825728e8f1b_terseLabel_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_label_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonRefundableUpfrontFees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees" xlink:href="mgnx-20210930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonRefundableUpfrontFees" xlink:to="lab_mgnx_NonRefundableUpfrontFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1abe01cb-14c9-48b9-81f6-3f9a7dc4415e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c7aab963-ecc3-4ae5-ab91-c0fb4147d2f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_17b6bdb2-10bf-47b1-9ad7-75f2a5ed966d_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6a45588b-f108-4d28-af00-19c93351b940_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_059ef539-33aa-4c17-acf2-44525e067682_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_80d37a22-45e0-4bf6-9efe-1ff2d543a0f9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_517ff818-48a1-4ed7-8912-3a9ecf6707e6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_47892d36-d443-4808-b349-d00e69c7ca20_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ddea010d-87a0-4b83-b396-997847575b6c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_e7097c01-043a-48f0-b51f-47b5448f5d2f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_03c95cd3-cf99-4e84-8e0e-61affca5eca6_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ddaae8fe-394d-46a1-b9de-374f1e763fb3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_75426298-2497-4768-8c97-c09cd763e55d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1a0f8e5f-d67c-4621-abae-bc955f79a4ca_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_70f1ee84-f2c8-49f8-91ba-761090522062_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_618a6f78-2265-42a4-80d4-b23e316a078f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock percent of the fair market value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1e21a4e0-c42a-411c-b1f9-286bab92465b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_48d9e719-72ff-4f4b-90a7-35077535e9d4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_04d1d5fa-e880-4cb3-8ccb-f5ad67e317ae_verboseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises and ESPP purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_label_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProceedsfromStockOptionsExercisedAndESPPPurchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:href="mgnx-20210930.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:to="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_e7f1b93d-f7f7-4646-aca0-287df424a790_terseLabel_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_label_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc [Member]</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_documentation_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember" xlink:href="mgnx-20210930.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenBiotechIncMember" xlink:to="lab_mgnx_JanssenBiotechIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d23d3b17-9ef6-4a34-a327-2360d6ccabf7_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_b7310b82-9706-47e0-8083-677076b3cd2a_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement - Clinical activities</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementClinicalActivitiesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:href="mgnx-20210930.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:to="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_e3ecbeb2-4062-410d-891d-46ee0c9a352c_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount available for issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:href="mgnx-20210930.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0b74e1bf-e358-434b-b1a1-b54830a57fdb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_31c56baf-9c64-4bf4-ae97-977fb4f79773_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software included in accounts payable or accruals</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_b7426e69-9fac-4b2b-8c22-dd31cd45206c_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember" xlink:href="mgnx-20210930.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012ClinicalServicesMember" xlink:to="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_1631be5d-9cac-43ca-b513-ee1d9a237ee1_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c5850de7-eabb-4ee4-9e30-9d16c87f9ad4_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_00208f2c-6ff0-4c0a-a525-9c41105fd6df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6d792c51-76de-4513-8d98-3d6ca2a3aaad_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0727c3f9-a44f-4823-8af9-42ecba9742ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_cbc2c544-63d3-4cbf-9738-3f3e904cbb2f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_035baa09-25bf-4129-ac94-49fd68815156_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c47207d8-b63e-4f63-8e3c-5be66296525f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_69775455-f835-4258-aab6-2456d7870c0e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_de890c32-fd1b-4de6-9129-bec9c0fff57e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_af999dc3-9447-4567-a8dd-d907e55fce13_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_43919608-0e79-479a-b5a5-d136f7ea5545_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_135c9067-455f-4024-834c-df4c61d715b8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_52d51870-ebc7-47d2-8876-a3bc236098ad_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f64df889-3169-4829-a8cd-4fb51455c119_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5aa48615-d34d-4ccb-8528-d1188206bc53_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_bd395d5e-fd87-4f2b-9a92-9259b52d9ba3_terseLabel_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:href="mgnx-20210930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1cca3d63-111c-4e2b-8753-5a3722b83b18_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_5dae8efa-cbe7-4f1f-add2-306bd0559e61_terseLabel_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the Market Offering</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember" xlink:href="mgnx-20210930.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AtTheMarketOfferingMember" xlink:to="lab_mgnx_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_715b94d6-0a24-4d87-9d2b-850800fc9244_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3d0459c-cfcd-4fc5-bdce-19c1bd61dae5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8ae0b9bb-d66b-4ff2-a8e3-c811656f0d7f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_997a404e-69e0-460d-94b7-7d812ca8d95b_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_df323b91-0f26-43f1-8e51-e98a1a5f687f_terseLabel_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium received on stock purchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_label_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PremiumReceivedOnStockPurchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_documentation_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PremiumReceivedOnStockPurchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase" xlink:href="mgnx-20210930.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PremiumReceivedOnStockPurchase" xlink:to="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_815197b6-3aac-4807-9407-436c000ed5a6_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable payment tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Payment Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Payment Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:href="mgnx-20210930.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:to="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_caf2ef0b-a2a3-44d9-99b0-8f420f05ce1b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_224e07ec-e12a-40f2-b851-86ae0b4c4379_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d4d21ee9-0cc5-420c-9c87-31493e63343f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee2f1bfe-3bf1-4435-9d1d-8b103ed2641e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a5955b27-6212-4f52-96e5-dcf5a72a3027_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_31b16511-982d-4f86-b849-8eaf5e89d74c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_eabfe7dc-cde3-4aad-8cb8-4d30c8537c28_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_26d58ab8-9d48-4391-a6db-923e55afdb96_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_db5887b9-8be2-4475-bbb7-658a6e9e4ba0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_7a2368ae-dbb6-4a5e-a419-29ada72ce720_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of stock purchase price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_62ce1054-8d67-4d82-aef2-761b6130a5f1_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_0f7af010-14aa-495c-9c54-c42764c0bffa_terseLabel_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated variable consideration</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_label_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:href="mgnx-20210930.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:to="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_a451d754-2753-4ffe-a7ec-d0fbd6ee7187_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_177ea086-601d-4d90-ae2d-b2da4ee0313c_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from collaborative and other agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromCollaborativeAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:href="mgnx-20210930.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:to="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_bb3a3131-8fd9-4a5e-aed4-d3e75137aedf_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_4a7339cf-dd2a-4204-bed8-4aab5d64cc0c_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_label_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:href="mgnx-20210930.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:to="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_21784522-ff89-4702-b664-602c42bce712_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8e661cb2-e32d-4828-8e15-6bb6675273fe_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_c008899c-841e-41b8-a054-9069bc166d31_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_b25ab081-6dd2-4119-b7be-9dc7faf4ad9f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_e3042f10-47e5-463b-bad5-60416f913834_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_3fa7572e-1045-4f52-b639-9c4bfa945159_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0e13938d-f656-46e4-8d79-477aa37aabbd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_b17d6061-5804-488e-8705-ff616cd9a057_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, TRIDENT molecule</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:href="mgnx-20210930.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a20e2e06-f6ec-45a1-b6cb-35cdbc5e89cc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7738e120-f40f-4456-b1f9-6fe6727dbccc_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3185e80f-cb69-4950-be64-6aef643b98cd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_75da907e-f9b4-4214-a232-6e0a8a2b6891_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_7cc79657-38ec-4e8f-8c02-e85ae6cc3794_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_03595932-d014-4eb8-8b07-2d27cbbb6cbc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_6d4bd535-75af-42eb-be26-7063175afd82_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_3ca93c1f-a7ff-46fb-afb0-1b9f2b674164_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_96c1b90b-c095-4031-8621-85a13b82c0cc_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Agreements</link:label>
    <link:label id="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_label_en-US" xlink:label="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Other Agreements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:href="mgnx-20210930.xsd#mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:to="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_55e2113e-7a8f-45bc-8eed-69f0c4553bcb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f5aeb4e7-295e-4534-85cb-8881089c475e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c5645b70-ca75-48e2-ad70-5565398076ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9a1bcae3-3453-472e-8c06-43de113aff29_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_975b0249-5f7c-4f7e-8a6f-07e1a77a70fc_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_2bf94592-9a4f-4bee-aa80-6f505fcce936_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and regulatory milestones recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_label_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_documentation_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:href="mgnx-20210930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:to="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_9bb748e6-ad98-4649-abe1-ac5835695d32_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments and royalties on product sales</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties On Product Sales</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_documentation_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties On Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:href="mgnx-20210930.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:to="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_c7df188b-8504-4478-829b-011f5d020a3f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9915cc8e-11f9-4a08-817f-cdf3f836632d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_645ca2cb-bc4d-4f66-b492-d491a663593d_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, Margetuximab</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:href="mgnx-20210930.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06874690-4c76-4fc6-8577-946de3f284f5_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_258e1d3f-9879-40e8-a079-a670c4b7f337_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_42cf7c52-b58d-47bb-8ebf-fc1fa3650ed7_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_eb0497f9-bacc-4a99-b8fe-5e71ecd0291a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_581a36d4-c854-45ee-b005-ed03c1adfb89_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_06261500-972f-4291-a791-a438a5cc9fb3_terseLabel_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Agreement</link:label>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20210930.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_d394d5ec-6928-48e8-876e-45a7a08324d2_terseLabel_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TwoThousandSixteenEmployeeStockPurchasePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:href="mgnx-20210930.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e8ab7ad1-63b9-4f88-a190-cd2de7bed311_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ef469e6d-8398-471a-bfaf-da4b7d175ffc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637294f7-8ed7-4ee5-9ba9-c26b7f61adf5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8a973c92-3d24-4c46-99a9-ccf8137a9ab0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_19c88261-1f80-4f7d-8e30-efb87e71ce8b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCorporationMember_6215bfc9-0892-41d3-8363-ca35cfbd6f8b_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_label_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteCorporationMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember" xlink:href="mgnx-20210930.xsd#mgnx_IncyteCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCorporationMember" xlink:to="lab_mgnx_IncyteCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesNetOfTaxWithholding_fcf1993a-07f4-443b-ae97-53f5cbc5b313_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, net of tax withholding</link:label>
    <link:label id="lab_mgnx_RevenuesNetOfTaxWithholding_label_en-US" xlink:label="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Net Of Tax Withholding</link:label>
    <link:label id="lab_mgnx_RevenuesNetOfTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Net Of Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding" xlink:href="mgnx-20210930.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesNetOfTaxWithholding" xlink:to="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c193f664-bda2-4226-8e96-a64084658e6a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_19f247d4-6c41-43d3-b6f1-d996b5120e28_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_0b1f065d-d86b-4835-bc41-c3ea84ec984f_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a0809af0-7d36-4f0f-90ef-23c5171fd95b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_46205038-c38e-4f31-a1cb-7d17eee926a5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_4954c985-adce-44ad-bf7b-917ed8523831_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From Grants</link:label>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromGrantsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember" xlink:href="mgnx-20210930.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromGrantsMember" xlink:to="lab_mgnx_RevenuesFromGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_05caf6b5-5acd-4b51-b6b4-8cbd61927caa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_58d2a045-11b3-4fe5-bcb3-abbd897ea473_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue, Net, Reserves for Variable Consideration, Customer Discounts and Service Fees, Product Returns, Provider Chargebacks and Discounts, and Government Rebates</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9defd017-cd2c-45e3-9365-f186d2a4d162_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_f6dac443-4cce-437a-ba85-69c2a85cfa7e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f5eb3c30-56f3-401b-a915-276d0d52390e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_0b5fb63e-226e-457f-bcfb-ee5b92a298e8_terseLabel_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual increase in shares reserved for future issuance as percentage of outstanding share</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_label_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:href="mgnx-20210930.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:to="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d0e33e20-cdcb-46a6-a663-178ec3c0fa84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_311a1fd4-4cf3-464b-824a-52da748eab08_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_0a14ba18-92f5-4603-94f9-dee498df0955_terseLabel_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll deduction percentage</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="mgnx-20210930.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_0bc0cd5a-62a8-4a78-a192-1a3c8cd2a3ff_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_1f13c1c9-ca2e-44ef-bd13-d8689df92cd8_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8a55ef65-52d8-4f4d-a1b9-ee257ce04608_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_8c536136-106d-4955-913a-99a7426d876d_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e2289b32-3898-474c-b7ff-65c04826d280_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_3ffd6c73-b51a-4384-b6ba-0b6d4514ed47_terseLabel_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration and License Agreement</link:label>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20210930.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_366f4265-eaa6-4b7e-ab7a-a26529b3a298_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_66e5733a-14b8-47c6-a249-3664e62aee0e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d31c7029-7ce0-49f8-854c-174669f42ece_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued or sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_dfe2ea49-2c89-4a65-88fa-fa723ed9c6ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_59375824-ce9f-4279-9fea-b5d3a287448d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_68327790-7361-4184-ba0c-2772bc09f7f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price of stock options outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_41b5f592-c785-4333-8523-8d461991fe35_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eb2f30cc-e416-4e19-b772-5d09fb2bd8aa_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_04395e74-4964-4886-9396-96be78b020dc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value -- 125,000,000 shares authorized, 61,254,693 and 56,244,771 shares outstanding at September&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_72b21cd4-b66a-4734-8b46-a5b7b8fe2f11_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_0dbe16d7-0c67-4932-8ee5-b5cb5d635bdc_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_42d1f5d7-8bf0-4e09-a752-18150f71e5e0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense recognition period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d581447d-d649-4448-8e08-244d053a3e03_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_42f22cf9-41a0-4f93-997a-d2c8161d2e12_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a9688eb6-8a43-4430-9511-8b3365fb1e54_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e0850c2d-9743-444d-a31f-e7c6866b9467_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1ec1c798-bbbe-4edd-a0c3-5f887be20a2b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_1c82083d-9ad2-455a-8cfe-d920184eceb2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Product Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_071deaed-4b76-4c65-8f69-5fda4ba745ad_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ce7502d0-319e-4a7a-86cd-bcb990c38113_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_1e268b95-14a3-49b3-8ad7-ddc632bbaa56_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaMember_9752d872-5273-43fa-b7d7-d92ff8a55886_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember" xlink:href="mgnx-20210930.xsd#mgnx_IMabBiopharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaMember" xlink:to="lab_mgnx_IMabBiopharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_010adf4d-d24d-4162-9a06-9b55c5f32a83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Assumptions Using the Black-Scholes Option-Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_fa366e06-5a26-4d48-8292-0a0c41c71a62_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of commercialized molecules</link:label>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_label_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:href="mgnx-20210930.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:to="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1ab50894-ea01-4d12-afac-472e1e4e249a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums and discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_02723161-93ef-4e8f-8029-2fec7c3666c1_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_da35cd3b-3fc3-4a92-8df3-609c5d1fe980_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f08a9fb1-59c8-4a95-aded-a221bacd7233_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_62b5d3ec-b5cf-41a8-a7b4-f7078ac286e9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory valuation reserves</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c6a8e61f-ec80-4e78-b74f-96d2e65a2cd5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bc8a1d2d-2e28-4f87-988a-555e1cb4d712_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_48997d3c-d86c-45d3-b74f-c7257b16ab74_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_9c472543-ee12-4b64-8047-ef1c52e7366e_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_3d9e2479-160d-4b9b-8d49-cf81c4103660_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_731fcbf4-451c-4550-8858-6857ed161c04_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a11cb867-cf5a-4634-bede-104ddf2d9ecf_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_70ae226d-2812-4e0c-8c72-6638b1f254e6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_de01d018-a74d-4ecf-9a36-e40e3783c71b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_fba59b18-3c2e-4d41-bb14-5a7912680b43_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss related to available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_084d293d-1414-46fb-85d0-39a5c642f87b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ffb35a1e-b940-4f89-82fe-903521a36b26_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8cec110d-5caa-4a29-8390-1647978142dc_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of stock sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_41f7ab6d-f174-43dd-b5b5-6b17cfadc8c5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a029fe3a-8c22-4e4e-b844-b20fd2bd9c2f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_74f4638f-8518-49b3-a786-33657f157bf5_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_07ab2a3b-712c-4897-bc63-6366cdab93e6_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b3921b96-b22c-45f9-8bfe-a12e7108afe9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_7f7a4b95-340a-4534-abf1-b99e5c184287_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_bca37669-0463-4e25-9bfb-765f1fd92ea3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_9025e724-448b-4c58-a252-dd20d89d1b5a_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration and License Agreement</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20210930.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_8fef2b6c-c93a-47f5-aac5-c29e657b5655_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_dfdf1136-2ce1-435b-90ff-75f488d059e4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2d510ae0-4f0c-4197-b97e-c9014bc9d882_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_56ce8af9-b314-48fa-9f65-732e7ddec633_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_ddc3950a-286a-49ff-accf-c52ca9dc9586_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_af040b7f-f6eb-473d-8555-e8effdc3f62e_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance of the Research and Development Activities</link:label>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_label_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance Of The Research And Development Activities [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance Of The Research And Development Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:href="mgnx-20210930.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:to="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_6b2f445a-992e-491b-a06b-bb0af58fc119_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0cfc6a69-92a3-4a83-8f32-a460c9f419c0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_f453c3d6-20b2-4cb7-9747-804d0d048b88_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_498d1c84-5dc6-424a-b671-53d9addb7368_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_04bcc0a0-8a64-4510-a75f-d086f42ad7ff_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement transaction price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborativeAgreementTransactionPrice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:href="mgnx-20210930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:to="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_25001bb4-0db2-461f-bd39-49e6a70c8875_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7723f829-9b60-42ce-96a7-4f34e920b9d9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fab81f6e-d090-486f-ad15-bd424ab4249e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_64964c9c-cced-495d-916c-a15beb7f18c8_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_957b6a8f-5d87-4426-aed3-79b5594525e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_16620008-3d92-4e2f-b64b-959759b7084f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4d064e31-c542-4d30-8974-e865b2f14619_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_6cbc5123-5683-463d-b90f-57337dabf076_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cb53f95b-9da1-41b6-9057-e8dc22585bcb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a9273e4d-0474-4ac6-b4ad-83e87f7628e0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_043042ec-6d2c-4712-b526-2aba8c8bebb1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26722a69-6d6f-4b39-a131-e4985819dff2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabMember_e99c81dc-c2be-480e-8e4e-a1921f059749_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember" xlink:href="mgnx-20210930.xsd#mgnx_ZaiLabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabMember" xlink:to="lab_mgnx_ZaiLabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3688fda1-fccd-47d4-95cc-753d4f80bd95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_228273fa-7206-4bf4-85cf-a1618fd85ae3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5c2ec308-e26e-4187-8fb9-04292f7cd89b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_3bb107e4-e2e0-4e08-b26b-52f405d904f7_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_e5368d5b-c378-4270-b62e-6df3221555e8_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromLicenseAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:href="mgnx-20210930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:to="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_6b66a1ab-7ed2-44b0-ab7c-959c0ede167d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_e077c401-4091-4786-96c1-bda9aae5297e_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from government agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromGovernmentAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:href="mgnx-20210930.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:to="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f7cb77a3-4f65-4830-a8c8-a374c1bbc990_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_55456648-b39e-49fd-9d69-6f796d5cda4a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_8b7f8536-5ae6-4ac6-81a7-c936d53e175b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_0679c07c-a315-4684-8b48-a617a839fcab_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2003StockIncentivePlanMember_391f12b7-3555-4fda-9644-0c3fd737beaa_terseLabel_en-US" xlink:label="lab_mgnx_A2003StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2003 Stock Incentive Plan</link:label>
    <link:label id="lab_mgnx_A2003StockIncentivePlanMember_label_en-US" xlink:label="lab_mgnx_A2003StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2003StockIncentivePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember" xlink:href="mgnx-20210930.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2003StockIncentivePlanMember" xlink:to="lab_mgnx_A2003StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_52be0d9e-c15c-4b22-86c6-1ef092b99cf6_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations" xlink:href="mgnx-20210930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfPerformanceObligations" xlink:to="lab_mgnx_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OptInFee_1a276bbc-e2fb-417a-808a-9044ea3bbd1a_terseLabel_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in fee</link:label>
    <link:label id="lab_mgnx_OptInFee_label_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in Fee</link:label>
    <link:label id="lab_mgnx_OptInFee_documentation_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee" xlink:href="mgnx-20210930.xsd#mgnx_OptInFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OptInFee" xlink:to="lab_mgnx_OptInFee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f0c734d7-257c-4da6-afb2-882199eaa614_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4d10a8c2-f982-4b6a-a9fb-29a6b1f09170_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_886e9b29-298f-4b75-ae78-d50f439f3046_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_c5ab22fb-f5bd-4aef-a5c0-851007dcd837_terseLabel_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration recognized</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_a36264dc-c555-431c-9648-6ebe38670c21_verboseLabel_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial activities selling price amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_label_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:href="mgnx-20210930.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:to="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e9129199-dd87-4289-88db-b8e803c0bd81_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bb62d80-7a40-4049-8411-efd69eeeb1c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d59b6ccf-a863-49ee-93cc-afaaa772762b_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7268a2b0-ea88-4c87-bdc7-a128099b20a8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_753c0e78-ed4f-4da3-a65d-7c95cecedfe5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_365d57e1-fae2-4ef1-b220-bd3ea2466502_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_f0309256-16fb-4c77-a5eb-266ea2214904_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0e5b99c6-6d78-40ac-bb21-e9ce83ef7c1c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_b56beba8-bbd7-4167-9218-eaec88fb1260_terseLabel_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential value</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_label_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TotalPotentialValueUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:href="mgnx-20210930.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:to="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_fb063b8c-f38a-4444-aac8-622229ecd978_terseLabel_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_label_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements [Member]</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:href="mgnx-20210930.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:to="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_45330578-f23b-4e8f-98ee-27b79963ceda_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7643b42d-1972-40bf-aa8b-1eb59337375e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bfce3a2d-5f8f-4afe-baef-8fa0b4274004_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8847a477-5f72-4d6b-8203-e44e58d44bc0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Ending Balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_815d9895-6b34-4214-8035-dc0a7a1bed48_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount available for issuance, increase</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:href="mgnx-20210930.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_af80c511-c740-44c3-9efb-527a1b550f35_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_82c05049-3c57-49da-bcd0-a2c5ca58238a_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual increase in shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:href="mgnx-20210930.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:to="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_1bf3710d-9d15-4f1c-901d-33ad013aecca_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4372cee8-53ea-436b-a00a-06336b77c115_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef8eef97-7fef-4eb6-8718-73b18df5c544_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_aff86722-44fb-41dc-a00f-814a99b8c3d3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_34623c6a-bd7e-43ab-b45a-3af304f7b037_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIncentivePlan2013Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member" xlink:href="mgnx-20210930.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2013Member" xlink:to="lab_mgnx_StockIncentivePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e2e65ac5-0902-464a-b179-3a9f83d6e9f1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_bcdd7252-eda0-4612-a36f-4e56f7af4332_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:href="mgnx-20210930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1e581256-c5e8-4480-84dc-001abbaf84e6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5cd5c4e-bd3d-4ec4-beae-bc0590857c71_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Other Agreements [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_e132c67d-19fa-412d-b7a0-53bb3a20b567_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>mgnx-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a503bed0-470c-42a0-8ff2-08d40b83c4e7,g:0544a414-ac6d-4106-af60-27149bd97a9a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c0d0db11-6a52-4451-b15c-3b5ed7810a9b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_DocumentType_c0d0db11-6a52-4451-b15c-3b5ed7810a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_13743fc2-27fe-4266-a52f-13b5019a8775" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_DocumentQuarterlyReport_13743fc2-27fe-4266-a52f-13b5019a8775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ff956ded-a389-4311-82cb-9149c25fd104" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_DocumentPeriodEndDate_ff956ded-a389-4311-82cb-9149c25fd104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e5a55209-21ec-46aa-aba5-ec54075f5c8c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_DocumentTransitionReport_e5a55209-21ec-46aa-aba5-ec54075f5c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b486297b-e4a6-43de-a161-484c725dd794" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_EntityFileNumber_b486297b-e4a6-43de-a161-484c725dd794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_579af6c1-6895-4178-b8ae-67dcc7282dd4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_EntityRegistrantName_579af6c1-6895-4178-b8ae-67dcc7282dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5d9cc5a2-c83a-4400-876c-bd70f139973e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5d9cc5a2-c83a-4400-876c-bd70f139973e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_2c2e30b9-6b56-4a4a-9feb-82a788ff417b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_EntityTaxIdentificationNumber_2c2e30b9-6b56-4a4a-9feb-82a788ff417b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_95b750d2-cb98-45a8-9736-db7b13c3f98b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_EntityAddressAddressLine1_95b750d2-cb98-45a8-9736-db7b13c3f98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_859728b4-5611-4ce7-b130-4bd6557669ef" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_EntityAddressCityOrTown_859728b4-5611-4ce7-b130-4bd6557669ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_fa8def1d-0bfe-487f-b5af-91dd1255d1d4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_EntityAddressStateOrProvince_fa8def1d-0bfe-487f-b5af-91dd1255d1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8eaf2ea2-a5b5-4795-8f36-af246d2c5886" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_EntityAddressPostalZipCode_8eaf2ea2-a5b5-4795-8f36-af246d2c5886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_392540c7-7c59-41a4-8d67-623e20c8caa1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_CityAreaCode_392540c7-7c59-41a4-8d67-623e20c8caa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_787c22c0-6fe5-4bce-9b02-d31ffde758bc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_LocalPhoneNumber_787c22c0-6fe5-4bce-9b02-d31ffde758bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_71b2971f-a566-416a-b23b-6f352bbd1cf1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_Security12bTitle_71b2971f-a566-416a-b23b-6f352bbd1cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f3cb138f-932f-4a3c-b911-a8b47a8b3d88" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_TradingSymbol_f3cb138f-932f-4a3c-b911-a8b47a8b3d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_df460e8c-7891-4343-85cb-2e654e532209" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_SecurityExchangeName_df460e8c-7891-4343-85cb-2e654e532209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_76ef8516-7808-47dc-abfa-41415bfe6f04" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_EntityCurrentReportingStatus_76ef8516-7808-47dc-abfa-41415bfe6f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_573a6e0c-d260-40c8-8ac6-9b9495c5dec2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_EntityInteractiveDataCurrent_573a6e0c-d260-40c8-8ac6-9b9495c5dec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_8956f585-867a-4d9f-96ac-45f7807c134a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_EntityFilerCategory_8956f585-867a-4d9f-96ac-45f7807c134a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_27cb383d-197f-4272-b920-3fac813d86cf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_EntitySmallBusiness_27cb383d-197f-4272-b920-3fac813d86cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c1b703db-1fd4-4dfe-988a-125eb96af0f2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_EntityEmergingGrowthCompany_c1b703db-1fd4-4dfe-988a-125eb96af0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_46322041-75e6-429b-80ca-acf1ce6d58f2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_EntityShellCompany_46322041-75e6-429b-80ca-acf1ce6d58f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_31a41ddf-11f2-4276-8447-962eb43d66ec" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_31a41ddf-11f2-4276-8447-962eb43d66ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d5dce37e-84c9-4600-8273-aa339412036a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_AmendmentFlag_d5dce37e-84c9-4600-8273-aa339412036a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5e131cc2-d2e5-459e-859a-f8e0bfb53df9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_DocumentFiscalYearFocus_5e131cc2-d2e5-459e-859a-f8e0bfb53df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_48ae9260-e045-4b0c-8f66-e9db2a9c34d2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_DocumentFiscalPeriodFocus_48ae9260-e045-4b0c-8f66-e9db2a9c34d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_64fe31c6-62e5-4936-8e5e-b9303f0e7bf9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_EntityCentralIndexKey_64fe31c6-62e5-4936-8e5e-b9303f0e7bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c6eaf85c-5cc1-4410-9bdc-5f5aa0a838bb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aeb6266a-c149-4274-9a13-89d97a43a203" xlink:to="loc_dei_CurrentFiscalYearEndDate_c6eaf85c-5cc1-4410-9bdc-5f5aa0a838bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8303dcdb-05a2-4545-b0fd-812d34c78f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_02319182-4267-457c-8ba7-22039f1306a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8303dcdb-05a2-4545-b0fd-812d34c78f75" xlink:to="loc_us-gaap_AssetsAbstract_02319182-4267-457c-8ba7-22039f1306a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c9d0a2a3-de4f-4999-aba7-dcfeaa9a1e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_02319182-4267-457c-8ba7-22039f1306a7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c9d0a2a3-de4f-4999-aba7-dcfeaa9a1e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_96665c05-8d48-406e-a0fb-117b98dfa862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c9d0a2a3-de4f-4999-aba7-dcfeaa9a1e78" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_96665c05-8d48-406e-a0fb-117b98dfa862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_f08b67ef-a375-4bb6-a12a-ac106c13c585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c9d0a2a3-de4f-4999-aba7-dcfeaa9a1e78" xlink:to="loc_us-gaap_Investments_f08b67ef-a375-4bb6-a12a-ac106c13c585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_74e934a1-ba6b-457a-a33e-6ece953aeb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c9d0a2a3-de4f-4999-aba7-dcfeaa9a1e78" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_74e934a1-ba6b-457a-a33e-6ece953aeb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f423f710-6663-4af9-872a-7a64168da47d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c9d0a2a3-de4f-4999-aba7-dcfeaa9a1e78" xlink:to="loc_us-gaap_InventoryNet_f423f710-6663-4af9-872a-7a64168da47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_efd91d08-e6f1-4589-884e-de10bb6d302e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c9d0a2a3-de4f-4999-aba7-dcfeaa9a1e78" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_efd91d08-e6f1-4589-884e-de10bb6d302e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5ddb08c3-4428-426f-97a9-98c748d79d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c9d0a2a3-de4f-4999-aba7-dcfeaa9a1e78" xlink:to="loc_us-gaap_AssetsCurrent_5ddb08c3-4428-426f-97a9-98c748d79d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_897e0b70-1211-4f31-adc3-23a85d883f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_02319182-4267-457c-8ba7-22039f1306a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_897e0b70-1211-4f31-adc3-23a85d883f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_31f3fd59-a08a-41e8-b715-5a41238b94bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_02319182-4267-457c-8ba7-22039f1306a7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_31f3fd59-a08a-41e8-b715-5a41238b94bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_47924e7b-2840-404f-bf6b-fc945ff7ed5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_02319182-4267-457c-8ba7-22039f1306a7" xlink:to="loc_us-gaap_Assets_47924e7b-2840-404f-bf6b-fc945ff7ed5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_73181bdd-dd82-4db6-9118-e64900b6380b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8303dcdb-05a2-4545-b0fd-812d34c78f75" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_73181bdd-dd82-4db6-9118-e64900b6380b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9d7fe4b1-e8a5-403d-9b6c-37366d7566cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_73181bdd-dd82-4db6-9118-e64900b6380b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9d7fe4b1-e8a5-403d-9b6c-37366d7566cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_95096918-5891-43cb-bb6c-317283218a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d7fe4b1-e8a5-403d-9b6c-37366d7566cb" xlink:to="loc_us-gaap_AccountsPayableCurrent_95096918-5891-43cb-bb6c-317283218a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9c6fb831-a511-4266-95ba-699a2c7dfab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d7fe4b1-e8a5-403d-9b6c-37366d7566cb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9c6fb831-a511-4266-95ba-699a2c7dfab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3bf6a4ea-8d16-440a-b8a0-ea79d6ba44b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d7fe4b1-e8a5-403d-9b6c-37366d7566cb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3bf6a4ea-8d16-440a-b8a0-ea79d6ba44b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d1c12cfe-1aed-4606-903a-6217261845a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d7fe4b1-e8a5-403d-9b6c-37366d7566cb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d1c12cfe-1aed-4606-903a-6217261845a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fd4a65ec-6ad2-4bc9-9b4e-732abbaa4af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d7fe4b1-e8a5-403d-9b6c-37366d7566cb" xlink:to="loc_us-gaap_LiabilitiesCurrent_fd4a65ec-6ad2-4bc9-9b4e-732abbaa4af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d5dd8a6f-9532-4ff0-8ca2-5eb0658508c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_73181bdd-dd82-4db6-9118-e64900b6380b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d5dd8a6f-9532-4ff0-8ca2-5eb0658508c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a366c92d-53b0-4487-8211-e3eb9073d529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_73181bdd-dd82-4db6-9118-e64900b6380b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a366c92d-53b0-4487-8211-e3eb9073d529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b494fb07-1273-434e-98cf-4923d612b8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_73181bdd-dd82-4db6-9118-e64900b6380b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b494fb07-1273-434e-98cf-4923d612b8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_db6165e6-ee7c-4ac8-9dc4-2be7b11c6c67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_73181bdd-dd82-4db6-9118-e64900b6380b" xlink:to="loc_us-gaap_Liabilities_db6165e6-ee7c-4ac8-9dc4-2be7b11c6c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_42088384-ab6c-4774-9628-c6604fa4b1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_73181bdd-dd82-4db6-9118-e64900b6380b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_42088384-ab6c-4774-9628-c6604fa4b1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f4a8b3ce-26aa-460e-bdca-5e28361a9c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42088384-ab6c-4774-9628-c6604fa4b1f6" xlink:to="loc_us-gaap_CommonStockValue_f4a8b3ce-26aa-460e-bdca-5e28361a9c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0abc1b06-720e-4400-8068-8faa4b494abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42088384-ab6c-4774-9628-c6604fa4b1f6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0abc1b06-720e-4400-8068-8faa4b494abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_814c0755-32c1-4def-9df2-6c55e5caaa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42088384-ab6c-4774-9628-c6604fa4b1f6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_814c0755-32c1-4def-9df2-6c55e5caaa1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bb9c84fa-c69b-4556-ba3e-ede6c484f4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42088384-ab6c-4774-9628-c6604fa4b1f6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bb9c84fa-c69b-4556-ba3e-ede6c484f4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3f0428c5-0cef-4579-9917-8e581fbe257a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42088384-ab6c-4774-9628-c6604fa4b1f6" xlink:to="loc_us-gaap_StockholdersEquity_3f0428c5-0cef-4579-9917-8e581fbe257a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae72c042-0e84-4899-ae1a-f0c8be15de40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_73181bdd-dd82-4db6-9118-e64900b6380b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae72c042-0e84-4899-ae1a-f0c8be15de40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1855816a-7f87-4779-a8cb-0d9015a6cd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3dfaffe9-6897-4e70-82f5-0eadd5c6d5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1855816a-7f87-4779-a8cb-0d9015a6cd1a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3dfaffe9-6897-4e70-82f5-0eadd5c6d5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ef81facf-a736-4d19-8398-f452ddc23eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3dfaffe9-6897-4e70-82f5-0eadd5c6d5e4" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ef81facf-a736-4d19-8398-f452ddc23eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_06e70672-6682-47f0-86ad-4a85261b0528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ef81facf-a736-4d19-8398-f452ddc23eb5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_06e70672-6682-47f0-86ad-4a85261b0528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c8e56c02-e9e7-4f83-b8a6-73a2b3d91ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ef81facf-a736-4d19-8398-f452ddc23eb5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c8e56c02-e9e7-4f83-b8a6-73a2b3d91ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f678ce0f-24ce-4d56-8b5e-df6374d42d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ef81facf-a736-4d19-8398-f452ddc23eb5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f678ce0f-24ce-4d56-8b5e-df6374d42d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_78c93f4a-1aad-4286-9849-f8a294982597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9a994a15-d971-4f2f-9ab4-83076f1336b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_78c93f4a-1aad-4286-9849-f8a294982597" xlink:to="loc_us-gaap_StatementTable_9a994a15-d971-4f2f-9ab4-83076f1336b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e4bc93e2-b9ff-4c60-928b-72151daabcdf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9a994a15-d971-4f2f-9ab4-83076f1336b4" xlink:to="loc_srt_ProductOrServiceAxis_e4bc93e2-b9ff-4c60-928b-72151daabcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_89329d38-8dbc-4e95-b6d9-9e4f7ef990df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e4bc93e2-b9ff-4c60-928b-72151daabcdf" xlink:to="loc_srt_ProductsAndServicesDomain_89329d38-8dbc-4e95-b6d9-9e4f7ef990df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_bc32a8b4-5cea-4d68-9f99-5f45bc7f2153" xlink:href="mgnx-20210930.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89329d38-8dbc-4e95-b6d9-9e4f7ef990df" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_bc32a8b4-5cea-4d68-9f99-5f45bc7f2153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_aa9b1dd3-457d-4f72-8878-138fef6538f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89329d38-8dbc-4e95-b6d9-9e4f7ef990df" xlink:to="loc_us-gaap_ProductMember_aa9b1dd3-457d-4f72-8878-138fef6538f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_17fc18e5-fff9-4ab5-b7a1-633f0875ca5a" xlink:href="mgnx-20210930.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89329d38-8dbc-4e95-b6d9-9e4f7ef990df" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_17fc18e5-fff9-4ab5-b7a1-633f0875ca5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9a994a15-d971-4f2f-9ab4-83076f1336b4" xlink:to="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_23517bd1-ec85-4232-83eb-d43a53fcc230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:to="loc_us-gaap_RevenuesAbstract_23517bd1-ec85-4232-83eb-d43a53fcc230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9dee226d-abd6-4e16-a0e9-b349e3677dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_23517bd1-ec85-4232-83eb-d43a53fcc230" xlink:to="loc_us-gaap_Revenues_9dee226d-abd6-4e16-a0e9-b349e3677dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_82a823e0-2e16-4615-befa-2bb7d4ae59a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_82a823e0-2e16-4615-befa-2bb7d4ae59a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0b133dca-927b-4e1f-aa58-659c452e6d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0b133dca-927b-4e1f-aa58-659c452e6d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5a74a869-812f-4d4b-89ac-edfb7c54b2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5a74a869-812f-4d4b-89ac-edfb7c54b2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_385e02cc-bc07-4958-b17d-893382e547dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:to="loc_us-gaap_CostsAndExpenses_385e02cc-bc07-4958-b17d-893382e547dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f74e4aba-b657-4ebc-885e-0f588b02ef45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:to="loc_us-gaap_OperatingIncomeLoss_f74e4aba-b657-4ebc-885e-0f588b02ef45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ef7a4c75-b1ad-41ca-9e6a-edb809010160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ef7a4c75-b1ad-41ca-9e6a-edb809010160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6af021b2-b915-4aba-ba44-8bee70d3f7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_042c5ebd-a96c-4032-829b-30459214c9b8" xlink:to="loc_us-gaap_NetIncomeLoss_6af021b2-b915-4aba-ba44-8bee70d3f7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2d7f7280-80eb-4fda-a7e6-d28c73df0efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2d7f7280-80eb-4fda-a7e6-d28c73df0efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_18db5ade-612b-4451-bf74-f46f2b68d1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2d7f7280-80eb-4fda-a7e6-d28c73df0efa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_18db5ade-612b-4451-bf74-f46f2b68d1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_57c55199-cfcd-4e57-b949-6160abd151a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_57c55199-cfcd-4e57-b949-6160abd151a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7a6afb41-0187-4d98-bff1-e76228cbc6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:to="loc_us-gaap_EarningsPerShareBasic_7a6afb41-0187-4d98-bff1-e76228cbc6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4ca0ef78-bf1c-4c0c-8d52-61e68ce10efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4ca0ef78-bf1c-4c0c-8d52-61e68ce10efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c2349a81-d7dd-4f5a-87a6-fd8bd85a2dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c2349a81-d7dd-4f5a-87a6-fd8bd85a2dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_43d478dc-48e9-45be-8c0f-ca5cab624bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95088414-4cea-4cc7-96e7-e545c9d94b75" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_43d478dc-48e9-45be-8c0f-ca5cab624bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a1f26707-5bcb-4454-9009-7280286b98c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8ea7872b-0747-46b3-89f0-686051246949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a1f26707-5bcb-4454-9009-7280286b98c4" xlink:to="loc_us-gaap_StatementTable_8ea7872b-0747-46b3-89f0-686051246949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5e902636-3657-49ea-a4db-51e7d821728b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8ea7872b-0747-46b3-89f0-686051246949" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5e902636-3657-49ea-a4db-51e7d821728b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_167897aa-d22f-4dd6-aa97-7661430db927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5e902636-3657-49ea-a4db-51e7d821728b" xlink:to="loc_us-gaap_EquityComponentDomain_167897aa-d22f-4dd6-aa97-7661430db927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_dcc45f5e-2546-4c13-8ce1-0558a5b6a066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_167897aa-d22f-4dd6-aa97-7661430db927" xlink:to="loc_us-gaap_CommonStockMember_dcc45f5e-2546-4c13-8ce1-0558a5b6a066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_46ca279e-58de-4b16-809d-35b58490826c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_167897aa-d22f-4dd6-aa97-7661430db927" xlink:to="loc_us-gaap_TreasuryStockMember_46ca279e-58de-4b16-809d-35b58490826c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d75f6601-b74d-4657-9da5-7d01ae5d84ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_167897aa-d22f-4dd6-aa97-7661430db927" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d75f6601-b74d-4657-9da5-7d01ae5d84ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4b237f35-97f4-4c1b-984f-e88e94b978eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_167897aa-d22f-4dd6-aa97-7661430db927" xlink:to="loc_us-gaap_RetainedEarningsMember_4b237f35-97f4-4c1b-984f-e88e94b978eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_87c4dcc5-59f2-4d79-a70f-f27736a635bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_167897aa-d22f-4dd6-aa97-7661430db927" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_87c4dcc5-59f2-4d79-a70f-f27736a635bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_508b2cd9-6a88-4a87-ab30-e73c27f7036e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8ea7872b-0747-46b3-89f0-686051246949" xlink:to="loc_us-gaap_StatementLineItems_508b2cd9-6a88-4a87-ab30-e73c27f7036e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_508b2cd9-6a88-4a87-ab30-e73c27f7036e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_09f48395-a08e-43e7-ae03-b5d05b32e6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_SharesIssued_09f48395-a08e-43e7-ae03-b5d05b32e6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11f48b29-c2c1-47bc-9671-be86a39abc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11f48b29-c2c1-47bc-9671-be86a39abc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_82177561-d290-407e-afe3-b1f7294e8950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_82177561-d290-407e-afe3-b1f7294e8950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_46fa2487-ba1f-4561-a7c5-28a5088477c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_46fa2487-ba1f-4561-a7c5-28a5088477c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9d67a393-e032-4c8f-bb29-b57452420e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9d67a393-e032-4c8f-bb29-b57452420e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_99ebc62e-2d67-4022-a63e-cec4e6552bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_99ebc62e-2d67-4022-a63e-cec4e6552bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_2938953a-9e10-43e7-a317-3bc549ec483d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_2938953a-9e10-43e7-a317-3bc549ec483d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_46a8d194-45c1-4f62-9259-2474be0f5153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_46a8d194-45c1-4f62-9259-2474be0f5153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_b7437093-ee3a-48d5-abb1-84096852b32e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_b7437093-ee3a-48d5-abb1-84096852b32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_32600531-04cf-422f-8e72-4861bf017094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_32600531-04cf-422f-8e72-4861bf017094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_61fa9adb-139e-4f76-8fdd-a8f20c50d0af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_NetIncomeLoss_61fa9adb-139e-4f76-8fdd-a8f20c50d0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_eea788eb-c82e-4e8a-886c-0ef04476791c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_SharesIssued_eea788eb-c82e-4e8a-886c-0ef04476791c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6591fef6-b602-4c74-8089-82015f7feeec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec51122-a9c4-47c5-9281-059291f9edd4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6591fef6-b602-4c74-8089-82015f7feeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8fed823c-1bf9-491f-94c6-88dc227536e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22595578-5455-483d-9ee1-75e6acc97238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8fed823c-1bf9-491f-94c6-88dc227536e5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22595578-5455-483d-9ee1-75e6acc97238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dd644091-f7f4-48ad-a69c-5553e59e9c66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22595578-5455-483d-9ee1-75e6acc97238" xlink:to="loc_us-gaap_NetIncomeLoss_dd644091-f7f4-48ad-a69c-5553e59e9c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42644266-2355-405f-baf7-25b34a719726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22595578-5455-483d-9ee1-75e6acc97238" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42644266-2355-405f-baf7-25b34a719726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_47e8e1e4-e72e-480b-8d93-da0e8a42d912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42644266-2355-405f-baf7-25b34a719726" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_47e8e1e4-e72e-480b-8d93-da0e8a42d912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d47d2443-933e-470d-b898-f70c22ec77da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42644266-2355-405f-baf7-25b34a719726" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d47d2443-933e-470d-b898-f70c22ec77da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cd704a37-f4b3-44f2-95d5-055533d226ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42644266-2355-405f-baf7-25b34a719726" xlink:to="loc_us-gaap_ShareBasedCompensation_cd704a37-f4b3-44f2-95d5-055533d226ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_58bc4cc2-224f-43fe-b00d-bbb3a2081413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42644266-2355-405f-baf7-25b34a719726" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_58bc4cc2-224f-43fe-b00d-bbb3a2081413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_af948c7e-dd62-4228-adce-2a5d9c8ff318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42644266-2355-405f-baf7-25b34a719726" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_af948c7e-dd62-4228-adce-2a5d9c8ff318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ad30eba6-e39f-4a44-97ce-68c76273f163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_af948c7e-dd62-4228-adce-2a5d9c8ff318" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ad30eba6-e39f-4a44-97ce-68c76273f163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3bb0a3c3-631c-4f2b-ab8b-6a539d1f7ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_af948c7e-dd62-4228-adce-2a5d9c8ff318" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3bb0a3c3-631c-4f2b-ab8b-6a539d1f7ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_be7f5c04-5ff0-455c-b33b-cc95b93275ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_af948c7e-dd62-4228-adce-2a5d9c8ff318" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_be7f5c04-5ff0-455c-b33b-cc95b93275ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3f5a882d-bd30-4bf5-8c0f-e8633c262602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_af948c7e-dd62-4228-adce-2a5d9c8ff318" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3f5a882d-bd30-4bf5-8c0f-e8633c262602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_0acfd34c-c873-4ffe-93ae-a5f3d1b45558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_af948c7e-dd62-4228-adce-2a5d9c8ff318" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_0acfd34c-c873-4ffe-93ae-a5f3d1b45558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_aec28784-7271-4002-a531-aa69fd2e0fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_af948c7e-dd62-4228-adce-2a5d9c8ff318" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_aec28784-7271-4002-a531-aa69fd2e0fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f2a84524-c7a9-4a8a-9c6e-1385289c4443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_af948c7e-dd62-4228-adce-2a5d9c8ff318" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f2a84524-c7a9-4a8a-9c6e-1385289c4443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7299190e-2dd7-42cd-acf1-3bd63980267f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_af948c7e-dd62-4228-adce-2a5d9c8ff318" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7299190e-2dd7-42cd-acf1-3bd63980267f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_d2cfbef7-c118-439f-9666-561d0af6088a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_af948c7e-dd62-4228-adce-2a5d9c8ff318" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_d2cfbef7-c118-439f-9666-561d0af6088a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cdc23e3a-d13a-4986-9e7e-887c17dbc87f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22595578-5455-483d-9ee1-75e6acc97238" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cdc23e3a-d13a-4986-9e7e-887c17dbc87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1efd0a06-f99e-4ba8-94a0-e3bb203ceecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8fed823c-1bf9-491f-94c6-88dc227536e5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1efd0a06-f99e-4ba8-94a0-e3bb203ceecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_cc0b292c-eca9-4eba-a995-0c787b8921a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1efd0a06-f99e-4ba8-94a0-e3bb203ceecd" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_cc0b292c-eca9-4eba-a995-0c787b8921a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_43a837d6-7832-4937-b036-ca42fc4330b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1efd0a06-f99e-4ba8-94a0-e3bb203ceecd" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_43a837d6-7832-4937-b036-ca42fc4330b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3915a107-f511-470d-af33-641308e4d2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1efd0a06-f99e-4ba8-94a0-e3bb203ceecd" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3915a107-f511-470d-af33-641308e4d2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50859c2d-37ab-4ad0-b0aa-c637cb816dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1efd0a06-f99e-4ba8-94a0-e3bb203ceecd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50859c2d-37ab-4ad0-b0aa-c637cb816dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ea85f33-de69-4085-9b34-69bdc09c5de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8fed823c-1bf9-491f-94c6-88dc227536e5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ea85f33-de69-4085-9b34-69bdc09c5de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d26a64d9-d63b-4f82-9da0-d57a21e2c72e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ea85f33-de69-4085-9b34-69bdc09c5de2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d26a64d9-d63b-4f82-9da0-d57a21e2c72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_ed574933-d59f-48f8-9513-4dd40a4e9808" xlink:href="mgnx-20210930.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ea85f33-de69-4085-9b34-69bdc09c5de2" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_ed574933-d59f-48f8-9513-4dd40a4e9808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_17ea7610-a4b7-4ddc-9dd7-342dc90afe69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ea85f33-de69-4085-9b34-69bdc09c5de2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_17ea7610-a4b7-4ddc-9dd7-342dc90afe69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe63f5bf-e6d2-4ce5-ae82-c12410284c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ea85f33-de69-4085-9b34-69bdc09c5de2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe63f5bf-e6d2-4ce5-ae82-c12410284c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a6eda60c-db72-431d-a304-29ce16726cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8fed823c-1bf9-491f-94c6-88dc227536e5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a6eda60c-db72-431d-a304-29ce16726cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_348ffce2-9444-4c66-a472-686a6d75ebaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8fed823c-1bf9-491f-94c6-88dc227536e5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_348ffce2-9444-4c66-a472-686a6d75ebaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_963687ef-470d-4704-b2a1-13239653a999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8fed823c-1bf9-491f-94c6-88dc227536e5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_963687ef-470d-4704-b2a1-13239653a999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_02ace666-caf9-47b7-b07c-9747369304be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8fed823c-1bf9-491f-94c6-88dc227536e5" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_02ace666-caf9-47b7-b07c-9747369304be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_bba74ccb-2ecc-4599-affe-bf1f906dc110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_02ace666-caf9-47b7-b07c-9747369304be" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_bba74ccb-2ecc-4599-affe-bf1f906dc110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/NatureofOperations" xlink:type="simple" xlink:href="mgnx-20210930.xsd#NatureofOperations"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/NatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eeb1373c-22cb-4eef-8427-4d29c4740712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_366322be-9d78-4f7d-85ec-bce64a2e0ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eeb1373c-22cb-4eef-8427-4d29c4740712" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_366322be-9d78-4f7d-85ec-bce64a2e0ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20210930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6023be8f-b186-47bc-b121-700eedb2d724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4902be77-5aa5-45ee-8729-353c0a32a063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6023be8f-b186-47bc-b121-700eedb2d724" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4902be77-5aa5-45ee-8729-353c0a32a063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20210930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_728ddc8d-070f-4724-b833-ae179bb6f15e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_dca5f124-5d32-437d-b870-6c62bd91e01b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_728ddc8d-070f-4724-b833-ae179bb6f15e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_dca5f124-5d32-437d-b870-6c62bd91e01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_78d05ff2-c782-441b-8ea9-e30faafba43e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_728ddc8d-070f-4724-b833-ae179bb6f15e" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_78d05ff2-c782-441b-8ea9-e30faafba43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_78268e3a-20d8-4f0c-9d93-79dd8e118f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_728ddc8d-070f-4724-b833-ae179bb6f15e" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_78268e3a-20d8-4f0c-9d93-79dd8e118f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_96471a1b-62e6-4556-b9f1-587272db7e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_728ddc8d-070f-4724-b833-ae179bb6f15e" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_96471a1b-62e6-4556-b9f1-587272db7e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4a81ea1c-c633-4f64-8f66-4506803cb971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_728ddc8d-070f-4724-b833-ae179bb6f15e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4a81ea1c-c633-4f64-8f66-4506803cb971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_e0752bd5-4db4-4823-969a-70366fe8e8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_728ddc8d-070f-4724-b833-ae179bb6f15e" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_e0752bd5-4db4-4823-969a-70366fe8e8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="mgnx-20210930.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_40ee2c8e-4b94-468c-9ac6-f7b32a054fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1ea89ec2-726d-4a1a-96c5-019b2ce64fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_40ee2c8e-4b94-468c-9ac6-f7b32a054fd6" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1ea89ec2-726d-4a1a-96c5-019b2ce64fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="mgnx-20210930.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0c7add68-96de-4e6b-bf60-a1e497c32f11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_5d39b0d7-f58a-4535-8cc4-24b55d4b0e26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0c7add68-96de-4e6b-bf60-a1e497c32f11" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_5d39b0d7-f58a-4535-8cc4-24b55d4b0e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_081a0e01-63e7-4e83-9868-73fb827744a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91136124-7439-4cb7-b881-15a69b3a4ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_081a0e01-63e7-4e83-9868-73fb827744a5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91136124-7439-4cb7-b881-15a69b3a4ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4ebdd628-88e8-4745-869c-bb4af56cc136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91136124-7439-4cb7-b881-15a69b3a4ddd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4ebdd628-88e8-4745-869c-bb4af56cc136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_23b45fb2-94a4-4a62-a24b-36c57b0162a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4ebdd628-88e8-4745-869c-bb4af56cc136" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_23b45fb2-94a4-4a62-a24b-36c57b0162a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_aaef1792-ceff-4233-9868-b7d1484fe61a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_23b45fb2-94a4-4a62-a24b-36c57b0162a2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_aaef1792-ceff-4233-9868-b7d1484fe61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_abf0b63e-c220-4333-81ac-d91ba2a78778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91136124-7439-4cb7-b881-15a69b3a4ddd" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_abf0b63e-c220-4333-81ac-d91ba2a78778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f1e3affa-c7ab-4bda-a3dd-dce646cb91bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_abf0b63e-c220-4333-81ac-d91ba2a78778" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f1e3affa-c7ab-4bda-a3dd-dce646cb91bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_56c172ea-0304-43e4-89b5-253986fceeda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f1e3affa-c7ab-4bda-a3dd-dce646cb91bd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_56c172ea-0304-43e4-89b5-253986fceeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4f937011-5633-4230-a219-1fede1482557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f1e3affa-c7ab-4bda-a3dd-dce646cb91bd" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4f937011-5633-4230-a219-1fede1482557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c663851f-b8b2-44bd-a7ae-6c8292b139c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f1e3affa-c7ab-4bda-a3dd-dce646cb91bd" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c663851f-b8b2-44bd-a7ae-6c8292b139c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f0caf576-2252-460a-b3dc-d7ef24f68972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f1e3affa-c7ab-4bda-a3dd-dce646cb91bd" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f0caf576-2252-460a-b3dc-d7ef24f68972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1dbc7107-1949-4aca-a064-4f988976871d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91136124-7439-4cb7-b881-15a69b3a4ddd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1dbc7107-1949-4aca-a064-4f988976871d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0b5e312-e915-41f8-b519-3561099789a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1dbc7107-1949-4aca-a064-4f988976871d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0b5e312-e915-41f8-b519-3561099789a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f6015465-8a68-4049-8dc1-73a4d89d5c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0b5e312-e915-41f8-b519-3561099789a0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f6015465-8a68-4049-8dc1-73a4d89d5c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_316c09e6-aabe-48dd-98b1-b5bcd2c4e9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0b5e312-e915-41f8-b519-3561099789a0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_316c09e6-aabe-48dd-98b1-b5bcd2c4e9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_88a331b9-9ca3-4ba2-857b-f9abb1e434cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91136124-7439-4cb7-b881-15a69b3a4ddd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_88a331b9-9ca3-4ba2-857b-f9abb1e434cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_35ef28d5-de79-4157-ab43-7c2f40540b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_88a331b9-9ca3-4ba2-857b-f9abb1e434cc" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_35ef28d5-de79-4157-ab43-7c2f40540b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_33308d16-b922-44cf-bf49-f2796e79a237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_35ef28d5-de79-4157-ab43-7c2f40540b28" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_33308d16-b922-44cf-bf49-f2796e79a237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_30b2ffe0-4192-43f0-a38a-5b65564dd322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_35ef28d5-de79-4157-ab43-7c2f40540b28" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_30b2ffe0-4192-43f0-a38a-5b65564dd322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e95c3b9e-32c2-4150-80ce-e3db13168ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_35ef28d5-de79-4157-ab43-7c2f40540b28" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e95c3b9e-32c2-4150-80ce-e3db13168ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20210930.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_30e2309b-d97e-4bf0-a578-4a284e73f486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_784090d2-4467-45f8-82ee-ff3a544fceea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_30e2309b-d97e-4bf0-a578-4a284e73f486" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_784090d2-4467-45f8-82ee-ff3a544fceea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20210930.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_410d1029-b7cd-4ced-90d8-3f55023ca5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_6849ca6a-0104-485f-a058-1d964f1ad985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_410d1029-b7cd-4ced-90d8-3f55023ca5e4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_6849ca6a-0104-485f-a058-1d964f1ad985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e7744bba-2287-495f-addd-2717c6c077f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_0b9e739c-1143-42ba-83fd-45f15b5e7dde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e7744bba-2287-495f-addd-2717c6c077f4" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_0b9e739c-1143-42ba-83fd-45f15b5e7dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_09ee1739-66ae-4b86-ba20-08bc68619dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_0b9e739c-1143-42ba-83fd-45f15b5e7dde" xlink:to="loc_us-gaap_FinancialInstrumentAxis_09ee1739-66ae-4b86-ba20-08bc68619dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97044cc5-e8be-410c-aa59-414d69c6bcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_09ee1739-66ae-4b86-ba20-08bc68619dfd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97044cc5-e8be-410c-aa59-414d69c6bcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f14cbc22-0af7-4bdf-ae79-8d7c62e905f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97044cc5-e8be-410c-aa59-414d69c6bcf3" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f14cbc22-0af7-4bdf-ae79-8d7c62e905f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_d639f079-43f4-4696-b1cf-9c20a66c9fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97044cc5-e8be-410c-aa59-414d69c6bcf3" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_d639f079-43f4-4696-b1cf-9c20a66c9fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_bd595fd6-34f4-4157-b086-aac30c211041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97044cc5-e8be-410c-aa59-414d69c6bcf3" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_bd595fd6-34f4-4157-b086-aac30c211041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9e1aedea-42c6-4ec2-a1d4-5c3b5e023dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_0b9e739c-1143-42ba-83fd-45f15b5e7dde" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9e1aedea-42c6-4ec2-a1d4-5c3b5e023dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_39b530f7-48d5-4f15-bedf-d095f21f630e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9e1aedea-42c6-4ec2-a1d4-5c3b5e023dc1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_39b530f7-48d5-4f15-bedf-d095f21f630e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_30c7644c-97dd-4d03-862b-afb53246f807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9e1aedea-42c6-4ec2-a1d4-5c3b5e023dc1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_30c7644c-97dd-4d03-862b-afb53246f807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_054bac90-0599-47f6-8b08-338ec4fb8695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9e1aedea-42c6-4ec2-a1d4-5c3b5e023dc1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_054bac90-0599-47f6-8b08-338ec4fb8695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9e1b38f4-fbac-420f-8023-eea1c6f6ad9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9e1aedea-42c6-4ec2-a1d4-5c3b5e023dc1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9e1b38f4-fbac-420f-8023-eea1c6f6ad9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_9b8b2e03-4c43-4678-943b-8a18a30badbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e7744bba-2287-495f-addd-2717c6c077f4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_9b8b2e03-4c43-4678-943b-8a18a30badbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNet" xlink:type="simple" xlink:href="mgnx-20210930.xsd#InventoryNet"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4dac510c-d279-461c-a24e-9005a3ad8a68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_2440d9a4-c9a8-4276-811f-d5aaf1399729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4dac510c-d279-461c-a24e-9005a3ad8a68" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_2440d9a4-c9a8-4276-811f-d5aaf1399729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetTables" xlink:type="simple" xlink:href="mgnx-20210930.xsd#InventoryNetTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_05cdb6b1-29e7-48a4-8d13-26b60e2a3c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_987e16dc-158c-412e-b7ab-01e261aa6cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_05cdb6b1-29e7-48a4-8d13-26b60e2a3c82" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_987e16dc-158c-412e-b7ab-01e261aa6cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#InventoryNetDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c2da5f3b-22b7-415e-8545-e32fd1461c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_393736dc-3283-4bc2-993e-f65b4a502ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c2da5f3b-22b7-415e-8545-e32fd1461c90" xlink:to="loc_us-gaap_InventoryRawMaterials_393736dc-3283-4bc2-993e-f65b4a502ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_2d2a5fc2-bfc8-40a0-9a44-11107cb16847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c2da5f3b-22b7-415e-8545-e32fd1461c90" xlink:to="loc_us-gaap_InventoryWorkInProcess_2d2a5fc2-bfc8-40a0-9a44-11107cb16847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_5ea3ebef-41f9-48cc-b652-599e0b4818cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c2da5f3b-22b7-415e-8545-e32fd1461c90" xlink:to="loc_us-gaap_InventoryFinishedGoods_5ea3ebef-41f9-48cc-b652-599e0b4818cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a7cbdd07-2c62-4635-a2d9-228ed17c2572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c2da5f3b-22b7-415e-8545-e32fd1461c90" xlink:to="loc_us-gaap_InventoryNet_a7cbdd07-2c62-4635-a2d9-228ed17c2572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_5019af36-3b91-49d2-a17b-254e59562a02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c2da5f3b-22b7-415e-8545-e32fd1461c90" xlink:to="loc_us-gaap_InventoryValuationReserves_5019af36-3b91-49d2-a17b-254e59562a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20210930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5dc12186-0a91-4047-b1c5-6c7d56dd43e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_de86f23e-8b75-4cb7-b435-4f8196794e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5dc12186-0a91-4047-b1c5-6c7d56dd43e0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_de86f23e-8b75-4cb7-b435-4f8196794e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3e43f5eb-ef20-4df2-85ef-bd5e093b5e84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ddfe20cd-d464-4967-a691-2fdcd9e363a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3e43f5eb-ef20-4df2-85ef-bd5e093b5e84" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ddfe20cd-d464-4967-a691-2fdcd9e363a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6593b116-98fb-4e69-8ab8-0cfe4362fb31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ddfe20cd-d464-4967-a691-2fdcd9e363a0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6593b116-98fb-4e69-8ab8-0cfe4362fb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2c17f1b4-6fc3-405a-b8fe-52d35418fb44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6593b116-98fb-4e69-8ab8-0cfe4362fb31" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2c17f1b4-6fc3-405a-b8fe-52d35418fb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_6ebd69b3-2737-4bbf-9fe4-47edcd29de72" xlink:href="mgnx-20210930.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2c17f1b4-6fc3-405a-b8fe-52d35418fb44" xlink:to="loc_mgnx_AtTheMarketOfferingMember_6ebd69b3-2737-4bbf-9fe4-47edcd29de72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e5df14b2-79c8-4e77-9faf-25fa55aacff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ddfe20cd-d464-4967-a691-2fdcd9e363a0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e5df14b2-79c8-4e77-9faf-25fa55aacff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6f6fa835-14a9-4648-bed8-83278e2b7391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e5df14b2-79c8-4e77-9faf-25fa55aacff5" xlink:to="loc_us-gaap_EquityComponentDomain_6f6fa835-14a9-4648-bed8-83278e2b7391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_79ca4cbe-a525-44b9-a13d-843589c8c225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6f6fa835-14a9-4648-bed8-83278e2b7391" xlink:to="loc_us-gaap_CommonStockMember_79ca4cbe-a525-44b9-a13d-843589c8c225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ddfe20cd-d464-4967-a691-2fdcd9e363a0" xlink:to="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_94c76df2-1c72-4a2b-a53c-e60f564ce408" xlink:href="mgnx-20210930.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_94c76df2-1c72-4a2b-a53c-e60f564ce408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6a6954e7-bacf-4402-b3d4-2cf9d5b13bda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6a6954e7-bacf-4402-b3d4-2cf9d5b13bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7fedfb76-9f9c-430f-ba7b-4e5d95913b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7fedfb76-9f9c-430f-ba7b-4e5d95913b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_80d9f201-dd4b-4116-abf4-e9250981714d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_80d9f201-dd4b-4116-abf4-e9250981714d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_8f565ca8-04ec-42a8-ac95-9991507a9361" xlink:href="mgnx-20210930.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_8f565ca8-04ec-42a8-ac95-9991507a9361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b1e4baf4-3f86-465b-9f9e-e6c0423ea20e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b1e4baf4-3f86-465b-9f9e-e6c0423ea20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3fb3bfb9-f6ec-4da5-9f36-da2009cf19c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a398a6b-c982-4812-88f4-5db9219f0cff" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3fb3bfb9-f6ec-4da5-9f36-da2009cf19c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CollaborationandOtherAgreements"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_238c6147-4787-43cf-ac7e-1bcc785aced3" xlink:href="mgnx-20210930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_d683241f-cf16-480e-ae13-7c558ba70a7a" xlink:href="mgnx-20210930.xsd#mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_238c6147-4787-43cf-ac7e-1bcc785aced3" xlink:to="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_d683241f-cf16-480e-ae13-7c558ba70a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_8905480a-31ae-434b-b943-9328a3719a07" xlink:href="mgnx-20210930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bb90457-0a53-4966-81fd-0f1e5bf6647c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_8905480a-31ae-434b-b943-9328a3719a07" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bb90457-0a53-4966-81fd-0f1e5bf6647c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_396e0ce0-b6fe-46e2-9917-bac428f6ce18" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bb90457-0a53-4966-81fd-0f1e5bf6647c" xlink:to="loc_srt_ProductOrServiceAxis_396e0ce0-b6fe-46e2-9917-bac428f6ce18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ef9a1ab9-f035-4be6-92c4-6e300af2187d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_396e0ce0-b6fe-46e2-9917-bac428f6ce18" xlink:to="loc_srt_ProductsAndServicesDomain_ef9a1ab9-f035-4be6-92c4-6e300af2187d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_73dc28cb-ddce-4867-9c78-83635f5731e7" xlink:href="mgnx-20210930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ef9a1ab9-f035-4be6-92c4-6e300af2187d" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_73dc28cb-ddce-4867-9c78-83635f5731e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9908b448-190d-42bd-a582-313c93670900" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bb90457-0a53-4966-81fd-0f1e5bf6647c" xlink:to="loc_srt_RangeAxis_9908b448-190d-42bd-a582-313c93670900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f490fe51-8f00-4621-a3c2-5b33dde55ae7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9908b448-190d-42bd-a582-313c93670900" xlink:to="loc_srt_RangeMember_f490fe51-8f00-4621-a3c2-5b33dde55ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ae751741-28d1-41d1-a57f-ff24ebfd5f6d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f490fe51-8f00-4621-a3c2-5b33dde55ae7" xlink:to="loc_srt_MinimumMember_ae751741-28d1-41d1-a57f-ff24ebfd5f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3886a91a-5ec8-42cb-8965-e27624e6c711" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f490fe51-8f00-4621-a3c2-5b33dde55ae7" xlink:to="loc_srt_MaximumMember_3886a91a-5ec8-42cb-8965-e27624e6c711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4aee8cf6-4702-4f5a-ab61-9954c246c288" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bb90457-0a53-4966-81fd-0f1e5bf6647c" xlink:to="loc_srt_CounterpartyNameAxis_4aee8cf6-4702-4f5a-ab61-9954c246c288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2884ed85-f7ad-4fa0-8bac-c1492fb080cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4aee8cf6-4702-4f5a-ab61-9954c246c288" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2884ed85-f7ad-4fa0-8bac-c1492fb080cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_3eb56b4d-2286-4185-be00-ac5479180dc9" xlink:href="mgnx-20210930.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2884ed85-f7ad-4fa0-8bac-c1492fb080cc" xlink:to="loc_mgnx_IncyteCorporationMember_3eb56b4d-2286-4185-be00-ac5479180dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1824519c-c767-4d41-b5dc-1a0ad05509f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bb90457-0a53-4966-81fd-0f1e5bf6647c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1824519c-c767-4d41-b5dc-1a0ad05509f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b3ff771f-3d74-4e11-a035-03bf4db91a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1824519c-c767-4d41-b5dc-1a0ad05509f2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b3ff771f-3d74-4e11-a035-03bf4db91a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_78a991c4-aa34-4810-b8c9-897669fb69f0" xlink:href="mgnx-20210930.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b3ff771f-3d74-4e11-a035-03bf4db91a49" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_78a991c4-aa34-4810-b8c9-897669fb69f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_fb86fdde-b700-492c-a87d-5e4e122eeab3" xlink:href="mgnx-20210930.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_78a991c4-aa34-4810-b8c9-897669fb69f0" xlink:to="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_fb86fdde-b700-492c-a87d-5e4e122eeab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember_899560af-799c-4440-a8f3-287c6c46cb3c" xlink:href="mgnx-20210930.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b3ff771f-3d74-4e11-a035-03bf4db91a49" xlink:to="loc_mgnx_IncyteMGA012ClinicalServicesMember_899560af-799c-4440-a8f3-287c6c46cb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012SupplyAgreementMember_ed9b5716-d1e5-4ea6-a427-f37ee9589693" xlink:href="mgnx-20210930.xsd#mgnx_IncyteMGA012SupplyAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b3ff771f-3d74-4e11-a035-03bf4db91a49" xlink:to="loc_mgnx_IncyteMGA012SupplyAgreementMember_ed9b5716-d1e5-4ea6-a427-f37ee9589693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bb90457-0a53-4966-81fd-0f1e5bf6647c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_f8c4adbe-2c42-4b0a-94b2-0d23d6cffe66" xlink:href="mgnx-20210930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_mgnx_NonRefundableUpfrontFees_f8c4adbe-2c42-4b0a-94b2-0d23d6cffe66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_cb4e8a8c-b18b-4d19-8be4-f01c5527a0fe" xlink:href="mgnx-20210930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_cb4e8a8c-b18b-4d19-8be4-f01c5527a0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_4487eb9e-c6fd-415e-97b8-f973d0ab1718" xlink:href="mgnx-20210930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_4487eb9e-c6fd-415e-97b8-f973d0ab1718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_5dd1565a-1111-4026-abe2-80248fa01411" xlink:href="mgnx-20210930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_5dd1565a-1111-4026-abe2-80248fa01411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_e1f40a8c-7baf-4335-b05b-882d22600523" xlink:href="mgnx-20210930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_e1f40a8c-7baf-4335-b05b-882d22600523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_f6b144c9-7960-4c38-804a-5be1a39aa0f8" xlink:href="mgnx-20210930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_mgnx_NumberOfPerformanceObligations_f6b144c9-7960-4c38-804a-5be1a39aa0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_a1f61003-eab5-4af3-a031-8660c06dcfd2" xlink:href="mgnx-20210930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_a1f61003-eab5-4af3-a031-8660c06dcfd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_467d2791-084c-4b33-b920-43f43f147071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_us-gaap_Revenues_467d2791-084c-4b33-b920-43f43f147071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_4db9669b-6a43-40e3-9c98-a18c0e985d8a" xlink:href="mgnx-20210930.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07ba7e5c-0d3b-485d-bbd4-b3719b72c045" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_4db9669b-6a43-40e3-9c98-a18c0e985d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_f0911409-c3db-4a25-a825-0942cd72ecfe" xlink:href="mgnx-20210930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0fd2bed7-7d1c-4066-8079-28baaadd7c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_f0911409-c3db-4a25-a825-0942cd72ecfe" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0fd2bed7-7d1c-4066-8079-28baaadd7c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bed10ea8-39c9-4236-9472-23243299709f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0fd2bed7-7d1c-4066-8079-28baaadd7c19" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bed10ea8-39c9-4236-9472-23243299709f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e5ed2e2f-66a6-4a0b-9e58-e31dff2e249d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bed10ea8-39c9-4236-9472-23243299709f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e5ed2e2f-66a6-4a0b-9e58-e31dff2e249d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_b0f14656-c784-4d8a-97ce-d8c39b2f4efc" xlink:href="mgnx-20210930.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e5ed2e2f-66a6-4a0b-9e58-e31dff2e249d" xlink:to="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_b0f14656-c784-4d8a-97ce-d8c39b2f4efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_43fcbfd4-53fd-4f52-a2f0-55473ad43b84" xlink:href="mgnx-20210930.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e5ed2e2f-66a6-4a0b-9e58-e31dff2e249d" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_43fcbfd4-53fd-4f52-a2f0-55473ad43b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_aa67e15f-7d52-44cf-80de-7143acb1aeb7" xlink:href="mgnx-20210930.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e5ed2e2f-66a6-4a0b-9e58-e31dff2e249d" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_aa67e15f-7d52-44cf-80de-7143acb1aeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_d824cd4b-9d3f-4d87-bbf2-2d44c137fa53" xlink:href="mgnx-20210930.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e5ed2e2f-66a6-4a0b-9e58-e31dff2e249d" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_d824cd4b-9d3f-4d87-bbf2-2d44c137fa53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_abd86d70-4f2f-443d-9849-b659c85539b4" xlink:href="mgnx-20210930.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e5ed2e2f-66a6-4a0b-9e58-e31dff2e249d" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_abd86d70-4f2f-443d-9849-b659c85539b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bffdd4f3-c51a-4e23-9c8e-92d46c917757" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0fd2bed7-7d1c-4066-8079-28baaadd7c19" xlink:to="loc_srt_CounterpartyNameAxis_bffdd4f3-c51a-4e23-9c8e-92d46c917757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d91eafad-c0ae-4fde-9fa2-031bea0e4a48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bffdd4f3-c51a-4e23-9c8e-92d46c917757" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d91eafad-c0ae-4fde-9fa2-031bea0e4a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_0f05f3a4-abe2-4d19-b593-e438a1a6ebf6" xlink:href="mgnx-20210930.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d91eafad-c0ae-4fde-9fa2-031bea0e4a48" xlink:to="loc_mgnx_ZaiLabMember_0f05f3a4-abe2-4d19-b593-e438a1a6ebf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a315bf16-ffd7-4e60-b766-0f0fb2ad5915" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0fd2bed7-7d1c-4066-8079-28baaadd7c19" xlink:to="loc_srt_RangeAxis_a315bf16-ffd7-4e60-b766-0f0fb2ad5915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2ea26a3c-ef28-4a25-a6d2-911679a4dae4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a315bf16-ffd7-4e60-b766-0f0fb2ad5915" xlink:to="loc_srt_RangeMember_2ea26a3c-ef28-4a25-a6d2-911679a4dae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fdf36963-aa1f-42d9-9045-3514deac686c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2ea26a3c-ef28-4a25-a6d2-911679a4dae4" xlink:to="loc_srt_MaximumMember_fdf36963-aa1f-42d9-9045-3514deac686c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_04c7852c-eae3-40b2-bbbf-4ec06bbe200a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0fd2bed7-7d1c-4066-8079-28baaadd7c19" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_04c7852c-eae3-40b2-bbbf-4ec06bbe200a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cc117b44-c00a-44ce-8b46-cc34c2fb40cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04c7852c-eae3-40b2-bbbf-4ec06bbe200a" xlink:to="loc_us-gaap_EquityComponentDomain_cc117b44-c00a-44ce-8b46-cc34c2fb40cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7243130b-a2d0-4671-b7fb-8f71a337d8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cc117b44-c00a-44ce-8b46-cc34c2fb40cc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7243130b-a2d0-4671-b7fb-8f71a337d8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0fd2bed7-7d1c-4066-8079-28baaadd7c19" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_17cf9a62-063b-47e6-8b0a-1c89b711b336" xlink:href="mgnx-20210930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_NonRefundableUpfrontFees_17cf9a62-063b-47e6-8b0a-1c89b711b336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_cdfe18c1-d5ad-4b34-880b-0dfcda5dd783" xlink:href="mgnx-20210930.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_cdfe18c1-d5ad-4b34-880b-0dfcda5dd783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_a943094f-1fec-4c9a-a2b2-ab4e3a28e5fa" xlink:href="mgnx-20210930.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_a943094f-1fec-4c9a-a2b2-ab4e3a28e5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f6703223-547b-4875-9e3a-7ef102951d8a" xlink:href="mgnx-20210930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f6703223-547b-4875-9e3a-7ef102951d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_b9283fff-07c5-480d-a649-b48e5db960e3" xlink:href="mgnx-20210930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_b9283fff-07c5-480d-a649-b48e5db960e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding_e9fbd057-cd09-4a4b-8e13-7cae624b03f3" xlink:href="mgnx-20210930.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_RevenuesNetOfTaxWithholding_e9fbd057-cd09-4a4b-8e13-7cae624b03f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesTaxWithholding_30be0cb2-cbb9-4da7-813a-56607cf60e50" xlink:href="mgnx-20210930.xsd#mgnx_RevenuesTaxWithholding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_RevenuesTaxWithholding_30be0cb2-cbb9-4da7-813a-56607cf60e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_1146495a-0ea3-4dd5-acd4-810fcb563271" xlink:href="mgnx-20210930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_1146495a-0ea3-4dd5-acd4-810fcb563271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_03ce5d94-c409-4ce8-87bd-c5f63e342fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_03ce5d94-c409-4ce8-87bd-c5f63e342fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ecd4865e-418d-4a4c-922b-4b137266a078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_us-gaap_Revenues_ecd4865e-418d-4a4c-922b-4b137266a078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee_c06c05ec-0082-4f5c-bb64-9db6868b5cfe" xlink:href="mgnx-20210930.xsd#mgnx_OptInFee"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_OptInFee_c06c05ec-0082-4f5c-bb64-9db6868b5cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d3e45961-b20b-4ff8-87b3-46bf53aafef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d3e45961-b20b-4ff8-87b3-46bf53aafef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_110fe69c-7998-4868-9184-3c94a567e480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_110fe69c-7998-4868-9184-3c94a567e480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1da28f26-49ff-4fde-bd4a-c021bd89abc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1da28f26-49ff-4fde-bd4a-c021bd89abc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_71fcae86-af5b-4163-9445-513e0b8846d2" xlink:href="mgnx-20210930.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_71fcae86-af5b-4163-9445-513e0b8846d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_bb4850a7-caa2-45a3-af02-88ac46a408e6" xlink:href="mgnx-20210930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_bb4850a7-caa2-45a3-af02-88ac46a408e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_292ef4f6-358f-4a0e-abb5-05f78d2bcb72" xlink:href="mgnx-20210930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_292ef4f6-358f-4a0e-abb5-05f78d2bcb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_b232e3ed-5299-4298-9dfa-143fdb33baaa" xlink:href="mgnx-20210930.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_b232e3ed-5299-4298-9dfa-143fdb33baaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_02037420-6683-432f-ae19-c8b644206605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_02037420-6683-432f-ae19-c8b644206605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_eef28d11-b612-498d-b3b8-58070d7a4f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_921c8335-99e6-42b2-827a-0d4b1fed302a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_eef28d11-b612-498d-b3b8-58070d7a4f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CollaborationandOtherAgreementsJanssenDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_a3d97976-2129-44b7-8cd2-29954e57695b" xlink:href="mgnx-20210930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fae8f7e7-1dbe-4088-91dd-628b51e70beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_a3d97976-2129-44b7-8cd2-29954e57695b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fae8f7e7-1dbe-4088-91dd-628b51e70beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_70902220-cb14-4dc0-aa04-5634cd81843b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fae8f7e7-1dbe-4088-91dd-628b51e70beb" xlink:to="loc_srt_CounterpartyNameAxis_70902220-cb14-4dc0-aa04-5634cd81843b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7015d9a5-a982-459c-9764-489df302a2d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_70902220-cb14-4dc0-aa04-5634cd81843b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7015d9a5-a982-459c-9764-489df302a2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_5d3f2aa2-5080-4664-80b9-dd3bed740933" xlink:href="mgnx-20210930.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7015d9a5-a982-459c-9764-489df302a2d3" xlink:to="loc_mgnx_JanssenBiotechIncMember_5d3f2aa2-5080-4664-80b9-dd3bed740933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_68cb64ec-7166-4bb6-bb4a-cf632d99cad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fae8f7e7-1dbe-4088-91dd-628b51e70beb" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_68cb64ec-7166-4bb6-bb4a-cf632d99cad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_459a061d-590c-47cd-923d-3fb35b399910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_68cb64ec-7166-4bb6-bb4a-cf632d99cad9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_459a061d-590c-47cd-923d-3fb35b399910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_865262db-ed85-4b0c-bd66-d4ef30b89299" xlink:href="mgnx-20210930.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_459a061d-590c-47cd-923d-3fb35b399910" xlink:to="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_865262db-ed85-4b0c-bd66-d4ef30b89299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1aa2a74a-923f-483e-be49-f02df7cbd68c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fae8f7e7-1dbe-4088-91dd-628b51e70beb" xlink:to="loc_srt_ProductOrServiceAxis_1aa2a74a-923f-483e-be49-f02df7cbd68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_edd74a78-fa89-42f8-9dfb-ae5d21884b0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1aa2a74a-923f-483e-be49-f02df7cbd68c" xlink:to="loc_srt_ProductsAndServicesDomain_edd74a78-fa89-42f8-9dfb-ae5d21884b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_9243c159-bbc2-4cd4-9e0c-6ec1871f76e3" xlink:href="mgnx-20210930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_edd74a78-fa89-42f8-9dfb-ae5d21884b0c" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_9243c159-bbc2-4cd4-9e0c-6ec1871f76e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_a4714781-208e-4461-8a3f-8c688677097b" xlink:href="mgnx-20210930.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_edd74a78-fa89-42f8-9dfb-ae5d21884b0c" xlink:to="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_a4714781-208e-4461-8a3f-8c688677097b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30b897fc-f857-4971-8c7f-7c5a04dab246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fae8f7e7-1dbe-4088-91dd-628b51e70beb" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30b897fc-f857-4971-8c7f-7c5a04dab246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_74bb8f18-4d49-463f-ae5b-f68f4e030a05" xlink:href="mgnx-20210930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30b897fc-f857-4971-8c7f-7c5a04dab246" xlink:to="loc_mgnx_NonRefundableUpfrontFees_74bb8f18-4d49-463f-ae5b-f68f4e030a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_ef4e4380-87f1-4082-9541-b4312ee6637f" xlink:href="mgnx-20210930.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30b897fc-f857-4971-8c7f-7c5a04dab246" xlink:to="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_ef4e4380-87f1-4082-9541-b4312ee6637f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_cd5df541-8492-4190-8479-f82512d6369a" xlink:href="mgnx-20210930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30b897fc-f857-4971-8c7f-7c5a04dab246" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_cd5df541-8492-4190-8479-f82512d6369a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_1bab74b9-f719-4bd8-af34-654b11bca94f" xlink:href="mgnx-20210930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30b897fc-f857-4971-8c7f-7c5a04dab246" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_1bab74b9-f719-4bd8-af34-654b11bca94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1467e722-a37b-47b3-a4c2-a995db4e6cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30b897fc-f857-4971-8c7f-7c5a04dab246" xlink:to="loc_us-gaap_Revenues_1467e722-a37b-47b3-a4c2-a995db4e6cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_b4646e65-ab01-4c4f-87df-17ac46ce0923" xlink:href="mgnx-20210930.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30b897fc-f857-4971-8c7f-7c5a04dab246" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_b4646e65-ab01-4c4f-87df-17ac46ce0923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_5b94d26a-a090-4b9a-9604-542583c53e8f" xlink:href="mgnx-20210930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2934805-ae77-4d6e-a19d-1efd41757162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_5b94d26a-a090-4b9a-9604-542583c53e8f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2934805-ae77-4d6e-a19d-1efd41757162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cdef4da8-66d5-4c93-8e7e-ddef09dc337a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2934805-ae77-4d6e-a19d-1efd41757162" xlink:to="loc_srt_CounterpartyNameAxis_cdef4da8-66d5-4c93-8e7e-ddef09dc337a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e47cadc-8099-47d0-88de-bdc4a2c072e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_cdef4da8-66d5-4c93-8e7e-ddef09dc337a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e47cadc-8099-47d0-88de-bdc4a2c072e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_4073243e-bd22-428d-ae72-3f482cd7bfb9" xlink:href="mgnx-20210930.xsd#mgnx_IMabBiopharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e47cadc-8099-47d0-88de-bdc4a2c072e8" xlink:to="loc_mgnx_IMabBiopharmaMember_4073243e-bd22-428d-ae72-3f482cd7bfb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1e977fa-5f76-4723-8f5e-4226b727eb20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2934805-ae77-4d6e-a19d-1efd41757162" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1e977fa-5f76-4723-8f5e-4226b727eb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_265e4bac-bd8e-4fd4-bdde-add109eb4554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1e977fa-5f76-4723-8f5e-4226b727eb20" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_265e4bac-bd8e-4fd4-bdde-add109eb4554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_8624005e-9976-4f78-ab62-1dabbb75ac04" xlink:href="mgnx-20210930.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_265e4bac-bd8e-4fd4-bdde-add109eb4554" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_8624005e-9976-4f78-ab62-1dabbb75ac04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e6a62075-3f9c-4220-b9d0-7562d1be0c7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2934805-ae77-4d6e-a19d-1efd41757162" xlink:to="loc_srt_RangeAxis_e6a62075-3f9c-4220-b9d0-7562d1be0c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_51c4f524-1191-423d-a702-97e04af22c7a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e6a62075-3f9c-4220-b9d0-7562d1be0c7d" xlink:to="loc_srt_RangeMember_51c4f524-1191-423d-a702-97e04af22c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_30b8356e-88ac-454a-91fb-733122781e7a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_51c4f524-1191-423d-a702-97e04af22c7a" xlink:to="loc_srt_MaximumMember_30b8356e-88ac-454a-91fb-733122781e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2934805-ae77-4d6e-a19d-1efd41757162" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_fe4acbb9-97d1-42b1-bc37-4d6a370ea5db" xlink:href="mgnx-20210930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_mgnx_NonRefundableUpfrontFees_fe4acbb9-97d1-42b1-bc37-4d6a370ea5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f3b7f883-c4ec-4115-bbc3-3f688367f02f" xlink:href="mgnx-20210930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f3b7f883-c4ec-4115-bbc3-3f688367f02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_050a5af2-4711-4524-be2e-b51ff497fe28" xlink:href="mgnx-20210930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_050a5af2-4711-4524-be2e-b51ff497fe28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding_1d25d9dd-64c7-4928-9c09-be53a7065933" xlink:href="mgnx-20210930.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_mgnx_RevenuesNetOfTaxWithholding_1d25d9dd-64c7-4928-9c09-be53a7065933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_02ea7a6b-565d-4590-a9b1-021840b43b7c" xlink:href="mgnx-20210930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_02ea7a6b-565d-4590-a9b1-021840b43b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_1e9f1127-f1bf-4742-a42c-0f872080e590" xlink:href="mgnx-20210930.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_1e9f1127-f1bf-4742-a42c-0f872080e590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0443523e-b7fc-40f5-a2d4-d8a090fcd7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_us-gaap_Revenues_0443523e-b7fc-40f5-a2d4-d8a090fcd7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cd1f77cb-6e53-4f04-abc7-e6aa58f35030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cd1f77cb-6e53-4f04-abc7-e6aa58f35030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_78584559-50b8-40d0-b7dc-4a44466320eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_78584559-50b8-40d0-b7dc-4a44466320eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7927ce36-5827-45b3-926e-6df8764ebd72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4cf7ba52-ad20-4fde-89d7-4cdc6173c886" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7927ce36-5827-45b3-926e-6df8764ebd72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_e285bf64-7ca9-4642-a746-d74e79f4b451" xlink:href="mgnx-20210930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ae216f9-be67-418e-88c6-dd4aeaa19616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_e285bf64-7ca9-4642-a746-d74e79f4b451" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ae216f9-be67-418e-88c6-dd4aeaa19616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_00317218-c494-45c9-ac51-e1a46aa2d274" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ae216f9-be67-418e-88c6-dd4aeaa19616" xlink:to="loc_srt_ProductOrServiceAxis_00317218-c494-45c9-ac51-e1a46aa2d274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_18e1788f-5ca2-4a86-886c-fbe66379a3bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_00317218-c494-45c9-ac51-e1a46aa2d274" xlink:to="loc_srt_ProductsAndServicesDomain_18e1788f-5ca2-4a86-886c-fbe66379a3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_46fa05ce-2b58-412a-8707-1aad61749df4" xlink:href="mgnx-20210930.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_18e1788f-5ca2-4a86-886c-fbe66379a3bc" xlink:to="loc_mgnx_RevenuesFromGrantsMember_46fa05ce-2b58-412a-8707-1aad61749df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_31e16461-a211-4bd0-b823-f48eef3d7aea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ae216f9-be67-418e-88c6-dd4aeaa19616" xlink:to="loc_srt_CounterpartyNameAxis_31e16461-a211-4bd0-b823-f48eef3d7aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_784a67b5-3782-460c-91e4-df5acc8d3387" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_31e16461-a211-4bd0-b823-f48eef3d7aea" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_784a67b5-3782-460c-91e4-df5acc8d3387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_4973e343-6577-4491-bad9-68f91f3a61fe" xlink:href="mgnx-20210930.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_784a67b5-3782-460c-91e4-df5acc8d3387" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_4973e343-6577-4491-bad9-68f91f3a61fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_695ffedd-85e3-45e7-ae1b-550cda62e3bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ae216f9-be67-418e-88c6-dd4aeaa19616" xlink:to="loc_srt_RangeAxis_695ffedd-85e3-45e7-ae1b-550cda62e3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0e9be272-cab9-4674-971f-39340a9c01f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_695ffedd-85e3-45e7-ae1b-550cda62e3bc" xlink:to="loc_srt_RangeMember_0e9be272-cab9-4674-971f-39340a9c01f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_11a030c3-8c02-4383-95d7-37c5ccb78f56" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0e9be272-cab9-4674-971f-39340a9c01f2" xlink:to="loc_srt_MaximumMember_11a030c3-8c02-4383-95d7-37c5ccb78f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a163e54f-46be-412f-8e88-40ace20e3165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ae216f9-be67-418e-88c6-dd4aeaa19616" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a163e54f-46be-412f-8e88-40ace20e3165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_dba7b3ab-71c0-4e9d-982d-b846f2627516" xlink:href="mgnx-20210930.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a163e54f-46be-412f-8e88-40ace20e3165" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_dba7b3ab-71c0-4e9d-982d-b846f2627516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_adbbc3c9-7a73-4eee-ae7e-2a9d1df782f7" xlink:href="mgnx-20210930.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a163e54f-46be-412f-8e88-40ace20e3165" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_adbbc3c9-7a73-4eee-ae7e-2a9d1df782f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a25aca5c-0b53-48f7-9180-13b2778f746d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a163e54f-46be-412f-8e88-40ace20e3165" xlink:to="loc_us-gaap_Revenues_a25aca5c-0b53-48f7-9180-13b2778f746d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mgnx-20210930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2e9b5e0d-337d-47d1-8ce3-fb77c3696dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6b8a3f88-ac6e-4afb-ba18-8268e065d837" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2e9b5e0d-337d-47d1-8ce3-fb77c3696dab" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6b8a3f88-ac6e-4afb-ba18-8268e065d837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20210930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e2604f42-feb4-4736-8fe3-9d7afe7671c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ab234359-7a2c-41d5-baef-179038d158d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e2604f42-feb4-4736-8fe3-9d7afe7671c2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ab234359-7a2c-41d5-baef-179038d158d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_05730f9b-8439-44ce-97a3-873d8ae3eb01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e2604f42-feb4-4736-8fe3-9d7afe7671c2" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_05730f9b-8439-44ce-97a3-873d8ae3eb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_8d8f872b-37c6-463b-9426-1b61d98f3b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e2604f42-feb4-4736-8fe3-9d7afe7671c2" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_8d8f872b-37c6-463b-9426-1b61d98f3b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_62b74318-ea99-4479-bb44-faa934493f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e2604f42-feb4-4736-8fe3-9d7afe7671c2" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_62b74318-ea99-4479-bb44-faa934493f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd76d253-9b26-4b7d-9a46-b5f95744f597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff1d17ad-39ce-45ff-8a38-d0fc3a17c629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd76d253-9b26-4b7d-9a46-b5f95744f597" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff1d17ad-39ce-45ff-8a38-d0fc3a17c629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_26e81ed7-c5f0-46f0-917b-0c4e146e1c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff1d17ad-39ce-45ff-8a38-d0fc3a17c629" xlink:to="loc_us-gaap_PlanNameAxis_26e81ed7-c5f0-46f0-917b-0c4e146e1c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d26d6ec7-2ba0-435a-a1ae-e560eff3b366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_26e81ed7-c5f0-46f0-917b-0c4e146e1c61" xlink:to="loc_us-gaap_PlanNameDomain_d26d6ec7-2ba0-435a-a1ae-e560eff3b366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_6fe0c381-53be-402f-89e6-f8823041243c" xlink:href="mgnx-20210930.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d26d6ec7-2ba0-435a-a1ae-e560eff3b366" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_6fe0c381-53be-402f-89e6-f8823041243c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember_3c44654f-ceba-413c-9c4b-cbf3d778b44c" xlink:href="mgnx-20210930.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d26d6ec7-2ba0-435a-a1ae-e560eff3b366" xlink:to="loc_mgnx_A2003StockIncentivePlanMember_3c44654f-ceba-413c-9c4b-cbf3d778b44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_963c9673-efd1-470b-bfa6-ca6d57358bc8" xlink:href="mgnx-20210930.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d26d6ec7-2ba0-435a-a1ae-e560eff3b366" xlink:to="loc_mgnx_StockIncentivePlan2013Member_963c9673-efd1-470b-bfa6-ca6d57358bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff1d17ad-39ce-45ff-8a38-d0fc3a17c629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3e1716c7-b7a6-460d-b3e0-4598aafe266a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3e1716c7-b7a6-460d-b3e0-4598aafe266a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_3a168f2b-8868-4e68-8a74-d4494e4946a3" xlink:href="mgnx-20210930.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_3a168f2b-8868-4e68-8a74-d4494e4946a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7cb31ae9-de0e-4b18-911a-82d45634a61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7cb31ae9-de0e-4b18-911a-82d45634a61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c2de1eef-a363-4c1e-926f-563a94b7990f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c2de1eef-a363-4c1e-926f-563a94b7990f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_02b121ba-32ac-4ba5-8c4d-a0b3583bd9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_02b121ba-32ac-4ba5-8c4d-a0b3583bd9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40c1f8c6-8f11-4bd4-9e84-1b7554e039dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40c1f8c6-8f11-4bd4-9e84-1b7554e039dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_32c01c2a-8a03-4b6e-a5f8-116886da8911" xlink:href="mgnx-20210930.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_32c01c2a-8a03-4b6e-a5f8-116886da8911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_e730c3d1-d0bf-4394-9828-6866e80523b4" xlink:href="mgnx-20210930.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc48e7f4-3bab-4858-b168-1996b811c1df" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_e730c3d1-d0bf-4394-9828-6866e80523b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b295b3b8-41cb-4219-8f4a-dfc7cb4a1db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd76d253-9b26-4b7d-9a46-b5f95744f597" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b295b3b8-41cb-4219-8f4a-dfc7cb4a1db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2aad4d25-e15b-4dee-9a46-0def71a824b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b295b3b8-41cb-4219-8f4a-dfc7cb4a1db9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2aad4d25-e15b-4dee-9a46-0def71a824b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7160a7af-c246-4009-8226-c2d8ffcd5870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2aad4d25-e15b-4dee-9a46-0def71a824b0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7160a7af-c246-4009-8226-c2d8ffcd5870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4a00d58b-3ca1-4f5a-8368-31020b95c186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7160a7af-c246-4009-8226-c2d8ffcd5870" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4a00d58b-3ca1-4f5a-8368-31020b95c186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_699bb0c1-842c-439d-b201-bc2119ff54b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7160a7af-c246-4009-8226-c2d8ffcd5870" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_699bb0c1-842c-439d-b201-bc2119ff54b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_caaf919f-484b-465c-a018-b5cc765dc09a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b295b3b8-41cb-4219-8f4a-dfc7cb4a1db9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_caaf919f-484b-465c-a018-b5cc765dc09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5fe8fb74-9913-4eb5-81a9-5aec11b94a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_caaf919f-484b-465c-a018-b5cc765dc09a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5fe8fb74-9913-4eb5-81a9-5aec11b94a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b71b8-47ba-4aee-abbb-9a79f3d8acc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a88a264-4a96-4957-82b8-6c65277d520f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b71b8-47ba-4aee-abbb-9a79f3d8acc4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a88a264-4a96-4957-82b8-6c65277d520f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_590e9066-c361-451c-99e7-f5c2cce5fada" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a88a264-4a96-4957-82b8-6c65277d520f" xlink:to="loc_srt_RangeAxis_590e9066-c361-451c-99e7-f5c2cce5fada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_70d68d98-6f43-44af-9c15-42f3f211faa0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_590e9066-c361-451c-99e7-f5c2cce5fada" xlink:to="loc_srt_RangeMember_70d68d98-6f43-44af-9c15-42f3f211faa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3b438574-fc00-4a48-bafe-dab6f75cda83" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_70d68d98-6f43-44af-9c15-42f3f211faa0" xlink:to="loc_srt_MinimumMember_3b438574-fc00-4a48-bafe-dab6f75cda83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0c33b846-de32-444a-97a4-bbb7c71b478a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_70d68d98-6f43-44af-9c15-42f3f211faa0" xlink:to="loc_srt_MaximumMember_0c33b846-de32-444a-97a4-bbb7c71b478a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ee10299-a40f-46fe-a872-ddc8f550f75d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a88a264-4a96-4957-82b8-6c65277d520f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ee10299-a40f-46fe-a872-ddc8f550f75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1f3306ae-5204-4be0-979f-9fe869d175cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ee10299-a40f-46fe-a872-ddc8f550f75d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1f3306ae-5204-4be0-979f-9fe869d175cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9c6718e8-8487-478d-b122-66e20af770a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ee10299-a40f-46fe-a872-ddc8f550f75d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9c6718e8-8487-478d-b122-66e20af770a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bf47d9f2-fe71-4509-adab-b83c75adff3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ee10299-a40f-46fe-a872-ddc8f550f75d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bf47d9f2-fe71-4509-adab-b83c75adff3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_249f5fbb-83a0-46c2-9310-4b7b61855e13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ee10299-a40f-46fe-a872-ddc8f550f75d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_249f5fbb-83a0-46c2-9310-4b7b61855e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19b5dfb5-811e-41fe-9e85-83e64a35a10f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56bc28d8-78b9-4b92-9229-46ed68d5923f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19b5dfb5-811e-41fe-9e85-83e64a35a10f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56bc28d8-78b9-4b92-9229-46ed68d5923f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c4720a27-6cf3-41e8-8748-50bce265bfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56bc28d8-78b9-4b92-9229-46ed68d5923f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c4720a27-6cf3-41e8-8748-50bce265bfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8a8cb367-610b-4fe4-92e9-d32a3e0474bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56bc28d8-78b9-4b92-9229-46ed68d5923f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8a8cb367-610b-4fe4-92e9-d32a3e0474bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e035484a-da0b-4923-8fdd-58e3d5b600c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56bc28d8-78b9-4b92-9229-46ed68d5923f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e035484a-da0b-4923-8fdd-58e3d5b600c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_53ab4703-acc0-460c-aaf8-321471e89737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56bc28d8-78b9-4b92-9229-46ed68d5923f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_53ab4703-acc0-460c-aaf8-321471e89737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d64cd649-a273-46ad-9af3-6a9378de5b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56bc28d8-78b9-4b92-9229-46ed68d5923f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d64cd649-a273-46ad-9af3-6a9378de5b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8feb918f-3809-422f-a015-df42cc3fc405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56bc28d8-78b9-4b92-9229-46ed68d5923f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8feb918f-3809-422f-a015-df42cc3fc405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f6a8b80b-700b-4433-ab03-1195ac062bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56bc28d8-78b9-4b92-9229-46ed68d5923f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f6a8b80b-700b-4433-ab03-1195ac062bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8997408d-7fda-4e23-a5b5-53716f3948a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19b5dfb5-811e-41fe-9e85-83e64a35a10f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8997408d-7fda-4e23-a5b5-53716f3948a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_62a50090-8fa3-41d7-bb4a-86e58e881010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8997408d-7fda-4e23-a5b5-53716f3948a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_62a50090-8fa3-41d7-bb4a-86e58e881010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ad43bf43-5e82-4baf-9f7b-37539f4f0062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8997408d-7fda-4e23-a5b5-53716f3948a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ad43bf43-5e82-4baf-9f7b-37539f4f0062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_450180b2-6a4a-4b92-a124-2a34907b5d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8997408d-7fda-4e23-a5b5-53716f3948a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_450180b2-6a4a-4b92-a124-2a34907b5d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_06cd7d7d-ec0e-4f5c-8e15-d1169d27ece4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8997408d-7fda-4e23-a5b5-53716f3948a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_06cd7d7d-ec0e-4f5c-8e15-d1169d27ece4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f511f103-0a30-4df4-a213-96cac792a968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8997408d-7fda-4e23-a5b5-53716f3948a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f511f103-0a30-4df4-a213-96cac792a968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ee5fd161-5414-43e8-aed5-a206e0b48e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8997408d-7fda-4e23-a5b5-53716f3948a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ee5fd161-5414-43e8-aed5-a206e0b48e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_11e207b1-95e1-483a-a52f-ba7ab6fa0aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8997408d-7fda-4e23-a5b5-53716f3948a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_11e207b1-95e1-483a-a52f-ba7ab6fa0aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7b6fbed7-4cc9-43b6-b422-6aee6ac76555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19b5dfb5-811e-41fe-9e85-83e64a35a10f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7b6fbed7-4cc9-43b6-b422-6aee6ac76555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_eba74287-beaf-45d3-9b5b-f58e7ace74ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7b6fbed7-4cc9-43b6-b422-6aee6ac76555" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_eba74287-beaf-45d3-9b5b-f58e7ace74ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c1000e7e-d51d-4c1a-8dcf-f0c884be4f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7b6fbed7-4cc9-43b6-b422-6aee6ac76555" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c1000e7e-d51d-4c1a-8dcf-f0c884be4f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9433dd87-6450-4044-8c6d-52347f123358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7b6fbed7-4cc9-43b6-b422-6aee6ac76555" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9433dd87-6450-4044-8c6d-52347f123358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_bc179df6-b1b1-4d1f-b140-6ad963fa1411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7b6fbed7-4cc9-43b6-b422-6aee6ac76555" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_bc179df6-b1b1-4d1f-b140-6ad963fa1411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f84b5f6d-0be1-479f-8a96-b0796b953bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7b6fbed7-4cc9-43b6-b422-6aee6ac76555" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f84b5f6d-0be1-479f-8a96-b0796b953bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_de4697f7-a98e-4c88-8954-058cd53d203c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7b6fbed7-4cc9-43b6-b422-6aee6ac76555" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_de4697f7-a98e-4c88-8954-058cd53d203c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7007519f-f1d6-4c3f-a7ac-5517b5a406ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19b5dfb5-811e-41fe-9e85-83e64a35a10f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7007519f-f1d6-4c3f-a7ac-5517b5a406ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3020d3d0-d850-4a52-9361-9faf141e066c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19b5dfb5-811e-41fe-9e85-83e64a35a10f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3020d3d0-d850-4a52-9361-9faf141e066c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_311b01a5-a150-42c3-a9ac-973fbf18310b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19b5dfb5-811e-41fe-9e85-83e64a35a10f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_311b01a5-a150-42c3-a9ac-973fbf18310b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_fbcd0b21-5d92-4e36-a741-bfa313caf5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19b5dfb5-811e-41fe-9e85-83e64a35a10f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_fbcd0b21-5d92-4e36-a741-bfa313caf5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d9fb0f22-346d-40dd-b2fa-cc3ec3e99dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19b5dfb5-811e-41fe-9e85-83e64a35a10f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d9fb0f22-346d-40dd-b2fa-cc3ec3e99dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e1cf2b41-c0fb-41ae-9ae1-5a33e7b04d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19b5dfb5-811e-41fe-9e85-83e64a35a10f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e1cf2b41-c0fb-41ae-9ae1-5a33e7b04d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20210930.xsd#StockbasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_add1e1dc-788d-4048-89da-3da317a62d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d64c2da4-88e7-41c4-b8a7-179afbc69f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_add1e1dc-788d-4048-89da-3da317a62d06" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d64c2da4-88e7-41c4-b8a7-179afbc69f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_325f7364-cb55-4b2c-837d-299b28bca928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d64c2da4-88e7-41c4-b8a7-179afbc69f1e" xlink:to="loc_us-gaap_AwardTypeAxis_325f7364-cb55-4b2c-837d-299b28bca928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32f55d22-028c-4e95-917b-c49191959b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_325f7364-cb55-4b2c-837d-299b28bca928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32f55d22-028c-4e95-917b-c49191959b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1aa8b3ae-34f5-450e-9259-98999f650747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32f55d22-028c-4e95-917b-c49191959b53" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1aa8b3ae-34f5-450e-9259-98999f650747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00740895-1ebe-426e-8ae5-aed64812afde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d64c2da4-88e7-41c4-b8a7-179afbc69f1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00740895-1ebe-426e-8ae5-aed64812afde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daf78d6b-53c6-458f-82f2-512edffef91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00740895-1ebe-426e-8ae5-aed64812afde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daf78d6b-53c6-458f-82f2-512edffef91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_87f9f97f-9a26-4c25-acf1-95ae1143232e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daf78d6b-53c6-458f-82f2-512edffef91f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_87f9f97f-9a26-4c25-acf1-95ae1143232e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_02fa37ed-88ad-4251-adb4-60290b740ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daf78d6b-53c6-458f-82f2-512edffef91f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_02fa37ed-88ad-4251-adb4-60290b740ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_7bcf3b50-00b0-48fd-9170-32c008a72382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daf78d6b-53c6-458f-82f2-512edffef91f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_7bcf3b50-00b0-48fd-9170-32c008a72382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_80e14dc6-9557-4711-af54-64b19590bec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daf78d6b-53c6-458f-82f2-512edffef91f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_80e14dc6-9557-4711-af54-64b19590bec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c3628307-518b-4a4d-a90c-74a74195ed93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daf78d6b-53c6-458f-82f2-512edffef91f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c3628307-518b-4a4d-a90c-74a74195ed93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8569e129-271a-4f0a-a9f1-922035dd7b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00740895-1ebe-426e-8ae5-aed64812afde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8569e129-271a-4f0a-a9f1-922035dd7b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1d0b2dbd-8d8d-4f7b-af15-4f23c55251eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8569e129-271a-4f0a-a9f1-922035dd7b41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1d0b2dbd-8d8d-4f7b-af15-4f23c55251eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ecb2357-387c-472a-ba98-d0d688f20535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8569e129-271a-4f0a-a9f1-922035dd7b41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ecb2357-387c-472a-ba98-d0d688f20535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1dcb8688-058e-46bf-87ea-64743f8a97bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8569e129-271a-4f0a-a9f1-922035dd7b41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1dcb8688-058e-46bf-87ea-64743f8a97bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9977c942-9b17-4642-a002-b0285cfe44ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8569e129-271a-4f0a-a9f1-922035dd7b41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9977c942-9b17-4642-a002-b0285cfe44ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4b6aab3b-a397-4f4b-b3d3-f77b6f4cb754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8569e129-271a-4f0a-a9f1-922035dd7b41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4b6aab3b-a397-4f4b-b3d3-f77b6f4cb754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6cf4c100-0417-4672-8ed5-3e2f286c556d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00740895-1ebe-426e-8ae5-aed64812afde" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6cf4c100-0417-4672-8ed5-3e2f286c556d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_347367f2-3247-46bc-b8f0-b78d72dc103a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00740895-1ebe-426e-8ae5-aed64812afde" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_347367f2-3247-46bc-b8f0-b78d72dc103a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20210930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_52c5782c-5d34-412e-8d54-2738b0e58c06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2eac37ba-34f0-45a1-8bf9-2ac027e3ce90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_52c5782c-5d34-412e-8d54-2738b0e58c06" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2eac37ba-34f0-45a1-8bf9-2ac027e3ce90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>mgnx-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mgnx="http://macrogenics.com/20210930"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20210930.xsd" xlink:type="simple"/>
    <context id="id224a007af7345f691c25b480130a570_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i972ac0a554d046a68379be874acd54db_I20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-10-29</instant>
        </period>
    </context>
    <context id="i68797193d4fe4a28bd0077b1e12763e2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iaabf44798f0b4137a1cd062271187dd4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie95edcd295ff48deb8618fc650417b92_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i546c554a2ee0420ea96d3bc20bc2c290_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id0bcdbf862314e17ae8630e4eb589a85_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib6657edfefea4b1a9ed79a2168bc7a7b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie043cccbc0a44110a07e3bb61c428168_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie137008876174548934b7aa0f11bbbdb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i80e0db72700b4ea497dbe948db25aa20_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibcc05602c5ac4fa59eb68dfc1e898e5c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ide26e919725d41559b15da9dcb0a928b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i959a5d44e3314580a0ac18e02aa9bafd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2a9ca21023dc4df0baec03f9c4eba112_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if4c884e39a884f8696523d9a33f5ef35_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib92c6189b72c447b8f1068b900a46c1f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0089074df40749cda994bd08f7cebc31_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34562cb47376442eaa203ab6023eb363_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic813efc42fbc4dd58d2a1dd2d3f5c0cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1395e2e157c84e9e97a685f193961623_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie54467d33fdf45529db11e8c19a075f6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i92e491e03d244d95acc39155f4bff6be_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4b5ad3e626c04694aaf53610a83fce1f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic3c55b26f9e94031991eb2780805e604_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1b75e289c90849cd817e71ea9a94d6c9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic74e7b8118db41abafcc6bb0b8372824_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0fcc348fc5e847e88eeadde0e0adcb08_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i190ac348f6dc46a6ac38f0d568759b66_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibd365da76df34d2db894b5c3007130a3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if7c5ea5419494505aabe9e7465d4670b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i51fffa70c15f473db18a09340f835b36_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic43acc02e0294959a3b21f958b70bc69_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i205d61628986439484c21a2ed5ad4721_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i844325c47f4d4863abe97d247a5fd1ac_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie86acd1be8634256903051e3b678e662_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3179fb8dbc27438ca7ed7fc6348f29f6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i586b4fc28f444eae89cd1925d85aa640_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id78260ca3b734c09b0e4cfd6e30b6911_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i763636992b5f478e80241f5eeae0f30d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i38708c79101b4e3fbc43d1d6b323a03a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i35415a234ac242ad8ea5c77e9808c2e9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i529e813dc38c4c33ae7cd08cb044ea48_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia0ccd33dc63c47e189ad4827959e843a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibdf5cd80b6b14743a7ea631042c021c3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idf40af9b54464df4b7d3b1125f9d9179_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4c8f4c62b536483799b051a34289338d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4d126b1a843b404783a3465235814e27_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i38a56f6d9c814dac9d125191db3566f1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i66955da827134291bef28c2ecf6e4055_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic06875b187ec41dcb7b1a15821218d7e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i65cfd5b11203487cb6091fe2f919527c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5f4ad9aa86ed438781238f7412b23e01_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i69bcf518b6f64b4eb86f5f40a6061a93_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i43d0b4f45e374b469456ad8fc84bf839_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0b7835f8392d46518da425a3f19dd697_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib6f9507cd9244da6a3c17dd33edf8e68_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7099a1f0709642f8b56969b8d261b209_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iefa62144550e44079146bf982176865e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9712c2e2c25f4f469e19daccd541cabc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6fb90850307344bdb2b62e4c657ff389_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icf4d14e52ac44346ae2be66f1872b003_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i02b854e6798d4d0bbd747c741fec06ad_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icd4383e6ffc54437af3047cc7d551c59_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib8465dd5b84f4677b7ef351c4e4a0629_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i72077576d2d24e2fb5a5f8426cae9925_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i88bdee85e14740838ddaa61690920077_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i43929274060145538939cfbe9ebb7d7f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i66fa665eac24481292baf200368ca1ba_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i33d616f3a92c43cbae84e15bf03190f8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iaf50d256b04c4e70a85bd5224d72ca21_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i906aa4f6d4c44c3ba0e305e35a7203c3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1164dbdf167740b2a496f6c88f38aac9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2935a1f381274d3ebe662dedbebbad3e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie2dbb00d209747a99fb78cfa9687763f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iad092482cde8453e9195f68fb28e18f2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7dac9970dbca4aaba71fb397a9144b68_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4a8e94f9c23740d392d77be412cf1da4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iab4b7193bca147449377324fe98c3afe_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic7da6fadb64042b4b028fc24eeb8c6ed_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iffca67721b4c43308a8bf5b3985400f5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idb94e98144414013a4b367b085227a01_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i304344aae2b14aa6b471cf77a9f4df60_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3d5fe7dc9ce749d7b4b4343243fc3448_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1471592823d141ed9982b46286c25e2a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia6c9cdd4f1d3447cb695fe45e3422587_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia65ece20c394482b8251eff40d234644_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6d00c49127754d849e79ffd0f091a235_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3aef0259fe304602914853bd229b6a2f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iac5626cc0d4d4f3eada7c592f37e6549_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie3d2893df5534deda5831f679ba7dd0d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id48171a2cf134b9b877b17e3ab1d96bf_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0a74388d699f4bd2ac58facdd9a4fd7b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia640a3c02d1f4c75a6f0cc21b9c2cb6d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i17cb614f00584923a41b3f540fa1cdbc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iabf613c73d3e4483a06ea6e38d8e670b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6e6b518462554e3cbdf3a5cadf5c10ea_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4b8bfb356e214cc9bfe9904bbc293017_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i73eb53766d6c4804a4e1e66a6df09c91_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i49de27c2929345d3a226185a435ab868_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8f048a39b44649b29657ceea4301f358_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4a7ed9e27b984af2aae1adfbb2125ce5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i99f0c1670d044e009dba1531620dc1c1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icb0787f0e3644860ba06eb1034fbb65b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie1ffbd08270d44d085deecec92b01243_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie0d6f6806ba94e9ea50c537546db47a7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iee759986b4274d298c370fdb8432435b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i148258350c6645d79c0d898ac35f6d87_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i747a2e68687f4fe8b192d169ccefd610_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea0bbc8e396f4f45a85696892ed3b146_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib121748b3b90427eb1b071912d8f8abb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ea12fcac00647eda4be75a5c687a73b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i288f5153e6b2498db8daba718939f0f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7451a81074d647e295bf3e8ebedffdb7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76162ba1a18c4fc4a980bcbba9264153_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id0e6f330c4624be993d0a2175e6edb7c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3585fd01cc1840feb99f41bf29e5c7e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4da6d04d2658412081cbb06f08d92d03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6438be1c7813480081d80920f7c7256d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80cbb34246294317b7336589ccf4350d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iebfbafa88c384397839bf6d6ddd589b5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i845134cd6052477bb77c2afc3b82e0ee_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia973c2256c1241e39d7549dbe6a90f11_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie69edf146b6449f7a4fb9cf05187e1ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i46a6e5fff27f4b6aa874171e8585d54f_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i06955b87c4604f8fb996dcb42b4dc99e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3fa4f2d5e48b4142942ab255dbbf4e2b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i022010ba69a04e73be7fc39c277aa5bc_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i4a6d5f9b9cb64ef1ab9cf00828b18921_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i22af05f406eb42a18864db9d550fb33b_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i427f349d621a4e20beb2de97f08f189f_I20210615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-15</instant>
        </period>
    </context>
    <context id="i4a20cea58d2e41dda0b283e8e60b23c0_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8c7dc4c308654b92a9b7eb8aa5fae842_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i44f9acd305254e98bb6059421e41afc8_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia6b3220211b34177a70814841776348e_D20180101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8f96961f110f4bd4a365d1cacb888a9d_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i793df4da4f6949ae8dc1104d14ce9e42_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i326f19028f6848eb90307ed07e34fb13_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="idaf80bf80aa94dcdbe58a0b47d56866c_D20170101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if11ae315139b4747abb6df067daf9f16_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i34ebcecab85244bd9dbc6977705c7569_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i98c0801d3b474ff6844f020bcdb35bd9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7cfb8e8a76924dac915a6ac2232abba3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4bdcdeefecaa42989b7b67f34d47899a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9531fc2fc03846f0b3768319934b4340_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if320066be1564b01af8dde722a25c31e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i98e991fb934846ab820b5a844c8830c5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4badc0f60dd14b6c8755357f7ac540fc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icc0dbc0dc52e4ad7bf077e11b26f5987_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i59a0c5813a0c46d786211fb05433da01_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1b58dca81bae4ab9b749cdc5b02a267b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie336f44ff7bd44ad8432ae58b5fff68f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia1fee744e4cf4ed1ad933a71b09d6beb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i383ab32255d644eaafc819796aa2870d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia9d0c680036d4325b5e7f41d64399b60_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iad7dbfa657cb4e6f87748b9ddf1e390c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3465bc8d05de421897c972d4b8fedeb8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idd7958be040c4fb89b305414df69d203_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0c250244fd7d4e4c9b409d38eb292272_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8f28dba3b3c54be6951e63e82446015d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i03d23314d63d45c8b35e795aaedab122_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if34089b9b5874ac5840731a4dd93f241_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i83adad7f523245b7b6e58f66a3dab006_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4a238ce78ac74f1b93c817ced866efa2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4022bd5da2824c7c8f8ee74203011a7d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ida2095e4cb994efe825c83b7c2569119_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8f5dc2b032524391af7887b322598d1d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8143c485591543ca8f9fa0ad6b05a533_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iede70fcdb85b4d5fadb7c778a198437a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iee958037590e47f9a647d7b398e799cb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i821467e83ad44bf4936cba83c4bf74cc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i251e9fe0e95a4f3f862b554c5b106612_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i35541777167844639ae2fde64553a505_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia0b95e5cfec444d08b7a167a497b2f2b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1b4c7ba6a9524139b98444a380751a27_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic57fab8151e64ac0a42999af4054508d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib0d488d61f554e5a8b0ce225092751fc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i99ab726c228e4d1680ccc1ddfb59679a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia3ab9f0060de41d18476fe3926db09c0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99a92e56710a44499fbc841789c43ddd_D20150915-20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-15</startDate>
            <endDate>2015-09-15</endDate>
        </period>
    </context>
    <context id="i71658aa1f269459cad8b975de86ba7af_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i487dec63017c4855b07e934da1351f90_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibb2565b6e20a47c380508ecb56852d3e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i01719b83dd334b3c8168fc3fa1f48b83_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i91df6dfeabf04146832cafe879f6de8d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie4219cd04f594173989928403a1925f5_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="i079475de71ee41f681213c129639bcad_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i87bf914abe0d42daa70a6e228105c4dc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0829ae725ca14ae7a41646663f3d6410_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5e8e35470de0483c81155d2739ab9223_I20131031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-10-31</instant>
        </period>
    </context>
    <context id="if5cf9831d6f24c2083b89a5456858d7b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibc4bd8d3b0504ef79236bd4a23c915f8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1afe44d7fcb449e8b8c3d8ac3bf6d9d6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2bae4045ab9643abbbe939388775bc12_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if0961f8433264f3a91406325b6f8539c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if1204e1a45b146edb8cf23bbe529b211_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib1a6178e54834b4f981abb57a3f32174_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i40192326e650444490369c6d8aed8c29_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i596efc1d3c914e7c99e852a6397e9d68_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1c37fd8583354f3e9a46dbbaef70aed7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie49c054c4de84c13bf9cf4e74329ad89_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1017f0e3d160493698b4b137f53cf6b9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9edd978d79794c06ae717443ae5079d0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if2db8a1a06494bb9acad2b6f55b81bac_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i671b1a548fa8453f8d15112d62dc2c2c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc9b2b5b948945ceb440f809f174f953_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic04f6c80a7bb4625a1ae6e61e5c93184_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2f5fcdf3d7064037aaefd67693a0f61c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="performanceobligation">
        <measure>mgnx:performanceObligation</measure>
    </unit>
    <unit id="molecule">
        <measure>mgnx:Molecule</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80L2ZyYWc6NzdlNWM4NmZhOGJhNDU1Y2ExM2YzODk2ZmE1YWRiYzIvdGFibGU6MjVkMjBhNmEyODRjNDczZGFmNzZiYWU1NjdkY2ExNTAvdGFibGVyYW5nZToyNWQyMGE2YTI4NGM0NzNkYWY3NmJhZTU2N2RjYTE1MF8yLTEtMS0xLTA_70cca93f-6a7d-4b0d-aaf2-dec1356ea106">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80L2ZyYWc6NzdlNWM4NmZhOGJhNDU1Y2ExM2YzODk2ZmE1YWRiYzIvdGFibGU6MjVkMjBhNmEyODRjNDczZGFmNzZiYWU1NjdkY2ExNTAvdGFibGVyYW5nZToyNWQyMGE2YTI4NGM0NzNkYWY3NmJhZTU2N2RjYTE1MF80LTEtMS0xLTA_18de2dbe-4a76-47f7-beea-ca52a80ad575">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80L2ZyYWc6NzdlNWM4NmZhOGJhNDU1Y2ExM2YzODk2ZmE1YWRiYzIvdGFibGU6MjVkMjBhNmEyODRjNDczZGFmNzZiYWU1NjdkY2ExNTAvdGFibGVyYW5nZToyNWQyMGE2YTI4NGM0NzNkYWY3NmJhZTU2N2RjYTE1MF81LTEtMS0xLTA_7c70e672-275a-4f8b-a1ed-845df807bbdf">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80L2ZyYWc6NzdlNWM4NmZhOGJhNDU1Y2ExM2YzODk2ZmE1YWRiYzIvdGV4dHJlZ2lvbjo3N2U1Yzg2ZmE4YmE0NTVjYTEzZjM4OTZmYTVhZGJjMl8xMzA_69b61279-fb06-425a-adbd-ddfed19f67b8">0001125345</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80L2ZyYWc6NzdlNWM4NmZhOGJhNDU1Y2ExM2YzODk2ZmE1YWRiYzIvdGV4dHJlZ2lvbjo3N2U1Yzg2ZmE4YmE0NTVjYTEzZjM4OTZmYTVhZGJjMl8xMzE_65d8c756-9219-4a1a-a8f1-05794aaba3e2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV84Mg_75047b5c-a00c-4624-ae84-5dd6223719ad">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6NjUzYmFiMTI3YTk0NGE3MzgzMDdhMzJlN2YzNDNjNmUvdGFibGVyYW5nZTo2NTNiYWIxMjdhOTQ0YTczODMwN2EzMmU3ZjM0M2M2ZV8wLTAtMS0xLTA_a33063f5-85f8-4d9f-80d7-d41570ae2a21">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8xMTc_8aad6e6e-1b6e-4955-85d5-15d3d7876277">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6YzIyOGZlNzc5ZGUzNGMzZGFkMmRkNzI5NjQ5N2RhZjAvdGFibGVyYW5nZTpjMjI4ZmU3NzlkZTM0YzNkYWQyZGQ3Mjk2NDk3ZGFmMF8wLTAtMS0xLTA_ab1aae69-8b0f-4207-98e4-fad2dc72c161">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8yMDg_3e48943f-0d0b-4c86-9a5e-4445ea3ddc5d">001-36112</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8yMTE_d2185158-390b-4416-af10-64958c61b273">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6NTk3NDMyOGQwYzg2NDBhM2E1MzBiNTRkNGMzY2FhMzAvdGFibGVyYW5nZTo1OTc0MzI4ZDBjODY0MGEzYTUzMGI1NGQ0YzNjYWEzMF8wLTAtMS0xLTA_364f2baf-a2b7-4d36-af74-5cc2010faebe">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6NTk3NDMyOGQwYzg2NDBhM2E1MzBiNTRkNGMzY2FhMzAvdGFibGVyYW5nZTo1OTc0MzI4ZDBjODY0MGEzYTUzMGI1NGQ0YzNjYWEzMF8wLTEtMS0xLTA_39e3cc63-dddd-48ee-8819-f3fbfdc8728c">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6NTk3NDMyOGQwYzg2NDBhM2E1MzBiNTRkNGMzY2FhMzAvdGFibGVyYW5nZTo1OTc0MzI4ZDBjODY0MGEzYTUzMGI1NGQ0YzNjYWEzMF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmMGRhZDFjYzRhYzg0OWY4ODNiMTMwMzViNGQ0OGI0OF81_d977fccf-8748-4ff2-9c60-fa84ff2e9dcb">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6NTk3NDMyOGQwYzg2NDBhM2E1MzBiNTRkNGMzY2FhMzAvdGFibGVyYW5nZTo1OTc0MzI4ZDBjODY0MGEzYTUzMGI1NGQ0YzNjYWEzMF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmMGRhZDFjYzRhYzg0OWY4ODNiMTMwMzViNGQ0OGI0OF84_57d2476b-070a-4249-b0ad-01ad8cbc9bff">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6NTk3NDMyOGQwYzg2NDBhM2E1MzBiNTRkNGMzY2FhMzAvdGFibGVyYW5nZTo1OTc0MzI4ZDBjODY0MGEzYTUzMGI1NGQ0YzNjYWEzMF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmMGRhZDFjYzRhYzg0OWY4ODNiMTMwMzViNGQ0OGI0OF8xMg_5334c548-0d77-490a-8abc-373551d3ac3b">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6NTk3NDMyOGQwYzg2NDBhM2E1MzBiNTRkNGMzY2FhMzAvdGFibGVyYW5nZTo1OTc0MzI4ZDBjODY0MGEzYTUzMGI1NGQ0YzNjYWEzMF8zLTEtMS0xLTA_dc906af2-bfd1-491c-8048-70eca85c2408">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8yNzA_f439bb3c-70a4-48f0-9d19-af62dd770559">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8yNzM_56f860df-a261-44da-99d5-f94c388fb65c">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6MDEwMGNjMDhiMDU5NGI3Y2ExMTFiZjU4NWQ0ZmQ1ZjgvdGFibGVyYW5nZTowMTAwY2MwOGIwNTk0YjdjYTExMWJmNTg1ZDRmZDVmOF8xLTAtMS0xLTA_10748155-9129-47ea-872c-50edc6113b8d">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6MDEwMGNjMDhiMDU5NGI3Y2ExMTFiZjU4NWQ0ZmQ1ZjgvdGFibGVyYW5nZTowMTAwY2MwOGIwNTk0YjdjYTExMWJmNTg1ZDRmZDVmOF8xLTEtMS0xLTA_d64ba663-5bf7-4bb5-aeaf-ccca5470ab1d">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6MDEwMGNjMDhiMDU5NGI3Y2ExMTFiZjU4NWQ0ZmQ1ZjgvdGFibGVyYW5nZTowMTAwY2MwOGIwNTk0YjdjYTExMWJmNTg1ZDRmZDVmOF8xLTItMS0xLTA_c558a435-b19c-4892-8143-b7146d58df12">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8xOTE3_aab32676-f36c-4bdc-85c7-50db59ba73b5">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8xOTE1_60b0c9a8-00b2-4f71-aaea-7bed8b9a5b7a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6OGI0ZGNkMzgxNTljNGM4Zjg3ZDIzMjNmMmQ2NjRjZDQvdGFibGVyYW5nZTo4YjRkY2QzODE1OWM0YzhmODdkMjMyM2YyZDY2NGNkNF8wLTAtMS0xLTA_c672719c-ad65-43d8-ac52-410cd7126e64">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6OGI0ZGNkMzgxNTljNGM4Zjg3ZDIzMjNmMmQ2NjRjZDQvdGFibGVyYW5nZTo4YjRkY2QzODE1OWM0YzhmODdkMjMyM2YyZDY2NGNkNF8yLTMtMS0xLTA_eff5c8fa-6e47-4a7c-bdc0-ef4d9677d23f">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGFibGU6OGI0ZGNkMzgxNTljNGM4Zjg3ZDIzMjNmMmQ2NjRjZDQvdGFibGVyYW5nZTo4YjRkY2QzODE1OWM0YzhmODdkMjMyM2YyZDY2NGNkNF80LTEtMS0xLTA_f6702109-8958-4f4c-bc2a-5dff6f6c7cdd">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8xOTE2_aa6d9942-d26a-4a6e-9092-08b7bd1e82cb">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i972ac0a554d046a68379be874acd54db_I20211029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xL2ZyYWc6MjZmZGIzYjhmMWExNDZkNmJiOTY1ODM2NzY4OGQ5MDkvdGV4dHJlZ2lvbjoyNmZkYjNiOGYxYTE0NmQ2YmI5NjU4MzY3Njg4ZDkwOV8xODI4_639e7a8d-89d7-49c1-8303-5b8f3e3eeeb9"
      unitRef="shares">61258001</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfNC0xLTEtMS0w_cac17c7f-e9a9-4c4d-9983-d7d558a3a141"
      unitRef="usd">190531000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfNC0zLTEtMS0w_6a1464de-31b5-4d03-b18f-8c04362718ee"
      unitRef="usd">181131000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Investments
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfNS0xLTEtMS0w_51f0d823-4fc5-450e-9e65-16fbe1a46b4b"
      unitRef="usd">108367000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfNS0zLTEtMS0w_02643257-46d4-48f4-a7b3-c7ed554efbd3"
      unitRef="usd">91400000</us-gaap:Investments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfNi0xLTEtMS0w_549802fa-16aa-4ece-90f3-ce040c6f5ccb"
      unitRef="usd">13759000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfNi0zLTEtMS0w_b375600a-057c-4dcf-ac4b-6e02a75a6a10"
      unitRef="usd">23081000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfNy0xLTEtMS0w_8b86fbb5-ecfe-4f4c-b1b6-72f4df45018e"
      unitRef="usd">3979000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfNy0zLTEtMS0w_69dd2439-d3e9-4314-98d0-d34976629026"
      unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfOC0xLTEtMS0w_1a23ef45-3101-403c-95fa-9ec97274356c"
      unitRef="usd">18062000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfOC0zLTEtMS0w_a95a9410-ca24-405f-864a-a4331c3c9d0e"
      unitRef="usd">16982000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTAtMS0xLTEtMA_c98a101f-b27d-4369-8b6d-2a10af3a7ae4"
      unitRef="usd">334698000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTAtMy0xLTEtMA_d25bbcb0-440d-4bc5-ae83-0860d77deec2"
      unitRef="usd">312594000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTEtMS0xLTEtMA_1fb9bc4f-955a-4be3-a94b-196697f99151"
      unitRef="usd">38684000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTEtMy0xLTEtMA_e7cdcb8d-146d-4b49-9e34-a833b933a770"
      unitRef="usd">42225000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTMtMS0xLTEtMA_b3775c8f-4dba-48da-adca-4666e4469f59"
      unitRef="usd">18778000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTMtMy0xLTEtMA_d7d07705-0c3f-4a4d-babd-67174539dafc"
      unitRef="usd">23924000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTQtMS0xLTEtMA_7e57fe6c-2ffb-4354-bb67-86e9e517155c"
      unitRef="usd">392160000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTQtMy0xLTEtMA_2e5890fc-a9db-41be-890a-e222fd6ea9de"
      unitRef="usd">378743000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTgtMS0xLTEtMA_50cae4ab-3958-43f6-8839-f35f16b2158f"
      unitRef="usd">6170000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTgtMy0xLTEtMA_04049a75-f222-46f8-8bdd-d474908b9b43"
      unitRef="usd">8031000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTktMS0xLTEtMA_4dba9d53-9e34-4afe-9769-afbebca78b9c"
      unitRef="usd">41859000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMTktMy0xLTEtMA_dd78a0f8-d4fe-416a-a6de-e0890009a210"
      unitRef="usd">34198000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjAtMS0xLTEtMA_4ab98e2a-aeec-4ecc-9054-812294d82601"
      unitRef="usd">16314000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjAtMy0xLTEtMA_35521871-9a7e-4b42-882a-4389797ef679"
      unitRef="usd">4456000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjEtMS0xLTEtMA_f5f49756-bc00-4bee-bc5a-834dbc78526b"
      unitRef="usd">4521000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjEtMy0xLTEtMA_f3d71d1f-f0dd-48aa-b918-7006374002f1"
      unitRef="usd">3988000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjMtMS0xLTEtMA_8de81a20-a1be-422b-862c-a04fc0fa4268"
      unitRef="usd">68864000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjMtMy0xLTEtMA_eccd51ca-3a84-42f8-883a-bbafe33f0855"
      unitRef="usd">50673000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjQtMS0xLTEtMA_8d507369-d18a-41fa-b235-351f5409203d"
      unitRef="usd">9575000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjQtMy0xLTEtMA_41609079-4c34-410f-b252-061862b2fd03"
      unitRef="usd">6926000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjUtMS0xLTEtMA_23dc53bd-e754-494a-8c45-ec7ed62a5a8a"
      unitRef="usd">22025000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjUtMy0xLTEtMA_5ea74473-9528-484c-a499-7a5516d8f639"
      unitRef="usd">25260000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjYtMS0xLTEtMA_f20bd31d-2c3a-4d25-a4b3-8347c741a200"
      unitRef="usd">258000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjYtMy0xLTEtMA_86c91384-cd94-4de2-baf7-fa508074aa07"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjctMS0xLTEtMA_74ff7ad6-d02b-42b4-a1ae-9a79051f08cc"
      unitRef="usd">100722000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjctMy0xLTEtMA_a23a6c9d-919e-4ad5-89c5-055a5d04d5bb"
      unitRef="usd">82859000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjFkYjA0ZWQ1MGNjYTQ1NzBiZmQ2MzNmY2Q3Zjc5MjljXzE4_0bd3c71b-ce6e-41ad-9974-5a86a950847e"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjFkYjA0ZWQ1MGNjYTQ1NzBiZmQ2MzNmY2Q3Zjc5MjljXzE4_441fb2f0-cac5-4a78-a181-a794e1a6f457"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjFkYjA0ZWQ1MGNjYTQ1NzBiZmQ2MzNmY2Q3Zjc5MjljXzM0_2eca3546-d748-479d-812a-828b1cd76243"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjFkYjA0ZWQ1MGNjYTQ1NzBiZmQ2MzNmY2Q3Zjc5MjljXzM0_3f5d4b8f-f9b5-4a9e-a5d4-568329354168"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjFkYjA0ZWQ1MGNjYTQ1NzBiZmQ2MzNmY2Q3Zjc5MjljXzU2_367c5e38-6a66-479e-bcdb-285fa875d7f2"
      unitRef="shares">61254693</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjFkYjA0ZWQ1MGNjYTQ1NzBiZmQ2MzNmY2Q3Zjc5MjljXzYz_81e5fc6d-7965-4279-94da-b75fb2a7c3ec"
      unitRef="shares">56244771</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjktMS0xLTEtMA_8adb0b05-3421-4746-807e-eed4ce9774a8"
      unitRef="usd">613000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMjktMy0xLTEtMA_546ef5c7-cf1e-4e0c-a8a1-effc0d6d1ad1"
      unitRef="usd">562000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzAtMS0xLTEtMA_ee26899f-9215-4146-ab32-4f1a0bdbf55b"
      unitRef="usd">1206742000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzAtMy0xLTEtMA_a279348d-d81b-4db8-b0a6-fa82e880b41d"
      unitRef="usd">1067150000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzEtMS0xLTEtMA_b1796355-9498-4381-909d-0d28cb772911"
      unitRef="usd">-3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzEtMy0xLTEtMA_3627e04f-178f-4ed7-a81c-77619eab6614"
      unitRef="usd">-7000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzItMS0xLTEtMA_781e5240-6e17-4c54-a6d8-dcde583dc8e6"
      unitRef="usd">-915914000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzItMy0xLTEtMA_4a1dd4a6-d04f-40cd-813a-0ebdb89a4bce"
      unitRef="usd">-771821000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzMtMS0xLTEtMA_0e7ce53d-2098-4501-8c13-83a15a99e3ef"
      unitRef="usd">291438000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzMtMy0xLTEtMA_8926dc00-828d-45f1-af49-14f272f064fe"
      unitRef="usd">295884000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzQtMS0xLTEtMA_562ee555-ead4-42ab-9f51-e27821b30931"
      unitRef="usd">392160000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8xOS9mcmFnOjIwZmQ5ZmQ5MmQ2NjQ0MjhhZDBjOWMwODFiYTIxYzlhL3RhYmxlOjEyN2M0MDY1YzYzODQwOWI4MWI1ZDc0MDBmYjRiZjkxL3RhYmxlcmFuZ2U6MTI3YzQwNjVjNjM4NDA5YjgxYjVkNzQwMGZiNGJmOTFfMzQtMy0xLTEtMA_f997970b-65ba-48f2-a4a9-34634b68a54b"
      unitRef="usd">378743000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="ie95edcd295ff48deb8618fc650417b92_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMy0xLTEtMS0w_7ed09cca-dcbe-4bf1-889b-0b0f3f2eebeb"
      unitRef="usd">11986000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i546c554a2ee0420ea96d3bc20bc2c290_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMy0zLTEtMS0w_78238e22-59e6-4471-8749-9cb273f3553e"
      unitRef="usd">17415000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id0bcdbf862314e17ae8630e4eb589a85_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMy01LTEtMS0w_a8358d0d-9085-4347-a3de-1bf00061a798"
      unitRef="usd">54338000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6657edfefea4b1a9ed79a2168bc7a7b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMy03LTEtMS0w_f555960c-6209-435c-a7dc-cf4ef18e688f"
      unitRef="usd">46018000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie043cccbc0a44110a07e3bb61c428168_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNC0xLTEtMS0w_af3333dc-45b1-4152-93d4-680b8a7bccd1"
      unitRef="usd">3591000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie137008876174548934b7aa0f11bbbdb_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNC0zLTEtMS0w_b9b6f2d4-cb09-4e3c-9f25-e8db6cac2456"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i80e0db72700b4ea497dbe948db25aa20_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNC01LTEtMS0w_001ea1db-fac2-434a-8aec-970c5945d1fd"
      unitRef="usd">7681000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibcc05602c5ac4fa59eb68dfc1e898e5c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNC03LTEtMS0w_58d54b4b-0a23-4641-8c2a-9de8cdc75356"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide26e919725d41559b15da9dcb0a928b_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNS0xLTEtMS0w_71795be2-45eb-49a7-bbb9-45c6c02837e6"
      unitRef="usd">85000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i959a5d44e3314580a0ac18e02aa9bafd_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNS0zLTEtMS0w_d7910416-3778-4a51-ad3d-6bc4c5becd32"
      unitRef="usd">838000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a9ca21023dc4df0baec03f9c4eba112_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNS01LTEtMS0w_136e25f9-06cb-431b-8f3f-91ca997c200a"
      unitRef="usd">1281000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4c884e39a884f8696523d9a33f5ef35_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNS03LTEtMS0w_c5cd438d-b913-42fe-9edd-eafc0f04425a"
      unitRef="usd">6174000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNi0xLTEtMS0w_9077bc8b-04ba-4d2b-9808-4ea6b63abe72"
      unitRef="usd">15662000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNi0zLTEtMS0w_8af8165b-63ff-4d38-b017-0d50c4a82efd"
      unitRef="usd">18253000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNi01LTEtMS0w_6f8ae691-d8c7-4cc2-9cd3-c811e8f9f6d3"
      unitRef="usd">63300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfNi03LTEtMS0w_577d34aa-8b19-4ac3-8caf-5e637f4e774e"
      unitRef="usd">52192000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfOC0xLTEtMS0w_5952b991-822d-43da-accd-5e6be1849a0d"
      unitRef="usd">1665000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfOC0zLTEtMS0w_db105f46-48ad-4569-9d0b-7ad9fe33697c"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfOC01LTEtMS0w_6bca272f-1a1e-481b-b738-d33564dab82f"
      unitRef="usd">1704000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfOC03LTEtMS0w_d22970f9-fc39-4640-a5bd-911a7c1d31a9"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfOS0xLTEtMS0w_86bffb1d-5bcc-4ebf-8c8c-94733e31acde"
      unitRef="usd">49823000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfOS0zLTEtMS0w_2fd76b62-b83e-448c-9e00-82ff2366c624"
      unitRef="usd">44656000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfOS01LTEtMS0w_ef85bee4-abfb-4758-920a-8be477417f44"
      unitRef="usd">158724000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfOS03LTEtMS0w_f206e267-5b85-447e-b390-dcb73eb7e39e"
      unitRef="usd">150901000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTAtMS0xLTEtMA_4a3bae6f-32c0-4b3f-95f6-1d7c71767a9d"
      unitRef="usd">17161000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTAtMy0xLTEtMA_b2cc5d3f-dc06-4e61-8cb7-7ca47aeee434"
      unitRef="usd">9732000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTAtNS0xLTEtMA_30b38445-d177-4cff-a36b-bc9bf00df03b"
      unitRef="usd">47431000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTAtNy0xLTEtMA_36807b7e-e817-43ae-81fa-9fb52c801f62"
      unitRef="usd">30181000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTEtMS0xLTEtMA_5fff8af8-6a8b-44ed-a504-d971e933a138"
      unitRef="usd">68649000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTEtMy0xLTEtMA_8811e265-52fe-4360-8dd6-1169e7fb6710"
      unitRef="usd">54388000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTEtNS0xLTEtMA_414f689f-dead-4838-b473-ed03cd1b18e0"
      unitRef="usd">207859000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTEtNy0xLTEtMA_9ac6a863-902c-4f74-b13c-e11e4f5e1696"
      unitRef="usd">181082000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTItMS0xLTEtMA_cee6a29b-1bb9-4e5b-b2e7-fc25b71a0b69"
      unitRef="usd">-52987000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTItMy0xLTEtMA_b0f71713-53d0-4777-b7ee-7c91b41856e8"
      unitRef="usd">-36135000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTItNS0xLTEtMA_c7546796-cafd-4140-b006-0830104445d3"
      unitRef="usd">-144559000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTItNy0xLTEtMA_d75a7612-b8db-4896-8339-fbba27082a40"
      unitRef="usd">-128890000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTMtMS0xLTEtMA_7b8e9ab9-dee3-4d82-a900-7ac282a0260e"
      unitRef="usd">101000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTMtMy0xLTEtMA_2432baf9-7a55-438e-886d-b9c3331ca907"
      unitRef="usd">92000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTMtNS0xLTEtMA_ea954632-d934-4dc2-8dc1-fe4130d6ace2"
      unitRef="usd">466000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTMtNy0xLTEtMA_509b1b01-84ad-4938-88b2-dec9de52cff9"
      unitRef="usd">1238000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTQtMS0xLTEtMA_45f38355-aa77-4206-acfe-b65ddbb38b65"
      unitRef="usd">-52886000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTQtMy0xLTEtMA_4c68f508-11e1-4354-827b-7ef1067edf6f"
      unitRef="usd">-36043000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTQtNS0xLTEtMA_4350258d-d635-4373-93cd-4a397dc1847d"
      unitRef="usd">-144093000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTQtNy0xLTEtMA_594a9693-ab59-46ea-b493-048fce045d42"
      unitRef="usd">-127652000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTYtMS0xLTEtMA_5330f3e7-3b78-4b42-bab6-d3bc6794754d"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTYtMy0xLTEtMA_601c38a6-788d-4b6a-bb0a-0170ea150303"
      unitRef="usd">-15000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTYtNS0xLTEtMA_51e4a4cc-0f4f-4ce7-bbbe-34711fb72f6f"
      unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTYtNy0xLTEtMA_cd980516-1807-445d-946d-ce56486fd18e"
      unitRef="usd">-14000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTctMS0xLTEtMA_b798c11a-c59d-4c0a-b4b8-ccba17673d11"
      unitRef="usd">-52890000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTctMy0xLTEtMA_659a9e5b-aee3-4933-9e9a-b20ccdbf9e54"
      unitRef="usd">-36058000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTctNS0xLTEtMA_97558506-fb85-4879-b1f5-f77ac76acaec"
      unitRef="usd">-144089000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTctNy0xLTEtMA_61b0f249-f371-420e-80a9-bd8f6b5363f5"
      unitRef="usd">-127666000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTktMS0xLTEtMA_b70dd40a-90a9-4750-a89b-fa4665bdd11b"
      unitRef="usdPerShare">-0.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTktMS0xLTEtMA_cce7a1fe-1295-49b1-9156-40fe76b8ea89"
      unitRef="usdPerShare">-0.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTktMy0xLTEtMA_6b253566-cc86-4759-bead-96d2235e4c83"
      unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTktMy0xLTEtMA_6dfe97eb-3272-4162-a69e-6b0847cd47c5"
      unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTktNS0xLTEtMA_21270a9c-067e-43d5-8f59-ba7a3fdee5b2"
      unitRef="usdPerShare">-2.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTktNS0xLTEtMA_73b09653-c011-43dc-ab84-6ae1c37c9c34"
      unitRef="usdPerShare">-2.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTktNy0xLTEtMA_6a8efc67-0977-4518-aa06-394eed2f53ed"
      unitRef="usdPerShare">-2.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMTktNy0xLTEtMA_8f86d321-2a8b-4595-a943-60e0986eb82a"
      unitRef="usdPerShare">-2.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMjAtMS0xLTEtMA_8a3b85d1-99d4-4f62-8987-2df9957271e3"
      unitRef="shares">61169754</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMjAtMS0xLTEtMA_8fabe284-973d-4492-ae52-c10d45519112"
      unitRef="shares">61169754</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMjAtMy0xLTEtMA_1b07b37e-525c-4036-853e-e0768aaa7315"
      unitRef="shares">54463412</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMjAtMy0xLTEtMA_f3ce892f-5baf-49c6-823b-286e9b0b7c78"
      unitRef="shares">54463412</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMjAtNS0xLTEtMA_10f23b12-b4f1-4fbe-9c3e-7e12ffdf1931"
      unitRef="shares">59494836</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMjAtNS0xLTEtMA_25b20744-7194-4e31-b12d-b983379184ac"
      unitRef="shares">59494836</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMjAtNy0xLTEtMA_1ce313a8-2b70-4338-9921-8bd377da893c"
      unitRef="shares">51176884</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yMi9mcmFnOmI3YzM3NDhmNDhkMzRmMjE5OTkyNDhiOWJmNmMzMDAwL3RhYmxlOjdmNGFhZmY5ZWNhYTRkNDFhNGE4MTkwNGQwMDM0NjNmL3RhYmxlcmFuZ2U6N2Y0YWFmZjllY2FhNGQ0MWE0YTgxOTA0ZDAwMzQ2M2ZfMjAtNy0xLTEtMA_2382d24c-5c23-4445-bceb-8b82df2b1f99"
      unitRef="shares">51176884</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="ib92c6189b72c447b8f1068b900a46c1f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMi0xLTEtMS0w_e6786b4f-19aa-481f-8671-25d18bd92f00"
      unitRef="shares">56244771</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib92c6189b72c447b8f1068b900a46c1f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMi0zLTEtMS0w_91bb0fa9-afb7-4bc4-82b7-f7d0bd2978b8"
      unitRef="usd">562000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i0089074df40749cda994bd08f7cebc31_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMi01LTEtMS0w_67cb466c-70f7-4e59-9571-19a21e6c5227"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0089074df40749cda994bd08f7cebc31_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMi03LTEtMS0w_68a953b2-4b76-438e-b5f0-c1ee74c48fd7"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34562cb47376442eaa203ab6023eb363_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMi05LTEtMS0w_0946843f-5152-40bc-b306-51f7c9364064"
      unitRef="usd">1067150000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic813efc42fbc4dd58d2a1dd2d3f5c0cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMi0xMS0xLTEtMA_2e7f2cf3-2880-4ce7-a7d1-4080c2ee4944"
      unitRef="usd">-771821000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1395e2e157c84e9e97a685f193961623_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMi0xMy0xLTEtMA_7cacad62-6a69-4d1a-a147-548eb9405991"
      unitRef="usd">-7000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMi0xNS0xLTEtMA_9972be50-4259-4863-8c9b-280c6544d57c"
      unitRef="usd">295884000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie54467d33fdf45529db11e8c19a075f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMy05LTEtMS0w_0d3338ba-a035-4cb0-8105-60353988aef1"
      unitRef="usd">5243000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i92e491e03d244d95acc39155f4bff6be_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMy0xNS0xLTEtMA_9fa073eb-d370-446e-aaac-1841d06b7680"
      unitRef="usd">5243000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4b5ad3e626c04694aaf53610a83fce1f_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNC0xLTEtMS0w_c97e39cb-f515-442a-ade7-c194ab41d2b2"
      unitRef="shares">3622186</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4b5ad3e626c04694aaf53610a83fce1f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNC0zLTEtMS0w_9984216c-d8aa-422d-a440-6461520244bb"
      unitRef="usd">36000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie54467d33fdf45529db11e8c19a075f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNC05LTEtMS0w_33867b88-68e2-4896-a87d-99470c1fafb0"
      unitRef="usd">98164000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i92e491e03d244d95acc39155f4bff6be_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNC0xNS0xLTEtMA_b1a6938e-7e0e-4040-96ab-b1a05c2fa96b"
      unitRef="usd">98200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i4b5ad3e626c04694aaf53610a83fce1f_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNS0xLTEtMS0w_f7b3a22c-c3aa-4ce2-b552-1f1d570b91d3"
      unitRef="shares">144249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i4b5ad3e626c04694aaf53610a83fce1f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNS0zLTEtMS0w_c5c5edcd-4b6f-41ff-b442-d4f1045dbae1"
      unitRef="usd">2000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ie54467d33fdf45529db11e8c19a075f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNS05LTEtMS0w_b17cfc94-362b-4348-8452-f58219e37cf1"
      unitRef="usd">2456000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i92e491e03d244d95acc39155f4bff6be_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNS0xNS0xLTEtMA_ea239c11-5263-4d24-803e-7fe38be9ed1c"
      unitRef="usd">2458000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ic3c55b26f9e94031991eb2780805e604_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNi0xMy0xLTEtMA_d83b1646-c934-4672-9472-31fb351c6a3e"
      unitRef="usd">18000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i92e491e03d244d95acc39155f4bff6be_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNi0xNS0xLTEtMA_1d69d65d-3b04-4bfc-a2bd-5fbd7b0ce0cd"
      unitRef="usd">18000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i1b75e289c90849cd817e71ea9a94d6c9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNy0xMS0xLTEtMA_cb62e9f2-ee5e-4e1a-a021-333e6a9ed8f7"
      unitRef="usd">-51272000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i92e491e03d244d95acc39155f4bff6be_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfNy0xNS0xLTEtMA_5b4ca2ff-1022-4c04-8e0d-f26f047354ea"
      unitRef="usd">-51272000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="ic74e7b8118db41abafcc6bb0b8372824_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOC0xLTEtMS0w_890dd3be-4881-4c12-8e79-d6a2e82c2f36"
      unitRef="shares">60011206</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic74e7b8118db41abafcc6bb0b8372824_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOC0zLTEtMS0w_a774d3fb-74f5-4ceb-a957-3897adc0bf61"
      unitRef="usd">600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i0fcc348fc5e847e88eeadde0e0adcb08_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOC01LTEtMS0w_2b40e2c0-f5ad-4c31-81d4-ca17a62bf00a"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0fcc348fc5e847e88eeadde0e0adcb08_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOC03LTEtMS0w_0d49ec52-f540-4b88-9433-58ab2ad02649"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i190ac348f6dc46a6ac38f0d568759b66_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOC05LTEtMS0w_f137d1f5-e138-42b7-865c-a890b622255e"
      unitRef="usd">1173013000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd365da76df34d2db894b5c3007130a3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOC0xMS0xLTEtMA_dd73f6c0-5025-4755-abd7-8a3207d6dd00"
      unitRef="usd">-823093000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if7c5ea5419494505aabe9e7465d4670b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOC0xMy0xLTEtMA_ba7c5e67-e660-46dc-9c7a-5be14c71f873"
      unitRef="usd">11000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i51fffa70c15f473db18a09340f835b36_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOC0xNS0xLTEtMA_7876dce3-fe22-4f83-96c8-4d0d9ee5dff3"
      unitRef="usd">350531000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic43acc02e0294959a3b21f958b70bc69_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOS05LTEtMS0w_b0b47563-ca4e-4299-8bf8-b0ab55b343dc"
      unitRef="usd">6113000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i205d61628986439484c21a2ed5ad4721_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfOS0xNS0xLTEtMA_56492991-0042-4ccd-b64f-0bd676aa4c0c"
      unitRef="usd">6113000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i844325c47f4d4863abe97d247a5fd1ac_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTAtMS0xLTEtMA_6e0060ae-ef49-4ec5-8d3f-97e9e2cc6e2c"
      unitRef="shares">122241</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i844325c47f4d4863abe97d247a5fd1ac_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTAtMy0xLTEtMA_0340530b-f0a5-4a73-b3e9-5a0cab48b1eb"
      unitRef="usd">1000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ic43acc02e0294959a3b21f958b70bc69_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTAtOS0xLTEtMA_df89558a-4b05-460e-9231-f89b48f7592c"
      unitRef="usd">2345000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i205d61628986439484c21a2ed5ad4721_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTAtMTUtMS0xLTA_4b73c7f5-196b-44d0-8a4e-17e302a3129b"
      unitRef="usd">2346000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ie86acd1be8634256903051e3b678e662_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTEtMTMtMS0xLTA_0b403a50-6cfc-4608-b441-ef2220da98ba"
      unitRef="usd">-10000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i205d61628986439484c21a2ed5ad4721_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTEtMTUtMS0xLTA_5a222556-2e24-4213-956d-cd37fc655f07"
      unitRef="usd">-10000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i3179fb8dbc27438ca7ed7fc6348f29f6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTItMTEtMS0xLTA_acbcf1f4-bd66-4a2a-a975-a31c6636069b"
      unitRef="usd">-39935000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i205d61628986439484c21a2ed5ad4721_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTItMTUtMS0xLTA_165c8a63-5336-4cf6-a849-4676434f36ba"
      unitRef="usd">-39935000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i586b4fc28f444eae89cd1925d85aa640_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTMtMS0xLTEtMA_090fb3cf-fa4b-436e-a830-90466658ba96"
      unitRef="shares">60133447</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i586b4fc28f444eae89cd1925d85aa640_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTMtMy0xLTEtMA_ba82662c-c6d6-4a5e-8550-23a58b4fa2b3"
      unitRef="usd">601000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="id78260ca3b734c09b0e4cfd6e30b6911_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTMtNS0xLTEtMA_21ad2d53-a9fc-438d-8edf-bc1a94eba13a"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id78260ca3b734c09b0e4cfd6e30b6911_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTMtNy0xLTEtMA_252b18ed-a3f3-4786-aada-d76ee3716dea"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i763636992b5f478e80241f5eeae0f30d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTMtOS0xLTEtMA_af51ec25-e620-43a6-a35b-1bb3ea2a2a7a"
      unitRef="usd">1181471000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38708c79101b4e3fbc43d1d6b323a03a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTMtMTEtMS0xLTA_76c9a0be-bc68-46b6-bd53-cf3c08329bfc"
      unitRef="usd">-863028000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i35415a234ac242ad8ea5c77e9808c2e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTMtMTMtMS0xLTA_24920050-171e-4aaa-b1ac-fa67bda7933c"
      unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i529e813dc38c4c33ae7cd08cb044ea48_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTMtMTUtMS0xLTA_03b04bc9-938e-4f45-a2e5-d7d1dfe7b5a3"
      unitRef="usd">319045000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia0ccd33dc63c47e189ad4827959e843a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTQtOS0xLTEtMA_9017519e-82de-49bc-8da4-508a1aa16b99"
      unitRef="usd">6309000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTQtMTUtMS0xLTA_a5cc743a-fc84-43a8-a171-a3c649cb3113"
      unitRef="usd">6309000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ibdf5cd80b6b14743a7ea631042c021c3_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtMS0xLTEtMTU5NzU_9f21f3b0-daae-488d-b4e8-aad83fd6e51f"
      unitRef="shares">958467</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibdf5cd80b6b14743a7ea631042c021c3_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtMy0xLTEtMTU5NzU_29be4a89-6b4a-49cb-a72a-aa28fde132f8"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia0ccd33dc63c47e189ad4827959e843a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtOS0xLTEtMTU5NzU_15af3d7a-e1c4-415a-9260-4c1ea42df556"
      unitRef="usd">19630000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtMTUtMS0xLTE2NzA2_a8896a55-25e4-469c-b3b0-9a7da0b8afaf"
      unitRef="usd">19640000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ibdf5cd80b6b14743a7ea631042c021c3_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtMS0xLTEtMA_065854c2-548b-47ac-8d3e-8c8966ec6c5f"
      unitRef="shares">162779</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ibdf5cd80b6b14743a7ea631042c021c3_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtMy0xLTEtMA_b23892d1-e840-40b2-a9de-4fbd8c94693a"
      unitRef="usd">2000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="idf40af9b54464df4b7d3b1125f9d9179_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtNS0xLTEtMA_bebfb9e4-d5fb-415f-907e-7992301d7c84"
      unitRef="shares">66295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="idf40af9b54464df4b7d3b1125f9d9179_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtNy0xLTEtMA_d8dd2175-0a6b-4b43-a396-31c519e71be6"
      unitRef="usd">-1457000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ia0ccd33dc63c47e189ad4827959e843a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtOS0xLTEtMA_b3325eda-41d2-49e4-8018-d184e0813336"
      unitRef="usd">789000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTUtMTUtMS0xLTA_6abdbabe-a14b-4972-969f-210166f56082"
      unitRef="usd">-666000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="idf40af9b54464df4b7d3b1125f9d9179_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTYtNS0xLTEtMTQ4Mzc_db7fe390-21c3-4641-98e3-f5140ba900f4"
      unitRef="shares">66295</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="idf40af9b54464df4b7d3b1125f9d9179_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTYtNy0xLTEtMTQ4NDM_8f0bb8e0-1e9f-4036-a652-c2a33d996616"
      unitRef="usd">-1457000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ia0ccd33dc63c47e189ad4827959e843a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTYtOS0xLTEtMTQ4NDk_be9aef8a-8909-4782-9d9d-7950ca2114d7"
      unitRef="usd">1457000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i4c8f4c62b536483799b051a34289338d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTYtMTMtMS0xLTA_cd500df5-a275-4302-9827-0cd2fd64b0f4"
      unitRef="usd">-4000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTYtMTUtMS0xLTA_134b1b11-913e-4662-a11f-b74833046ea6"
      unitRef="usd">-4000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i4d126b1a843b404783a3465235814e27_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTctMTEtMS0xLTA_fc53bcdc-5c10-44ac-9fcd-bf1db0d0c1e1"
      unitRef="usd">-52886000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4c8f4c62b536483799b051a34289338d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTctMTMtMS0xLTA_7192fa18-18f0-4083-a492-bcf67fade141"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTctMTUtMS0xLTA_0457a1ac-29e6-4638-a0fb-06845ea1a665"
      unitRef="usd">-52886000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i38a56f6d9c814dac9d125191db3566f1_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTgtMS0xLTEtMA_aa2d4e70-6ce6-4833-b3ba-35dd7280c10f"
      unitRef="shares">61254693</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38a56f6d9c814dac9d125191db3566f1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTgtMy0xLTEtMA_82df51ea-286c-4475-bcfb-c56e77a349df"
      unitRef="usd">613000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i66955da827134291bef28c2ecf6e4055_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTgtNS0xLTEtMA_03ba5adf-2680-44ed-b8c0-009a363954c7"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66955da827134291bef28c2ecf6e4055_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTgtNy0xLTEtMA_f5d71598-4102-4d92-bf6d-205d0b96a9e8"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic06875b187ec41dcb7b1a15821218d7e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTgtOS0xLTEtMA_51c0c450-4f47-4788-ba51-2267b706e7a2"
      unitRef="usd">1206742000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i65cfd5b11203487cb6091fe2f919527c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTgtMTEtMS0xLTA_e7afb03b-3f67-40ba-b0cf-7531e24e33ca"
      unitRef="usd">-915914000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f4ad9aa86ed438781238f7412b23e01_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTgtMTMtMS0xLTA_5ca22035-593d-4340-bbbd-d24be5787239"
      unitRef="usd">-3000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOjAwMzBiY2E3YzRhZDQ4ZDc5MWEzNjI3YTdkZTcxMzk2L3RhYmxlcmFuZ2U6MDAzMGJjYTdjNGFkNDhkNzkxYTM2MjdhN2RlNzEzOTZfMTgtMTUtMS0xLTA_5d2f96fe-8236-4ea6-912d-afd1b6eb9057"
      unitRef="usd">291438000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i69bcf518b6f64b4eb86f5f40a6061a93_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMi0xLTEtMS0w_a15ffbf6-3cf8-4fc4-812f-887350a1f076"
      unitRef="shares">48958763</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i69bcf518b6f64b4eb86f5f40a6061a93_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMi0zLTEtMS0w_192f8adb-c090-4cf7-872a-80a69e8ae2ec"
      unitRef="usd">490000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i43d0b4f45e374b469456ad8fc84bf839_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMi01LTEtMS0w_1b98f35b-dd2f-4a99-a529-221a224f7baa"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i43d0b4f45e374b469456ad8fc84bf839_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMi03LTEtMS0w_a86aafd0-9464-44f8-9904-baabc02b85ea"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b7835f8392d46518da425a3f19dd697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMi05LTEtMS0w_dc539bfd-3445-47b7-9cad-2be4587189e5"
      unitRef="usd">872204000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6f9507cd9244da6a3c17dd33edf8e68_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMi0xMS0xLTEtMA_0186e585-56f2-4409-b445-6bbf2b954e41"
      unitRef="usd">-642082000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7099a1f0709642f8b56969b8d261b209_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMi0xMy0xLTEtMA_897871b8-dcfb-468c-a619-a691eeced08b"
      unitRef="usd">16000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iefa62144550e44079146bf982176865e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMi0xNS0xLTEtMA_052aa2ad-4777-4dd9-85b3-82c5d52316fd"
      unitRef="usd">230628000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9712c2e2c25f4f469e19daccd541cabc_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMy05LTEtMS0w_0a621d71-2dda-4fad-a890-e3d5f31146dc"
      unitRef="usd">4451000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6fb90850307344bdb2b62e4c657ff389_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMy0xNS0xLTEtMA_a76ad6cc-3df2-4fdb-909d-5b7063bd20fe"
      unitRef="usd">4451000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="icf4d14e52ac44346ae2be66f1872b003_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNC0xLTEtMS0w_1a3eb77b-6b8a-44fb-b15b-e19cdf805f68"
      unitRef="shares">172387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="icf4d14e52ac44346ae2be66f1872b003_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNC0zLTEtMS0w_442d0e8e-1a5c-43e4-8cc6-10413751af82"
      unitRef="usd">2000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i9712c2e2c25f4f469e19daccd541cabc_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNC05LTEtMS0w_5dce817a-817b-4ff2-805e-3cca0c162359"
      unitRef="usd">160000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i6fb90850307344bdb2b62e4c657ff389_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNC0xNS0xLTEtMA_43869383-eef7-4525-98b0-3b41d3adf260"
      unitRef="usd">162000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i02b854e6798d4d0bbd747c741fec06ad_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNS0xMy0xLTEtMA_8ac23c2d-2fa0-4ad2-83db-8732a78899f7"
      unitRef="usd">56000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i6fb90850307344bdb2b62e4c657ff389_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNS0xNS0xLTEtMA_364aa964-ee8e-4fcb-aa11-a1c4b2d2698c"
      unitRef="usd">56000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="icd4383e6ffc54437af3047cc7d551c59_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNi0xMS0xLTEtMA_73ad7f30-9995-49a3-bd09-254dae0d0f30"
      unitRef="usd">-44724000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6fb90850307344bdb2b62e4c657ff389_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNi0xNS0xLTEtMA_389d6e25-e9e2-44cb-89ae-c2460a3ccce6"
      unitRef="usd">-44724000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="ib8465dd5b84f4677b7ef351c4e4a0629_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNy0xLTEtMS0w_1ab27c52-fa84-4209-ba59-83bb2a1f535e"
      unitRef="shares">49131150</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib8465dd5b84f4677b7ef351c4e4a0629_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNy0zLTEtMS0w_ac09f133-ce4f-4cc4-9004-45408da88c40"
      unitRef="usd">492000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i72077576d2d24e2fb5a5f8426cae9925_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNy01LTEtMS0xNjczMQ_88abb7a7-a06c-4ec0-8a37-84e3e08504df"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i72077576d2d24e2fb5a5f8426cae9925_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNy03LTEtMS0xNjczMQ_015ed250-6e9f-4e33-9974-330376408189"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88bdee85e14740838ddaa61690920077_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNy05LTEtMS0w_e400de54-ff7d-4bf9-a19d-12628f7886d7"
      unitRef="usd">876815000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i43929274060145538939cfbe9ebb7d7f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNy0xMS0xLTEtMA_cb3077c0-502a-4cf5-8c2c-165a86e07635"
      unitRef="usd">-686806000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66fa665eac24481292baf200368ca1ba_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNy0xMy0xLTEtMA_6c2689d0-4509-442e-9f73-5a9ba8dbf773"
      unitRef="usd">72000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33d616f3a92c43cbae84e15bf03190f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfNy0xNS0xLTEtMA_63c294e8-116d-460e-ad1c-b0219deb5092"
      unitRef="usd">190573000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaf50d256b04c4e70a85bd5224d72ca21_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfOC05LTEtMS0w_06a485e4-3473-4e16-ac66-4fd818e6510d"
      unitRef="usd">5136000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i906aa4f6d4c44c3ba0e305e35a7203c3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfOC0xNS0xLTEtMA_ba12c892-2b79-45a1-9227-3d37a4db8b32"
      unitRef="usd">5136000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1164dbdf167740b2a496f6c88f38aac9_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfOS0xLTEtMS0w_6369764f-05bb-4a82-adce-ada7a9bd2c00"
      unitRef="shares">4060482</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1164dbdf167740b2a496f6c88f38aac9_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfOS0zLTEtMS0w_d9a84ed2-7ad5-45bc-8a75-03b089c29b6f"
      unitRef="usd">40000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iaf50d256b04c4e70a85bd5224d72ca21_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfOS05LTEtMS0w_9f9f0b9d-2eae-4730-a320-111588d7ea72"
      unitRef="usd">96472000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i906aa4f6d4c44c3ba0e305e35a7203c3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfOS0xNS0xLTEtMA_7e8b5103-a2ce-426b-ab0f-6015f186ec88"
      unitRef="usd">96512000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i1164dbdf167740b2a496f6c88f38aac9_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTAtMS0xLTEtMA_b8f36021-ae98-40dc-8a67-99d0b4391aab"
      unitRef="shares">173371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i1164dbdf167740b2a496f6c88f38aac9_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTAtMy0xLTEtMA_fb41874c-ed4d-473f-8b89-81e1467ed640"
      unitRef="usd">2000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="iaf50d256b04c4e70a85bd5224d72ca21_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTAtOS0xLTEtMA_ff044165-dcb7-40f2-90b0-b79b731c789a"
      unitRef="usd">2501000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i906aa4f6d4c44c3ba0e305e35a7203c3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTAtMTUtMS0xLTA_2d1179c9-eba7-4503-9396-618f5bb53c01"
      unitRef="usd">2503000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i2935a1f381274d3ebe662dedbebbad3e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTEtMTMtMS0xLTA_50742170-5af8-4941-b404-ed624b2df204"
      unitRef="usd">-55000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i906aa4f6d4c44c3ba0e305e35a7203c3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTEtMTUtMS0xLTA_95f1d228-376e-45f8-8752-a3ea0464cfc6"
      unitRef="usd">-55000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="ie2dbb00d209747a99fb78cfa9687763f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTItMTEtMS0xLTA_21d9fcd5-2e67-406f-9705-534abf96c9a2"
      unitRef="usd">-46885000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i906aa4f6d4c44c3ba0e305e35a7203c3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTItMTUtMS0xLTA_097e4516-fe05-4d29-8868-9fccdcaae5d1"
      unitRef="usd">-46885000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="iad092482cde8453e9195f68fb28e18f2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTMtMS0xLTEtMA_2a6e5d56-05db-4544-9c25-0b7da01a1c96"
      unitRef="shares">53365003</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad092482cde8453e9195f68fb28e18f2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTMtMy0xLTEtMA_0f75e959-ce9f-4c19-afd0-866a04b79895"
      unitRef="usd">534000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i7dac9970dbca4aaba71fb397a9144b68_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTMtNS0xLTEtMA_0be01de7-e7f6-4e09-b56b-6f7499d2b906"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7dac9970dbca4aaba71fb397a9144b68_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTMtNy0xLTEtMA_b524d0a6-8bf9-4501-94b7-a2a692569002"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a8e94f9c23740d392d77be412cf1da4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTMtOS0xLTEtMA_d502bdc4-a09f-4481-a5ed-13cc709e8be6"
      unitRef="usd">980924000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab4b7193bca147449377324fe98c3afe_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTMtMTEtMS0xLTA_62fb5f54-5c3e-4a6b-b98f-d5b8339d6419"
      unitRef="usd">-733691000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7da6fadb64042b4b028fc24eeb8c6ed_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTMtMTMtMS0xLTA_5c2b9ec9-453c-442a-a5cb-3c5c71f7888a"
      unitRef="usd">17000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iffca67721b4c43308a8bf5b3985400f5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTMtMTUtMS0xLTA_b4281aa5-122e-46a0-945f-2bbd00d480be"
      unitRef="usd">247784000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idb94e98144414013a4b367b085227a01_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTQtOS0xLTEtMTU5ODQ_c517def8-381a-48ea-995c-0bad174aba82"
      unitRef="usd">5796000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTQtMTUtMS0xLTE1OTg0_c4cb17d7-e42d-402c-8e70-9c3b6f4af91b"
      unitRef="usd">5796000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i304344aae2b14aa6b471cf77a9f4df60_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTQtMS0xLTEtMTQwODk_0406d1d9-347a-4435-bfed-3cc9ed699a79"
      unitRef="shares">2552333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i304344aae2b14aa6b471cf77a9f4df60_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTQtMy0xLTEtMTQwOTY_a79cd1e7-0416-488a-bb2c-c21a611f855d"
      unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idb94e98144414013a4b367b085227a01_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTQtOS0xLTEtMTQxMDI_43b7ddaa-abb8-4d26-998f-cafd14df4401"
      unitRef="usd">73956000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTQtMTUtMS0xLTE0MTA4_37bb8b57-6006-4f13-862e-33c77cd64581"
      unitRef="usd">73981000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i304344aae2b14aa6b471cf77a9f4df60_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTUtMS0xLTEtMA_d76a1d05-ca30-4c2b-b202-ba13507f6a32"
      unitRef="shares">257596</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i304344aae2b14aa6b471cf77a9f4df60_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTUtMy0xLTEtMA_bc975e20-3d66-4698-b180-a22e74ac2b82"
      unitRef="usd">3000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i3d5fe7dc9ce749d7b4b4343243fc3448_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTUtNS0xLTEtMA_d98b8edc-d622-4796-849e-f20c3af6b0a1"
      unitRef="shares">74632</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i3d5fe7dc9ce749d7b4b4343243fc3448_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTUtNy0xLTEtMA_3201f834-7494-47d3-a762-27a373bc22ef"
      unitRef="usd">-2012000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="idb94e98144414013a4b367b085227a01_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTUtOS0xLTEtMA_8c678040-3368-46f1-8442-44c114620d33"
      unitRef="usd">2091000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTUtMTUtMS0xLTA_32ce4b0c-19fe-40f4-9f76-6da78793f3b8"
      unitRef="usd">82000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i3d5fe7dc9ce749d7b4b4343243fc3448_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTctNS0xLTEtMTQ2Mjc_7c3bb7c4-29de-409e-83a3-221141b80c09"
      unitRef="shares">74632</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i3d5fe7dc9ce749d7b4b4343243fc3448_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTctNy0xLTEtMTQ2Mzg_ad895e1d-71c9-47f8-a988-bb239a290a15"
      unitRef="usd">-2012000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="idb94e98144414013a4b367b085227a01_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTctOS0xLTEtMTY3MDg_19e0562a-5a91-48f1-bbfe-5de1ad0cd368"
      unitRef="usd">2012000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i1471592823d141ed9982b46286c25e2a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTYtMTMtMS0xLTA_f1ffc63e-aa6f-4ac2-b67a-882fe39bbd4c"
      unitRef="usd">-15000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTYtMTUtMS0xLTA_235b7fec-115d-4f90-815a-7af972dd4171"
      unitRef="usd">-15000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="ia6c9cdd4f1d3447cb695fe45e3422587_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTctMTEtMS0xLTA_d1b07507-1df9-4f8d-a1fc-7c44d7752ff9"
      unitRef="usd">-36043000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTctMTUtMS0xLTA_e7d0bffc-5db5-47b5-9065-8305056e7374"
      unitRef="usd">-36043000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="ia65ece20c394482b8251eff40d234644_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTgtMS0xLTEtMA_91864c4a-9038-4323-888c-b77e4968e04f"
      unitRef="shares">56174932</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia65ece20c394482b8251eff40d234644_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTgtMy0xLTEtMA_e80636d7-1cc7-405b-b56b-a8f721fc770a"
      unitRef="usd">562000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i6d00c49127754d849e79ffd0f091a235_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTgtNS0xLTEtMA_32446886-4a7f-423b-a572-fe90e2c76551"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d00c49127754d849e79ffd0f091a235_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTgtNy0xLTEtMA_4be95d3c-82f0-437f-9eb0-53c9c9795f24"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3aef0259fe304602914853bd229b6a2f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTgtOS0xLTEtMA_6779dc3b-fe6d-45c9-8cf4-6cddc6ed7518"
      unitRef="usd">1060755000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac5626cc0d4d4f3eada7c592f37e6549_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTgtMTEtMS0xLTA_67010ab5-188b-468f-9622-7518e730409d"
      unitRef="usd">-769734000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3d2893df5534deda5831f679ba7dd0d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTgtMTMtMS0xLTA_2bc98471-2cdc-4916-bcb1-32a8cb2405b0"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id48171a2cf134b9b877b17e3ab1d96bf_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yNS9mcmFnOjRkMDNiYjgxM2RhYzRjYmM5ODNhZDQ2OTgxZTdiYjI4L3RhYmxlOmZlYmJjNjhkNmZkZDRiYzM4OGEzZDk3OTFhMTBlZWVmL3RhYmxlcmFuZ2U6ZmViYmM2OGQ2ZmRkNGJjMzg4YTNkOTc5MWExMGVlZWZfMTgtMTUtMS0xLTA_64ed0ac1-93e4-4c2b-9132-2378bc04f29b"
      unitRef="usd">291585000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMy0xLTEtMS0w_ec332339-9cb6-4bef-9f4d-bbce81313585"
      unitRef="usd">-144093000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMy0zLTEtMS0w_91cd1aa2-ec2b-405c-81d1-46e9cb961041"
      unitRef="usd">-127652000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfNS0xLTEtMS0w_b9073d0b-8aca-4c15-ad42-acd018d63d5b"
      unitRef="usd">8306000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfNS0zLTEtMS0w_cf9ee1f2-7b4c-4d52-b318-82a85ba0dae1"
      unitRef="usd">9067000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfNi0xLTEtMS0w_0dcdeded-b4e9-4698-923b-f978c6bb677e"
      unitRef="usd">-1267000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfNi0zLTEtMS0w_8ca601e5-5365-4f04-9f28-edd60c41e734"
      unitRef="usd">387000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfNy0xLTEtMS0w_b537632a-3511-4b7e-b151-2e26f807fd2c"
      unitRef="usd">17714000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfNy0zLTEtMS0w_290a4f40-f177-43e1-ad3a-79a24ea54fb1"
      unitRef="usd">15419000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfOC0xLTEtMS0xNzQ5Nw_c173cfc2-1dcf-405b-b73e-7f352c67cecb"
      unitRef="usd">-1602000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfOC0zLTEtMS0xNzUwNg_f18649b2-2e71-4b39-a287-09534f60c328"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfOS0xLTEtMS0w_bfec0561-4e65-4927-ad58-a54d0cdbfa02"
      unitRef="usd">-9322000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfOS0zLTEtMS0w_f91889b1-ff9a-46ed-956c-611451c977a5"
      unitRef="usd">6033000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTAtMS0xLTEtMA_8734e34b-9e28-4344-a050-45458715344c"
      unitRef="usd">5582000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTAtMy0xLTEtMA_22bdff76-cbd8-41cb-9a56-759b035161f4"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTEtMS0xLTEtMA_4c824d78-f625-47de-a7e0-65855c61dfee"
      unitRef="usd">1080000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTEtMy0xLTEtMA_2172a386-731c-4825-bdac-469ff2db4ca7"
      unitRef="usd">-654000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTItMS0xLTEtMA_6d3f1502-b559-4c37-9278-8fe571dcaf7e"
      unitRef="usd">-5146000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTItMy0xLTEtMA_fde6325f-0d94-4215-a902-78a879b8b4c3"
      unitRef="usd">-1615000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTMtMS0xLTEtMA_e19633a2-83bd-40ff-9312-405327c69db7"
      unitRef="usd">-1931000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTMtMy0xLTEtMA_a6211f7e-c5bf-4c7a-bdb9-66494e9d5cad"
      unitRef="usd">137000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTQtMS0xLTEtMA_4697804f-2b8c-468b-8e9f-f64ba74bbaf5"
      unitRef="usd">7744000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTQtMy0xLTEtMA_4797d741-b624-4cec-bc8e-ceb3af137057"
      unitRef="usd">5499000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTUtMS0xLTEtMA_5841e2c0-9773-42bc-a181-3a210ce74812"
      unitRef="usd">-2701000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTUtMy0xLTEtMA_3681bafa-6a11-4508-9e5d-581b496c5fca"
      unitRef="usd">-2113000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTYtMS0xLTEtMA_95469175-46f0-4f93-a973-c5102e6601bb"
      unitRef="usd">14507000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTYtMy0xLTEtMA_27b7bddb-75e2-4bf2-9711-0edeb2ef3a12"
      unitRef="usd">-4816000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTctMS0xLTEtMA_02df6559-cf3e-4fb1-b19f-171a01f15524"
      unitRef="usd">258000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTctMy0xLTEtMA_bceb39eb-4aae-417b-8063-a91f53e00ea7"
      unitRef="usd">2245000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTgtMS0xLTEtMA_227add9c-b29c-4607-aab0-522d8991dfad"
      unitRef="usd">-89521000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMTgtMy0xLTEtMA_cba78efa-3719-4946-a883-6d7b7732f9c9"
      unitRef="usd">-106365000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjAtMS0xLTEtMA_d4c4e350-2ba3-4438-a355-0eca93d02701"
      unitRef="usd">164780000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjAtMy0xLTEtMA_4319ed53-5f9a-4488-a263-b1f9aa81b0ea"
      unitRef="usd">151230000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjEtMS0xLTEtMA_5e1507e5-859c-42fe-bdf8-8a810a548b28"
      unitRef="usd">146550000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjEtMy0xLTEtMA_5af8ff38-2391-46a4-a58c-d454afd412a3"
      unitRef="usd">161866000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjItMS0xLTEtMA_1fab2a92-1379-48b5-81d6-d2f2d7bc5f7a"
      unitRef="usd">4826000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjItMy0xLTEtMA_8f6cf3e8-2fe1-4083-9162-504aac35e095"
      unitRef="usd">2346000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjMtMS0xLTEtMA_b11fa958-a7c5-4d4a-ad03-c1a059308a4b"
      unitRef="usd">-23056000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjMtMy0xLTEtMA_7e3816eb-df64-4168-873f-e78fc5b99990"
      unitRef="usd">8290000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjUtMS0xLTEtMA_27694f57-19ae-49c3-8110-741f620affcf"
      unitRef="usd">117818000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjUtMy0xLTEtMA_35f2e477-726a-4c9e-bee1-2730ec8fdd42"
      unitRef="usd">170494000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjYtMS0xLTEtMA_6afc4dc5-d32e-4030-84c0-ae2a58dc7d2a"
      unitRef="usd">5722000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjYtMy0xLTEtMA_d01fb93b-f6e5-4d69-b3cd-2afe33b5d7f6"
      unitRef="usd">4757000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjctMS0xLTEtMA_b8a26b3e-74f9-4e50-be86-16047ba42034"
      unitRef="usd">1563000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjctMy0xLTEtMA_41403c0c-12be-4d79-9873-dff787cd41c1"
      unitRef="usd">2011000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjgtMS0xLTEtMA_ecca0519-8c8b-413f-a44a-24bcd975ccc6"
      unitRef="usd">121977000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjgtMy0xLTEtMA_f5d0553f-77d2-433c-8519-9d6434c66aac"
      unitRef="usd">173240000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjktMS0xLTEtMA_5e261881-e33b-4ad7-beae-eb5fed78892a"
      unitRef="usd">9400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMjktMy0xLTEtMA_32115326-4c2f-4cbc-8be9-63805d09343c"
      unitRef="usd">75165000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMzAtMS0xLTEtMA_7b2aede9-36b5-4dc6-b8ae-00f14dd352b8"
      unitRef="usd">181131000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iefa62144550e44079146bf982176865e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMzAtMy0xLTEtMA_8ecad74d-a1c5-44af-bf3c-70ed56cf0342"
      unitRef="usd">126472000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMzEtMS0xLTEtMA_53a552f1-fedb-4225-a2b5-754e0192e14c"
      unitRef="usd">190531000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id48171a2cf134b9b877b17e3ab1d96bf_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMzEtMy0xLTEtMA_1fce7179-d9db-449e-9851-ba07df48504e"
      unitRef="usd">201637000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMzQtMS0xLTEtMA_e10c26fe-3514-432d-8cc3-da1718d5aa33"
      unitRef="usd">69000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8yOC9mcmFnOmUwNTY3OTU3NDUyNzQ4NzlhZjZhMzFjNmY5MmEwYmFiL3RhYmxlOjQxZDgxMWZiYmQ2YjQ0YTdhM2RkMzJhMmU3YTNlNTVhL3RhYmxlcmFuZ2U6NDFkODExZmJiZDZiNDRhN2EzZGQzMmEyZTdhM2U1NWFfMzQtMy0xLTEtMA_6bea7e9a-d012-47b7-994e-27914a8d849a"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8zNC9mcmFnOjY2ZDU5ZDlkYmQ1YjRmMzg4ZjZkNWQzMTBmZWE0YzBkL3RleHRyZWdpb246NjZkNTlkOWRiZDViNGYzODhmNmQ1ZDMxMGZlYTRjMGRfNTEzMQ_6c7ff079-255e-4c4c-beb8-0dcd35190914">Nature of Operations&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Description of the business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. In December 2020, the U.S. Food and Drug Administration (FDA) approved MARGENZA (margetuximab-cmkb) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.  The Company launched MARGENZA in collaboration with its commercialization partner, Eversana Life Science Services, LLC (Eversana), in March 2021. In addition, the Company has a pipeline of product candidates in human clinical testing that have been created primarily using its proprietary, antibody-based technology platforms. The Company believes its product candidates have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management regularly reviews the Company&#x2019;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#x2019;s working capital, and anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities. Based on the Company&#x2019;s most recent cash flow forecast, the Company believes its current cash, cash equivalents and marketable securities is sufficient to fund its operating plans for a minimum of twelve months from the date that this Quarterly Report was filed. The Company plans to meet its near-term operating requirements primarily through cash and marketable securities on hand, and a combination of product sales and current and future strategic collaborations and alliances and marketing, distribution or licensing arrangements.  In the longer term, the Company plans to meet its operating requirements by generating revenue from product sales to the extent its other product candidates receive marketing approval and can be commercialized, or by potential future equity or debt issuances. There can be no assurances that new sources of capital will be available to the Company on commercially acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require the Company to give up some or all rights to a product or technology at less than its full potential value. If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, and/or downsize its organization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to the COVID-19 pandemic, the Company will continue to evaluate the nature and extent of the impact of the pandemic on its business and financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2020 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8zNC9mcmFnOjY2ZDU5ZDlkYmQ1YjRmMzg4ZjZkNWQzMTBmZWE0YzBkL3RleHRyZWdpb246NjZkNTlkOWRiZDViNGYzODhmNmQ1ZDMxMGZlYTRjMGRfNTEyNw_e3756ac0-9d50-4e46-9216-9b2242917842">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2020 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8zNy9mcmFnOmRhOWNjZDk4ZWFlZDRiNWI5MjA1MTM2OWI4MjJjY2UyL3RleHRyZWdpb246ZGE5Y2NkOThlYWVkNGI1YjkyMDUxMzY5YjgyMmNjZTJfODc2MQ_b4766ac5-c913-46bf-93ba-b67788683167">Summary of Significant Accounting Policies&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2021, the Company adopted the following significant accounting policies in addition to those previously disclosed in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the FDA in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of sales in the statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenue, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 606). The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#x2019;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the three and nine months ended September 30, 2021, the shipping costs incurred were immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Discounts and Service Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provider Chargebacks and Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#x2019;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Cost of product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 is part of the FASB&#x2019;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The adoption of this standard as of January 1, 2021 had no impact on the Company's consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these ASUs will not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8zNy9mcmFnOmRhOWNjZDk4ZWFlZDRiNWI5MjA1MTM2OWI4MjJjY2UyL3RleHRyZWdpb246ZGE5Y2NkOThlYWVkNGI1YjkyMDUxMzY5YjgyMmNjZTJfODc2Mg_bd82088c-7448-4afc-9bf7-ef5364f3435c">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the FDA in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of sales in the statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8zNy9mcmFnOmRhOWNjZDk4ZWFlZDRiNWI5MjA1MTM2OWI4MjJjY2UyL3RleHRyZWdpb246ZGE5Y2NkOThlYWVkNGI1YjkyMDUxMzY5YjgyMmNjZTJfODc2Mw_b310b033-e304-4a4b-b7e8-58a30e034cfd">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenue, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 606). The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#x2019;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the three and nine months ended September 30, 2021, the shipping costs incurred were immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Discounts and Service Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provider Chargebacks and Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#x2019;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8zNy9mcmFnOmRhOWNjZDk4ZWFlZDRiNWI5MjA1MTM2OWI4MjJjY2UyL3RleHRyZWdpb246ZGE5Y2NkOThlYWVkNGI1YjkyMDUxMzY5YjgyMmNjZTJfODc2NA_b7b17f8d-7a9f-4a51-8306-8d32ea48f11f">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Cost of product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV8zNy9mcmFnOmRhOWNjZDk4ZWFlZDRiNWI5MjA1MTM2OWI4MjJjY2UyL3RleHRyZWdpb246ZGE5Y2NkOThlYWVkNGI1YjkyMDUxMzY5YjgyMmNjZTJfODc2NQ_caaa3799-4cad-46e9-9459-3978a8016c74">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 is part of the FASB&#x2019;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The adoption of this standard as of January 1, 2021 had no impact on the Company's consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these ASUs will not have a material impact on the Company's consolidated financial statements</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RleHRyZWdpb246N2Y0OGQyMzJmZTBjNDJkN2IyMWYxMTA3ZjZmNjg3NDdfMzE2Mw_630eb02c-b06d-4aec-876a-78722cc9c329">Fair Value of Financial Instruments&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value &lt;/span&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at September&#160;30, 2021 includes approximately $34.8 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2020 includes approximately $52.0 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between levels during the periods presented, and the Company has no Level 3 securities in its portfolio.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RleHRyZWdpb246N2Y0OGQyMzJmZTBjNDJkN2IyMWYxMTA3ZjZmNjg3NDdfMzE2NQ_f6295774-a8da-40da-9a4a-fda91b5dbdaf">&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value &lt;/span&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RleHRyZWdpb246N2Y0OGQyMzJmZTBjNDJkN2IyMWYxMTA3ZjZmNjg3NDdfMzE2Ng_68f3070b-9fd3-4b9c-ab42-a57ba536eae0">&lt;div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at September&#160;30, 2021 includes approximately $34.8 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2020 includes approximately $52.0 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0a74388d699f4bd2ac58facdd9a4fd7b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNC0xLTEtMS0w_ae5ec16e-a05d-4c04-aace-12cb740052cd"
      unitRef="usd">15334000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia640a3c02d1f4c75a6f0cc21b9c2cb6d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNC0zLTEtMS0w_8d314587-28a9-444c-9622-4d3dbca674ec"
      unitRef="usd">15334000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i17cb614f00584923a41b3f540fa1cdbc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNC01LTEtMS0w_b4776ab6-7e89-4fb4-ac82-bfe24313ee31"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iabf613c73d3e4483a06ea6e38d8e670b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNS0xLTEtMS0w_61b05f52-a3ab-48d7-85ae-9ce42e05665e"
      unitRef="usd">68017000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6e6b518462554e3cbdf3a5cadf5c10ea_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNS0zLTEtMS0w_24866f4b-286f-485f-9b15-7cdae0a5f123"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4b8bfb356e214cc9bfe9904bbc293017_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNS01LTEtMS0w_6c1323b8-e0a3-458f-926c-b3562c53ebf9"
      unitRef="usd">68017000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i73eb53766d6c4804a4e1e66a6df09c91_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNi0xLTEtMS0w_9015ef4b-c5a7-4638-a31d-7094c3a49b55"
      unitRef="usd">12278000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i49de27c2929345d3a226185a435ab868_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNi0zLTEtMS0w_9cbcf752-a0a7-4327-98ce-34983fbc25ca"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f048a39b44649b29657ceea4301f358_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNi01LTEtMS0w_7db74217-ce69-48de-946d-ea801dfd81e0"
      unitRef="usd">12278000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a7ed9e27b984af2aae1adfbb2125ce5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNy0xLTEtMS0w_78c0f04d-7073-4015-9ce8-f9ad2519edf9"
      unitRef="usd">47570000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i99f0c1670d044e009dba1531620dc1c1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNy0zLTEtMS0w_f339d576-5b07-42db-84ea-210a4336f2f7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icb0787f0e3644860ba06eb1034fbb65b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfNy01LTEtMS0w_e49d75fe-0148-453c-9b8a-cb29f3eef271"
      unitRef="usd">47570000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie1ffbd08270d44d085deecec92b01243_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfOS0xLTEtMS0w_552e457d-10da-4ee1-bf2a-2cacee04e695"
      unitRef="usd">143199000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie0d6f6806ba94e9ea50c537546db47a7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfOS0zLTEtMS0w_84a46618-2cbf-4710-b369-81399500aa20"
      unitRef="usd">15334000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iee759986b4274d298c370fdb8432435b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmIzYWE3YzUyYzc0MjQ1YWZhNzUwOGNmNWI4NzkwY2QxL3RhYmxlcmFuZ2U6YjNhYTdjNTJjNzQyNDVhZmE3NTA4Y2Y1Yjg3OTBjZDFfOS01LTEtMS0w_d8dcb80a-eb6f-409b-be09-e2237032739c"
      unitRef="usd">127865000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i148258350c6645d79c0d898ac35f6d87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNC0xLTEtMS0w_c45a017a-f0a6-41de-8c95-4e2796d6dfb1"
      unitRef="usd">49004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i747a2e68687f4fe8b192d169ccefd610_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNC0zLTEtMS0w_d7786d43-b4e9-485e-99bc-8b09f081776a"
      unitRef="usd">49004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iea0bbc8e396f4f45a85696892ed3b146_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNC01LTEtMS0w_9c346550-0984-43e0-abcd-103b1b3b7050"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib121748b3b90427eb1b071912d8f8abb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNS0xLTEtMS0w_3e1f990f-b92c-42ff-8282-5e3a00db43dd"
      unitRef="usd">60623000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5ea12fcac00647eda4be75a5c687a73b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNS0zLTEtMS0w_6d799146-32b3-4c99-ace3-9d5ca36b8ef9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i288f5153e6b2498db8daba718939f0f2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNS01LTEtMS0w_ad0f1f73-277e-4e64-8801-5f78369851ba"
      unitRef="usd">60623000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7451a81074d647e295bf3e8ebedffdb7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNy0xLTEtMS0w_a167402b-c89c-486d-a3d1-c156e4eaf0d6"
      unitRef="usd">33776000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i76162ba1a18c4fc4a980bcbba9264153_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNy0zLTEtMS0w_cbc1de87-4873-4d23-80b8-a433b930f4eb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id0e6f330c4624be993d0a2175e6edb7c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfNy01LTEtMS0w_a5d009e7-8f70-4338-997f-3b9c28a07838"
      unitRef="usd">33776000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3585fd01cc1840feb99f41bf29e5c7e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfOS0xLTEtMS0w_9cb2a1ff-3999-4a8c-9774-23a6c7f289ed"
      unitRef="usd">143403000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4da6d04d2658412081cbb06f08d92d03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfOS0zLTEtMS0w_be6ac094-59dd-4996-b4ac-8b3438c4189c"
      unitRef="usd">49004000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6438be1c7813480081d80920f7c7256d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RhYmxlOmJlMTU5ZDZhODlhOTRkNWY5MDhkZGQyNjYyYWRkYzM4L3RhYmxlcmFuZ2U6YmUxNTlkNmE4OWE5NGQ1ZjkwOGRkZDI2NjJhZGRjMzhfOS01LTEtMS0w_cbf12785-9ca2-4e79-b1ad-fe013f921775"
      unitRef="usd">94399000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie1ffbd08270d44d085deecec92b01243_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RleHRyZWdpb246N2Y0OGQyMzJmZTBjNDJkN2IyMWYxMTA3ZjZmNjg3NDdfMjUwNA_35799333-f877-4f38-8fa4-406260c21669"
      unitRef="usd">34800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3585fd01cc1840feb99f41bf29e5c7e2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80MC9mcmFnOjdmNDhkMjMyZmUwYzQyZDdiMjFmMTEwN2Y2ZjY4NzQ3L3RleHRyZWdpb246N2Y0OGQyMzJmZTBjNDJkN2IyMWYxMTA3ZjZmNjg3NDdfMjY0OQ_b8eabb1a-97fd-4820-8e88-536c1caf53ae"
      unitRef="usd">52000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RleHRyZWdpb246MDY5MGRmYzJmNjE0NDJlZmIyM2Q4NmVlYWU3NjlkM2ZfMTAyNw_2b075568-30bd-441c-9ba9-98652d7371f2">Marketable Securities&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's marketable debt securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;All available-for-sale marketable debt securities held as of September&#160;30, 2021 and December&#160;31, 2020 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of September&#160;30, 2021 and December&#160;31, 2020 were in a loss position for less than 12 months.&#160; Unrealized losses on available-for-sale debt securities as of September&#160;30, 2021 and December&#160;31, 2020 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for any periods presented. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RleHRyZWdpb246MDY5MGRmYzJmNjE0NDJlZmIyM2Q4NmVlYWU3NjlkM2ZfMTAyOQ_0ee85b01-bfd5-4355-9aac-7d44c920751a">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's marketable debt securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i80cbb34246294317b7336589ccf4350d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfMi0xLTEtMS0w_8b119cf4-ab10-4291-b2ab-8f96f19a5284"
      unitRef="usd">68019000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i80cbb34246294317b7336589ccf4350d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfMi0zLTEtMS0w_f01c654a-5abd-4594-9a74-92e60036c4d2"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i80cbb34246294317b7336589ccf4350d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfMi01LTEtMS0w_bf86baea-717b-4cd1-8420-f42830cc1e2c"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i80cbb34246294317b7336589ccf4350d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfMi03LTEtMS0w_9526c24b-184c-4b5f-933d-abd2c0f17970"
      unitRef="usd">68017000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iebfbafa88c384397839bf6d6ddd589b5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfMy0xLTEtMS0w_be41c70c-a9ca-4e8a-a4a8-d57bbc8e30bf"
      unitRef="usd">12278000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iebfbafa88c384397839bf6d6ddd589b5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfMy0zLTEtMS0w_46286b83-e482-416c-8bae-e9af1013ec12"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iebfbafa88c384397839bf6d6ddd589b5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfMy01LTEtMS0w_e12e3e2c-4cee-4c7c-b104-32ceb8d95431"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iebfbafa88c384397839bf6d6ddd589b5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfMy03LTEtMS0w_9eacf5f8-ba58-45e6-a8ea-e3aaa9c784a3"
      unitRef="usd">12279000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i845134cd6052477bb77c2afc3b82e0ee_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfNC0xLTEtMS0w_24d5859b-777b-4b13-8735-c88bd54d72a3"
      unitRef="usd">28074000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i845134cd6052477bb77c2afc3b82e0ee_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfNC0zLTEtMS0w_131afb5e-abb5-49d9-a936-e7755bd94216"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i845134cd6052477bb77c2afc3b82e0ee_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfNC01LTEtMS0w_eed1c999-3841-4960-a168-0e60624e1e73"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i845134cd6052477bb77c2afc3b82e0ee_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfNC03LTEtMS0w_e061b37b-e436-4cbb-9809-8eb6d596e8f5"
      unitRef="usd">28071000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfNS0xLTEtMS0w_03a9ba54-fc2f-41da-8757-b96f0b9263f0"
      unitRef="usd">108371000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfNS0zLTEtMS0w_9e517b50-23a4-4ae2-a84d-d3e45b63f9ec"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfNS01LTEtMS0w_26728454-5775-4a63-8bf9-614ce873882b"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOmE0NWU2NmE4NDIzNzQ5YzU4MmM1ZTVjNDJlMmIyZDE5L3RhYmxlcmFuZ2U6YTQ1ZTY2YTg0MjM3NDljNTgyYzVlNWM0MmUyYjJkMTlfNS03LTEtMS0w_22f05aa4-bf52-4bd5-acfa-f90c1fa0745e"
      unitRef="usd">108367000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia973c2256c1241e39d7549dbe6a90f11_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfMi0xLTEtMS0w_c3b1d221-2116-463b-a31e-6cbbf8723e56"
      unitRef="usd">60630000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia973c2256c1241e39d7549dbe6a90f11_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfMi0zLTEtMS0w_ed21ea33-2b2e-4f63-82a3-e830a7b593ad"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia973c2256c1241e39d7549dbe6a90f11_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfMi01LTEtMS0w_36e63f9b-daa1-46e8-8bbd-8abac83906e0"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia973c2256c1241e39d7549dbe6a90f11_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfMi03LTEtMS0w_773243c7-fe19-48e1-b7fb-b34adfcd9599"
      unitRef="usd">60624000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie69edf146b6449f7a4fb9cf05187e1ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfNC0xLTEtMS0w_c480cb8e-5e24-4ba0-8b76-77020cdb6ec7"
      unitRef="usd">30777000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie69edf146b6449f7a4fb9cf05187e1ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfNC0zLTEtMS0w_daeefbcb-47bd-45b4-8f3b-740ad7bcec93"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie69edf146b6449f7a4fb9cf05187e1ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfNC01LTEtMS0w_51047ea8-4aca-4e4f-806b-3db81dd40a51"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie69edf146b6449f7a4fb9cf05187e1ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfNC03LTEtMS0w_4bdadf5b-64fa-4e67-b424-d88bf5117cf9"
      unitRef="usd">30776000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfNS0xLTEtMS0w_d283dfc1-fe56-4589-9ec7-232e9f79fd38"
      unitRef="usd">91407000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfNS0zLTEtMS0w_c9483aa5-5826-433b-acc6-a30bbef30e48"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfNS01LTEtMS0w_63000d68-fc9d-4e6b-94b9-606c3f0b32fa"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RhYmxlOjBlMjRjMGU5MmFhMTQ0OTViYjRjMDU0OTM3ZGRlMDFiL3RhYmxlcmFuZ2U6MGUyNGMwZTkyYWExNDQ5NWJiNGMwNTQ5MzdkZGUwMWJfNS03LTEtMS0w_d94f4e7e-4cce-47fc-b2ef-7252db13ff5f"
      unitRef="usd">91400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RleHRyZWdpb246MDY5MGRmYzJmNjE0NDJlZmIyM2Q4NmVlYWU3NjlkM2ZfNjc2_31d1a0f1-3bcf-4ee0-a5f3-5ec8871ac8b9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80My9mcmFnOjA2OTBkZmMyZjYxNDQyZWZiMjNkODZlZWFlNzY5ZDNmL3RleHRyZWdpb246MDY5MGRmYzJmNjE0NDJlZmIyM2Q4NmVlYWU3NjlkM2ZfNjc2_c44c2bed-ed30-4cc9-ba63-bc4a878be7a6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80Ni9mcmFnOmFjOTlmZjlhZGI2NDQ4YTI4MTBiNWNhZGU1ZmZlOTVhL3RleHRyZWdpb246YWM5OWZmOWFkYjY0NDhhMjgxMGI1Y2FkZTVmZmU5NWFfNDQy_176aab48-2098-4168-9d95-edf8da45939d">Inventory, Net&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of September&#160;30, 2021, is net of a reserve of $1.6 million for unsaleable inventory which is reflected in cost of product sales for the three and nine months ended September 30, 2021.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80Ni9mcmFnOmFjOTlmZjlhZGI2NDQ4YTI4MTBiNWNhZGU1ZmZlOTVhL3RleHRyZWdpb246YWM5OWZmOWFkYjY0NDhhMjgxMGI1Y2FkZTVmZmU5NWFfNDQz_03270e59-0aeb-4d74-a685-b3c827ebfc33">&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80Ni9mcmFnOmFjOTlmZjlhZGI2NDQ4YTI4MTBiNWNhZGU1ZmZlOTVhL3RhYmxlOmY5Y2Y1ZTk2ZTI2OTQ4NmM5YTUxMTMxMWNhMWY0NzFiL3RhYmxlcmFuZ2U6ZjljZjVlOTZlMjY5NDg2YzlhNTExMzExY2ExZjQ3MWJfMi0xLTEtMS0w_9f1241be-a4dc-4905-8965-8e5ecfe11779"
      unitRef="usd">608000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80Ni9mcmFnOmFjOTlmZjlhZGI2NDQ4YTI4MTBiNWNhZGU1ZmZlOTVhL3RhYmxlOmY5Y2Y1ZTk2ZTI2OTQ4NmM5YTUxMTMxMWNhMWY0NzFiL3RhYmxlcmFuZ2U6ZjljZjVlOTZlMjY5NDg2YzlhNTExMzExY2ExZjQ3MWJfMy0xLTEtMS0w_5ad299aa-9266-41dd-83ad-5e252b4b354b"
      unitRef="usd">3095000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80Ni9mcmFnOmFjOTlmZjlhZGI2NDQ4YTI4MTBiNWNhZGU1ZmZlOTVhL3RhYmxlOmY5Y2Y1ZTk2ZTI2OTQ4NmM5YTUxMTMxMWNhMWY0NzFiL3RhYmxlcmFuZ2U6ZjljZjVlOTZlMjY5NDg2YzlhNTExMzExY2ExZjQ3MWJfNC0xLTEtMS0w_1c5a1286-d3ee-4f9f-baf2-8f827f7b1cb2"
      unitRef="usd">276000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80Ni9mcmFnOmFjOTlmZjlhZGI2NDQ4YTI4MTBiNWNhZGU1ZmZlOTVhL3RhYmxlOmY5Y2Y1ZTk2ZTI2OTQ4NmM5YTUxMTMxMWNhMWY0NzFiL3RhYmxlcmFuZ2U6ZjljZjVlOTZlMjY5NDg2YzlhNTExMzExY2ExZjQ3MWJfNS0xLTEtMS0w_18226065-7fc4-47df-94cf-98e3385b35b1"
      unitRef="usd">3979000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80Ni9mcmFnOmFjOTlmZjlhZGI2NDQ4YTI4MTBiNWNhZGU1ZmZlOTVhL3RleHRyZWdpb246YWM5OWZmOWFkYjY0NDhhMjgxMGI1Y2FkZTVmZmU5NWFfMTA5OTUxMTYyOTAwOA_bf81735f-4bf4-45af-8111-0ba1bb3000cb"
      unitRef="usd">1600000</us-gaap:InventoryValuationReserves>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfMTE4NQ_b81e6dd4-7333-47da-b530-e6b9db3a7380">Stockholders' EquityIn November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0 million through an &#x201c;at the market offering&#x201d; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the three months ended March 31, 2021, the Company sold 3,622,186 shares &lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of common stock at a weighted average price per share of $27.60, resulting in net proceeds of approximately $98.2 million, net of underwriting discounts and commissions and other offering expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#x2019;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $100.0&#160;million to an aggregate offering price of up to $300.0&#160;million.  During the three and nine months ended September 30, 2021, the Company did not sell any shares of common stock related to the ATM Offering.  &lt;/span&gt;&lt;/div&gt;As part of the consideration for the rights granted to Zai Lab US LLC under the collaboration and license agreement described more fully in Note 7, Collaboration and Other Agreements, the Company and Zai Lab US LLC entered into a separate stock purchase agreement (Stock Purchase Agreement).  Under this Stock Purchase Agreement, Zai Lab US LLC paid the Company approximately $30.0 million to purchase 958,467 newly issued shares of the Company's common stock, par value $0.01, at a fixed price of $31.30 (Offering) which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. The Offering closed in July 2021.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="i46a6e5fff27f4b6aa874171e8585d54f_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfMjE4_851cb4aa-43a8-4702-9c03-8e5e3e3bf8bf"
      unitRef="usd">100000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i06955b87c4604f8fb996dcb42b4dc99e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfNTk0_cf3af9a4-39ef-40a7-9c1b-68540cc2dd42"
      unitRef="shares">3622186</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i3fa4f2d5e48b4142942ab255dbbf4e2b_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfNjYx_1a469f1a-9240-4433-92b7-35c2fe440577"
      unitRef="usdPerShare">27.6</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i06955b87c4604f8fb996dcb42b4dc99e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfNzA4_351a2546-116e-4769-a72b-5736e38ef6fd"
      unitRef="usd">98200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="i46a6e5fff27f4b6aa874171e8585d54f_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfMTA0MA_b1476fc9-da58-4029-b694-5896768a3f3a"
      unitRef="usd">100000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease
      contextRef="i022010ba69a04e73be7fc39c277aa5bc_D20210401-20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfMTA4Mw_7704851e-6495-4c4b-b2ec-bc4e1a23a160"
      unitRef="usd">300000000</mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i4a6d5f9b9cb64ef1ab9cf00828b18921_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfNTQ5NzU1ODE0MjI0OA_b895ab78-1658-4f92-8145-2f0df3b8fb68"
      unitRef="usd">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i22af05f406eb42a18864db9d550fb33b_D20210601-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfNTQ5NzU1ODE0MjI2NA_acb8946b-ed33-47a7-ab9f-8327953a5e32"
      unitRef="shares">958467</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfMTA5OTUxMTYzMjkyNg_5dffed8d-59a3-4e73-bdcf-75f4fd54ef6c"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i427f349d621a4e20beb2de97f08f189f_I20210615"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfNTQ5NzU1ODE0MjM0Ng_9262208a-df7a-47b5-9e0a-eb3362dca488"
      unitRef="usdPerShare">31.3</us-gaap:SaleOfStockPricePerShare>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="i4a20cea58d2e41dda0b283e8e60b23c0_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV80OS9mcmFnOjkxOTY4YTg1ZjRlMjRkNDRiMTU2ZWUzMzMyNWYyZTNmL3RleHRyZWdpb246OTE5NjhhODVmNGUyNGQ0NGIxNTZlZTMzMzI1ZjJlM2ZfNTQ5NzU1ODE0MjM4MQ_4848ba33-fc6f-45ea-ad07-0edfcddcc5cc"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMzA4Mzc_85131fa5-ee9d-40ec-aec1-4c2a3b47e0b0">Collaboration and Other Agreements &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incyte Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Incyte License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab  (formerly known as MGA012 and INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017. In July 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal.  Incyte&#x2019;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte is reviewing the CRL and will discuss next steps with the FDA.  More recently, Incyte withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab.  Assuming successful development and commercialization of retifanlimab by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones and up to $330.0 million in commercial milestones. From the inception of the Incyte License Agreement through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company has recognized $70.0 million in development milestones under the Incyte License Agreement.  If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company evaluated the Incyte License Agreement under ASC 606 and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From 2018 through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;September&#160;30, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, it became probable that a significant reversal of cumulative revenue would not occur for deve&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;lopment milestones totaling $70.0 million related to &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#x2019;s initiation of a Phase 3 clinical trial&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.  Therefore the associated consideration was added to the estimated transaction price.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognized the $150.0 million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017.  The $4.0 million allocated to the clinical activities was recognized ratably as services were performed over a period spanning 2017 and 2018.  During the nine months ended September 30, 2021, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;it became probable that a significant reversal of cumulative revenue would not occur for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$15.0 million in milestones related to development progress of retifanlimab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue. No revenue was recognized under the Incyte License Agreement during the three and nine months ended September 30, 2021.  During the three and nine months ended September 30, 2020, $15.0 million in milestone revenue was recognized under the Incyte License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Incyte Clinical Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte&#x2019;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement).  The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services.  During the three months ended September 30, 2021 and 2020, the Company recognized revenue of $0.2 million and $0.7 million, respectively, for services performed under the Incyte Clinical Supply Agreement. During the nine months ended September 30, 2021 and 2020, the Company recognized revenue of $1.0 million and $8.1 million, respectively, for services performed under the Incyte Clinical Supply Agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Incyte Commercial Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#x2019;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services.  During the three and  nine months ended September 30, 2021, the Company recognized revenue of $1.4&#160;million and $7.4&#160;million, respectively, for services performed under the Incyte Commercial Supply Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Zai Lab Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2018 Zai Lab Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab)  under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#x2019;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab (formerly known as MGD013), a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million ($22.5 million after netting value-added tax withholdings of $2.5 million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, $4.0 million of which ($3.6 million after netting value-added tax withholdings of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.4 million) was earned during the three months ended March 31, 2020. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#x2019;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#x2019;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#x2019;s territory, which may be subject to adjustment in specified circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#x2019;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the tebotelimab performance obligation was recognized on a straight-line basis as the Company performed research and development activities under the agreement. The fixed consideration related to the margetuximab performance obligation was also recognized on a straight-line basis as the Company performed research and development activities under the agreement due to the short-term nature of the recognition period. Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate. The variable consideration related to the margetuximab performance obligation was recognized upon certain regulatory achievements during 2020.  The Company recognized revenue of $3.6&#160;million during the nine months ended September 30, 2020 under the 2018 Zai Lab Agreement.  There was no revenue deferred under this agreement as of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2021 or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Zai Lab Clinical Supply Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#x2019;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements).  The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  During the three months ended September 30, 2021 and 2020, the Company recognized revenue of $0.6 million and $0.5 million, respectively, related to the Zai Lab Clinical Supply Agreements. During the nine months ended September 30, 2021 and 2020, the Company recognized revenue of $2.3 million and $1.9 million, respectively, related to the Zai Lab Clinical Supply Agreements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2021 Zai Lab Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#x2019;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay the Company $85.0&#160;million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into the Stock Purchase Agreement whereby Zai Lab paid the Company approximately $30.0 million to purchase shares of the Company&#x2019;s common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assuming successful development and commercialization of the Programs, the Company could receive up to approximately $800.0&#160;million in development and regulatory milestones and $600.0&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai Lab&#x2019;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#x2019;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#x2019;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the estimated transaction price is $40.4 million, consisting of the $25.0 million upfront payment, the $10.4 million premium related to the purchase of the Company&#x2019;s common stock, and the estimated $5.0 million expected to be reimbursed by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price of $40.4 million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes the market is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#x2019;s estimate of the probability of success for each Program. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue related to the Lead Program license and related research and development services performance obligation is being recognized over time as the research and development activities are performed. The Company will utilize a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. During the three and nine months ended September 30, 2021, the Company recognized revenue of $3.7 million and $18.1 million, respectively, under the 2021 Zai Lab Agreement.  As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2021, there was $17.8 million in deferred revenue under the agreements, $13.6 million of which is current and $4.2 million of which is non-current.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Biotech, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company entered into a research collaboration and license agreement with Janssen Biotech, Inc. (Janssen) to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#x2019;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $20.0&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $312.0&#160;million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales. &lt;/span&gt;&lt;span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#x2019;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $22.2&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:42pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the $20.0&#160;million allocated to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $2.2&#160;million allocated to the research and development activities is being recognized over the Company&#x2019;s involvement in the research term, which is estimated to be less than two years. During the three and nine months ended September 30, 2021, the Company recognized revenue of $0.2&#160;million and $1.1&#160;million, respectively, for research and development activities performed under the Janssen Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;I-Mab Biopharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the I-Mab Agreement, I-Mab paid the Company an upfront payment of $15.0 million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $135.0 million in development and regulatory milestones, of which $5.0 million  has been earned from the inception of the I-Mab Agreement through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2021. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to 20% on annual net sales in I-Mab's territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the I-Mab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#x2019;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million. I-Mab paid the Company for the cost of this study as the costs were incurred and I-Mab received a one-time credit of eighty percent of the total amount of such costs against the milestone achieved during the three months ended September 30, 2021, at which point the Company reassessed the transaction price for that milestone. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Revenue under the I-Mab Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, i n management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligations.  The Company recognized revenue of $1.0 million  during each of the three month periods ended September&#160;30, 2021 and 2020  under the I-Mab Agreement.  During the nine months ended September 30, 2021 and 2020, the Company recognized revenue of $3.3 million and $3.5 million, respectively, under the I-Mab Agreement.  At September&#160;30, 2021, $8.1 million of revenue was deferred under this agreement, $2.7 million of which was current and $5.3 million of which was non-current.   At December&#160;31, 2020, $11.4 million of revenue was deferred under this agreement, $4.5 million of which was current and $6.9 million of which was non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2021, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;it became probable that a significant reversal of cumulative revenue would not occur fo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;r a $5.0&#160;million milestone ($4.5&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NIAID Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a contract with National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, including MGD014 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of September 30, 2021 is $25.1 million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023.    During the three months ended September 30, 2021 and 2020, the Company recognized revenue under the NIAID Contract of $0.1 million and $0.8 million, respectively.  During the nine months ended September 30, 2021 and 2020, the Company recognized revenue under the NIAID Contract of $1.3 million and $6.2 million, respectively.</mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i8c7dc4c308654b92a9b7eb8aa5fae842_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNzE0_c02e8812-466f-4b5e-bf75-c8c99d8eb1fa"
      unitRef="usd">150000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i44f9acd305254e98bb6059421e41afc8_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTY2MQ_540d2e07-ea4a-4e56-99bd-f14ed1668628"
      unitRef="usd">420000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i44f9acd305254e98bb6059421e41afc8_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTcxNQ_32e751c6-36d6-457c-8bab-bab88b06ffb4"
      unitRef="usd">330000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ia6b3220211b34177a70814841776348e_D20180101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTgzNA_f4f45af7-5e8c-4d30-994b-797d69864b62"
      unitRef="usd">70000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i8f96961f110f4bd4a365d1cacb888a9d_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjAwOQ_ccbb5d47-36ff-4562-aacc-5a18e3096e15"
      unitRef="number">0.15</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i793df4da4f6949ae8dc1104d14ce9e42_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjAxNQ_85b778a6-ebb4-446d-a13b-d128bfea3167"
      unitRef="number">0.24</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NumberOfPerformanceObligations
      contextRef="i44f9acd305254e98bb6059421e41afc8_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjU1Nw_955d4c82-76b3-477d-a846-1a038ce5721f"
      unitRef="performanceobligation">2</mgnx:NumberOfPerformanceObligations>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i44f9acd305254e98bb6059421e41afc8_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMzM0NA_d48a230d-1d4f-48dd-88a2-36290ea25a2d"
      unitRef="usd">154000000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ia6b3220211b34177a70814841776348e_D20180101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNDkyMw_f4f45af7-5e8c-4d30-994b-797d69864b62"
      unitRef="usd">70000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="i326f19028f6848eb90307ed07e34fb13_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNTE5OQ_452e30b7-af62-4bf9-8eae-47877590987e"
      unitRef="usd">150000000</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="idaf80bf80aa94dcdbe58a0b47d56866c_D20170101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNTMyNA_8c227d1a-3239-46fd-8728-ca5ffae51b13"
      unitRef="usd">4000000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="if11ae315139b4747abb6df067daf9f16_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNTU3NQ_86af62c1-f18a-485a-9b1c-1471d20a1b4a"
      unitRef="usd">15000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="i34ebcecab85244bd9dbc6977705c7569_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNTc3MA_8d175a8a-0ae0-4785-b280-55449ed2a082"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98c0801d3b474ff6844f020bcdb35bd9_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNTc3MA_aa6a433b-9e9e-475e-92e9-c8079ca9ceaa"
      unitRef="usd">0</us-gaap:Revenues>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i7cfb8e8a76924dac915a6ac2232abba3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNDM5ODA0NjU0MzUyOQ_153450bb-3ba6-4e65-a1cd-9bf4b213ef4d"
      unitRef="usd">15000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i4bdcdeefecaa42989b7b67f34d47899a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNDM5ODA0NjU0MzUyOQ_17f7e0d0-45d3-4f35-be7c-da3e0f90d1c8"
      unitRef="usd">15000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="i9531fc2fc03846f0b3768319934b4340_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNjkzOQ_023dc796-c54f-4af9-8592-8c0689d431e7"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if320066be1564b01af8dde722a25c31e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNjk0Ng_a844d648-a959-43dd-ada3-d3e9db1eb4b2"
      unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98e991fb934846ab820b5a844c8830c5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNzA4Nw_1bfe1439-99c2-4faf-8523-051f98c6066b"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4badc0f60dd14b6c8755357f7ac540fc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfNzA5NA_42aea264-36f6-4241-9a76-61f76c5af110"
      unitRef="usd">8100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc0dbc0dc52e4ad7bf077e11b26f5987_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfODQxMA_5465d1c5-3731-4eca-a955-298fef5a7c1b"
      unitRef="usd">1400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i59a0c5813a0c46d786211fb05433da01_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfODQxNw_7e385209-32b4-427d-bf68-94bb1503b4f7"
      unitRef="usd">7400000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i1b58dca81bae4ab9b749cdc5b02a267b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTM2Ng_c89e2986-430f-43da-8879-86752e70c865"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="i1b58dca81bae4ab9b749cdc5b02a267b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTM3MA_8ded64f1-0ef4-489b-b98a-1c37ac0de7dd"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <mgnx:NonrefundablePaymentTaxWithholding
      contextRef="i1b58dca81bae4ab9b749cdc5b02a267b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTQxOQ_829f9dff-e308-42cd-ae92-f71e5b7bf15a"
      unitRef="usd">2500000</mgnx:NonrefundablePaymentTaxWithholding>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="ie336f44ff7bd44ad8432ae58b5fff68f_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTU2NQ_3e06fced-13d2-451a-bd39-ecd9a7dd4cd1"
      unitRef="usd">140000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ia1fee744e4cf4ed1ad933a71b09d6beb_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTYxMA_7ed25cd8-5532-429f-a1ef-67fb0197eb1f"
      unitRef="usd">4000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:RevenuesNetOfTaxWithholding
      contextRef="ia1fee744e4cf4ed1ad933a71b09d6beb_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTYyMw_77595063-deda-4a07-9418-742d583411c0"
      unitRef="usd">3600000</mgnx:RevenuesNetOfTaxWithholding>
    <mgnx:RevenuesTaxWithholding
      contextRef="ia1fee744e4cf4ed1ad933a71b09d6beb_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTY3Mg_3bb43ba1-5c3b-4904-9d73-ba27752537e3"
      unitRef="usd">400000</mgnx:RevenuesTaxWithholding>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i383ab32255d644eaafc819796aa2870d_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTgyOQ_21989fe4-a5ae-4dd0-8189-c8b4eba17b10"
      unitRef="number">0.20</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="ia9d0c680036d4325b5e7f41d64399b60_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfOTk1Mg_71fd251f-349f-4961-9ba7-ecef8b555965"
      unitRef="number">0.10</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="i1b58dca81bae4ab9b749cdc5b02a267b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTEyNTc_8ded64f1-0ef4-489b-b98a-1c37ac0de7dd"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <mgnx:RevenuesNetOfTaxWithholding
      contextRef="iad7dbfa657cb4e6f87748b9ddf1e390c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTMzMTk_ccc409ff-42af-472a-8b03-08767acefce2"
      unitRef="usd">3600000</mgnx:RevenuesNetOfTaxWithholding>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i3465bc8d05de421897c972d4b8fedeb8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTMzODE_21f1f9d1-6002-4107-b62e-e7e1b513b56e"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="idd7958be040c4fb89b305414df69d203_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTMzODE_955621af-5c88-44d3-9c26-d3b1839779dc"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues
      contextRef="i0c250244fd7d4e4c9b409d38eb292272_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTQzNzI_66cb9f60-e3cd-4fed-ac9c-f05964cab670"
      unitRef="usd">600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8f28dba3b3c54be6951e63e82446015d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTQzNzk_40dce5b8-63a1-41f1-b133-3ee5bde1ddf8"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03d23314d63d45c8b35e795aaedab122_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTQ1MDQ_ddb579bf-31aa-4556-a063-7b61afaa06f7"
      unitRef="usd">2300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if34089b9b5874ac5840731a4dd93f241_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTQ1MTE_0b1c8aed-f631-4204-b946-4c0740d8d54b"
      unitRef="usd">1900000</us-gaap:Revenues>
    <mgnx:OptInFee
      contextRef="i427f349d621a4e20beb2de97f08f189f_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTU1ODU_a01149d4-4bb8-46a3-8960-9678a252e8e7"
      unitRef="usd">85000000</mgnx:OptInFee>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i4a6d5f9b9cb64ef1ab9cf00828b18921_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTYzNDk_e6be771e-0a30-403f-b2be-63ee9b998f84"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i4a6d5f9b9cb64ef1ab9cf00828b18921_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTY2NTM_b895ab78-1658-4f92-8145-2f0df3b8fb68"
      unitRef="usd">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTY3MTY_1da96673-0677-4ed7-820d-c1c7244f59df"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i427f349d621a4e20beb2de97f08f189f_I20210615"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTY3NDA_9262208a-df7a-47b5-9e0a-eb3362dca488"
      unitRef="usdPerShare">31.3</us-gaap:SaleOfStockPricePerShare>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="i4a20cea58d2e41dda0b283e8e60b23c0_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTY3NzQ_4848ba33-fc6f-45ea-ad07-0edfcddcc5cc"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i427f349d621a4e20beb2de97f08f189f_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTY5OTY_3f50f268-2c81-4874-bb53-20cab7daac13"
      unitRef="usd">800000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i427f349d621a4e20beb2de97f08f189f_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTcwNDQ_5786e6c4-7422-4755-bc3e-b0c9b78c279d"
      unitRef="usd">600000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i427f349d621a4e20beb2de97f08f189f_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTg3OTc_c87fbfed-d68e-42c3-8345-2b3f9bc1dc16"
      unitRef="usd">40400000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i4a6d5f9b9cb64ef1ab9cf00828b18921_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTg4MTk_0c3f3191-4f92-4af3-9533-da329c50a3e7"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="i4a20cea58d2e41dda0b283e8e60b23c0_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTg4NDM_7798bfed-3337-4809-a3f4-509ac0e17851"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="i4a6d5f9b9cb64ef1ab9cf00828b18921_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTg5Mjc_305165d6-e5ac-4e58-87cd-bf32376f7b02"
      unitRef="usd">5000000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i427f349d621a4e20beb2de97f08f189f_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTk4MDE_c8b04961-0bcc-4fc3-9494-0946a647dd51"
      unitRef="usd">40400000</mgnx:CollaborativeAgreementTransactionPrice>
    <us-gaap:Revenues
      contextRef="i83adad7f523245b7b6e58f66a3dab006_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTA5OTUxMTY1OTIwNQ_d39520f1-c694-4b22-900f-53205a4f5f0a"
      unitRef="usd">3700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a238ce78ac74f1b93c817ced866efa2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTA5OTUxMTY1OTIyMA_46b0d990-faac-4b15-b2f8-968b256963fc"
      unitRef="usd">18100000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i4022bd5da2824c7c8f8ee74203011a7d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjE0NDc_6dbdd3f3-038f-4599-b776-e60596096403"
      unitRef="usd">17800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i4022bd5da2824c7c8f8ee74203011a7d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjE0OTI_90e40781-6e04-402d-bf8b-825bdde59114"
      unitRef="usd">13600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i4022bd5da2824c7c8f8ee74203011a7d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjE1MTk_58019752-a45a-4189-8ea2-4d3b8b13b76b"
      unitRef="usd">4200000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ida2095e4cb994efe825c83b7c2569119_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjIwMjc_54741d60-bcc1-4115-86c4-f22dbacd7ddb"
      unitRef="usd">20000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales
      contextRef="i8f5dc2b032524391af7887b322598d1d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjIxNTY_eeef2750-2994-46e1-993c-a467c89bcea4"
      unitRef="usd">312000000</mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="ida2095e4cb994efe825c83b7c2569119_D20201201-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjIyMjE_4f897625-4f4e-49ec-bfac-3eb6d447fd5a"
      unitRef="number">0.10</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i8f5dc2b032524391af7887b322598d1d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjMzMDA_2417da2d-442d-4f94-bdcd-fb156069510f"
      unitRef="usd">22200000</mgnx:CollaborativeAgreementTransactionPrice>
    <us-gaap:Revenues
      contextRef="i8143c485591543ca8f9fa0ad6b05a533_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjQ5MTU_678cd655-ddd4-413d-b0a9-e22500ee7da0"
      unitRef="usd">20000000</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="ida2095e4cb994efe825c83b7c2569119_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjUwNDk_a7878e33-7ff7-4c9b-94b9-b8f81067295d"
      unitRef="usd">2200000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <us-gaap:Revenues
      contextRef="iede70fcdb85b4d5fadb7c778a198437a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjUyODM_1abeeb05-d06e-44c8-9160-0dd7d768a71e"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee958037590e47f9a647d7b398e799cb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjUyOTA_e4e4c6b9-1678-407d-9870-5a02a35fe484"
      unitRef="usd">1100000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i821467e83ad44bf4936cba83c4bf74cc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjYwNTI_89f18b43-a6b7-4d8b-9d82-a7669e19f08d"
      unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i251e9fe0e95a4f3f862b554c5b106612_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjYxNjE_d9b38178-da20-4479-a2e5-19832bfacf07"
      unitRef="usd">135000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i35541777167844639ae2fde64553a505_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTA5OTUxMTY2Njk2MA_064cecdc-fd7e-449d-a9ce-1dd84aecf013"
      unitRef="usd">5000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="ia0b95e5cfec444d08b7a167a497b2f2b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjYyOTA_ce74684f-eb98-4d04-b257-bf9aa6a2c9e2"
      unitRef="number">0.20</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i821467e83ad44bf4936cba83c4bf74cc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjcwOTE_89f18b43-a6b7-4d8b-9d82-a7669e19f08d"
      unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount
      contextRef="i821467e83ad44bf4936cba83c4bf74cc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjc1MDY_78fd89b2-2dc3-4c5d-8a0f-2e674b577665"
      unitRef="usd">1000000</mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount>
    <us-gaap:Revenues
      contextRef="i1b4c7ba6a9524139b98444a380751a27_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjg5MzY_471fc448-81b3-4477-b8be-7eb98e6c1d3f"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic57fab8151e64ac0a42999af4054508d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjg5MzY_4d8b3c8c-28c6-437c-859b-f321c5e38bb6"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i35541777167844639ae2fde64553a505_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjkwNDU_8cf25977-969e-464d-a97c-39b4f74b48e8"
      unitRef="usd">3300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib0d488d61f554e5a8b0ce225092751fc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjkwNTI_90a150c2-b738-4cf2-a4bb-c43ed6abe084"
      unitRef="usd">3500000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i99ab726c228e4d1680ccc1ddfb59679a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjkxMDU_44a0e027-a023-41f3-81b3-60002a45d9e5"
      unitRef="usd">8100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i99ab726c228e4d1680ccc1ddfb59679a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjkxNTQ_49365f1b-046a-4818-9557-a1260bc8b991"
      unitRef="usd">2700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i99ab726c228e4d1680ccc1ddfb59679a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjkxODI_2f5d2dc7-9000-4d85-8e5d-c462ea44e7c0"
      unitRef="usd">5300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia3ab9f0060de41d18476fe3926db09c0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjkyMjA_8f521893-9331-40e0-8381-7be9f32f370b"
      unitRef="usd">11400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia3ab9f0060de41d18476fe3926db09c0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjkyNjk_029dde45-ee0c-415b-a2cb-53dd02b47aea"
      unitRef="usd">4500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia3ab9f0060de41d18476fe3926db09c0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjkyOTc_acdd5f16-291a-430b-a66a-901e6ccf5bf7"
      unitRef="usd">6900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i1b4c7ba6a9524139b98444a380751a27_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTA5OTUxMTY2NjgwNg_8f9929a7-565f-400f-ab75-e7165b1f7d78"
      unitRef="usd">5000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:RevenuesNetOfTaxWithholding
      contextRef="i1b4c7ba6a9524139b98444a380751a27_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTA5OTUxMTY2NjgyMA_e3bbed22-9da5-4092-998b-089862d07889"
      unitRef="usd">4500000</mgnx:RevenuesNetOfTaxWithholding>
    <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement
      contextRef="i99a92e56710a44499fbc841789c43ddd_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMjk1MzM_1f08d9ee-7bb9-4b3e-8ef2-0cc7b357e2cf"
      unitRef="molecule">2</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement>
    <mgnx:TotalPotentialValueUnderAgreement
      contextRef="i71658aa1f269459cad8b975de86ba7af_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMTA5OTUxMTY2Njk2OQ_eb95597b-2c05-4ec0-9c61-f5513c1bf93c"
      unitRef="usd">25100000</mgnx:TotalPotentialValueUnderAgreement>
    <us-gaap:Revenues
      contextRef="i487dec63017c4855b07e934da1351f90_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMzA3MDI_306b0c7b-83f4-49ef-b49b-51d9d3a42bd0"
      unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibb2565b6e20a47c380508ecb56852d3e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMzA3MDk_63990157-8d14-440d-a7b9-b33016f018e3"
      unitRef="usd">800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01719b83dd334b3c8168fc3fa1f48b83_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMzA4MDk_54d30da6-6ffb-4e55-9050-fa4344c53016"
      unitRef="usd">1300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i91df6dfeabf04146832cafe879f6de8d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81Mi9mcmFnOmQ3ZjNkN2ViNzgwOTQyZWM4ZjNiZGQwZTg2YThhM2EyL3RleHRyZWdpb246ZDdmM2Q3ZWI3ODA5NDJlYzhmM2JkZDBlODZhOGEzYTJfMzA4MTY_7cdafb8c-346c-43c3-a315-b84b5fb9a010"
      unitRef="usd">6200000</us-gaap:Revenues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNTM0Ng_8d010dc7-f66b-4cad-a889-148bf8b66db9">Stock-Based Compensation&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company&#x2019;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#x2019;s common stock on the last day of the offering period.  During the nine months ended September&#160;30, 2021, 12,305 shares of common stock were purchased under the 2016 ESPP.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Option Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of September&#160;30, 2021, under the 2003 Plan, there were options to purchase an aggregate of 188,944 shares of common stock outstanding at a weighted average exercise price of $2.94 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the nine months ended September&#160;30, 2021, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 13,856,781.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of September&#160;30, 2021, there were options to purchase an aggregate of 8,341,645 shares of common stock outstanding at a weighted average exercise price of $21.94 per share under the 2013 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation expense was recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.2% -87.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.3% - 109%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6% - 1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4% - 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the nine months ended September&#160;30, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,258,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,914,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,530,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of September 30, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,314,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,135,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of options granted during the nine months ended September&#160;30, 2021 and 2020 was $15.21 and $10.50, respectively. The total intrinsic value of options exercised during the nine months ended September&#160;30, 2021 and 2020 was approximately $3.2 million and $3.9 million, respectively.  The total cash received for options exercised during the nine months ended September&#160;30, 2021 and 2020 was approximately $5.4 million and $4.5 million, respectively.  The total fair value of shares vested in the nine months ended September&#160;30, 2021 and 2020 was approximately $14.8 million and $12.4 million, respectively. As of September&#160;30, 2021, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $36.3 million, which the Company expects to recognize over a weighted-average period of approximately 2.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company awarded restricted stock units (RSUs) under the 2013 Plan to all employees with at least six months of service as of the date of grant except executive officers. Each RSU entitled the holder to receive one share of the Company's common stock when the RSU vested. The RSUs vested in two equal installments on the first and second anniversary of the grant date and have all vested as of September&#160;30, 2021. Compensation expense was recognized on a straight-line basis. The Company also grants RSUs to employees from time to time as a component of their compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the nine months ended September&#160;30, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2021, there was $0.5 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of approximately 2.3 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ie4219cd04f594173989928403a1925f5_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDI3_ac849a40-bf85-45ee-8c89-2646bdf52542"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i079475de71ee41f681213c129639bcad_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNjI2_d25773b5-92ef-4c36-818c-8a2d8cd04f4a"
      unitRef="number">0.10</mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i079475de71ee41f681213c129639bcad_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfODcz_5ad56616-a42b-45ea-9d59-94368606473f"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i87bf914abe0d42daa70a6e228105c4dc_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMTAwMw_8d9cd328-0cf5-4774-85f8-7d0400599991"
      unitRef="shares">12305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0829ae725ca14ae7a41646663f3d6410_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMTkyNQ_2727aeb8-7253-4244-8b6a-b715e79d2072"
      unitRef="shares">188944</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0829ae725ca14ae7a41646663f3d6410_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMjAwMw_fb94a2e3-4d92-480f-b9b8-74c37e93c887"
      unitRef="usdPerShare">2.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance
      contextRef="i5e8e35470de0483c81155d2739ab9223_I20131031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMjQxNQ_432a1e58-040e-4d4f-af45-064252dcad42"
      unitRef="shares">1960168</mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance>
    <mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan
      contextRef="if5cf9831d6f24c2083b89a5456858d7b_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMjQzMA_e790101e-1c9e-463f-b93e-823dd9d640c7"
      unitRef="number">0.04</mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ibc4bd8d3b0504ef79236bd4a23c915f8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMjc4Mg_359c9a67-7ace-49d2-b205-050a04e2a4d0"
      unitRef="shares">13856781</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibc4bd8d3b0504ef79236bd4a23c915f8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMzM1OA_7265d757-e428-4718-bb84-2200bd1c8650"
      unitRef="shares">8341645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibc4bd8d3b0504ef79236bd4a23c915f8_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMzQzNg_217e6466-bccb-446a-b325-fd4311f030e6"
      unitRef="usdPerShare">21.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNTM0MA_595bf2d4-af63-4f9c-baf1-78419d5ef64d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation expense was recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1afe44d7fcb449e8b8c3d8ac3bf6d9d6_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfMi0xLTEtMS0w_0f67ea31-eb61-4a0f-9752-539b2b3b3471"
      unitRef="usd">3109000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2bae4045ab9643abbbe939388775bc12_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfMi0zLTEtMS0w_6a448b70-dedf-4c77-881c-4dd61280498a"
      unitRef="usd">3059000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if0961f8433264f3a91406325b6f8539c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfMi01LTEtMS0w_408b41ee-038a-4521-8caf-3ff648b22403"
      unitRef="usd">8894000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if1204e1a45b146edb8cf23bbe529b211_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfMi03LTEtMS0w_52464c3a-25e8-4521-b6a8-956097472467"
      unitRef="usd">8082000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib1a6178e54834b4f981abb57a3f32174_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfMy0xLTEtMS0w_3ee941f1-ab63-42eb-8a3f-6d3bce5f07aa"
      unitRef="usd">3249000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i40192326e650444490369c6d8aed8c29_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfMy0zLTEtMS0w_ae508969-c1e2-4a4b-a824-0eb3dffda032"
      unitRef="usd">2773000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i596efc1d3c914e7c99e852a6397e9d68_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfMy01LTEtMS0w_b7135a7e-c263-47bc-937f-7207e558546d"
      unitRef="usd">8820000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1c37fd8583354f3e9a46dbbaef70aed7_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfMy03LTEtMS0w_e05931e7-693d-4be1-af43-bd1e5791c004"
      unitRef="usd">7337000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfNC0xLTEtMS0w_7d247994-ceb3-463b-8763-ab27a4267b7d"
      unitRef="usd">6358000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib3f809536e594bee9f7de041edd44fa0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfNC0zLTEtMS0w_51045dbd-55d6-45e6-9195-b9daa1415a57"
      unitRef="usd">5832000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfNC01LTEtMS0w_43f820b9-9ed5-48c4-8b7e-ca3b285ad43d"
      unitRef="usd">17714000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmIwNjM0ZTc1NDkyNzRjN2VhYTE0MDQ2YTFiOWJmMzlhL3RhYmxlcmFuZ2U6YjA2MzRlNzU0OTI3NGM3ZWFhMTQwNDZhMWI5YmYzOWFfNC03LTEtMS0w_0ce8b05b-273f-410c-b768-563de98b26c8"
      unitRef="usd">15419000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNTM0OA_4f3197bf-6d5b-4d1b-8480-fa4bcbb87bbc">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.2% -87.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.3% - 109%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6% - 1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4% - 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfMi0xLTEtMS0w_18b6c500-33f7-41b0-85fb-dec1cfb7202d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfMi0zLTEtMS0w_71c2ea85-4b26-4a36-9e8a-82bc1b57320a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie49c054c4de84c13bf9cf4e74329ad89_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfMy0xLTEtMS0wL3RleHRyZWdpb246Yjk2MTJkN2M0OWQxNGMyZWI0Y2FlMWRhZDI1NzQzMGZfNA_f409e958-ad36-4453-a386-0e476ba4f625"
      unitRef="number">0.862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1017f0e3d160493698b4b137f53cf6b9_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfMy0xLTEtMS0wL3RleHRyZWdpb246Yjk2MTJkN2M0OWQxNGMyZWI0Y2FlMWRhZDI1NzQzMGZfOA_64cc19cc-5432-4e42-8486-0dbc318d0061"
      unitRef="number">0.874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9edd978d79794c06ae717443ae5079d0_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfMy0zLTEtMS0wL3RleHRyZWdpb246ODI0ZTMyZTYzOGJlNGM0NGE4ODEzYjM5ZTM0NjY1ZTlfNA_725fa324-0288-4de5-8be1-5133bc93cebc"
      unitRef="number">0.673</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if2db8a1a06494bb9acad2b6f55b81bac_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfMy0zLTEtMS0wL3RleHRyZWdpb246ODI0ZTMyZTYzOGJlNGM0NGE4ODEzYjM5ZTM0NjY1ZTlfOQ_3fd06fe5-ad82-4486-a54e-515f28fff11d"
      unitRef="number">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie49c054c4de84c13bf9cf4e74329ad89_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfNC0xLTEtMS0wL3RleHRyZWdpb246Y2Y1MDFmOGQxZmI2NGQ2NThmMWExZmZkMWEzZDYzZWVfNA_8a2d84be-b77b-464a-ae2b-3e0846cad87f"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1017f0e3d160493698b4b137f53cf6b9_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfNC0xLTEtMS0wL3RleHRyZWdpb246Y2Y1MDFmOGQxZmI2NGQ2NThmMWExZmZkMWEzZDYzZWVfOQ_c09fd288-2668-402f-b086-b03c48d73ede"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9edd978d79794c06ae717443ae5079d0_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfNC0zLTEtMS0wL3RleHRyZWdpb246YWYxNTUyMDc4MjRiNDc1NzllNGQ2ZDM3YmQwOWE4OWRfNA_750dc1ea-ac79-4b45-9f70-2b72ee1c1ca0"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if2db8a1a06494bb9acad2b6f55b81bac_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfNC0zLTEtMS0wL3RleHRyZWdpb246YWYxNTUyMDc4MjRiNDc1NzllNGQ2ZDM3YmQwOWE4OWRfOQ_e8391b99-2969-4a31-b63f-51986c0d823c"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfNS0xLTEtMS0w_40563dfd-0902-4e3b-98a3-6a7b4ea05819">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjQ1YTFlZTdhOTFhNjQxYjVhZjU5MTllNWZiNTY2NzY0L3RhYmxlcmFuZ2U6NDVhMWVlN2E5MWE2NDFiNWFmNTkxOWU1ZmI1NjY3NjRfNS0zLTEtMS0w_0edb7dc4-00cf-42b9-bc65-618ddd8d746f">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNTM0Mw_01fe7786-8aa7-48e9-b0fc-c776057d7906">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the nine months ended September&#160;30, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,258,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,914,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,530,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of September 30, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,314,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,135,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfMS0xLTEtMS0w_df64cd27-09d0-40c1-8607-a4b2aa81c947"
      unitRef="shares">7258353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iaabf44798f0b4137a1cd062271187dd4_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfMS0zLTEtMS0w_7a08f5b4-9075-4236-b54f-9086454a6726"
      unitRef="usdPerShare">21.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i671b1a548fa8453f8d15112d62dc2c2c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfMS01LTEtMS0w_87e1e5bd-efb6-4e55-b5ed-0ceafa6cb67c">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfMi0xLTEtMS0w_9fc364e6-1645-4589-aea9-80a9e4d31cff"
      unitRef="shares">1914846</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfMi0zLTEtMS0w_884d124e-5531-4022-9cf3-dd308820fc47"
      unitRef="usdPerShare">20.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfMy0xLTEtMS0w_652f226d-71c6-4f6f-a865-1ff39f7857bf"
      unitRef="shares">302649</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfMy0zLTEtMS0w_f7d1abb9-735d-4614-a508-5eeac3305cb5"
      unitRef="usdPerShare">17.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNC0xLTEtMS0w_39b45ebc-df69-421a-b761-701cd35bdbce"
      unitRef="shares">339961</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNC0zLTEtMS0w_9f7c3193-4d69-4554-90ca-168198d7a628"
      unitRef="usdPerShare">19.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNS0xLTEtMS0w_ea666986-a555-4457-a120-3507c369c377"
      unitRef="shares">8530589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNS0zLTEtMS0w_22419b4b-dc27-4fa4-82d2-f1e374fe84cd"
      unitRef="usdPerShare">21.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNS01LTEtMS0w_f023004a-2887-495f-bd82-112a6b0bbb18">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNS03LTEtMS0w_8cd73cc0-6c7a-441b-9240-fc1ea99f9dec"
      unitRef="usd">19925000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNy0xLTEtMS0w_158bd106-e078-4a3b-b5d2-4386fd3205c6"
      unitRef="shares">5314252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNy0zLTEtMS0w_7aabc5a9-3ba6-46e8-8e16-88d7f1d569d2"
      unitRef="usdPerShare">22.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNy01LTEtMS0w_cf9743c2-a48b-488c-8774-3fde688d2cf5">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfNy03LTEtMS0w_1f9a0e83-9b91-4684-97e0-8ffbf3880b86"
      unitRef="usd">10445000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfOC0xLTEtMS0w_a4eda3bf-9cd0-484c-b5c6-2ff206a58963"
      unitRef="shares">8135407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfOC0zLTEtMS0w_53441b84-095c-4ee6-8834-dd0e4868a627"
      unitRef="usdPerShare">21.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfOC01LTEtMS0w_8e646b0c-d404-4941-9c36-da3aad53fd64">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOmQ4NjI0YmQyODM5MTQzM2M5ZGE5OGNlYzAzZTMyMzBkL3RhYmxlcmFuZ2U6ZDg2MjRiZDI4MzkxNDMzYzlkYTk4Y2VjMDNlMzIzMGRfOC03LTEtMS0w_e92cfbf1-2c9d-4165-b154-c171622a8e61"
      unitRef="usd">18793000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMzk3Mg_1e7c4ab3-90a6-4a12-8aee-d0690d2c5e53"
      unitRef="usdPerShare">15.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfMzk3OQ_1f142ab7-d798-4d30-bb27-ce570360f0ba"
      unitRef="usdPerShare">10.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDA5OQ_7b87d298-b0b4-4353-829a-e9d407310aa4"
      unitRef="usd">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDEwNg_6f57c686-9ad8-43c6-b90b-f0e533ade237"
      unitRef="usd">3900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDIyNg_6544fa26-5fb7-4869-b0e6-fefa0401829d"
      unitRef="usd">5400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDIzMw_5f7c3350-aa39-45e1-a9f0-de999193a466"
      unitRef="usd">4500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDM0MQ_f69b0142-9ce1-4272-8443-62601b861fcd"
      unitRef="usd">14800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDM0OA_38cf8474-eba8-413f-9718-e9f4562465ce"
      unitRef="usd">12400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i68797193d4fe4a28bd0077b1e12763e2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDUxMA_27893f4d-c04c-4229-a72b-160c2a749dec"
      unitRef="usd">36300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNDYwMQ_c4d3c6cd-6857-49c8-a55e-3c2d2cb8d7af">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNTM0NA_b3d10068-2c64-4b61-8e0f-2d4a39bebc3d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the nine months ended September&#160;30, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="icc9b2b5b948945ceb440f809f174f953_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfMS0xLTEtMS0w_6b2f3023-e3f4-4869-839d-0f579650d603"
      unitRef="shares">209250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="icc9b2b5b948945ceb440f809f174f953_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfMS0zLTEtMS0w_283e6c9b-e383-4b47-92b6-841e869a1120"
      unitRef="usdPerShare">15.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic04f6c80a7bb4625a1ae6e61e5c93184_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfMi0xLTEtMS0w_2406e19e-788e-460a-825f-ff350a1b8634"
      unitRef="shares">16500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic04f6c80a7bb4625a1ae6e61e5c93184_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfMi0zLTEtMS0w_58e4070f-378d-4845-9cf7-d43c0e253649"
      unitRef="usdPerShare">26.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="ic04f6c80a7bb4625a1ae6e61e5c93184_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfMy0xLTEtMS0w_e3c6877b-27a5-4cf5-93d8-842747b0bafb"
      unitRef="shares">184100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic04f6c80a7bb4625a1ae6e61e5c93184_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfMy0zLTEtMS0w_ad65e8f5-37cc-4117-8f34-880f20019b2f"
      unitRef="usdPerShare">15.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ic04f6c80a7bb4625a1ae6e61e5c93184_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfNC0xLTEtMS0w_c061a681-f2bc-4471-a74f-b3c440a81285"
      unitRef="shares">17650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ic04f6c80a7bb4625a1ae6e61e5c93184_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfNC0zLTEtMS0w_d24a912f-ce78-4308-8a62-e240611c1ba9"
      unitRef="usdPerShare">15.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2f5fcdf3d7064037aaefd67693a0f61c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfNS0xLTEtMS0w_e8784745-5c9c-4c12-96cc-6f77f2ea8a4b"
      unitRef="shares">24000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2f5fcdf3d7064037aaefd67693a0f61c_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RhYmxlOjA0NTJkYmY4MDAyZjQyZTc4YmZjM2NlYzdiOTE1NTdjL3RhYmxlcmFuZ2U6MDQ1MmRiZjgwMDJmNDJlNzhiZmMzY2VjN2I5MTU1N2NfNS0zLTEtMS0w_22fa1d04-3b3c-4072-9c17-362172fc35fa"
      unitRef="usdPerShare">25.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i2f5fcdf3d7064037aaefd67693a0f61c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNTE3Mg_0e3c27ce-3600-4bca-9d06-e7f2341aa5b1"
      unitRef="usd">500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic04f6c80a7bb4625a1ae6e61e5c93184_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81NS9mcmFnOjdhOGMxNjFhOTQ1YTRmMWU4OWRhNTg2YTg1ZTkzMGI1L3RleHRyZWdpb246N2E4YzE2MWE5NDVhNGYxZTg5ZGE1ODZhODVlOTMwYjVfNTMzOA_05b14583-0848-4c3a-a2a0-735f016eec87">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="id224a007af7345f691c25b480130a570_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkOTdmMmY2N2ZjODRkZWZiNTNiZmZiY2FlNDYwNmMxL3NlYzpkZDk3ZjJmNjdmYzg0ZGVmYjUzYmZmYmNhZTQ2MDZjMV81OC9mcmFnOjdiNDdhY2QyYWM0NzQyODRhMzQ4YjU2NjMyMjMxZjI1L3RleHRyZWdpb246N2I0N2FjZDJhYzQ3NDI4NGEzNDhiNTY2MzIyMzFmMjVfMTE2OQ_9a27d4b5-13ae-4cc4-a639-85d9524fd74e">Commitments and ContingenciesOn September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#x2019;s SOPHIA trial.   On August 17, 2020, the Employees&#x2019; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint.  The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020.  Plaintiff filed an Opposition brief on January 29, 2021, to which the Company filed a timely reply. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108715099672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 29, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-5172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,258,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108719730568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 190,531<span></span>
</td>
<td class="nump">$ 181,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Marketable securities</a></td>
<td class="nump">108,367<span></span>
</td>
<td class="nump">91,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">13,759<span></span>
</td>
<td class="nump">23,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">3,979<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">18,062<span></span>
</td>
<td class="nump">16,982<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">334,698<span></span>
</td>
<td class="nump">312,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">38,684<span></span>
</td>
<td class="nump">42,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">18,778<span></span>
</td>
<td class="nump">23,924<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">392,160<span></span>
</td>
<td class="nump">378,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,170<span></span>
</td>
<td class="nump">8,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">41,859<span></span>
</td>
<td class="nump">34,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">16,314<span></span>
</td>
<td class="nump">4,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">4,521<span></span>
</td>
<td class="nump">3,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">68,864<span></span>
</td>
<td class="nump">50,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">9,575<span></span>
</td>
<td class="nump">6,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">22,025<span></span>
</td>
<td class="nump">25,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non current liabilities</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">100,722<span></span>
</td>
<td class="nump">82,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value -- 125,000,000 shares authorized, 61,254,693 and 56,244,771 shares outstanding at September&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,206,742<span></span>
</td>
<td class="nump">1,067,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(915,914)<span></span>
</td>
<td class="num">(771,821)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">291,438<span></span>
</td>
<td class="nump">295,884<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 392,160<span></span>
</td>
<td class="nump">$ 378,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108710676296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">61,254,693<span></span>
</td>
<td class="nump">56,244,771<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108714584232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 15,662<span></span>
</td>
<td class="nump">$ 18,253<span></span>
</td>
<td class="nump">$ 63,300<span></span>
</td>
<td class="nump">$ 52,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">1,665<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,704<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">49,823<span></span>
</td>
<td class="nump">44,656<span></span>
</td>
<td class="nump">158,724<span></span>
</td>
<td class="nump">150,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">17,161<span></span>
</td>
<td class="nump">9,732<span></span>
</td>
<td class="nump">47,431<span></span>
</td>
<td class="nump">30,181<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">68,649<span></span>
</td>
<td class="nump">54,388<span></span>
</td>
<td class="nump">207,859<span></span>
</td>
<td class="nump">181,082<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(52,987)<span></span>
</td>
<td class="num">(36,135)<span></span>
</td>
<td class="num">(144,559)<span></span>
</td>
<td class="num">(128,890)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">466<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(52,886)<span></span>
</td>
<td class="num">(36,043)<span></span>
</td>
<td class="num">(144,093)<span></span>
</td>
<td class="num">(127,652)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (52,890)<span></span>
</td>
<td class="num">$ (36,058)<span></span>
</td>
<td class="num">$ (144,089)<span></span>
</td>
<td class="num">$ (127,666)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in usd per share)</a></td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (2.42)<span></span>
</td>
<td class="num">$ (2.49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in usd per share)</a></td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (2.42)<span></span>
</td>
<td class="num">$ (2.49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="nump">61,169,754<span></span>
</td>
<td class="nump">54,463,412<span></span>
</td>
<td class="nump">59,494,836<span></span>
</td>
<td class="nump">51,176,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">61,169,754<span></span>
</td>
<td class="nump">54,463,412<span></span>
</td>
<td class="nump">59,494,836<span></span>
</td>
<td class="nump">51,176,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue from collaborative and other agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 11,986<span></span>
</td>
<td class="nump">$ 17,415<span></span>
</td>
<td class="nump">$ 54,338<span></span>
</td>
<td class="nump">$ 46,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,591<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,681<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember', window );">Revenue from government agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 838<span></span>
</td>
<td class="nump">$ 1,281<span></span>
</td>
<td class="nump">$ 6,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108714599400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,958,763<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 230,628<span></span>
</td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 872,204<span></span>
</td>
<td class="num">$ (642,082)<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">4,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,131,150<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">190,573<span></span>
</td>
<td class="nump">$ 492<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">876,815<span></span>
</td>
<td class="num">(686,806)<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,958,763<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">230,628<span></span>
</td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">872,204<span></span>
</td>
<td class="num">(642,082)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(127,652)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,174,932<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">291,585<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,060,755<span></span>
</td>
<td class="num">(769,734)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,131,150<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">190,573<span></span>
</td>
<td class="nump">$ 492<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">876,815<span></span>
</td>
<td class="num">(686,806)<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,060,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">96,512<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(46,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,365,003<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">247,784<span></span>
</td>
<td class="nump">$ 534<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">980,924<span></span>
</td>
<td class="num">(733,691)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,552,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">73,981<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,596<span></span>
</td>
<td class="nump">74,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (2,012)<span></span>
</td>
<td class="nump">2,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,012<span></span>
</td>
<td class="num">(2,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,174,932<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">291,585<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,060,755<span></span>
</td>
<td class="num">(769,734)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,244,771<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">295,884<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,067,150<span></span>
</td>
<td class="num">(771,821)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,622,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">98,200<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">2,458<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(51,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,011,206<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">350,531<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,173,013<span></span>
</td>
<td class="num">(823,093)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,244,771<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 295,884<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,067,150<span></span>
</td>
<td class="num">(771,821)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="nump">1,914,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (144,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,254,693<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">291,438<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,206,742<span></span>
</td>
<td class="num">(915,914)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,011,206<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">350,531<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,173,013<span></span>
</td>
<td class="num">(823,093)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">6,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">2,346<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(39,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,133,447<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">319,045<span></span>
</td>
<td class="nump">$ 601<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,181,471<span></span>
</td>
<td class="num">(863,028)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">6,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">19,640<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,779<span></span>
</td>
<td class="nump">66,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="num">(666)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">$ (1,457)<span></span>
</td>
<td class="nump">789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,457<span></span>
</td>
<td class="num">(1,457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(52,886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,886)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,254,693<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 291,438<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,206,742<span></span>
</td>
<td class="num">$ (915,914)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121321822&amp;loc=d3e3913-113898<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121323062&amp;loc=d3e15009-113911<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108716671656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (144,093)<span></span>
</td>
<td class="num">$ (127,652)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">8,306<span></span>
</td>
<td class="nump">9,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities</a></td>
<td class="nump">1,267<span></span>
</td>
<td class="num">(387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">17,714<span></span>
</td>
<td class="nump">15,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">1,602<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">9,322<span></span>
</td>
<td class="num">(6,033)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(5,582)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,080)<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">5,146<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable</a></td>
<td class="num">(1,931)<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">7,744<span></span>
</td>
<td class="nump">5,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(2,701)<span></span>
</td>
<td class="num">(2,113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">14,507<span></span>
</td>
<td class="num">(4,816)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other non current liabilities</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(89,521)<span></span>
</td>
<td class="num">(106,365)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(164,780)<span></span>
</td>
<td class="num">(151,230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sale and maturities of marketable securities</a></td>
<td class="nump">146,550<span></span>
</td>
<td class="nump">161,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and software</a></td>
<td class="num">(4,826)<span></span>
</td>
<td class="num">(2,346)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(23,056)<span></span>
</td>
<td class="nump">8,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">117,818<span></span>
</td>
<td class="nump">170,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases', window );">Proceeds from stock option exercises and ESPP purchases</a></td>
<td class="nump">5,722<span></span>
</td>
<td class="nump">4,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(1,563)<span></span>
</td>
<td class="num">(2,011)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">121,977<span></span>
</td>
<td class="nump">173,240<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">9,400<span></span>
</td>
<td class="nump">75,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">181,131<span></span>
</td>
<td class="nump">126,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">190,531<span></span>
</td>
<td class="nump">201,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property, equipment and software included in accounts payable or accruals</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108713694760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Nature of Operations</a></td>
<td class="text">Nature of Operations<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the business</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. In December 2020, the U.S. Food and Drug Administration (FDA) approved MARGENZA (margetuximab-cmkb) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.  The Company launched MARGENZA in collaboration with its commercialization partner, Eversana Life Science Services, LLC (Eversana), in March 2021. In addition, the Company has a pipeline of product candidates in human clinical testing that have been created primarily using its proprietary, antibody-based technology platforms. The Company believes its product candidates have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital, and anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities. Based on the Company&#8217;s most recent cash flow forecast, the Company believes its current cash, cash equivalents and marketable securities is sufficient to fund its operating plans for a minimum of twelve months from the date that this Quarterly Report was filed. The Company plans to meet its near-term operating requirements primarily through cash and marketable securities on hand, and a combination of product sales and current and future strategic collaborations and alliances and marketing, distribution or licensing arrangements.  In the longer term, the Company plans to meet its operating requirements by generating revenue from product sales to the extent its other product candidates receive marketing approval and can be commercialized, or by potential future equity or debt issuances. There can be no assurances that new sources of capital will be available to the Company on commercially acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require the Company to give up some or all rights to a product or technology at less than its full potential value. If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, and/or downsize its organization.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to the COVID-19 pandemic, the Company will continue to evaluate the nature and extent of the impact of the pandemic on its business and financial position.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2020 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108712224168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, the Company adopted the following significant accounting policies in addition to those previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the FDA in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of sales in the statement of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue, Net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606). The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the three and nine months ended September 30, 2021, the shipping costs incurred were immaterial. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the nine months ended September 30, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of product sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 is part of the FASB&#8217;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The adoption of this standard as of January 1, 2021 had no impact on the Company's consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these ASUs will not have a material impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108713686808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value </span><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </span></div><div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:15pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,199&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,865&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,399&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at September&#160;30, 2021 includes approximately $34.8 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2020 includes approximately $52.0 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods presented, and the Company has no Level 3 securities in its portfolio.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108712214504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,019&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,017&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,371&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,630&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,624&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>All available-for-sale marketable debt securities held as of September&#160;30, 2021 and December&#160;31, 2020 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of September&#160;30, 2021 and December&#160;31, 2020 were in a loss position for less than 12 months.&#160; Unrealized losses on available-for-sale debt securities as of September&#160;30, 2021 and December&#160;31, 2020 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for any periods presented. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108713686808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory, Net</a></td>
<td class="text">Inventory, Net<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,979&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of September&#160;30, 2021, is net of a reserve of $1.6 million for unsaleable inventory which is reflected in cost of product sales for the three and nine months ended September 30, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108712187944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' EquityIn November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0 million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the three months ended March 31, 2021, the Company sold 3,622,186 shares <div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of common stock at a weighted average price per share of $27.60, resulting in net proceeds of approximately $98.2 million, net of underwriting discounts and commissions and other offering expenses. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#8217;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $100.0&#160;million to an aggregate offering price of up to $300.0&#160;million.  During the three and nine months ended September 30, 2021, the Company did not sell any shares of common stock related to the ATM Offering.  </span></div>As part of the consideration for the rights granted to Zai Lab US LLC under the collaboration and license agreement described more fully in Note 7, Collaboration and Other Agreements, the Company and Zai Lab US LLC entered into a separate stock purchase agreement (Stock Purchase Agreement).  Under this Stock Purchase Agreement, Zai Lab US LLC paid the Company approximately $30.0 million to purchase 958,467 newly issued shares of the Company's common stock, par value $0.01, at a fixed price of $31.30 (Offering) which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. The Offering closed in July 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108713686808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock', window );">Collaboration and Other Agreements</a></td>
<td class="text">Collaboration and Other Agreements <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte License Agreement</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab  (formerly known as MGA012 and INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017. In July 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal.  Incyte&#8217;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte is reviewing the CRL and will discuss next steps with the FDA.  More recently, Incyte withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal.   </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab.  Assuming successful development and commercialization of retifanlimab by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones and up to $330.0 million in commercial milestones. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $70.0 million in development milestones under the Incyte License Agreement.  If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company evaluated the Incyte License Agreement under ASC 606 and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From 2018 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, it became probable that a significant reversal of cumulative revenue would not occur for deve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">lopment milestones totaling $70.0 million related to </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#8217;s initiation of a Phase 3 clinical trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.  Therefore the associated consideration was added to the estimated transaction price.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognized the $150.0 million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017.  The $4.0 million allocated to the clinical activities was recognized ratably as services were performed over a period spanning 2017 and 2018.  During the nine months ended September 30, 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">it became probable that a significant reversal of cumulative revenue would not occur for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$15.0 million in milestones related to development progress of retifanlimab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue. No revenue was recognized under the Incyte License Agreement during the three and nine months ended September 30, 2021.  During the three and nine months ended September 30, 2020, $15.0 million in milestone revenue was recognized under the Incyte License Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement).  The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services.  During the three months ended September 30, 2021 and 2020, the Company recognized revenue of $0.2 million and $0.7 million, respectively, for services performed under the Incyte Clinical Supply Agreement. During the nine months ended September 30, 2021 and 2020, the Company recognized revenue of $1.0 million and $8.1 million, respectively, for services performed under the Incyte Clinical Supply Agreement.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte Commercial Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services.  During the three and  nine months ended September 30, 2021, the Company recognized revenue of $1.4&#160;million and $7.4&#160;million, respectively, for services performed under the Incyte Commercial Supply Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab Limited</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2018 Zai Lab Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab)  under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab (formerly known as MGD013), a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million ($22.5 million after netting value-added tax withholdings of $2.5 million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, $4.0 million of which ($3.6 million after netting value-added tax withholdings of </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.4 million) was earned during the three months ended March 31, 2020. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the tebotelimab performance obligation was recognized on a straight-line basis as the Company performed research and development activities under the agreement. The fixed consideration related to the margetuximab performance obligation was also recognized on a straight-line basis as the Company performed research and development activities under the agreement due to the short-term nature of the recognition period. Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate. The variable consideration related to the margetuximab performance obligation was recognized upon certain regulatory achievements during 2020.  The Company recognized revenue of $3.6&#160;million during the nine months ended September 30, 2020 under the 2018 Zai Lab Agreement.  There was no revenue deferred under this agreement as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021 or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Zai Lab Clinical Supply Agreements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements).  The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  During the three months ended September 30, 2021 and 2020, the Company recognized revenue of $0.6 million and $0.5 million, respectively, related to the Zai Lab Clinical Supply Agreements. During the nine months ended September 30, 2021 and 2020, the Company recognized revenue of $2.3 million and $1.9 million, respectively, related to the Zai Lab Clinical Supply Agreements.  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Zai Lab Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#8217;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay the Company $85.0&#160;million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into the Stock Purchase Agreement whereby Zai Lab paid the Company approximately $30.0 million to purchase shares of the Company&#8217;s common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the Programs, the Company could receive up to approximately $800.0&#160;million in development and regulatory milestones and $600.0&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai Lab&#8217;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#8217;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#8217;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the estimated transaction price is $40.4 million, consisting of the $25.0 million upfront payment, the $10.4 million premium related to the purchase of the Company&#8217;s common stock, and the estimated $5.0 million expected to be reimbursed by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $40.4 million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes the market is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#8217;s estimate of the probability of success for each Program. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to the Lead Program license and related research and development services performance obligation is being recognized over time as the research and development activities are performed. The Company will utilize a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. During the three and nine months ended September 30, 2021, the Company recognized revenue of $3.7 million and $18.1 million, respectively, under the 2021 Zai Lab Agreement.  As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021, there was $17.8 million in deferred revenue under the agreements, $13.6 million of which is current and $4.2 million of which is non-current.  </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Biotech, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a research collaboration and license agreement with Janssen Biotech, Inc. (Janssen) to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#8217;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $20.0&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $312.0&#160;million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales. </span><span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#8217;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $22.2&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $20.0&#160;million allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $2.2&#160;million allocated to the research and development activities is being recognized over the Company&#8217;s involvement in the research term, which is estimated to be less than two years. During the three and nine months ended September 30, 2021, the Company recognized revenue of $0.2&#160;million and $1.1&#160;million, respectively, for research and development activities performed under the Janssen Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab Agreement, I-Mab paid the Company an upfront payment of $15.0 million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $135.0 million in development and regulatory milestones, of which $5.0 million  has been earned from the inception of the I-Mab Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to 20% on annual net sales in I-Mab's territory.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million. I-Mab paid the Company for the cost of this study as the costs were incurred and I-Mab received a one-time credit of eighty percent of the total amount of such costs against the milestone achieved during the three months ended September 30, 2021, at which point the Company reassessed the transaction price for that milestone. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Revenue under the I-Mab Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, i n management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations.  The Company recognized revenue of $1.0 million  during each of the three month periods ended September&#160;30, 2021 and 2020  under the I-Mab Agreement.  During the nine months ended September 30, 2021 and 2020, the Company recognized revenue of $3.3 million and $3.5 million, respectively, under the I-Mab Agreement.  At September&#160;30, 2021, $8.1 million of revenue was deferred under this agreement, $2.7 million of which was current and $5.3 million of which was non-current.   At December&#160;31, 2020, $11.4 million of revenue was deferred under this agreement, $4.5 million of which was current and $6.9 million of which was non-current.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur fo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r a $5.0&#160;million milestone ($4.5&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, including MGD014 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div>Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of September 30, 2021 is $25.1 million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023.    During the three months ended September 30, 2021 and 2020, the Company recognized revenue under the NIAID Contract of $0.1 million and $0.8 million, respectively.  During the nine months ended September 30, 2021 and 2020, the Company recognized revenue under the NIAID Contract of $1.3 million and $6.2 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108712228728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#8217;s common stock on the last day of the offering period.  During the nine months ended September&#160;30, 2021, 12,305 shares of common stock were purchased under the 2016 ESPP.   </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Option Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of September&#160;30, 2021, under the 2003 Plan, there were options to purchase an aggregate of 188,944 shares of common stock outstanding at a weighted average exercise price of $2.94 per share.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the nine months ended September&#160;30, 2021, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 13,856,781.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of September&#160;30, 2021, there were options to purchase an aggregate of 8,341,645 shares of common stock outstanding at a weighted average exercise price of $21.94 per share under the 2013 Plan.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,773&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,820&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,337&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,358&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,714&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,419&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.2% -87.4%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3% - 109%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6% - 1.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4% - 1.8%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the nine months ended September&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,258,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,914,846&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302,649)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339,961)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,530,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of September 30, 2021:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,314,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,135,407&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,793&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during the nine months ended September&#160;30, 2021 and 2020 was $15.21 and $10.50, respectively. The total intrinsic value of options exercised during the nine months ended September&#160;30, 2021 and 2020 was approximately $3.2 million and $3.9 million, respectively.  The total cash received for options exercised during the nine months ended September&#160;30, 2021 and 2020 was approximately $5.4 million and $4.5 million, respectively.  The total fair value of shares vested in the nine months ended September&#160;30, 2021 and 2020 was approximately $14.8 million and $12.4 million, respectively. As of September&#160;30, 2021, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $36.3 million, which the Company expects to recognize over a weighted-average period of approximately 2.6 years.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company awarded restricted stock units (RSUs) under the 2013 Plan to all employees with at least six months of service as of the date of grant except executive officers. Each RSU entitled the holder to receive one share of the Company's common stock when the RSU vested. The RSUs vested in two equal installments on the first and second anniversary of the grant date and have all vested as of September&#160;30, 2021. Compensation expense was recognized on a straight-line basis. The Company also grants RSUs to employees from time to time as a component of their compensation.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the nine months ended September&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,650)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021, there was $0.5 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of approximately 2.3 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108713602136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and ContingenciesOn September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial.   On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint.  The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020.  Plaintiff filed an Opposition brief on January 29, 2021, to which the Company filed a timely reply. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108710223112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2020 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the FDA in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of sales in the statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Product Revenue, Net, Reserves for Variable Consideration, Customer Discounts and Service Fees, Product Returns, Provider Chargebacks and Discounts, and Government Rebates</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue, Net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606). The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the three and nine months ended September 30, 2021, the shipping costs incurred were immaterial. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the nine months ended September 30, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Product Sales</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of product sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 is part of the FASB&#8217;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The adoption of this standard as of January 1, 2021 had no impact on the Company's consolidated financial statements and related disclosures.</span></div>The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these ASUs will not have a material impact on the Company's consolidated financial statements<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value </span><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div>The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108713564392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Financial Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:15pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,199&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,865&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,399&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at September&#160;30, 2021 includes approximately $34.8 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2020 includes approximately $52.0 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108713711992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-sale Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,019&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,017&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,371&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,630&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,624&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108713681544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,979&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108713754104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,773&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,820&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,337&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,358&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,714&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,419&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Valuation Assumptions Using the Black-Scholes Option-Pricing Model</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.2% -87.4%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3% - 109%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6% - 1.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4% - 1.8%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of Stock Options Roll Forward</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the nine months ended September&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,258,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,914,846&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302,649)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339,961)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,530,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of September 30, 2021:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,314,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,135,407&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,793&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the nine months ended September&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,650)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108716975496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 108,367<span></span>
</td>
<td class="nump">$ 91,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">34,800<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">143,199<span></span>
</td>
<td class="nump">143,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">15,334<span></span>
</td>
<td class="nump">49,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">127,865<span></span>
</td>
<td class="nump">94,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">15,334<span></span>
</td>
<td class="nump">49,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">15,334<span></span>
</td>
<td class="nump">49,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">68,017<span></span>
</td>
<td class="nump">60,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">68,017<span></span>
</td>
<td class="nump">60,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">12,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">12,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">47,570<span></span>
</td>
<td class="nump">33,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 47,570<span></span>
</td>
<td class="nump">$ 33,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108716715160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 108,371,000<span></span>
</td>
<td class="nump">$ 91,407,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(7,000)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">108,367,000<span></span>
</td>
<td class="nump">91,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss related to available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">68,019,000<span></span>
</td>
<td class="nump">60,630,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">68,017,000<span></span>
</td>
<td class="nump">60,624,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">12,278,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">12,279,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">28,074,000<span></span>
</td>
<td class="nump">30,777,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3,000)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 28,071,000<span></span>
</td>
<td class="nump">$ 30,776,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108710643944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">3,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory, net</a></td>
<td class="nump">3,979<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory valuation reserves</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108716742312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="nump">958,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958,467<span></span>
</td>
<td class="nump">3,622,186<span></span>
</td>
<td class="nump">2,552,333<span></span>
</td>
<td class="nump">4,060,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember', window );">At the Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuance', window );">Maximum amount available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,622,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sales of stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease', window );">Maximum amount available for issuance, increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108719764840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Incyte Corporation (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1">45 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>performanceObligation</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 15,662,000<span></span>
</td>
<td class="nump">$ 18,253,000<span></span>
</td>
<td class="nump">$ 63,300,000<span></span>
</td>
<td class="nump">$ 52,192,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPerformanceObligations', window );">Number of performance obligations | performanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Variable consideration recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012SupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012SupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108802251880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Zai Lab (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 15, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,662<span></span>
</td>
<td class="nump">$ 18,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,300<span></span>
</td>
<td class="nump">$ 52,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember', window );">2018 Zai Lab Agreement | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding', window );">Non-refundable upfront payment, net of tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonrefundablePaymentTaxWithholding', window );">Nonrefundable payment tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenuesNetOfTaxWithholding', window );">Revenues, net of tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenuesTaxWithholding', window );">Revenues, tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember', window );">Zai Lab Agreement, Margetuximab | Zai Labs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember', window );">Zai Lab Agreement, TRIDENT molecule | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember', window );">Zai Lab Clinical Supply Agreements | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember', window );">2021 Zai Lab Agreements | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OptInFee', window );">Opt-in fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sales of stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Variable consideration recognized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember', window );">2021 Zai Lab Agreements | Zai Labs | Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PremiumReceivedOnStockPurchase', window );">Premium received on stock purchase</a></td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundablePaymentTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Payment Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundablePaymentTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Upfront Fees, Net Of Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptInFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Opt-in Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OptInFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PremiumReceivedOnStockPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PremiumReceivedOnStockPurchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PremiumReceivedOnStockPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenuesNetOfTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues, Net Of Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenuesNetOfTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenuesTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues, Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenuesTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108715156296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Janssen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,662<span></span>
</td>
<td class="nump">$ 18,253<span></span>
</td>
<td class="nump">$ 63,300<span></span>
</td>
<td class="nump">$ 52,192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc | Janssen Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales', window );">Potential milestone payments and royalties on product sales</a></td>
<td class="nump">$ 312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="nump">$ 22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Clinical trial activities selling price amount</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc | Janssen Collaboration and License Agreement | Revenues From License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc | Janssen Collaboration and License Agreement | Revenue From Performance of the Research and Development Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments and Royalties On Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108716776856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 15,662<span></span>
</td>
<td class="nump">$ 18,253<span></span>
</td>
<td class="nump">$ 63,300<span></span>
</td>
<td class="nump">$ 52,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">16,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">9,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenuesNetOfTaxWithholding', window );">Revenues, net of tax withholding</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount', window );">Estimated variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration and License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used To Assess Variable Consideration, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenuesNetOfTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues, Net Of Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenuesNetOfTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108716788280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - NIAID Contract (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2015 </div>
<div>Molecule</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,662<span></span>
</td>
<td class="nump">$ 18,253<span></span>
</td>
<td class="nump">$ 63,300<span></span>
</td>
<td class="nump">$ 52,192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement', window );">Number of commercialized molecules | Molecule</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TotalPotentialValueUnderAgreement', window );">Total potential value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember', window );">Revenues From Grants | NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalPotentialValueUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalPotentialValueUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108821046216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,530,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,530,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,258,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,358<span></span>
</td>
<td class="nump">$ 5,832<span></span>
</td>
<td class="nump">$ 17,714<span></span>
</td>
<td class="nump">$ 15,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent', window );">Payroll deduction percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock percent of the fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember', window );">2003 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,856,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,856,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,341,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,341,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance', window );">Potential annual increase in shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan', window );">Potential annual increase in shares reserved for future issuance as percentage of outstanding share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,109<span></span>
</td>
<td class="nump">3,059<span></span>
</td>
<td class="nump">$ 8,894<span></span>
</td>
<td class="nump">8,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,249<span></span>
</td>
<td class="nump">$ 2,773<span></span>
</td>
<td class="nump">$ 8,820<span></span>
</td>
<td class="nump">$ 7,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108717591176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Option Pricing Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">86.20%<span></span>
</td>
<td class="nump">67.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">87.40%<span></span>
</td>
<td class="nump">109.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108715295512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">7,258,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted (in shares)</a></td>
<td class="nump">1,914,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised (in shares)</a></td>
<td class="num">(302,649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited or expired (in shares)</a></td>
<td class="num">(339,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">8,530,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,258,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable (in shares)</a></td>
<td class="nump">5,314,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares, Vested and expected to vest (in shares)</a></td>
<td class="nump">8,135,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 21.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Granted (in dollars per share)</a></td>
<td class="nump">20.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercised (in dollars per share)</a></td>
<td class="nump">17.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Forfeited or expired (in dollars per share)</a></td>
<td class="nump">19.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)</a></td>
<td class="nump">21.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercisable (in dollars per share)</a></td>
<td class="nump">22.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 21.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term, Outstanding (in years)</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Exercisable (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested and expected to vest (in years)</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Ending Balance</a></td>
<td class="nump">$ 19,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">10,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 18,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 15.21<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received for options exercised</a></td>
<td class="nump">5,400<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">14,800<span></span>
</td>
<td class="nump">$ 12,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates</a></td>
<td class="nump">$ 36,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period (in years)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140108714552936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Restricted Stock Unit Activity (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period (in years)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in shares) | shares</a></td>
<td class="nump">209,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">16,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(184,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited or expired (in shares) | shares</a></td>
<td class="num">(17,650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares) | shares</a></td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">26.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">15.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited or expired (in dollars per share) | $ / shares</a></td>
<td class="nump">15.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 25.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized compensation cost | $</a></td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period (in years)</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>45
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *" 8E,'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "@@&)3@>0"^.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)\D6#Z';B^))07!!\1:2V=U@DX9DI-VW-ZV[740?P&-F_GSS
M#4QKHC)#PN<T1$SD,-],O@]9F;AE1Z*H +(YHM>Y+HE0FOLA>4WEF0X0M?G0
M!P3)^2UX)&TU:9B!55R)K&NM42:AIB&=\=:L^/B9^@5F#6"/'@-E$+4 ULT3
MXVGJ6[@"9AAA\OF[@'8E+M4_L4L'V#DY9;>FQG&LQ\V2*SL(>'MZ?%G6K5S(
MI(/!\BL[1:>(6W:9_+JYN]\]L$YR*2HA*BYWDBO>J*9YGUU_^%V%_6#=WOUC
MXXM@U\*ON^B^ %!+ P04    " "@@&)3F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M *" 8E,"X!K_.@4  &<5   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
ME5A=<^HV$'V^_14:I@_M3 !+!A+N$&:(25*F"2&0?MQV^B!L 9YK6ZXL0_CW
M71FP2<:LW1>P;._QT>[J[$J#G53?DXT0FKR'093<-C9:QU_;[<3=B) G+1F+
M")ZLI JYAJ%:MY-8">YE1F'09I;5:X?<CQK#079OIH8#F>K C\1,D20-0Z[V
M=R*0N]L&;9QNS/WU1IL;[>$@YFNQ$/JW>*9@U,Y1/#\44>++B"BQNFV,Z%?'
M9L8@>^-W7^R2LVMBIK*4\KL93+S;AF48B4"XVD!P^-L*1P2!00(>_QY!&_DW
MC>'Y]0G](9L\3&;)$^'(X _?TYO;QDV#>&+%TT#/Y>X7<9Q0U^"Y,DBR7[([
MO-OI-(B;)EJ&1V-@$/K1X9^_'QUQ;F!=,&!' _;)@%[Z@GTTL+.)'IAETQIS
MS8<#)7=$F;<!S5QDOLFL839^9,*XT J>^F"GAX[<"D5F$#'2),F&*Y$,VAJ
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MO<- RS@[&%M*K66876X$]X0R+\#SE93Z-# ?R,]6A_\!4$L#!!0    ( *"
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MLPG*^(K5N?XA'S_SSJ$&8"ISU?Q%CZUM$D]06BLMBZXS("A$V?YG3UT@=CK
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MXY<+Y,P&F20X'*!T6$4AGKMASK<PYUZ8UWK-*U3*\J#)2:%YX8SCW)X\#L@
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M\<H8P.\K*?7+BYE@^]7GY']02P,$%     @ H(!B4QY:/QXE"@  FQ@  !@
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M6?:[@6.4<DT(VFV8>)2$%%%?X":)BV(*=C5 ;965#XX)7!)'K,FZR-1(9I]
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M-HO&/9%,:$KGB?*:$5T6;A:40!7.F6Y!\+XQ,Q]I/?BF^&#G)2U352X"$%1
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M&C"2K;@@/41V2I#5,(NJS6*6\30;(\W[&C!M<^<H^27SEHL2("%= QKS,8Y
M4\C7:HF<,<XN,I.3H:PH4B:.TTC+M9YG:)F+_4EW*;W$*[,X.%E&B(+SW'U)
MCM1X< !'X',T\OZ!C(N1LZ+OVH?$H&MG[L5TQ]C@9-IT&J:$QX!!EN,V$"(H
M0\GWQB21EVJ6Z&6IOA^[O??2[<T*D.79QJ]&9A8E:97R+/WA+"-)-\!@0[W%
M$8VV7/$V0>_@-?(H2#<_Z^8VP4SG;//N;GH")1N9\P.P4Y\@K2#/W&BB!ZQK
M*M"N$Y+]4</MP/QC8W*BQ.K-(V[(J8D9%*5GE^500,7U<YS)B88L'<L,@B8N
M<)^0YL,ULC.#PY[T3@6GNH1VA?#,(PJ4Y(,6\Y);CLR)M'3A^5S) ;,-N?CF
M?<Q6\?F=;LULBI29CB.8S0TEWR+EB2UYM; O01D_%Y5<*QU?<AP,T$D3^. F
M+%^9%GMPE^IK9X=@YLL?($C=\5R#+_CA@N=EMC:3^]YYS&(Z?AFG=,5+."IR
M@R90XA;G31D<9<X#Q7N^?)L._HHQBU/2Z/\A0EWD&=T<41]^*@$E^*/<M^Z/
MP>M\CKO0,I=;[-VVL."SD=YB"FZ#OT'^)!%0^(M]QO'([-CS$0CM#P?K('-V
M;S>]X=R_PY/YQ'AU^OD+T+V>)5>&YJ#^*-5YFN</Y4ZZ]]'2((;*+"@P:-7S
MZD:H)M9KYA&]2S3J.'+[67&7^[5@[$<&)[,D7Q. VOIK@$6^MZQ13[<1'3U8
MF0U%[PBY1,[)37)+PJ49+S2=;<S>>Q+!.T]7O5(L?I@9Y/0;:4[?6 >GA1\=
MOA)YY?&A'KTYOWSUN)3$@PL_]-S>/SJ__/"8R3\Y/5O@3 2943_I3[#1([E2
M^>K9R>-OU26,@HI^4\92$Z*4 N8;0;30? RW'+_QM$Z'.G\C/FL1X3M"*#?*
M404<H2]+5F9TDB0(5E'<98ZD)YZS8X6=Q.P W0TD+0=8KJ^;P<JD5EKAG;^:
M_DIWBGT>(I"?\';JT<LN@L/ Z/PJEW0_R+BP";T*$L4CN)O4ZT0SN6+&TR_D
MK9 \$J:$L,O9.XX3#7I%94HOSV'I_9><MK$P$H9@6W(+O%9_A[_1>SCRXLDI
MZD^+2IACJ>2_L0&=9<)U=:HZ2RE# L$-^349^'*\/4PR-&3B960]R<&P>2S^
M-[X78F2F="L3U_-COL7(6 X<C+.N CWGBJ!$RX?5R6R^BBOY]G_7P/+0FU?'
MDW?<4&HW_"8?$8/WR>MN]6E]6?!<WI$;E\N;AF]1&RES=&:-K2?+K[XXDA%2
M^9)\SV_,K7Q"7>=_@:915VD!?E][G\H7.J"^0OGR/U!+ P04    " "@@&)3
M[@1G>" '  !U$P  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;*U8:V_;
M.!;]*X1WL#L%'#]DYSE)@*3=[@XP!8JFG?FPV ^4=&VQD4B5I.SZW^^YI"0K
M#R?%['Q)1)D\//=U+JG+K;'WKB#RXGM5:G<U*KRO+Z93EQ5423<Q-6G\LC*V
MDAY#NYZZVI+,PZ*JG":SV<FTDDJ/KB_#NX_V^M(TOE2:/EKAFJJ2=G=+I=E>
MC>:C[L4GM2X\OYA>7]9R37?DO]0?+4;3'B57%6FGC!:65E>CF_G%[9+GAPF_
M*]JZP;-@2U)C[GGP:WXUFC$A*BGSC"#Q;T-OJ2P9"#2^M9BC?DM>.'SNT-\'
MVV%+*AV]->4?*O?%U>AL)'):R:;TG\SVW]3:<\QXF2E=^"NV<>[B9"2RQGE3
MM8O!H%(Z_I??6S\,%IS-#BQ(V@5)X!TW"BS?22^O+ZW9"LNS@<8/P=2P&N24
MYJ#<>8M?%=;YZ_=26?&[+!L29B7>*RUUIF0I?M7.VP;>]^YRZK$13Y]F+>AM
M!$T.@)Z+#T;[PHE_ZISRA^NG(-BS3#J6M\F+@'=43\1B-A;)+)F_@+?HK5X$
MO,7K5K]3+BN-:RPY\9^;%%8C4?[[PA[+?H]EV&/YUWKV_P85GPL2;TU52[W[
MAQ.K?HX:S,D,RLIY!LFD*X34>7R@;XW:R)(GC9%G]IZ\3$L2CK+&*J\(KV66
MF891+&6$V?A]\+*6N[""(?'2-I0+^@X1<>0F@5PFK=TIO1:RXB5,XL]#"FE)
MK$F3E66YBX;E9#'#&Y$2 "%6#O9(+G_>RQ<$)^)E34$2Q(J=NF&G.JS(9.,&
M\UQAK#_R9"NAI4>:3(8.WG.$/C+YQMI@&9AJHX_V;_:;B(HDYUN,A-(!P^:(
M$J'X?2'>W]S=BIL(S$OO/."DS1UVS=5*93((VL\W=V_?B+,$93%(BP]#<*8Q
M3'!>PBO>3$3[Q J&'',#?F-!CH.NH"J &#(O%-QLLV(7S)7.4;M)J62JRI ?
MG7D(E7^ RO,LYQ<S0?@DBX/(!_1DBK9QR%/1[QWM/1,K];WC8(EOC02%'<?.
M4L<H#)6N&T[H2+JI:G8@QHATSA'@U3EQD%$MP;E8-.#Q@/H!LSFKU6.KVR3,
M2BQ"Y/AGW=L<]S:ZRS8XM423Y)#[PA(7BJ>U :J[$'__VUF2G/PB?J,-E6(N
MCF+0XR[*]?0!FNY@&*,T6N9?T4/P[EMC^%]M54;L+;#DPI$;J<I06ZKKD&W5
MQXQ&*2$',ZC'\U9/'O%*?HA7#(<PL-DR%]U;=8!F#L=G'N7-E/1^E#JR02PF
M4," F0%,Z:QL<GH$QN8X5<'<@YG[U =8\Q3E-:<P#O+H =)$?*)2^A#RGJ@L
MG>G9^@(9T6<D^Z_-1-LZBAFP]RJ34XGD=4T&X>;=X&&4+"K!4R2S4U1"T!N[
MZ;S(VW$B&FM-:FQ@D@X]V!(5.4X1CZ.Z>"6JK4E]N!H]P(U2Z)]L_6"_+[WD
M.NK@E-Z8D@UP:JV#[*%7,)IKTJ^M=']M\G64NEAHE80G 2Y9]R'<["\.%F3@
M2-!D/1GWU*-,"UG7UL"UH"5BM3 >P\E0IZ%#K1!,Q"$$ORP5A"!G2(3?9"H8
M%(1;BC5(Z:Y9[AZV"HHQI6%//I! K87,XE#?X!/MH.'@9*J"$_K(!$496E>&
M6")$VT(A<S"WE:4=3ZT$2;S=NZTFJTS.)@SB'5.RET(_, ]XE;RGYZ,C S>>
MO@]F1GMI[O-^&)U' KQ%$5#,^G91J6+';!7\26^8#$Y(K:>?;T[/>W/+^TG7
MRC*Z9]C'- YLW)N+PUW7"QQ8/54IJK8[M8K/QH-&)W2=7-X$6A=\8*:^)E8-
M-A _B?GQ>+%8#A^X+N?)+^++Y Z1L6'7W>!P)D[.QK/Y:3^O'?[+;,AJ9G?D
M:G0^PQX@U@WD!A^BYLDX.3WKE[7#M\;6H6 1EM0/MUF>CH]/9_W\=AA-?-G3
M/\LW;-!R,9Z?GS^P,3D=GYT<O^35=S@<1J?.@U-G?\:IR_/Q;+8</KSNU-GX
M)%GLG1J'A[VS6(Q/3T_Z^>WPA[R3=MY9SA9#CN?+\0+^8N_]",[S*=BV&A=E
MX;O"I9;01G]:+"=GN%Q"V4)QLP+$:CQX-^""X9+CX[8I51Y%79:AJL-M=!)L
M^4&N3P-[B.IQ,IG]]519IH=JL.I3:1#5AVUO94W5I5;7F7G[V*N?]M56LH:G
MD &V2;W<PVXDI+=A>54V/ZJE1:_A/HF-S(9O-_$PO&^5I,*N_5WG]://LT>=
M0F*<$K$,6_S6TCET2/@<!#FHI(:XXR#N5N &!+]ED-!PX+3&QB,MM3T%%[I(
MD_)X*QBVD0*""[3NX#'T/TY5?!E$R*'(RDR>NZ1/!Y]"*K+K\,&'[[MHX_&K
M2/^V_Z9T$S^E[*?'#U(?I%WCS@PS5E@ZFYP>CX2-'WGBP)LZ?%A)C?>F"H\%
MX0!B>0)^7QD$H1WP!OV7MNO_ 5!+ P04    " "@@&)3S94CJN@"  "'!@
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MRO*K^'RN+IM&6(U"C!S0$@1N&S1#?RA\&08%BFH1LY P.1VL]'6QB;XW#;\
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MLTB@E=*S](<31))N@(L-]=[0D:_EC+?V>DNGHOS(2S<_Z>;6WI1SMFEW5^Y
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M)T=R,)4^]*[CGQDM7=^[+?^Y,5"1IQ?P_<K!M^,'VB#_[NSU?P!02P,$%
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MX(1SRPK_4H"R#OB]E-(<#$LP_$G9_ -02P,$%     @ H(!B4S:EK5C\ @
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M![X%:0SP^TX(_3 PU]GZWQ>+_P%02P,$%     @ H(!B4VJMO'UL @  0@8
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MS4(_\B#, CV_Y5P=.N8=Z?\VTE]02P,$%     @ H(!B4PNFH\/8 P  G0T
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M"GGL5,U(WI\P*P+D^)92<7PH$M0WLNG_4$L#!!0    ( *" 8E,&"N?-% 4
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M@I+972E[T2*U9_N5T'A3L(];O%^"- ;X?2VPM/(7$Z"XL8[^!5!+ P04
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M4*@B_R21WRB^R5YP/W*E>)Q=KAD-F- "\'S)H<L6-WJ"\L/0]#]02P,$%
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MO/VT?-Y<?"H3SAJ.#H^_4$L#!!0    ( *" 8E,<F@E=C $  .<4   3
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MR7$/DN,!) <?H01!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M
M(:M (:M (:M (:M (:M (:M (:M (6N*0M84A:PI"EG3_R3KA];+O_[UUJY)
M+55S\&?=_\W9%U!+ 0(4 Q0    ( *" 8E,'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ H(!B4X'D
M OCN    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ H(!B4YE<G",0!@  G"<  !,              ( !S $
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "@@&)3 N :_SH%  !G
M%0  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ H(!B4XJEC=-Z!0  &14  !@              ("!?0T
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( *" 8E,OC1F"
M9@(  /L%   8              " @2T3  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " "@@&)3U@+/>?0%   ?&0  &
M@(')%0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ H(!B
M4]GU,^_H"@  V40  !@              ("!\QL  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( *" 8E.FA[6?JP8   $:   8
M      " @1$G  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" "@@&)3'EH_'B4*  ";&   &               @('R+0  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ H(!B4UYYRI]S#@  3BD  !@
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M970Q,BYX;6Q02P$"% ,4    " "@@&)3+.@689@;  #-?P  &0
M    @(%W6   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M *" 8E-2Z\3;/@L  % ?   9              " @49T  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ H(!B4VQAY97? P  D@@  !D
M             ("!NW\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " "@@&)3B92G.3P2  "#-@  &0              @('1@P  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( *" 8E-;#4G]:P,
M + (   9              " @426  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ H(!B4S:EK5C\ @  C08  !D              ("!
MYID  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "@@&)3
MIR;S;),"  !B!0  &0              @($9G0  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( *" 8E,\BNRZ% 4  *L,   9
M      " @>.?  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ H(!B4THRJB7%!   F1H  !D              ("!+J4  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "@@&)3D,R;T^8#  #*$
M&0              @($JJ@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( *" 8E-JK;Q]; (  $(&   9              " @4>N  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ H(!B4PNFH\/8
M P  G0T  !D              ("!ZK   'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " "@@&)3!@KGS10%  "]&   &0
M@('YM   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( *"
M8E/(2$K6N 8  %P@   9              " @42Z  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ H(!B4PW5:>KU P  O0X  !D
M         ("!,\$  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    " "@@&)3_N[1!(X$  "#$@  &0              @(%?Q0  >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( *" 8E."J<L&Z@(  ,$)
M   9              " @23*  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ H(!B4UI0 "3'!0  )!H  !D              ("!1<T
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "@@&)3L*?P
M$@,#   H"P  &0              @(%#TP  >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( *" 8E/'O#LPU@4  .$8   9
M  " @7W6  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
MH(!B4^<6<E6I P  /PT  !D              ("!BMP  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " "@@&)3_)F0"P\#   L$0  #0
M            @ %JX   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *" 8E.7
MBKL<P    !,"   +              "  :3C  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( *" 8E,YFGMA4@,  *@6   /              "  8WD  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " "@@&)3X#T)5V@!  !*%   &@
M        @ $,Z   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " "@@&)3')H)78P!  #G%   $P              @ &LZ0  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     *0 I !8+  !IZP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>211</ContextCount>
  <ElementCount>272</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/NatureofOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107104 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110105 - Disclosure - Inventory, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNet</Role>
      <ShortName>Inventory, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113106 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2115107 - Disclosure - Collaboration and Other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreements</Role>
      <ShortName>Collaboration and Other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121108 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2127109 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecurities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2311303 - Disclosure - Inventory, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetTables</Role>
      <ShortName>Inventory, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/InventoryNet</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/FairValueofFinancialInstrumentsTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Inventory, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetDetails</Role>
      <ShortName>Inventory, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/InventoryNetTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2416405 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails</Role>
      <ShortName>Collaboration and Other Agreements - Incyte Corporation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2417406 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails</Role>
      <ShortName>Collaboration and Other Agreements - Zai Lab (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Collaboration and Other Agreements - Janssen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails</Role>
      <ShortName>Collaboration and Other Agreements - Janssen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails</Role>
      <ShortName>Collaboration and Other Agreements - I-Mab Biopharma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails</Role>
      <ShortName>Collaboration and Other Agreements - NIAID Contract (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Option Pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mgnx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-based Compensation - Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="mgnx-20210930.htm">mgnx-20210930.htm</File>
    <File>exhibit31-1q32021.htm</File>
    <File>exhibit31-2q32021.htm</File>
    <File>exhibit32-1q32021.htm</File>
    <File>exhibit32-2q32021.htm</File>
    <File>mgnx-20210930.xsd</File>
    <File>mgnx-20210930_cal.xml</File>
    <File>mgnx-20210930_def.xml</File>
    <File>mgnx-20210930_lab.xml</File>
    <File>mgnx-20210930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>50
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mgnx-20210930.htm": {
   "axisCustom": 0,
   "axisStandard": 13,
   "contextCount": 211,
   "dts": {
    "calculationLink": {
     "local": [
      "mgnx-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgnx-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mgnx-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 323,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 5
   },
   "keyCustom": 25,
   "keyStandard": 247,
   "memberCustom": 25,
   "memberStandard": 18,
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://macrogenics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107104 - Disclosure - Marketable Securities",
     "role": "http://macrogenics.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110105 - Disclosure - Inventory, Net",
     "role": "http://macrogenics.com/role/InventoryNet",
     "shortName": "Inventory, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113106 - Disclosure - Stockholders' Equity",
     "role": "http://macrogenics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115107 - Disclosure - Collaboration and Other Agreements",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreements",
     "shortName": "Collaboration and Other Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121108 - Disclosure - Stock-Based Compensation",
     "role": "http://macrogenics.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i530d63b0677b4d8a9edad8802c868c5a_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127109 - Disclosure - Commitments and Contingencies",
     "role": "http://macrogenics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Marketable Securities (Tables)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311303 - Disclosure - Inventory, Net (Tables)",
     "role": "http://macrogenics.com/role/InventoryNetTables",
     "shortName": "Inventory, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i68797193d4fe4a28bd0077b1e12763e2_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i68797193d4fe4a28bd0077b1e12763e2_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://macrogenics.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i68797193d4fe4a28bd0077b1e12763e2_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406401 - Disclosure - Fair Value of Financial Instruments (Details)",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
     "shortName": "Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "ie1ffbd08270d44d085deecec92b01243_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i68797193d4fe4a28bd0077b1e12763e2_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Marketable Securities (Details)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i68797193d4fe4a28bd0077b1e12763e2_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i68797193d4fe4a28bd0077b1e12763e2_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412403 - Disclosure - Inventory, Net (Details)",
     "role": "http://macrogenics.com/role/InventoryNetDetails",
     "shortName": "Inventory, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i68797193d4fe4a28bd0077b1e12763e2_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i68797193d4fe4a28bd0077b1e12763e2_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414404 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://macrogenics.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i22af05f406eb42a18864db9d550fb33b_D20210601-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416405 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
     "shortName": "Collaboration and Other Agreements - Incyte Corporation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i8c7dc4c308654b92a9b7eb8aa5fae842_D20170101-20171231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417406 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
     "shortName": "Collaboration and Other Agreements - Zai Lab (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i1b58dca81bae4ab9b749cdc5b02a267b_D20180101-20181231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Collaboration and Other Agreements - Janssen (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
     "shortName": "Collaboration and Other Agreements - Janssen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "ida2095e4cb994efe825c83b7c2569119_D20201201-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
     "shortName": "Collaboration and Other Agreements - I-Mab Biopharma (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i821467e83ad44bf4936cba83c4bf74cc_D20190101-20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
     "shortName": "Collaboration and Other Agreements - NIAID Contract (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i99a92e56710a44499fbc841789c43ddd_D20150915-20150915",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "molecule",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i68797193d4fe4a28bd0077b1e12763e2_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i68797193d4fe4a28bd0077b1e12763e2_I20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i68797193d4fe4a28bd0077b1e12763e2_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Option Pricing Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "iaabf44798f0b4137a1cd062271187dd4_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)",
     "role": "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails",
     "shortName": "Stock-based Compensation - Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "icc9b2b5b948945ceb440f809f174f953_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i5e49a5b7f8be463e951adb58142f5cf0_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i69bcf518b6f64b4eb86f5f40a6061a93_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "i6fb90850307344bdb2b62e4c657ff389_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Operations",
     "role": "http://macrogenics.com/role/NatureofOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210930.htm",
      "contextRef": "id224a007af7345f691c25b480130a570_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 46,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mgnx_A2003StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A2003StockIncentivePlanMember",
        "terseLabel": "2003 Stock Incentive Plan"
       }
      }
     },
     "localname": "A2003StockIncentivePlanMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Zai Lab Collaboration And License Agreement",
        "label": "2018 Zai Lab Collaboration And License Agreement [Member]",
        "terseLabel": "2018 Zai Lab Agreement"
       }
      }
     },
     "localname": "A2018ZaiLabCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_A2021ZaiLabAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Zai Lab Agreements",
        "label": "2021 Zai Lab Agreements [Member]",
        "terseLabel": "2021 Zai Lab Agreements"
       }
      }
     },
     "localname": "A2021ZaiLabAgreementsMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At the Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://macrogenics.com/20210930",
     "xbrltype": "stringItemType"
    },
    "mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration And Other Agreements Disclosure [Text Block]",
        "terseLabel": "Collaboration and Other Agreements"
       }
      }
     },
     "localname": "CollaborationAndOtherAgreementsDisclosureTextBlock",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_CollaborativeAgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CollaborativeAgreementTransactionPrice",
        "terseLabel": "Collaborative agreement transaction price"
       }
      }
     },
     "localname": "CollaborativeAgreementTransactionPrice",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
        "terseLabel": "Potential annual increase in shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Maximum Amount Available For Issuance",
        "label": "Common Stock, Maximum Amount Available For Issuance",
        "terseLabel": "Maximum amount available for issuance"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuance",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Maximum Amount Available For Issuance, Increase",
        "label": "Common Stock, Maximum Amount Available For Issuance, Increase",
        "terseLabel": "Maximum amount available for issuance, increase"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuanceIncrease",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "label": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "terseLabel": "Development and regulatory milestones recognized"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
        "terseLabel": "Payroll deduction percentage"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma Collaboration And License Agreement",
        "label": "I-Mab Biopharma Collaboration And License Agreement [Member]",
        "terseLabel": "I-Mab Biopharma Collaboration and License Agreement"
       }
      }
     },
     "localname": "IMabBiopharmaCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma",
        "label": "I-Mab Biopharma [Member]",
        "terseLabel": "I-Mab"
       }
      }
     },
     "localname": "IMabBiopharmaMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncyteCorporationMember",
        "terseLabel": "Incyte Corporation"
       }
      }
     },
     "localname": "IncyteCorporationMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementClinicalActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncyteMGA012AgreementClinicalActivitiesMember",
        "terseLabel": "Incyte MGA012 Agreement - Clinical activities"
       }
      }
     },
     "localname": "IncyteMGA012AgreementClinicalActivitiesMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncyteMGA012AgreementMember",
        "terseLabel": "Incyte MGA012 Agreement"
       }
      }
     },
     "localname": "IncyteMGA012AgreementMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012ClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte MGA012 Clinical Services",
        "label": "Incyte MGA012 Clinical Services [Member]",
        "terseLabel": "Incyte MGA012 Clinical Services"
       }
      }
     },
     "localname": "IncyteMGA012ClinicalServicesMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012SupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte MGA012 Supply Agreement",
        "label": "Incyte MGA012 Supply Agreement [Member]",
        "terseLabel": "Incyte MGA012 Supply Agreement"
       }
      }
     },
     "localname": "IncyteMGA012SupplyAgreementMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_JanssenBiotechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Biotech Inc",
        "label": "Janssen Biotech Inc [Member]",
        "terseLabel": "Janssen Biotech Inc"
       }
      }
     },
     "localname": "JanssenBiotechIncMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_JanssenCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Collaboration And License Agreement",
        "label": "Janssen Collaboration And License Agreement [Member]",
        "terseLabel": "Janssen Collaboration and License Agreement"
       }
      }
     },
     "localname": "JanssenCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
        "terseLabel": "NIAID"
       }
      }
     },
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_NonRefundableUpfrontFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NonRefundableUpfrontFees",
        "terseLabel": "Non-refundable upfront payment"
       }
      }
     },
     "localname": "NonRefundableUpfrontFees",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundablePaymentTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrefundable Payment Tax Withholding",
        "label": "Nonrefundable Payment Tax Withholding",
        "terseLabel": "Nonrefundable payment tax withholding"
       }
      }
     },
     "localname": "NonrefundablePaymentTaxWithholding",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "label": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "terseLabel": "Non-refundable upfront payment, net of tax withholding"
       }
      }
     },
     "localname": "NonrefundableUpfrontFeesNetOfTaxWithholding",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
        "terseLabel": "Number of commercialized molecules"
       }
      }
     },
     "localname": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_OptInFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opt-in Fee",
        "label": "Opt-in Fee",
        "terseLabel": "Opt-in fee"
       }
      }
     },
     "localname": "OptInFee",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
        "terseLabel": "Potential annual increase in shares reserved for future issuance as percentage of outstanding share"
       }
      }
     },
     "localname": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_PotentialCommercialMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PotentialCommercialMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential commercial milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialCommercialMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential development and regulatory milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Milestone Payments and Royalties On Product Sales",
        "label": "Potential Milestone Payments and Royalties On Product Sales",
        "terseLabel": "Potential milestone payments and royalties on product sales"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsAndRoyaltiesOnProductSales",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PremiumReceivedOnStockPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PremiumReceivedOnStockPurchase",
        "label": "PremiumReceivedOnStockPurchase",
        "terseLabel": "Premium received on stock purchase"
       }
      }
     },
     "localname": "PremiumReceivedOnStockPurchase",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProceedsfromRoyaltiesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ProceedsfromRoyaltiesPercent",
        "terseLabel": "Potential proceeds from royalties (percent)"
       }
      }
     },
     "localname": "ProceedsfromRoyaltiesPercent",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
        "verboseLabel": "Proceeds from stock option exercises and ESPP purchases"
       }
      }
     },
     "localname": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenueFromCollaborativeAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenueFromCollaborativeAgreementsMember",
        "terseLabel": "Revenue from collaborative and other agreements"
       }
      }
     },
     "localname": "RevenueFromCollaborativeAgreementsMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromGovernmentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenueFromGovernmentAgreementsMember",
        "terseLabel": "Revenue from government agreements"
       }
      }
     },
     "localname": "RevenueFromGovernmentAgreementsMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Performance Of The Research And Development Activities",
        "label": "Revenue From Performance Of The Research And Development Activities [Member]",
        "terseLabel": "Revenue From Performance of the Research and Development Activities"
       }
      }
     },
     "localname": "RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "label": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "terseLabel": "Estimated variable consideration"
       }
      }
     },
     "localname": "RevenueInformationUsedToAssessVariableConsiderationAmount",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "label": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "terseLabel": "Variable consideration recognized",
        "verboseLabel": "Clinical trial activities selling price amount"
       }
      }
     },
     "localname": "RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenuesFromGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenuesFromGrantsMember",
        "terseLabel": "Revenues From Grants"
       }
      }
     },
     "localname": "RevenuesFromGrantsMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenuesFromLicenseAgreementsMember",
        "terseLabel": "Revenues From License Agreements"
       }
      }
     },
     "localname": "RevenuesFromLicenseAgreementsMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesNetOfTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues, Net Of Tax Withholding",
        "label": "Revenues, Net Of Tax Withholding",
        "terseLabel": "Revenues, net of tax withholding"
       }
      }
     },
     "localname": "RevenuesNetOfTaxWithholding",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenuesTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues, Tax Withholding",
        "label": "Revenues, Tax Withholding",
        "terseLabel": "Revenues, tax withholding"
       }
      }
     },
     "localname": "RevenuesTaxWithholding",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_StockIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockIncentivePlan2013Member",
        "terseLabel": "Stock Incentive Plan 2013"
       }
      }
     },
     "localname": "StockIncentivePlan2013Member",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_TotalPotentialValueUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "TotalPotentialValueUnderAgreement",
        "terseLabel": "Total potential value"
       }
      }
     },
     "localname": "TotalPotentialValueUnderAgreement",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
        "terseLabel": "2016 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabClinicalSupplyAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab Clinical Supply Agreements",
        "label": "Zai Lab Clinical Supply Agreements [Member]",
        "terseLabel": "Zai Lab Clinical Supply Agreements"
       }
      }
     },
     "localname": "ZaiLabClinicalSupplyAgreementsMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab",
        "label": "Zai Lab [Member]",
        "terseLabel": "Zai Labs"
       }
      }
     },
     "localname": "ZaiLabMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, Margetuximab",
        "label": "Zai Labs Collaboration And License Agreement, Margetuximab [Member]",
        "terseLabel": "Zai Lab Agreement, Margetuximab"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, TRIDENT molecule",
        "label": "Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]",
        "terseLabel": "Zai Lab Agreement, TRIDENT molecule"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember",
     "nsuri": "http://macrogenics.com/20210930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r41",
      "r43",
      "r91",
      "r92",
      "r191",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r190",
      "r201",
      "r241",
      "r242",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r359",
      "r384",
      "r386",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r190",
      "r201",
      "r241",
      "r242",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r359",
      "r384",
      "r386",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r135",
      "r228",
      "r230",
      "r363",
      "r383",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r135",
      "r228",
      "r230",
      "r363",
      "r383",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r190",
      "r201",
      "r232",
      "r241",
      "r242",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r359",
      "r384",
      "r386",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r190",
      "r201",
      "r232",
      "r241",
      "r242",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r359",
      "r384",
      "r386",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r42",
      "r43",
      "r91",
      "r92",
      "r191",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27",
      "r328"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r6",
      "r14",
      "r138",
      "r139"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premiums and discounts on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r275",
      "r276",
      "r277",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r244",
      "r246",
      "r281",
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r246",
      "r271",
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r46",
      "r49",
      "r55",
      "r56",
      "r57",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r89",
      "r124",
      "r127",
      "r133",
      "r154",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r293",
      "r296",
      "r316",
      "r326",
      "r328",
      "r365",
      "r375"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r40",
      "r89",
      "r154",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r293",
      "r296",
      "r316",
      "r326",
      "r328"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r304"
     ],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r143",
      "r161"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r141",
      "r144",
      "r161",
      "r367"
     ],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r247",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r79",
      "r80",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property, equipment and software included in accounts payable or accruals"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r25",
      "r78"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r73",
      "r78",
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r73",
      "r317"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaboration And Other Agreements [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r178",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13",
      "r328"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value -- 125,000,000 shares authorized, 61,254,693 and 56,244,771 shares outstanding at September\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r51",
      "r53",
      "r54",
      "r60",
      "r369",
      "r381"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r226",
      "r227",
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r226",
      "r227",
      "r229"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r226",
      "r227",
      "r229"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r233",
      "r240",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r64",
      "r363"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Product Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r145",
      "r161",
      "r164",
      "r165"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss related to available-for-sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Available-for-sale Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r76",
      "r123"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r61",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r107",
      "r109",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r302",
      "r303",
      "r370",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r61",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r109",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r302",
      "r303",
      "r370",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense recognition period (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r55",
      "r56",
      "r57",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r117",
      "r155",
      "r215",
      "r222",
      "r275",
      "r276",
      "r277",
      "r288",
      "r289",
      "r301",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r387",
      "r388",
      "r389",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Financial Assets Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r304",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r192",
      "r194",
      "r195",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r305",
      "r332",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r304",
      "r305",
      "r307",
      "r308",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r192",
      "r233",
      "r234",
      "r239",
      "r240",
      "r305",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r192",
      "r194",
      "r195",
      "r233",
      "r234",
      "r239",
      "r240",
      "r305",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r192",
      "r194",
      "r195",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r332",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r310",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value Measurements, Recurring Basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r148",
      "r149",
      "r151",
      "r152",
      "r153",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r162",
      "r163",
      "r166",
      "r167",
      "r193",
      "r213",
      "r300",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r75",
      "r360"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r75",
      "r325"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other non current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory, Net"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://macrogenics.com/role/InventoryNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r38",
      "r328"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://macrogenics.com/role/InventoryNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net",
        "totalLabel": "Total inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r39",
      "r84",
      "r116",
      "r168",
      "r169",
      "r171",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://macrogenics.com/role/InventoryNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r38",
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory valuation reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://macrogenics.com/role/InventoryNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r150",
      "r364",
      "r373",
      "r393",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r89",
      "r128",
      "r154",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r294",
      "r296",
      "r297",
      "r316",
      "r326",
      "r327"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r89",
      "r154",
      "r316",
      "r328",
      "r366",
      "r377"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r89",
      "r154",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r294",
      "r296",
      "r297",
      "r316",
      "r326",
      "r327",
      "r328"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r73",
      "r74",
      "r77"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r50",
      "r52",
      "r57",
      "r59",
      "r77",
      "r89",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r105",
      "r106",
      "r110",
      "r124",
      "r126",
      "r129",
      "r132",
      "r134",
      "r154",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r303",
      "r316",
      "r368",
      "r380"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r124",
      "r126",
      "r129",
      "r132",
      "r134"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r93",
      "r120",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Nature of Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/NatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r44",
      "r45",
      "r47"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other non-cash items"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r67",
      "r69",
      "r142"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and software"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r247",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r67",
      "r68",
      "r142"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sale and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r71",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received for options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r172",
      "r328",
      "r374",
      "r378"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r285",
      "r362",
      "r397"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r222",
      "r278",
      "r328",
      "r376",
      "r390",
      "r391"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r155",
      "r275",
      "r276",
      "r277",
      "r288",
      "r289",
      "r301",
      "r387",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Product Revenue, Net, Reserves for Variable Consideration, Customer Discounts and Service Fees, Product Returns, Provider Chargebacks and Discounts, and Government Rebates"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r58",
      "r89",
      "r121",
      "r122",
      "r125",
      "r130",
      "r131",
      "r135",
      "r136",
      "r137",
      "r154",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r316",
      "r371"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds of stock sale"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sales of stock purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "License And Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r246",
      "r270",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r246",
      "r270",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r20",
      "r21",
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r247",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Valuation Assumptions Using the Black-Scholes Option-Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r32",
      "r87",
      "r118",
      "r119",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r208",
      "r213",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based compensation, number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Shares, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Shares, Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Shares, Granted (in shares)",
        "verboseLabel": "Stock plan related activity (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r252",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares, Outstanding, Ending Balance (in shares)",
        "periodStartLabel": "Shares, Outstanding, Beginning Balance (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)",
        "periodStartLabel": "Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)",
        "terseLabel": "Weighted-average exercise price of stock options outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Shares, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock purchased (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r245",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r266",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Vested and expected to vest (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock percent of the fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r83",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r34",
      "r55",
      "r56",
      "r57",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r117",
      "r155",
      "r215",
      "r222",
      "r275",
      "r276",
      "r277",
      "r288",
      "r289",
      "r301",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r387",
      "r388",
      "r389",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r117",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "auth_ref": [
      "r243",
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock plan related activity"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r215",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares issued or sold (in shares)",
        "verboseLabel": "Issuance of common stock, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r215",
      "r222",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares, Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r215",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r17",
      "r18",
      "r89",
      "r140",
      "r154",
      "r316",
      "r328"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r56",
      "r89",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r154",
      "r155",
      "r222",
      "r275",
      "r276",
      "r277",
      "r288",
      "r289",
      "r291",
      "r292",
      "r298",
      "r301",
      "r316",
      "r318",
      "r319",
      "r323",
      "r388",
      "r389",
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r200",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r222",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r148",
      "r149",
      "r151",
      "r152",
      "r153",
      "r193",
      "r213",
      "r300",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r33",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r13",
      "r215",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of treasury stock"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r13",
      "r215",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "negatedTerseLabel": "Retirement of treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r233",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Government-sponsored enterprises"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r90",
      "r233",
      "r240",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r108",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r107",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121321822&loc=d3e3913-113898"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121323062&loc=d3e15009-113911"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r398": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r399": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r401": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r402": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r403": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r404": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r405": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r406": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r407": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r408": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r409": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r410": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r411": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>51
<FILENAME>0001125345-21-000115-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-21-000115-xbrl.zip
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MXG?GQ#LC':MC*H4',+>ZXI[\N07XO43UJ.9&+! &S$L^DDJZN5<%MW7KUUL
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MM=NN\H$//IIK_/8D? 5S^B=02P,$%     @ H(!B4Y[+RCX[!P  8B,  !4
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MB<INBOS)[>OFW5P$ZROI^#=02P,$%     @ H(!B4\N,T>;8C0$ XRH1 !$
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M$P.$C"ESF[2U>6\?=9_Q+M'0AF+(W0]^_3 >Q?,P[8WG)[W?&Z;;]=G8WAY
MJX2$&,H0@@^,$#EGQ$R2WFL>4-C"02TD].#L<_QT*21$69;_%;I!Y3D4ATM
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M$IC@N$=NE4YV;U_J/I>7VYDT#MAQ#MA  *-QP,-PP%(P(QB%VC@-@7($Y,C
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MCO/BG6O>Y]KUC;I<@]GJKA^UAE@S^M]PWRG<+^Q>[IGQTB100@5 )C78XO!
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MIR0-US$U>FCT<#4]&"W+_YT3O@Z\L,DR@3RK5+P"EB6+-Z.'-O"BBQRQU$.
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M*7:>MQ!K_U/4-@!I[LH7QU,**3+K]_;YY3;XS?AK5+<+5)<R:<&+]E<L%4O
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M19V$@N12[>8;/%A'"8) S4B&<HIUMZAV%W*'/@\7/:)Q>',Q652P=9*&=G@
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M:?WF*.=4NW*7IY.=ZT*\6FZP9"@1B9+PO/RA/1H>LC'D,L:L_XKU5BX9NGI
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M(L^!$2)*-$7,Y#E2QE&46VX4S;1T83]LLXONR8LRD=)SS*G+-&&YM%I:I97
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MBQ8*F<T2-J+>ZMX:5[ZK[-*PS'_=JM8@&YK!.@LQ'9ZBZDC6_<WS:@;TG*W
MQA"S0?1P^UZ\Y\?-0IXR-\M*X. ,T) RR8SP5DJ1."%6 [PC6A63R4$(YNW[
M_-X1=.-BGM:'%+05(#&.!Q#+7)S[P4D='V3U!"YMP6-4BKDU\][WAO[B!&R,
M;\[U]L*RS%)"Z^_UP*7,!&6+AZX>E;M9HWKTX"NW!8$7!($G<6+V*B.YV%Y!
MK')Q<E'[4(TAK#+]8/"*F!3_ TSY U7,RJ,MJ'B<PZ@'T..;@MD/%B'M[WZZ
MZE[>2\&LY1H]I!:9N.O3;G#+>Y]Q/]/%L*CP&F2W"':T!5F ["?!&9@!TO7
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M$P.U6-.UAOL9[;'&)$!+-4_@+_.$*7;9IV$B[^@*?;39PK6WT%II.6,.F6C
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M$?76 R0[=7D#: ':_(=W+2Z(QU-<6-[XM+B^T*I7E[K4J##&Y[6_U: %8$P
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M!NK-5*0J??)(2QN;_KRO/29_7@+9KE5:Z<@84BDI!)/_D.'.(*>3)E@J:D2
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M%_T9JYRW7[+MXXQ:$H5&F..8]0Y/.3CE F')J:#!VP!%#K)E)-XB<@&$K!*
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MKB]MM.M&NVZTZYQVO5-W^D:[/BKMV@(N95M)L3/(Q" 0UQZH4"%7:)FC6MC
M6?9=B=I2Y)Z12QOUNE&O&_4ZGQJXRQS'C7I]5.IUDO'%/FJ'A4-4L80XP1XY
M)342DH5HM*/2ZZQ>Q18G]XR)?T#U6C+)_U-H/E[-CZA<:]PJ$0_+GK-D4DTA
M#ZUXF/ZR_6JVQLYH='%2O78(C_Z<*7,.=HYX8L0H!]";+/X\$(=TW@28'.V\
M<UHYYQ\/90Y,>1J/=ZJFB=6D>87^KS?*=WJ>%6@9LU -=PHUHUU%GG<Q:HA
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M'R:$6NFP<XYH "6J[P%*_&I;^_1;)GZ0KHA[<1_6G.E]C\[%N+.R-%7^(&/
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MTC3!U6GC;/#?8=,Q&HU.KV[:G5:]->P8]9YHC.JFT[*:_:$8VDVPT@28:3/
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MZ?:2]-WW( [B6SOJ0W'W[,H'D01EZ6K/5N*'%L7(R^UZOSK&J94-T;3-KBV
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M/PW>L<UXV_*(,A)(0.\.ST$4!=/-!^)K-&K9N%+ ,]A-(-,"F@R;#+&4+N;
M&XXRE18B""+XRQ:4%8.?C$:*/FP5-<S)1?Q\%6T ^!% [FA.J$R1OTPB-;:K
M8@X+@LV74GL4 XGC#]!4A8?P^XP5,-X7%?9"[BSXN):<Q3Y$TA88!/-PHJN4
MXJ'E$L7;U@RM:B)B@@_;.2CYDS /R8Q5XDD8)&,.3\V2H8?DXQ,O7?,$W)'
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M%-F4^@T.Y =O"F2N?I5:YUBGRS;2G8I*&NT@IC"?2]W1AQ,0%37MEP!X][<
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MI7D9BA%((8'62XCA83"P4H/3]54)WD('0KX_0.ZD'OA>UEM5?#,GMS_+[][
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M4S>99MU^M NU)M/Y.CA(-8 F@7JE)@T-5Z67,:VRA_QQ[^A(WFK<C$97!T8
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M-V=+R=<#! 2+>[*1-CD[*I@4'S4UL"I[";6TX"4]CBN#;RR@Y8[2RVE&P$N
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M'565%*7'D=FH"I+*CJ.#CKY%E+!"SY/W.#VY>;)[#?@2DJ]7 EXO[N^X[F]
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MAR&<@ZDA@B?FJ?Z#;<)FQXCR9 :' VL-'K100R(MT;=6"CA$="8H8.L>>O<
M&U]SD>T2>&X&LL3';((&ZBP!T_!DA)+$PI?Y"CJD/P!9\$\$:F%[K/Z \(#.
MIE)_2WV.WTGP9'( /PR&L05B):?!4UJYD7$*0*8*12C$A<H DH"<(Q8E9!PV
M'#UKCK()3L_N460#2P#R:_A6C-E1]PF@FN V!<Y0I*]@MM:42&?,PX.+1@,Q
MREOXP@EN?.1ZYL9P;/GNWT01MX@6(<RNV7I$T0*^Z"XEV\"+)T$RG@#-H;GO
MN"AV0%L0V0"N7.DAH[9"XI<8E4(!:3$50,S73!/1I$9_DDP!VB7:RCB,A9$
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MS]98<+^/Q9U,1U9L:0=<($/=9A%\C4]K1&W<?.;C[;9<LB?3M!IPF&S#PT)
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M_?S>=!BV/OAN7%;E7T[[0S^&0T"'?[[=E?[O]/P X!N8[>=W_M.(,2="#)X
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M1)243M!]28;-7NR'!Z+_G01\4^%J5X6_^8P5@*./KT;DS^-OX^GTM%B%*L0
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M)]) %S).DBW$_;4LCYOYYANMN#^3KT?MC%N+MD%J[Y+U)3$A^,ASEF1SVNK
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M3OJA_X'C;?\Z;I"9]#W'9/IA?)+S7$%A^#8,\JO1L_!Y, O#^<ZJ?1AR34?
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M$/,0E+ZKC!OL\S6Y%Q>8M+H80_J)5F6R?^AL\SEHL)GQ@#H[E=K$+6\EZR%
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M/M3& $X6.K$UV14D&SJ]&TWCW(;<O34>W1NZVFOM:*JE;C:SF(<<R6U'3LR
M,:$VS7(&8A!T)KN8C#/<Y]+H/6HU00=K5]H>"=<#*CUHI('M1ER.I@4GWT=;
M$\]O5C9#^4 ?.5W]HV7 J0LO31^?^N3F0&]3?<#D1O>\ ^OXV''K+2/O*6E
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M$H- P@1MI$K9<:=D)TP_I>)N"(B[4G$W4<S!TBJ[$/GH4W$WTN16^97;J.&
MF.$Z^T!V@:^=QK5/X*VIP[U]+K7KB<B=FM[>!ZQLFHJ[#ZATEW[?H:?EP\.O
M@_$,TZ=7H[1\?-)9%E&;76KFZN,3D>,8>;8YRYHCH<B\[V;YKUG@6!-T-]+%
MN&=!-L@IZJ?K@'$I&H4)+#<&5(P&8JS]EHN1(GN?0F[3F.JI'\_NYLSAH-!C
M4+3?BKXN3#SUXUF-Z@/ J$D?DVTP<+3]>.BB"LSP#-JS!,JF#%[(#+)$J:/T
MWO-6$=^C!?)>^O$<'L>;J+Z1]=BQW8LS6AB1(V!VFF1%Y,9,4LL*RSR.)+S?
MQ*9\V'UX-M+K"DNT@5)ZKB5;OK^_F;S'R9<:I*X;BI.M'"SM(&*VD-DM$2(J
M#X6)7&PBVEQ_U0NK*'CDUF(OBNFYV&Q)3^5_2=%TN4FZ$-5[L&LM.?L/;NVN
MJ9MJ[TG,/0>SUA.'F=SH8!V4X&I+O#+O:A]K9E@6W+EZIMU7W=\2K-J3ZC>1
M;M_FQ<5;^DMB_/KU==%'Q0LE$]>>S*XDH/;6 8]TB1E,W%E>K,'-!IS?LMA^
M@U8]Z635K.J^!-IWCN62ODK>TC(*HT0WXH=/N,:HHNONRZ F;5W4TBK+E76<
M%.SHRE.&@PNT%5PRSAEKF;=Q$SAL3\I# <N>E+'V[-AC!<.KWT/\=3#^_"D0
MK^WJ&%8NT[R:X6[FKM<TI$C:$BIC(D5*[J/&Y+4H/G,>#;NKIF'E@D=4V:!2
ML3'4AI!9L$4O#N=K^7?*R7 K$V'TD58V%%0AQ>C!V\SK( 0.,4D2339!6H9!
MYVZGZ .M;-@$.MTJ&S:1>+/*ABMG.6WG=_CQ?%C_W;>[QN,5&6UQ3D*JD3#%
MN:[&@P19Z)R7QI+UN6&5PY:4/%98[56#?5OY5RV(#6A^AVG\<33X;\RG3+.@
M0R%KU7+:/%HH\GH$N3Z:EZ*\+2A<)_SM3,IC!>!^==AWL<6%6_0:9V3>AJ]U
M]-2G\3 /1A]/>18Z^QHT4ZDF. HRGQ,C[PBU#)89W341XI9%'BMJ^I)[WXUR
M;ZT*8@*##2:"-CK7#!$&P=-U30IWBD5%)VFWB0(/N!YK^XNL+\DWJJAX-9K[
MP97=/Z:8/XQ/IE.<3O\1)H-JT3TC*0QHM<6;RR+GGJ,OG L+A=<>$5:15)1(
MP(JSY!<S)#XV.4 V)^&Q@FD_.FM0)W%90\24DEK4(&Y-L5>LZ-H,0D%V@7E6
M4K:AS9C*!U+(M0UT=E+"33!L/<FYTSS,TY1YL39%,'0O$H>L-@6E"Q--"-H5
MJ9ELD_AQ*UF/&#;]J>LFEO8S@-DZ[936'C2+CO">:S/$3,@/2BECI&"-2JH>
MP0#F9LC:1GDW ;:W^<O6"YM0&M".;EFEHP0O#(+)=,,:A3%;L7^,/9CYR\U@
MMJ4*;R+M&,<O)^&E<HRN=[3SR"M"X#X#QY(5M]IRTP:43[6D.Z/VP' XVEK2
M1+I7.3@P)FN2I)?@T")D^C[S.4EI.W6-?:HEW1 0=]62;J*8@]4%=B'RT=>2
M;J3)K0H$MU'#P3"C4-D4R.1TS'M0EBQ0Y^@HCSFI(!*S A_M6)?V4-E$^GT_
MY/V0\'$Q?Y/9.IFX$B $*.%R/3T%R**<2-G&$KOE_*_X\&.M(=U(!^,>!7BT
M]:.%H[>V!-#%&I*((-P7C<2.,-$*BU$<77G2@ZP?W<:$.1P4CK9^M L33_6C
MJU%] !@UJ;O;!@-'6S\JC$850ZW]<O.Y9(J^HBLKY$SW,$:E=:>9/P\)R'NI
M'ST\CC=1?5.+L7/!HE",D8B\KQ(KUD&(1@#/(<9H=4BLVZ3B+1:_K[6D&^EX
MK47:0$'-IA.B"48PJ\E.]JGN)@;1DR%NM1&91V3)YOZ\T <XG7#;8-=V*F@X
MG; +&0]U.N%&*E@SUVX;^36<3JAY4J5FAW+N:Z*\)'_8,@'>(E.A")%Z#&@W
M5V.GZ81]:'$3L36=3EA["DA-IXES=!\I76M5>8E@I>1"6,>Q1_T=R73"C82_
M=CKA)I([AGE KU^=O'I^89ZTJZ9;N4SS:KJ[F;M631>]J<T"$5D1BDOC:NR.
M,R.DS]JCOJN:;N6"1U1-%[B1J%4!96JO"2X*.'0U!24D% PE-VU2%8^GFNZ\
M;M,WY7>"3R)C;/IA_"LNC7;,1,VS\=D9V72#,*P5#]<J<'(,-LI VYDG!@K)
MU/).9(A.F2*,L)IW&X.^$QGW/.]E$Q#^6)>W-]WU7;SW83P+P\OZKW^$X3E>
MHR[D6LJ5/-A@)5&'6&UZ!!%\YIG<,U%L)V3=N=1C14^_.F@2)%SF,@=![G?0
M"5BL^:>N6+(A' ,NH["6_JI,)[?XL2:4;P.1G930X FD0;! !A3<E%J=92R)
MQ54C-1G(604,@7MS_?)ZRIP[%E@>& ['D#FWLI428Y);P1TDY16Y6W1XAZ0Y
M( _*A""RL)V>1)X:T6T(B+L:T6VBF+TU(>M"U*-K1+>1ICIU(]M&S'O# ,&:
M6^<*Z!0$J. ,H=PD*'$^/M('&1]-([K^5;^)=%LVHOL[G6Z7S=+(OPM,)S+D
MHW;UX@W@++/ 0\B&6^5SZ?88N6Z%8^DBMI'TU[6<VUIT/3\3KLS-E!RYJ2W*
M@J@-*&*MG')"0E$.L<ALZ:9ZRI1O>]_OK)@>W:7-<CZ[$/GH,^4WTN16Z<_;
MJ.%P4Y><"L9&#=+663.&)? <%>2B0THN2^GL0\'*IIGR[:&RB?3[MB=>+QYY
MAJ]&T]E@=CZCL_=D.,3)QV]TTKX:%:R'Z?GT^6"*Q,GEC>FM1*DD&%U3,I3G
M$$/V8%SQO,A@>+GS,6W[Y8\UVWXC/8[WJH1FV4W&ZU(P9W :)5G7:"$@CZ U
M2SD8@7UZ&@\QNVE; V4[%33,;NI"QD/-;MI(!6OR8K:17\/L)H8^HK "4HB>
M#C.KP%M>0'JI6/")\=*I!/TXU-@INZD/+6XBMJ;939P')EF2X!*CRT@Z"5YG
M2W=3TBE%ZXKN]!!RG[*;-A+^VNRF322WE^RF][-Q^M>O=//7M__/!.FYN;#Z
MNR^^UB]QAR2G'5;;/=>I+U:OI3S)5 P6$;C*3)$9%JQG1D>-)A2,J9SNL.Z.
M3Z"?P@1O+''%8OCUV_=?6;8N/?DS3/+W)[><R!.Q18&,(8)RVD'DQ@'WWD3'
M>>*Y=-GIFS]Y[DS[S@_(VU)PD64S_^GTY'SV:3R9-W^5R"TWR4*TP50;/D.4
MR&J/1Q<(+,*83K&W_0ES'2O[SV_8,Y9O/!\?% Q]9U.]H+-Z_ UQ?@:]77J@
M;X=AM+RL3D:C\S"<IV$.XOG<H7B+DXM_==&H5 :27A&QAL@=**0_Z/ CEY3<
M187T/Q.Z]0SNA9Q' \D#:;!!OM9<.O%N <;K KQD>#)(<W_Y[&QYH5YP9E.4
M/* G)XLAJ,CK3#@>P(FLZDCS8'B;[G[M>'HT #\R>+3(3=M6L(M;Y-5T>H[Y
MU8BX&8SS:1(9.6*!( VYEHEC;5%7@!@)7D7K/3LR&VT5&X\3W@<!08^!NIV9
M>?-Y?CF].9]-ZRR/P>CCPF(Z92)RP6, *6H=4 R:?&:5(; HM9,Q^]*IP=+^
M4+V.E2=D[Q4,/?;$;\#0/W'P\=,,\\D7G(2/^.)K+;=87E6GBB5>:H#>E<5S
M8!U*Z!3P:+56R*3/;?+6]\3@TTXX N#TV,E_[HI<,:^>A<^#61@N+JC?2;GD
MB;P:I4E]67PU6GR[MGJ8?,'\<CQY>3X[GV"]R.K(Q5,I$N.I)D@%1E=8K+7X
MNI"@>9VCF(,C$ZV3/]D718\&KH?38X^3!!:3518&/FV0BY#+W/[_'$;?IE<8
MO+*OB/Y;6+M@:E[HM' AR,D^15N#^)E#9G5RAO2JEL(Y,,X8=$P+&;LE1.Z'
MWL<%Y"/$0(,A!]_3!>Z4]72=L!=9 J7PS&W(('TB9UB74N?7.N*K)!FX34;X
M-E9'7RSLJYKIT-;$051^Z-*E"^[KIKM,G!.TQ3AF"TD7!LK0'Y[;""PIY,H@
M3X8WP>Q5*@Z?*;17'(Q[TD>#2/(%+9>-P.ZFIFGCRA_I.4P'RNWULT;1.PBW
MO<JS,-E@LB!B(*JD#A!X0$!M&)8BHS1M:G/WH>H[>C2VTO0F,NT[=_C#G^,/
MG\;G4S+0W@^^SA!'ZY^\ECEN!<D><QRTK-7!K%8'>S10G!.2*2Z4[#:Q<N.E
M]V]>[Z*H\=ZDW/>S]8E@3,X)(VN]=J'X<I4RF90RM3H\80R@N$S@DXJ08DVD
MMRXJU4W_MRYS?W7=G_3ZWNLWB1*,RR5AWLCDC96 I8Z,MRQ"+,% "B9K*[6+
MJ=O4Z]M6N;]:[4UV#9XY+\^219'E&F-U./\@^NI-^3XH>_&J]6P\G5WI_Y!"
M*)Y[<K8=(9/@FB P3@Z43LD:G1/S;?*G>F9D5[DN5\*\FI!E#N&I+NA*K'FJ
MGM=N/%&#X\&##I@XCUX%VR8'HAM]^]]SA\3C=5.K@0X;S,7X[FGV([N%UQF%
MUU'6P8T\D=P$]^"*"I!+LBFJP//U:2F]!YQZ9&=?P:=C0N_A<;'JNCI$5(JN
MWO$96<NTE>O'_;;D<^&*A9!5%AJ0:^(G(X(/R@ CD%@>G%"QS3R86X@Z?,SJ
M8(@9M]%<@]C&&M(N C =B&L:W;J5O,,$NWI39C>0[*")O</%<L."#>39"2)-
M,49[1 AR D1VI:2LG=WK*73 0-EA4+*) O8V.F=I8%Z4>P?&B(X(,@5R% NY
MGTX:1QIE@D6O$W=MHJ<=B-N_G]"C.CO-LME>%PU,_K_C""=A2!2>Y#,2]72V
M*#3_D4CC?8PL<7!*I/KXG2$*4F],@I--6;1J9,)W(N\A0:9_?:P]8]K7E2[2
MVFK.VF#T\60Z/3];Y+GU7E)ZUT*MJDDW8O!:(:E@*2NE?=$EJ&QR4)%^&%!X
M^E,*N::0]*XE#UY#*A#IZ/(>@F*U=VM!",X*R#FYHC4K5A]95FMOD;JM*7@9
M!I-YA^TK"JT[/LTP/Q]\&60"SCLZ;$YYD9*9@* %4Z B,O"6G'I?T!F?N=7I
MR(3;E;5[F;2V"=9[2Q9N I86T<06#/YC/*2/&0YFW^8L^F0L=^CH(G06E'5T
M$7(AP!@4+!1KZ2*^/_OA1^:>=L2! =.J!K8O%M\-IO]Z.4%\53N(X70V9S 6
M9;,O @I:\B<T&9\AAPC1R61UR*5(//X=L8JUI_UP4+"T*HS=IN3WM@W_ 2=G
M_%2H:EC'2,YT?6$W28 GEYIN01L-=UHCE^VV01.>'B?^#P^/%O6SO:7T^N!<
M$(;,N^ -**\M.!$=F&2TL#:3Z=>H&OP19O/O!.:#J/S0V?P_=L73GJ%GQD"2
MIEXW/('W:*'H)%)"7>CRZ0+6^];A<Z\:7]G8<Q/)MYQSVX&,A]K8<R,5K!MX
MNX7\&JK3LFQ<]@3$HB0H%0KXQ#4H4601G)<0.KTU'H<:.S7V[$.+FXBM[\:>
MB^K>BRS@J*335D%)C&R?H!S$0)<:N0"FU.A0<)V,Y&Z-/:\N?;C&GAL)?]R'
MY'INF/UCAU&6I*P3.>D4DH+8J?.3;5 08[3)\JBL>W"3I[=6X=:2V]\;V@UW
MYQWYZI-!]5SF/_^#ECE)L\&7P>S;KL]HVZS5TTO:SFQ>?TSSF1PYVHLQ964+
M#SHQC\EPP4PT!D^W7O7@[VF,6<6<U\"QEN"(.BL]H(: V2C'12CYR )ZAW]/
M>_%?YZ3".@-A<CZWK^=SQS]\"LOGT^GK\>@+Z1[SN_%P^'(\J?_H-(=B7381
MM$QD9FM7R,PN C07F$O!.@OAN"2]%9_W,HZTR2[H+8[:'D;'].S6G=MEFRYG
MBR_>TNU+SBFH)$@=J7#P.B#G2@HICNQDVI3%>[15]H#5_6^K+8!V3(]V=S*Z
MF!UXV=61B1*DQ0S.A4R'G.80<E1@F/ LT@&8L&$;VSUP^+2?#K*?=H#9,;7#
M?7V1_7:#X8OV>/G4QE1DU S(%6!U#'VN_1 8U"YES 4KI.LT:V9_6Z@#5T_;
MIL6VZ1M.Q]1G]TXUD.0+#F976@H[AEQE$K_7NF;&<#H5BJ93047N-1T,Y$X?
MU\[9G,FGC720^V<WL!U3A]^-3=<DC7"26=* BS50G"%XEL"J8!6QBMDWS$/9
MOX]TE+JXUDQW;@X]#S.\S!.YNH6<-AZY\" L#Z *"Z2QZFP(P:3.V4;5IM?<
MD0GB'IV5]R9,U R(]\KK[2Z.4YY9%#F2JY(=N2K%1KHGZE-/$3)I3:[+O?.(
MNW-_CW;@,6R!(]S.&^'W7NWA'T,*=PN"88I"DJTGG4UD\(D ,?C:>C0;YXI@
M6NI[MI$W%,'3;C[.W=P2R<<4/;M3$/^8:[2[('A.T1'+P+0C6\M$\C4M!O+A
MK)+%!6^[S6L_HBV]H0B>MO1Q;NF62+Z/4;[S"4[OEH+WUB:O!/C(+4F!O@J,
M"8A,.)T**A7NVW[>A/^GS7R<F[D9AN]G7/%N&:AH0HB2/ WI209%18@R2RC6
M1E-4BE:K>[:/M_69-]=@IW9UE^3,J9]^&,_J\-WO/Z\MZUZ/9_\;9]^;V7W_
MI,4_NL[BJ4FD&\X8,#6'KA7@,&N0*(IPAKQ%TZ:UP\%8OD<G;C\1QOL!KD.U
MAMZ&\86%1U?$\EOU]_BI5%8:6P1(H2JW,4%TA4&T+EN121#R@)VC>^/S:?\<
M#XR.NDB8))M$#@J<0UN;IRIB)%C@UH<2DR$CKU&BYB,L$M[I">H@*C]TD? %
M]PORZ9?GE792Z$+[3T&*6H.*(H&3-H/P/@H74_"BS43H'\BX_\7#&R'A>MOZ
MK35RB,>,M8+XSL8H7YO$T86GIMV56W!UF*;,.X!ETV#"OC1]?U!<M,Y" !,N
M@4*Z?>93P)+RW->$JJ@/E&5T-.B]HU?TT8.WNX+;-)6^7B<Y???^CV4E+0_!
M11D0I"JZ=I%"\$)[\,Y[7XPF@ZA-$[Y;R3I"[ZBYYF_VG^Y);6OKU-840"^_
M7?^(Q.Q__-O_#U!+ P04    " "@@&)3HQUO82:2   -7@8 %0   &UG;G@M
M,C R,3 Y,S!?;&%B+GAM;.R]69/DMI(F^MZ_ E?S,))9XH@+N.!8=X]E;9H<
M*U75K2H=38]L+ QK9K0BR6PR(E79O_X"7&(/!L  &:RV^W".*C-)P/T#\<'A
M<+C_\__X]K@ SZ(HYWGV+S_X?_-^ ")C.9]G]__RPV]?W\'TA__QK__T3__\
M_T#XOU]]?@_>Y&SU*+(E>%T(LA0<_#5?/H#?N2C_!++('\'O>?'G_)E ^*_5
M2Z_SIY=B?O^P!($7^/M_+?Y.(B^D@GL0)1Z#*" >3*4,H)=RY-$T9$@D-_=_
M]R*$"/(1)"SF$/E>#(F,/1@D/L*4XX3@NM'%//OS[_K_*"D%4,IE9?7CO_SP
ML%P^_?WGG__ZZZ^_?:/%XF]Y<?]SX'GAS^W3/S2/?SMX_J^P>MK'&/]<_77]
M:#D_]J!JUO_Y?__Z_@M[$(\$SK-R23*F.RCG?R^K7[[/&5E6F)^5"YQ\0O\$
MV\>@_A7T QCZ?_M6\A_^]9\ J.$H\H7X+"30__WM\]W)+O'/^HF?,W&O1_:3
M*.8Y_[(DQ?(]H6*AI*]:6[X\B7_YH9P_/BU$^[N'0LCCS2Z*8J=5+2764OJQ
MEO*_G>KLYPO$=R3O\E!6!\)5ZGYP)6,7IA^<B?M5\8,87N"M;BX6N?Z@WF9\
MK&]WW=7%H@\OL:O/(E^2Q0B?Q::;+9$7^A?OU;^:;G1#'61:]=-0]Y:HXMM2
M9%S4;+G3-)CS?_E!_6NV*N$](4^S+ZLGI95>^\CB-2D?WBWRO^XRF1>/%9'?
MTG)9$+:<H33R*.8<LH!$:D7S4IB&80@#24,_8BBEV)LMUY_Z3&3PMR^M5%77
MO?K]P0*'Y8GY7(@R7Q5LLQ(^+HXM;VIETVMA^G-&'D7Y1)H7E/#::*CU^==M
ML8&6&VC!P9;DX(]6]O_[SS]OM'<W$HMKX;OX'J#-V8Z "VV0Y,4^4#GK"]1F
MWI=*QPHE24I:J=DT^;.V"7\6BV79_@;JWT#/;XR8_V;;]\\'7\]MT>I)"G9F
M\)HG?F:YLM:>EG!G'+5U>Q$@R_RB#Z\>)B7B#R ON"B4M7Y$W8/)\O%)%*J]
M[/Z]4$;B^SFA\\5\^?)!J;@J"M7Y#"-$PS1 D/G4APA[!-*(*R)&D1?Y:>R3
MD-L0UMD>IT95E9Q@T0@Z%^4-4*8>R"5H! 9/>:&'Q(ZFSB-O1E!.\1R8FM:R
M@DK8&[ 6]P9L!';'2<;8.&6C\[V.RD/&(.PSD/F+_;CG'9D7_R"+E?A5M;\J
M*JY[5XC_6(F,O;S)'\D\FWDL\;U44*A,(P%1BCR84@4YPXE PHL#B; -^QCT
M.37^T2*#2N8;L"4U6(L-_J@%M[233. WHR#'H Y,0CTQM"8?"U2<TH])OZ,2
MD 40^Q1D\VH_$KK+GE6;>?&B?8]WV:<B9Z(L9SP-,4UY"$-.)$0B)) 0%D&*
M$/8EYGY*D0WO'.]F:E2CA0/S##S5XMGQR0DDS2CD<GP&9HVU@#>@1:D1\@;\
M4N0=8%D31S<63KGB1%>CTD.WNON,<.9I=Y9(N?[E_YPK.ZA@#^VB2'#@,8%#
MF'"B3QO2$!)/1I"'O@A8ZL5"!I?:)"=[GQIE;*P3L)84D(R##[?_<&B8G!Z-
M_B:*$XP'IIW+X'5BLYR%:7#KY;0$5[=CSH)C8M&<;Z0?K7T0R[N,Y8_BO5J?
M9I&7!CRD$B9QRB!"OJ^V4H1"CGTD?4)$')'9<NU-/SNE=EJWHJ43!P,NYXT2
M#BRZ5F4#P 1"5.TO8XA]CT 4IQ$DL4^AAZ7:>I(H(IC9\'Q_P$;@<1> R< C
M(5*?E!<$&*(D32$F)(3*D,8HP6'B$3E[%@7-!X=LNY=I@V:V?O4&8N#U22-0
M"P9^U*+]!&Z7RV).5TM"%P(L<_")N/7I'47"Z1*TV\.H2\Q1Y?:7D.,/V2T1
M7,QG;[/E?/GR]E$4]_/L7FUB_EH^O,X?GTCV,I,L)#S%#(9!I*8R2]14CF(&
MTT217AQZ@M#4A/O.]#,U%JQ%!:VLH!86--*:3?-ST'9/>(> #3SU>V)E/.$-
MD3@R]4O!_G:?/_^L6JAGO?I'-=FK:7ZNW5$FO*%R[=0W?=R.!![OLV^S3_E2
M\?.<+%1;JFVF_O7K?"'*99Z)3^2ELD]_RU1CM_>%J,S5&>6QGX0IA8GP0HC2
M$$,2"@Z%)WP42Q0I0\"$''KV/S726&L V%H%\-CJ )X:)<!*:P%(JX89F_0=
MHVZ6&0'Y@=G'7OC+&>E"U&JFTHU49.3AT*L(J6^SHQ#5A3JW!'9I,_;6S6M%
MEK>%(*]S+F8)2=2NS5=;.<FURR[FD/@XA($R;#P:1CS@1N[\_8:G1D5:-J"%
M UHZ<WME!ZSS!DI?" ;F!$/MK2R08ZKV,CEV&AK-QC@F_K91<?3O?4_2])[D
MRY(LJZG;AK#??IN7,R],?3^1VN,D XB(E) $$84B$9$?)UX<(-_N..UD7U.;
MDLWN>"TK:(4%?VAQ+7WC72";GK0Y@6[PX[:>J/4X;3N+A^,CM]/]C7SN=E;Q
MP\.W\Z_8D4=9+&>?U<"+7\4C%<4LC$44!() D5)%%&F$(,&4P##P2:C^B$(2
MF1#%7KM3(X5*-,OCL7VHNJ?[!0 ,/+7UYS,OEW.F=DG;L3CN3K-.Z-XUC=4K
M6U-8_;0_???;'&6JGE"DG9:G_MQO_?XLE@I^P=^2(IMG]^4M8ZO'U4+?L7@C
MY)S-ES,>Q53(.(!!@B1$H0B508TQI%'H^4D4)DQ8Q0*?[W)J$W=+0L!K$>T6
M< .4S=9QM]@-/.=;84$K+?AQ&\E&X)_<K>KFZ#A=W VZ'76--X=A?ZFW>+/O
MR<,MY^H;*YO_O%>]^;/01QAS2B'STQ2B)& 04R^&+$28A4'$)#.*K>GL96JD
MTGC2&Q%OVG\ +2SXF%GLXT\#:WKJ<"%<XYPYV"/5X]2A XD+SAR.M3KRB4.'
M8H?G#5T/][4SRF4Q9XI(OBQS]N=OV7Q9?O[R6[L!H#[S41C#)$T4 8A($8 ?
M^= /XC@1+ A2873P:-3;U(A@(RRHI 65N+8&1A>\IK:%(] &-RN.X05^5+*6
M/X$_:GD=^@J,<'%L4'3U.+(M8:#\H1EA\E(_(EG[(3[*JO&'?*%>+M_^QTKS
MEN4U7Y.V)O3E;QQCN03;$O]W4,L\S!U?&Y3<WO UZGG<^[TV8!S<[K5ZN>?\
M>""%>$5*P768@,C*VEE7%-IEH/M^];)YI#E_N_V+%'P=CGI;EJO')_U6^7E>
M_OFN$.(N4PNAFM2?E?RS$,5>&D@"TU3GW1&^A%@OVZD@:8*0G\2^M$IF,+3$
MDUOPE8Q0*B'!O)$2%$I,RX0'@X^S(8=.:?2&YE^M"-2)E3C8UA9LJ0OH"]A^
MKE$95#K?@*W0_BV];X#67%],%*#5'7SN^B;L67RL<7*[ @PN];BKQUB#<+#R
MC-;QR*M6O7;>96KMK'+0E1^7#Z+X^D"RC[6P[_)"BOERI03]7>BD<X+?/HN"
MW(M?5./+-TKVM8XS06-*1!I C#P)$1?J7QA1&" J*/&C4*UOHRQM3M6:VOK7
MR*[(,2^ ^/8T+]0_?YQG@.>+!2E*\"0*4&I<3ON&I_P5#;QP7NW;F/[JVNR"
MMK !%3A@J= !']O%=@N@&]!"!!J,0 42T"AMK=836(@'&?=IK-9N5?L^EO1!
MAM/9NC^,='TBU?5=;\%+C?SG_(4L=#*F3T)Q3K:<I4GH2<PCZ%$_TC'I:E,:
MI0SB4$0^\;F?"*,(L[,]36T)W42?/S52UYEVBU9N\.-3+;GA$GH>Z^Y5S2F"
M R\T76*ZBA<W0*([,KRK@1%CP WTV(WV-GFAWQ[AMR]?BRIRZ.6+8*NBRLK6
M''"0B 8\4H8Z"K7=GH0!I#+@4)*0D]A#C*=6=OOIKJ9&!+_][<O?0"LL*-?2
MVAG.'=":&;-N !MXWO_V98/41LP!3HS.H^'4[.KH;E13Z+S:^^:)P1M.PM(M
MSX5.O#VA3_D@4GJ(@Y\S, P9('V=PYTS"I\)C+[P $='7]RJ=GB5[FQ![F<L
MD12Q2"<_1#H)*T\AB7  (TK"D)!8US@P#8O::7EJB]A:.*"E,P]\VH6K>VY?
M!,+ L]E0?ZMPIJ.Z]@IAVFUIM+"EHPILARH=?Z#?>G'+^5QO:\GB$YGSN^PU
M>9HOZRN+>5:=U<Z8%P6"^BD, R$@$FI*DL3CD M"& T88Z'5L>?Y+B<W3=<2
M@R<E,IQG@-5"VUF;!F";K=-N(1QZDF_0T]+J7(*-O#>@EK@.Z7"W?IO#XW0I
M-^AVU%7='(;]!=[BS;[AT._F"U&\5A;$?5Z\S **)8UQ!#U),$0T\"!FGH"<
MI0Q%(?($L@R$WFE_:H32!/96,H)62-NXYUT$SQL!%^(R,$O80=(CP/FHXA>$
M-N^V-W)0\U%E#L.9CS\V\DGUH=_\+JO+!,U"WT^CD*;0HZ%V7RD"P)&G?DR#
M* C].*8!FFW7Z1GN</&TE$:3Y&S5(N<'AIOCO,/SY.H,N1SK$+EC@ <^$;YP
MT+Z;X]UC![A53N9*UPD<T9X?B&F<MW;(^7T<GIX'VME)J$%7%R:A?S,OV2+7
M5Z*M_90G6YC0Q%]+"39B#N2O/ O','G4C_1WG63JIQ4_F5&]XY4+TZK?EJ58
MELUE?_XQ^ZQ=_,4\NU=3;%[^EN6T%,6SSAAZESVMENK/2MOY8EY-S%<OU>NO
M%Z0LFYS?:81C+Z$((C_@$,4X@#C$!(91',LDC4-)C-RA0PLZM5U6)1^H!+PT
M-[OK(36CN2D,U-#.(9LQZI_@?2  A\D%[UK8ZZ2-'PCRDQGFA^JO1^C6!U([
MSW04F;*<EN*CO%VHG?C]RVW&[S(IF/K[JE0KD"XUU@8<I#%C:L,;0:IVOQ!1
M3"'%B=#YPQ*4)H*FTN@N<'\1ID;@'^YN[]Y8A''UP[V;B\=!<V"6[26_HXBP
MB[#K#!7KU_)X,607:;X37'992SUKI>JXUYI4MZITDB1B<1@**'U?V:)J0/3U
MQPBRD!#N>4*$S"AC66<O4^.A.I2>5%):ECT]"J*9]7<Q- .32HU*+>! !4V[
M$'!;Q/1H3^,6+NU2]J!8:>?#/1W\[$'PU4)QRUF747G*9_15VU<S+%BD."F
M2:SMET#]'_6U;U\1!(]2%@:!U8;5F613(Y96L2JM@8&;N.ST$X,_*B5M"\@[
M&W9#9_\U!G-H%_^XXVCOUW>-N5MOOC/IQO7ANP;UP'/OO(-^"T-[M>&=@J *
M_FA.!MY^TUGM58<SP;FR!Y,4$@_KA-<"*:Y/E6E(HH#&88!X2FP(_VR/4R/R
MUZ1\ (5@8OZL9K/,"Y#7$@/1BFS'RN<Q-V-;IT@.S**?=FYTU2FN&G'!V[,P
M6I.B,31.R>Y\KZ.2F#$(^^1D_N($TOF\_?8D=%:N-_/G.1<9K]*\$%^DA*JM
M;$A8#)&D!%(1$,A\WTM"BCSFV5FI0TL\-=)K902\$1*\S,7"DNB&'^>!8U"&
M&+WI1Z2<2N>S_B9:U:><S:=KF*81KV(L]?<1O6(["(-F\^GLN,^I3YZI;V:5
M<6UR__:D8,N6[X0H/XCE1_F5?/M]OGS0B>_FV?W,%R+Q8F4A>U*HM2>.&*1I
M0B%%L0P2DF JC0QFVXZGMH0HT>%&=K"JA6^+R-V 3%0I'Y?D&_AKHX7-D9#%
MH)@<! T#]=#'/]M2@T9LH.6^ ;JD[4<)E.S@]\$1YCFKDFI4T_8J2.](\%T@
M;GG:9@];]QF;17LCGJS9:[E[GM;C_7[;&.T8T/_3:66>R4*[:C9)@O4?;M7"
ML_.+K2?K:,N[C.F[XN*-J/^K?EZLM&AOO[$'O?#IA>NMU(> LS"4D2<(@CCP
M4[6N\!A2G/H0><B+_(@QD7";JO?CBF^U.JV5&' 6JYE:RPBJ*W_E R#*HJW^
M(39ZVFUX1OXBS'8_TQWG@9=&K<H-J-QW6QK=@*U<ZZ_;<=__W<X+-0B@10'\
MV.+PTPU80P%:+*I=$:C1<+<YNLXH.MTIC:S"J-NFZPS/_A[J2E(,Y 4\>?!Q
M^O;"7M:VUF'Y22DL9C1*&,(1@1Q)M8 &^M1:BE1]KD3PA 28VEUV'UN!J6WP
M6EGA.LMD*RZHY.VXQ#9X4E37WXXC1^,5OX@)^!V[C\;/784[DM5T]WL;T1,Y
MT#B.ZYATK<2T_)0##9&UVW(H.?I6FMDOT;%>X#_E127Z4ID'=+74V^>ON8Y
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M?$AQZ$.2A"*(?$J\E-NPE$&?4R.H5N3*6M\2VHZC3, VHR?'$ [,3*?0 XW
MYT_#K!G) B"G9&32[Z@\9 '$/@79O'I!Q>$F//#-2N]/ZJB>:H-SO*;(S,,<
MTSB.8" 2"E'*]5D1(E#&'HZX3W@<6)7TZ"'#U-BI(W2V1V%:R_$PW=\-BO+0
MIE45M=H&LMZT?IZSQ9GJ$B*;6$C'M6;[X>F^L*RE'.-7D>T'U-&2L3V;LN/'
MLEC./A4Y7['EQZ(IGE3E#P]))$F@<[]1+B#R*84II2FD*?7U'74I0B-3[%0'
M4V.V1L;*<&C$M,K*?A+(;M9R <_ E-0#&6.2.:=^%X.H=[?80_VTSQPG&Q^%
M%LZIUL[YL\_U-'A6M)SS.2E>MI(_51\D$2)*D620>T+J,LT<IDF"H>^%B40H
MY#$*K<R:4SU-;8KOI2GK4W+A)*B&MHD+J(:V0&Q0LK<FSB'@UF8XV=NXEL$Y
MI0_6_[,O] V%N\M87CSE164S5 [JU[JR6?'R.N=B)J5 . D)9)0R10UJQT-E
MFBA8 YP0+Z:Q3M-L$QW7V=_4"*()$]N1^::^0P"JFJ>5Y$"+;AM)UXU[-WL,
M@.; '.("R!Z!>$;P7!";U]W^R.%Z1LH>1O"9O=:77KX\DL7BU:J<9Z)4E@:-
MJ0QEI!,V*3KQ UV816TI(LJ\D"-,4& 4RW>B_8G21R4C:(6T)8I=!$V)H3<N
MXQ"!(20]IOQ1Q2^8XKOMC3RECRIS.(6//]9OF_#V\6F1OXBV;O+Q*Y,?\NQ9
ME$O!J]N1996@;/OONACXAWSY;V+95%S^3\$W+=4O[>?8FT48^R%./1AYQ(<(
MQ0FD/N+0#]1?9)"(*+'RKEY-DZG14)T_;J4C<1H- -N^?,V4CG;;GNM])&;;
MJN]BZ,=P''=YB-?ZK_.[?F.+E4Z(U%RRUS=KRZ5Z;@E>Q!)L4+@!MX_:1G"W
M"[SZ@#G=95Y/FU%WL5<?M/U=\O4%FEJR]-V,!;^+^?V#UOQ9%.1>5']\HPS^
M=6#GC,1(^G[BP5"&*40L#"'E20(C(<. B<CS/'^4+#.N-9O:FKR=F(;GBP4I
M2O DBCI)S612K-M^/H9.SZG(.]'5>MCT[(=Y<UJ<0 -4_0C04('-W8()Y-(9
M:ORGD8;'N7;?1P:?H09UO.SP?06<0K; \YR.!.*<( JYB$-E$L0$TE 9!P&*
M@S#B7'C2NU[BN>]NX6\%AJ0AVWLM,N2:;*4FV^>J+FHN05[K6S]P;5-AF@;!
M_[_L=R;$^VX6]O\*R_=_Z45Z(DOQ51;<>OW7DN:9$J2IVB=1A(/$C]6D3!A$
M<80A]F,*D20TEI'DQ*P4:F<O4UN\FBW&6LJ>11&/(VKHVKT4IZ$/N*PALG>6
M=D'@UI%YM*=QG8Q=RAXX #L?=GE-:8NL7N=9=7/S:Z[X2.;%X[N\J+8(Y5?5
M8_-Q8\$C/XH83+@0$-'8@ZD0"902B2!.$<>^49HIIU)-C5Y.7M;9.;=H-0/+
M'#2Z ?5_M;-#5\A0<O4D)C=C;49DHX_@P,0WYN YNI/5$^P1;FW92C:!>UT]
MP32[^=6W\8%<+.4I [7Z/RV'SB*KIH<NKMNP0BH3FE+,H"#8ARB0"<01BB".
M4T$1CH) NCU:Z2'DU!:$2M)+"'V0D73DU!AX? :F>YNA<>](N "[<;T%?02=
MEDO@ JBM]_V7]#6R-[V^EWE7EJNM M0^0KZ?DACBT,,0A2&%A)! ?34>Y4&0
MB@1;I2MP*MW4R%VI])AGH*QO$*M6'RKWYOBE6HX.Y<">ZTL':/I^Z>;B<JWB
MI$J!=V$_#5_R40FGM2ST =>9'[BSDWX+09/3KDT=%T0T#(A/88PC#I'P$"1I
M'"OC7<84DSCQ/*MR6[O-3XV*:^GLZ'8/,#.^[ _#T.9LG3=SB.1YQW5V2C1[
M78S*%,?5VY_J)YZZ3@C$+>=5SCVR>#,OV2+7B2LW7W+HAT@D80Q9$E&U4>>)
M,N(0AFG,@Y 3245DE^5E2&FGQB0N#[0WBH,MS4WFZ!6^FG$B'9Q]"].W'QU\
M!J,',!@-SS1,3".)OP^3TP9\UZ$(9IU>9YE[^TT4;%[JG(U-S1;&?5]('D*B
MUCB(0A3!E"()D9^@T&-A3+D<<VD[D'"2RUFIKT:M!;U>+=G#\1QGT;EHE+ZC
MA69+SQMG58$&'X1)+2>'4GY72\A)D%TO&Z<[NC =_OMU30Q&I1]1G\.("K6-
M";&$:9HRZ(6>\!/L4>(;I6XYW<7DR'J=&;]_79(C0!J2[$7P#,V2=LCTKP]P
MH/PPU0#>7Z?*QFDU3V;Z/WSR.K;@/^HKKQG7.729^N?77/_JXVI9+DFF+WWO
MA=$V#"4^%7,F9@'SI.#*7.0TP!!A@2'F0D(_2A(JO$ 28E<MX*KJ3(VXUG="
MUH'ZK;B@DO<&U/I6H56BT5A'4.F+S).X%W+AYS6.'3O>1_,=&;U;7];;K2]+
M_UH]M8'FR&V2W8]T.J:RFW&>E%U]H4K?E1'N9OA<6^R.I.JW^M]EK!!*L#>B
M_N]=5D4\-E4YMJIPS2+?$X01M3R'.(2(ZT*I,4?0BUD0A F. V(59V[<\]36
MU/KJ>Z;3&S55:!8;8>T61W/TS=:Q03 =>,EI908_ME+_I&,Z:I3;.C_O#1"V
M7@VLT7)*W.:]C\JQUJ#LTZ%] ZZ8JXW?_GV^?'B]*I?YHRC:_EYF-/581*2
M89(F$$4BAL0C$?0X]H(PH)Q%5K?-+?N?&HN]$5(4NFYG(9Y%UG%7UPGX?>G+
M&:37(;'UG92_E/R@5>!F36>G*YDX(#,C[ :FM&X9KDQL1@"=IS>S9BXMNECE
MY6XLQL]J3_XN+ZK(Y=TZ@#RD4G@!@@*ED4Z#RR"-_!"FU(M(1$3H2;N$^W;]
M3XWDMJL'UDGF&PV 5@$T.O2MR6@V)(8>B.& 'MIE8(3Q2)4:K< ;J&"CF0Q7
MJMMH!=#I\HUVS=AQW^-]]FWV(<\^"[G*N&[QMR>E4K9\)]1&R,<(J:UF!%FJ
M&8ZD&%*&$*1I$"5!*E+I4Q.&Z^QE:CRFY(3%6E"PJB4%3[4SP8R_NF'M9BEG
M8 W,1:=$O)QJC!"H"44_6K&$AT.OXHCNET=A B/YV_EN]O"T,Y+.?-6]YS,*
M?<0P1"G%,/5E#$.)2<(59?B1F&+"T:EQSW8^T7&#DVQ'?."SG@''<?JG.CU3
M@$[@Z*;GL$WCD,96^._C.*;GD%PK[^:5 RP,#X*T&2YK,WS&$D(HCD,H& N5
MD2PBJ'[V(?,D13Y*N.N,$,Y5F-HJ>"Z08MR@B!Z?Q#B!$,,.]/27R?5":!/?
M,,D+)_U'<AHK9W\UOH\U].)A<AW&<($D?0\ =9!:M7[/_(3&E-, ^AZ5$"74
MAYCP!":1#$@D.(YCJ_086VU/;27ZE11_BF7E!RH%6Q6]P@XVR)F>S/7"8_!3
MM[54+@_2#E1U?$BV:7_D [ #Q0X/MPX?N;K1V]Q(B@F*HC2E4/I>"A$/4DBD
MYT$?,QR&D4\Q&C5;_(&$4R.*]A@FWPAZO1MFA^/I15C(*,0P# F!B/D))$P&
M$*$HB(07)W$:S)ZJ#=B7)2F6W\&H[DL[L*FZ;V:^$O?S+-/#_(JHI]D5+Q0>
M#G?J\3 A0: C;SR(J(RA&G\!?2D#'J&0>!(WP_TVX]_-8+>RCCS4;^OI/,%Q
M'GV?^5_ZXNC.H$_MXNC)09CJ#O![O#AZ$N0!]V\771S=% ^^Y5S-J_*U^N?'
MXFO^5S:+_$3*U%?F6ZH+\0JU0TNQ'\"08,%DG'B)B.VJ=!_T,34KK!83-'+>
M "VI+DRO9;4MV'T(:#?;.H)I8+[LA5"/^MTG,;B@AO=AFR/7\3ZIU&$M[]./
M]LQK]TSF"^V'>)<77\A"?%E[(]X(NMS\-$-)B@,>QI C%*JIK[9O-$08<L\3
M,68)(X$W>Q8%S8USWAEV;?.5;PLPH''0TV5C##;G@GB^QV&:$&UGIZ$"&RMC
M&R<I2J(DHK'5Y?PAH!Z#=PVJ4%T&M)FA.P1\ _.Q%@QL)+L!:QV@S M8*BT<
MIC"TQ,=M<D/3SL=->V@)R4%"1-OW^U:O69)Y)OA;4FB?0_FKJ/9_(O%PPA36
MGMK3*[*7GHY KWSR$5(_1CRP2@1UO)NIL<TM8ZO'U8+H0[XW0L[9W# J\PR:
M9B1S.48#4THK(&@E!'_4,CHMQ-(%@N/**D>[&KE42I>ZA[5/.I^V8X"R6*H&
MV[SJM_>%:,JGK#(UUYY(L7S9JFGAA0Q'C(>028S5GB]%,!6>@+%/I&0D$HP8
M[?FL>IT:/VQ+";28EE5'["#O9HW!@!R81'I@:$PBO3#IXA35X!:?J)_VN<2N
MQU&HI1<(+=/T>]G5U=]/A7@B<]Y>:M69%+)2E_2H(OOJ%-%J:T2(2/4-8(PX
M1#'Q(<5<7PA&TA=)'$H:SC)QKU=Q,^.DGR!&<PK7<VI;G.&F5B-UE0%(B5M6
M25OR*KZWS7% >B1R[SE.9D;/@-A?]<YP.Q:-^-50U*'69W+I.[@R;(/@P#>'
MC42Y\@5B&[C.WR.V:JT?<7[57:V*E^KZGK()YX4^+2B7OXKE0\YO'S59SY((
M!7& 4Q@@G*A]6YS"E*E_,0\SKEA21!%O:?*K^4;.I.\>S/AU!.NMEK8ZH,LE
M6#:*U/6%[!C1: #,^,\9GN.P72MN?4?X!C02Z[J=Y1+40M^ 6FQW%&<#DE-"
M,^IX5/JR@6*?K*S>O?"XL$IP^;'X5.3/<Z78S">>3$4D(8^K<N@*;D*)@%1M
M*R.98(*84;V<<QU-;<NX?RQ6B:O/Q5J!>YX>[N-K>81X 6HCGR.: ];_,/$$
M&I>?*.XW?)UCQ1/JG3Q;//5\/VM%E_&;U]&HR@K2:5;FV;W(F/9DKTLB;!)M
M))[:Q6GWD@Q8"A&6*<0^)3")?0][41!XL54F6;ONIT8?6])76X@=^>V,%LMQ
M,#-?AD-W<#=4![!;=63 'X/D.NF'FU/;QE*$4:V<?O#LVSL]6[D@5)Z>#]RB
M^X%;GQIG6W6OYJ.LJYY6)MHGH3YVM9.(=<E8F:BM7!!'$ 4$P=3C"-(@%*$?
M$R])[:NR#"+JU.BS%1@\53?TU+:/[125K:6NMH,/ D@=;/!87<P!S_8Q!P-^
M 69D/(UQ'9BX'<3EKK^*3^U7T90:;C:UC=*.0W0''1CWL;K#B#M^T.Z@L!^-
MWAVVQWZKDXZCJL*H[K*GU;)\+Y[%(FBB$WP1^ 0)#S*UM$#D^PQ27V(8I#$E
M% <HCHQR<1GT-;7UH9(-!'8\WX6E&5$[0FA@IMW$WMV 6M ;T  V0."' 29.
M2:ZKOU%9RD#Q?9HQ>:7O9KTC"^H'I5!]CCA#*<<B\3%, BDADHA"[)$$AI&7
M)%$8"<R1W2[=J-^I\<=^^N4;D(G*G&S/6Y_R0J\ MCMULT$PW:([AW;PO?F9
M?,LW8".WRSVY%5".-^-F?8^\"[<"Y'#[;?=ZC_RBGXJ<"<%++?MV,M,V5T55
MC^/+IT^M>57./,1]'DD"19IZ$#$:PI0Q"F5$>)RH[71"A-DMAGX"V$RS<>XR
MM"H K4.S,<XK+8!HM*A=9%H/T(8&&3H?>XY2-[,-C_S !&<MNZ/,I[TQZTR)
M:M_J>+E2>VN\DT2U?RL]..U_D:PL1?9JGB\%>[C+V#HD7_H4AQS*1"80Q2B&
MA!%/;=,2+E& 2(*-,F=T=3(U^ZH1$S1RJFT(L^"=4T@:L(L#? ;FD"/0G-^5
MF6/$<U8E5:P<&(-CM=/;-#XG.V8]@T$G?YYZ=SR6/"/]#A>>>];-+=3=.TZW
MCWH;]9]UM,HK4L[+&0]"'E(_T>E'8HA(B" )@P0&8>SQF#%"93);YDNR,-N
MV@I@Q91K,8;[M-<25I%8EUV6/ N^V<9S2$@')E>#RY-5E)L)Y!=?IC3%;=!+
ME6>%N.KE2E.(SEVR-&ZGAUVGJ/)E*7[]Y=;S@\W%"O7TG)'%+5O.GZM.F_67
M)J'OT32 ./$4OR7"@ZF7AC!.$B^):<AX8!0O9]_UU&S 6GA02P_6X@,(6@T
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M*8Y?]8C*[\;:C%&<(3@PHQR]T*/H9!"SS B482)KC_9XG=C:+N5/1M=VOC3
MS>+7JT+?)I_%'%$>A1%,(B+5/E=02$40P\2+0U__CJ?![%D4-'=RQ;CIUF:"
M;'<^X'G-<'>-6ZA#1G#(? E)(A74L:202.I!GV(9T#A!?FQI#+H%^AI7NF\
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MQX52Z"=]96R^*7AIY[5R-H9FWJYKC,S +/GQ]=W-N72Y6IT;\$LU9EK5GVX
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M&/Q1J6QYDW^8C\/0X7;M(1_:07<LP]8F]=%-2\"\(N?7Y&F^K.]#JA%_U'Z
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MF$XQN^O$3:J:W5KX[ZJ<W75*?->S.X]_91G0>].7\YL4/Z]6HIQE19IG!"+
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M2O%8G\]0X&#MC9Z*Z4=R:V"B#C)-S\.-QF87Y]W"<R+*6T$4&8PB U(=*)A
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M?$C(3RT20<<;V,V$EM_,_T8 [7P9\?3BM5G/^48*\PLMR?X'G2MGC!.:""@
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M/1FUSV5Q3T[ 8>["SW*I;[RX7XI[\3A?SHT/8DYGFJ[Q38('1@5&O." <RD
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MC1@["M]%V\? Z.PYUR/HM/A/W@@C[OC9&$%A/YE>$7;$88O."6)16L \E4B
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M'>S !90M#($_[ );@@:V3RKJB!I]LH#-S1K8 =)K#B[<8CQ[8*?+GD&P_,H
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MJ=C1%]0J1JU6IHBRT^/9L!]$6SVC2C.WP], TVUWOGK;20QLVSI3U*CR6-?
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M=Y7.[7]:?:=_!Y#PG*?1?=NT?_+W?_NG]A/]AY'OW_[I_P)02P,$%     @
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M(/01#Y[KU)_;RTLFDL\LB" AHRIT>GI?6QPMY%0P!#+!:!^JLS@4.3?(&1=
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M"RK&F9W1UM3L)>$.T/%VB9_#-#__XS/.5TBG[)OU)UQ>D]$$2_8\,P=H"B?
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M)AXL^PX =&6LQGF+3TY)Z:(1A%:&_$E.>XN"6V!:NZ"C"<RT>:[A%BGC F<
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M&6)AD=P82$(P4)(8(><F0?8\!A&LL[;-"-M[21JWKJ2[<_8 ??4$O#-QWB'
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M1 ?!PP!AVZO+#@)F8["H$[ L(YT).D.,64&LA6C1BD1Q7:..B^&X&+?OK+.
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MP<.Y,Y<2YS8J1<X<"S6]B>"B,I"25$F4J+8<,+HS"N\D9^0RC.'4O1A:]AT
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MV2Q'7S@7%@J/A:RP(BDJD8 59P5S#(GO70S7[B3\0$70AYJUQOKK("]TV7[
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M#GW >7"%]H772_E=ES#)<)I(R!OV-]-KKGWGM_F4)'WV7/S7&[(P(EHE*:;
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MNZGF0>A?TSIU>N$/R]^6B>+]3Q34+'B1DAG,0(PGH83,R AXLB<E.^,3K\=
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M,2YH=&U02P$"% ,4    " "@@&)3GLO*/CL'  !B(P  %0
M@ %S!P  97AH:6)I=#,Q+3)Q,S(P,C$N:'1M4$L! A0#%     @ H(!B4R)B
M=Z#P P  D@\  !4              ( !X0X  &5X:&EB:70S,BTQ<3,R,#(Q
M+FAT;5!+ 0(4 Q0    ( *" 8E.C*/EJX0,  .T.   5              "
M 003  !E>&AI8FET,S(M,G$S,C R,2YH=&U02P$"% ,4    " "@@&)3RXS1
MYMB- 0#C*A$ $0              @ $8%P  ;6=N>"TR,#(Q,#DS,"YH=&U0
M2P$"% ,4    " "@@&)36IDV_CH,  #(<P  $0              @ $?I0$
M;6=N>"TR,#(Q,#DS,"YX<V102P$"% ,4    " "@@&)3FH--%282  ":I
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E,#(Q,#DS,%]P<F4N>&UL4$L%!@     *  H E@(  .WO @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
